<SEC-DOCUMENT>0000320017-21-000067.txt : 20210506
<SEC-HEADER>0000320017-21-000067.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506160834
ACCESSION NUMBER:		0000320017-21-000067
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CALADRIUS BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		21897779

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-842-0100

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>clbs-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:d9eba1cb-e72d-43c9-86c5-dbb9216f38d8,g:166abcdb-ccb3-45de-adfb-a1da6bb60890,d:4b25ca7d61014564ad831413af96ade6--><html xmlns:clbs="http://www.caladrius.com/20210331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>clbs-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN18zLTEtMS0xLTA_a0a2008d-f0fa-4bbc-af04-1a99f1a48bcf">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN180LTEtMS0xLTA_839e699b-1369-4bd4-9b4d-9bdec2d10a89">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN181LTEtMS0xLTA_bda56b26-7fda-49bf-b2b3-3d3c8d2368d2">2021</ix:nonNumeric><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN182LTEtMS0xLTA_37baddaa-61b1-4831-87c0-fef45d91e010">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN183LTEtMS0xLTA_5faa75af-b2b2-4cf1-9ec4-d2fc7bfe2e93">false</ix:nonNumeric><ix:nonNumeric contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82MS9mcmFnOmNkMWFiMjVlMjkzZjQyNmNhNmRjMmUwMjFiNzI3MTc5L3RleHRyZWdpb246Y2QxYWIyNWUyOTNmNDI2Y2E2ZGMyZTAyMWI3MjcxNzlfMzU_09f095b6-0fdd-404b-b968-c07397e03a0b">P5Y6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="clbs-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5b23b6c1a5fe4d4c8bdb981ced74fa45_I20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38fe760abf524b1f9fc7025d34a428f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41bb661c1032422799be713e40ad8635_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia525a7cd4cf8438fb5f3cba58bc350cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32a9ade1a1d14e93b37b75e67f601a91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id072402eb2074150a1eb3fdd22afd12c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i589da21b9cd3494bb5d59a64f84a8c12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcea2fbb21824e578b12c0844d468746_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe02162890344d1fbf90456b0bead153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd907497bf9499ab23f6889b68495e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98213f01318841c58e971c61065d059b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5533fa9fbc549e3ae2bdac8c681fe78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788bbf0e008d40dfa6fd131e136a8984_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c094ccaf714cea8477934f4b218fbf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2fea10ae844d2097b54a25c64f6e32_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e16651f8d7949d58de041929b8d2de2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0548a2ff6f4f1b99d092c805f2a489_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccb52a1055149e9b884edffba7b0c9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0867f814915348b5bdb4e08faea3ba19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f7c29d762741c784b2f2e5280bba2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a7731dee2e425cadcef9131a3f1611_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232ac432d803493e882af56dc9654ec2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6a615e6ae547058117f5e18a5dba6d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588195ddb3e14a50b4ad59be6d72d358_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97509a62a4a4419bb9b6e60ac0a55a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef01373193f4f92b43d3255e62c34e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e147676a9d347cdb2e16b52523ff885_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0536559cd0b54911a2cea21fc56aed37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c07dd6e75a243069a60c6bf7db68018_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3d95bdf08242159f078fb83657a19d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea27c84c39b4c3ca91f6aaa91387695_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebefcd2c95f49fdb51cf02aeec47cce_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4eeca0cde7433db812f696fe9f6f5b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d385d56f17c46bba3c7db051eabde22_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f829607cf341adad7ed6ed97c8e4b9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f1c3ec495342668f144f3ae1f669b6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15c0e3aae5c4517a60ff1bf682aa1ab_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17df6bc95b14a6a91bd4d7107a927f7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ecb9460cf04d2b971feeef71d2b6e7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic47c3d63fff74ae6a6360be7e478b1be_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic572abd8348545418bc389f5eda0860b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d643ab02b0d434e8d777c9ea8ed75d8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd979cbd8b84bbb887c9f1f556f8f9e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264a67c0128540ff86e03277435eec08_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdcbdf98a7ca4a708730bbebd3ba7714_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">clbs:IschemicRepairCD34CellTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3bc96434426403a9bd2301ded3b4994_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i115a0e9999e14fdcb9279eee27425491_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a759825b1a41819d598d7d7e1af92d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic89c436a48cc48ef91082d25c26d3752_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i499338433b98478ba449207f9bded52e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i777bc9631ae24b4aa509c6ab60a91a57_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b54c799369442588b92ab156347688_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3f2806d8764f13bec22b3ff8cf87ed_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdb907e20cf4c1b9603607b2905156a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132ae7e2b40f4aacbfb45d310a8825e2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffea5c40fbc940929f1156d78435b50f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9f9eb3437d453dbe79a9bff47d7f5f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bdf6d06fccf49ae9869c434a423e19b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4537dc4974b74981b566969155de0b54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25ae7a16882454a89235836a00c085e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0034e259507451381d712e51c59a110_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17695a58a11c417395bec355c88d7fdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad507469e2c44e1c81b999fe3754c26f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="office"><xbrli:measure>clbs:office</xbrli:measure></xbrli:unit><xbrli:context id="iad9e8e338fc54edf89217db73847c29b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26a96d4091904e6b919d8e86339a5d99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ced2f706c534f1d91b7bc6ba399fe9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b76807e468541f4b8af73ed9c91b2fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37e538a949044dd7ac2e7157cd069c22_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaa95386fd914df2ab6e70d41a0648dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a98eb81842e4748b436585c87156f1a_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03c497fe3a647068aff689400691742_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253f4e81f39240bfa1478bea971064bb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47215ddbef4645acbdcebd547430280c_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb45e4366f343b387c5ac5a70b7d93c_D20180201-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d5d5e90b62441eb1838b078677e72b_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec9ddeca5314500aed87a027edc3fbe_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8d0caecfc8478a9763718f92a1c601_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf4ed15255a740ccbc038f0987ef5f67_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5885d9e0c6b24703a32d31ff18fa6628_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f840f3881574b5db5784970c5024047_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c77a9975714e5bb66f65c196bcb6f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd25e43236aa4b5696a0696badf143fe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48a0e1d6f4147ebb6edcba9191e4ea5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d54f54529cf4daea43de35b41341f98_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759214c1bb7f4003972143f129ebe638_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7bf07503274c4ba141b5cbc1970f3f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe5f0e3fd7141d6b7317b9c81f7225c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb173d03e633477ead116cda9d9948a3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eab163f6b9e41e5b784b249926dbd6e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c54fa8f52bb4465a41b34646f8ffcce_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a59d2dafdc848809ac87c686c29886a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e73ba2637749b6bbc62bc908b6e954_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e428d7942a045c8984c14fda8656fa5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id723fbccd73440de8762bc38568bf063_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43284901a884f78a402755fd3b41aaa_I20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1905a146945439d89ff1228516dc50e_D20170501-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe95d09252c410489923fdd656451ce_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d49bafd16540ef92725c78f1429358_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c059030f14c498b9bf58d821d59c031_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc32f1fee1574a39a7e75cd277331948_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619b7221c8b6420b9d72d12bbca2851d_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0023b178cff546c5a4ed4572f1675a89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64fbc9ce8d824790bfc3e917a2bd92b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20ab50a11fb4b0f89cb676e7cf79d61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i448dfa4c0bd046df85903ca8cc449d02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f0f64709a44444b6515aa9f4cba303_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4b25ca7d61014564ad831413af96ade6_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDMx_08ccdbab-73e0-4fde-b1e1-5ba026613115">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWZhNWYxMmRmZWJhNDIzMjg1ZTc1MGJiOTk4YWI2NGQvdGFibGVyYW5nZToxZmE1ZjEyZGZlYmE0MjMyODVlNzUwYmI5OThhYjY0ZF8wLTAtMS0xLTA_760fe0d1-719b-4d82-bb23-1d8561c6fd77">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8xMjY_32218f7b-2087-4be5-89b0-1ec03b2ad2fc">March&#160;31, 2021</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6OWY0ZTZhNThmNWJlNGMyZDg5MmFiMjJiZGIzMmYxYzcvdGFibGVyYW5nZTo5ZjRlNmE1OGY1YmU0YzJkODkyYWIyMmJkYjMyZjFjN18wLTAtMS0xLTA_7207ac75-9917-4997-af40-add4f9f720e4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM3_824237fa-4482-4e67-89ce-1ac4a89700d3">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDMy_e0a72439-1f6f-465b-90c5-bd8a5286fc11">CALADRIUS BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8wLTAtMS0xLTA_d9ea0d86-6c00-43f1-beaa-0b6d9fa091c1">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8wLTEtMS0xLTA_c216a6b7-c23b-4300-9225-f0407c78db34">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjowMDg3MGZiY2Y5OTg0M2RjYjQ0YzZkN2QyZDUzY2ZjYV80_5b5d80bf-fe74-44b1-9932-714e4e5bac60">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjowMDg3MGZiY2Y5OTg0M2RjYjQ0YzZkN2QyZDUzY2ZjYV84_d90d21ff-0ceb-4aa6-b438-bd0c33b607d1">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjowMDg3MGZiY2Y5OTg0M2RjYjQ0YzZkN2QyZDUzY2ZjYV8xMg_1c32f831-6146-4f3d-b66a-56b1778df138">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTEtMS0xLTA_3e1f3d80-0652-416a-a335-68e7c690bebc">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDMz_1979834b-c222-4b38-8410-efee56ba0771">908</ix:nonNumeric>-<ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM4_cfccc28e-86fb-4654-9847-2349190e5d5e">842-0100</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:34.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MzRiNjcwZjQ2YjE2NDQxZmIyNWJjNzM4NTcyZmUxZDMvdGFibGVyYW5nZTozNGI2NzBmNDZiMTY0NDFmYjI1YmM3Mzg1NzJmZTFkM18yLTAtMS0xLTA_9b58dae7-737f-4c2d-88b9-5504de2af08e">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MzRiNjcwZjQ2YjE2NDQxZmIyNWJjNzM4NTcyZmUxZDMvdGFibGVyYW5nZTozNGI2NzBmNDZiMTY0NDFmYjI1YmM3Mzg1NzJmZTFkM18yLTEtMS0xLTA_7c9dadd2-26b5-4e25-a0e8-75fdda582879">CLBS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MzRiNjcwZjQ2YjE2NDQxZmIyNWJjNzM4NTcyZmUxZDMvdGFibGVyYW5nZTozNGI2NzBmNDZiMTY0NDFmYjI1YmM3Mzg1NzJmZTFkM18yLTItMS0xLTAvdGV4dHJlZ2lvbjo1OTIzYzFhZWJiNzQ0MjU3YWEwM2NmZjQ1ZjM3NGQ3N184_4f878843-fdb4-4815-9ef1-d4c326608496">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> None</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM0_053f5ff6-b08a-4db3-9c57-06365d81e2f7">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDQw_0b99fc94-a7d3-494b-95ef-7f1d2db8d237">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6YjMxMDFiMTI0NzExNGNlZmI4Y2ExZWIwMjZkOTA3OTUvdGFibGVyYW5nZTpiMzEwMWIxMjQ3MTE0Y2VmYjhjYTFlYjAyNmQ5MDc5NV8xLTAtMS0xLTA_15f9a1b6-f9a5-492e-9ce0-080241e69cd6">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6YjMxMDFiMTI0NzExNGNlZmI4Y2ExZWIwMjZkOTA3OTUvdGFibGVyYW5nZTpiMzEwMWIxMjQ3MTE0Y2VmYjhjYTFlYjAyNmQ5MDc5NV8xLTQtMS0xLTA_43e7bc4e-10dd-4b4d-b357-e1c96425e5d5">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6YjMxMDFiMTI0NzExNGNlZmI4Y2ExZWIwMjZkOTA3OTUvdGFibGVyYW5nZTpiMzEwMWIxMjQ3MTE0Y2VmYjhjYTFlYjAyNmQ5MDc5NV8yLTQtMS0xLTA_a8adc0d2-640f-45e0-b6e8-58973b9c30a8">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM2_5c776158-affb-4d0c-99ca-eeb414a2aaf4">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:331.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of May 6, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b23b6c1a5fe4d4c8bdb981ced74fa45_I20210506" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6OTA0YjVhNThmYWQyNDAyOThhMTA0OWFkOTM5YjNlMmMvdGFibGVyYW5nZTo5MDRiNWE1OGZhZDI0MDI5OGExMDQ5YWQ5MzliM2UyY18xLTEtMS0xLTA_65d0ea44-0a88-4778-8768-7fb6a57331d2">59,498,958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this "Quarterly Report") contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our cell-based products and services and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business;&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the COVID-19 coronavirus may impact our business, including our clinical trials and financial condition; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed in "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 25, 2021 (our "2020 Form 10-K").</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in "Item 1A. Risk Factors" and elsewhere in our 2020 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:8.3pt;margin-top:5pt;padding-left:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page No.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16"> (unaudited) and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">20</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">, 2020 and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">Consolidated Statements of Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25"> (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_28">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_79">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_91">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_94">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_100">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_103">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_106">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_109">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_112">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_115">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_118">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4b25ca7d61014564ad831413af96ade6_121">27</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM I. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMi0xLTEtMS0w_bad68ca7-b8c2-4d21-bd96-4a77d26c861e">28,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMi0zLTEtMS0w_6ad2f137-2cd4-49e6-ab8d-723e72629a8d">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMy0xLTEtMS0w_51924661-0f9b-4a15-9ab4-328a3e53b3d1">82,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMy0zLTEtMS0w_e14d9c46-625c-44ab-a21d-ab2d37379557">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNC0xLTEtMS0w_eaaa1ba7-4098-4518-afcb-a6f369740ed1">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNC0zLTEtMS0w_3bc18985-bde6-4c38-97c8-109250f48fe0">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNS0xLTEtMS0w_53412836-0e92-4b26-8f59-83a75c39ef37">114,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNS0zLTEtMS0w_e204490f-8066-4bbe-a6fb-065301855b4d">35,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNi0xLTEtMS0w_d004a40a-7191-409f-9e49-06ae75535fad">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNi0zLTEtMS0w_93f130cb-2614-446c-93a0-d22f4722c0e8">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNy0xLTEtMS0w_ad9a2323-fd37-4921-882e-7475d986b567">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNy0zLTEtMS0w_bb7e558a-81ef-46de-b66e-594160c874ce">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfOC0xLTEtMS0w_f1ee2d8a-db73-4b75-adf9-72d6eafc7ffd">114,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfOC0zLTEtMS0w_36cceda4-0f4b-4862-bd5d-46641a89aa0f">36,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTItMS0xLTEtMA_88a1993c-b7d4-49e3-ae1f-77bcf5122195">2,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTItMy0xLTEtMA_ad7603c8-4273-4fd3-a67e-16c6ea0a6418">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTMtMS0xLTEtMA_713dea0b-2e3a-40a2-b421-4fbf851244b1">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTMtMy0xLTEtMA_39c99051-f811-447f-a8d4-6f61380becb3">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTQtMS0xLTEtMA_d8614cab-03e2-42f2-9c69-e3da2c976712">4,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTQtMy0xLTEtMA_6650435b-7019-42a8-adaa-4e7db668ce9b">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTUtMS0xLTEtMA_d05c12b4-0113-4e5c-962d-b10df7458365">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTUtMy0xLTEtMA_45539a00-c2f8-4b93-a9f7-9464c0b0a64c">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTYtMS0xLTEtMA_9506461b-cb2c-4265-b949-7db090139534">4,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTYtMy0xLTEtMA_7dc35cf1-e160-472c-83cf-14f9ab1fffaf">3,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTctMS0xLTEtMA_cea340e0-fd0d-4682-abba-d6d92b3f2eda"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTctMy0xLTEtMA_91b24375-a159-466e-a7c1-7b5c411f360d"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, authorized, <ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzM0_132343b0-4765-4ecd-a6b5-08395487cdf1"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzM0_eedec326-3a3b-40d1-9a48-f673564094f6">20,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B convertible redeemable preferred stock liquidation value, <ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzExMQ_89e52f7f-fc3e-4a9b-9bf9-d9c73c671813"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzExMQ_a301d552-57a4-4e0c-b318-2b0d503f9024">0.001</ix:nonFraction></ix:nonFraction> share of common stock,</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzEzNw_aed5007d-0a17-47cc-a3b9-9e400441d35b"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzEzNw_e7fd06c8-30f8-4ead-952a-9204e0ec55ca">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="clbs:PreferredStockSharesDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE1MQ_104ee782-880b-4350-a40b-6c92a55b7dc6"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="clbs:PreferredStockSharesDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE1MQ_4bc3f02c-8e5d-4af1-aadb-a1319a8fc870">825,000</ix:nonFraction></ix:nonFraction> shares designated; issued and outstanding, <ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_3a8ee107-fa4f-4755-a638-d9f816e4b39b"><ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_5abeb93c-18de-4b3f-b5ef-6053f81e53d6"><ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_c605c64e-550d-4897-b0f8-daa2de8256a2"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_f976c298-0eab-4274-bee7-5c7b6f7b35f8">10,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares at March 31,</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMS0xLTEtMA_3c81211b-298b-4f55-a81c-fb5f474ffe2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMy0xLTEtMA_dd6f1ba4-3f68-4d8d-b32f-d23e7a4b94d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzE5_8514cc1b-f012-4b4c-a2fb-b8b707c0033e"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzE5_a8cf19ee-3b2b-44d2-abcb-4254b2823233">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzQ0_42f65ed7-c64f-4b13-bb21-1a67e0f3b22b"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzQ0_d20d351a-ddb0-4596-a449-c423c344de05">500,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzc5_449bf20e-d1ad-47a5-84e4-ca581c8f1101">59,510,038</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzg2_4ecf81a9-ee18-4437-8d8c-0f9ac11b7f96">19,389,413</ix:nonFraction> shares at March 31, 2021 and December 31, 2020, respectively; and outstanding,</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzEwOTk1MTE2MjgyMDE_cb51f5fd-3010-4bcf-80f2-3b0602453edb">59,498,958</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzEwOTk1MTE2MjgyMTY_11030c7a-f0f9-42ce-addf-882ee522f8ca">19,378,333</ix:nonFraction> shares at March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMS0xLTEtMA_7fa4d182-f374-49a1-bbab-4bda65849792">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMy0xLTEtMA_4370155d-bb08-4ec2-a76b-8c9bb91ce7c9">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjItMS0xLTEtMA_76a89eaf-e605-4091-8a0f-d18de6814a09">544,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjItMy0xLTEtMA_cb871620-2550-4dec-a6b6-825583e11347">458,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOjAwZmVlZWUxNDZhZTRmZDc4OWQwNDE1NzQzZjBiNmExXzI5_213a90da-3a91-4f11-9020-beed2cd806f8"><ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOjAwZmVlZWUxNDZhZTRmZDc4OWQwNDE1NzQzZjBiNmExXzI5_a592f757-ec27-4ec9-81bb-fe97f01f0b73">11,080</ix:nonFraction></ix:nonFraction> shares at March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMS0xLTEtMA_fa19dfef-d421-477f-83c9-2c9111fbc71e">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMy0xLTEtMA_9a32b772-1a80-4af8-8766-b3476d4ffa59">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjQtMS0xLTEtMA_caec4086-bdba-4ff7-836f-67362ceca51c">433,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjQtMy0xLTEtMA_6d556aa0-e9c1-426e-976d-0c92a0f29bb1">425,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjUtMS0xLTEtMA_56d5a488-f9cf-4e10-a839-d6a0a71d24d8">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjUtMy0xLTEtMA_cd179134-43ba-4c10-b24b-d240e957b4b2">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Caladrius Biosciences, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjYtMS0xLTEtMA_9742e598-5bdc-41a8-9f29-6fcfb58ea43e">110,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjYtMy0xLTEtMA_ea0713ff-44a7-40de-889f-35fc30ed6e13">32,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjctMS0xLTEtMA_23f39d7d-d90c-45f8-a605-1951d114887b">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjctMy0xLTEtMA_52590729-1280-4c78-a932-1d28740c8eb7">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjgtMS0xLTEtMA_370bc4b0-82aa-4e60-b710-5f4683754dda">110,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjgtMy0xLTEtMA_7da7e0a4-3cfb-46c7-9495-381176d3e845">32,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjktMS0xLTEtMA_934f0fb5-57ad-470c-bb63-d299fb9dcade">114,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjktMy0xLTEtMA_a9405a8b-9f99-494d-897c-601054918b2c">36,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.649%"><tr><td style="width:1.0%"></td><td style="width:67.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.666%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMy0xLTEtMS0w_4f6b39de-1b2b-4aeb-ae70-87f8430689d5">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMy0zLTEtMS0w_25c1b72c-d3bf-4a43-a1ad-21306a72b249">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNC0xLTEtMS0w_7a9f2cf5-bd08-492d-a025-d43596f8504d">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNC0zLTEtMS0w_08a0e8c4-ac56-4570-8e15-4e3de36b475d">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNS0xLTEtMS0w_477f0ff1-cf88-4198-bf80-d875651dd145">8,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNS0zLTEtMS0w_ae7159ce-ca45-4d3a-a2af-3f1ce3c7dc1d">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNy0xLTEtMS0w_c11c1786-a8f8-4004-85bd-7573511e3001">8,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNy0zLTEtMS0w_06fddd37-e5c5-4f6a-b890-fa3b7dcff5e5">4,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTAtMS0xLTEtMA_accd1e0d-53b5-4c95-bc02-954c37f672bc">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTAtMy0xLTEtMA_e8321a25-a9b2-4106-96c2-36e8e2703dd0">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTItMS0xLTEtMA_577630c3-112d-4f77-8eb3-67631b443026">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTItMy0xLTEtMA_2c07a4d0-d759-4e3f-9bc5-d042046647cc">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTYtMS0xLTEtMA_b46f02ad-86e4-4c24-981f-6117100bada3">8,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTYtMy0xLTEtMA_f636c29f-28c0-4467-b7f5-ed5b7d73e528">3,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:25.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTctMS0xLTEtMA_b1784c45-9ba9-4904-9b58-e233d17355d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTctMy0xLTEtMA_c54d3d86-15b7-4762-91dc-3b5313e391c5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Caladrius Biosciences, Inc. common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTgtMS0xLTEtMA_5d2a495d-a24d-42b1-a30c-80958463662d">8,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTgtMy0xLTEtMA_5d5b0b3e-7b81-4948-943f-6126d5f796a8">3,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caladrius Biosciences, Inc. common stockholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMS0xLTEtMA_15692c7e-6113-492c-93ee-b1f32a8906a2"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMS0xLTEtMA_ed8f5158-d879-448f-ba7e-c5cdbd3f4f31">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMy0xLTEtMA_14155284-4c90-4467-94ab-21a5b8e0cc39"><ix:nonFraction unitRef="usdPerShare" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMy0xLTEtMA_6348faec-cc9f-4ef1-ae23-cbbb722c8cdd">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMS0xLTEtMA_085230ae-4a1f-4875-9614-2f739b0cf210"><ix:nonFraction unitRef="shares" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMS0xLTEtMA_9fcbc3ce-8063-4746-b3d6-2493f8463fe3">42,117</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMy0xLTEtMA_0b1fae9e-e3a9-4946-85f8-717bb4ae1ccf"><ix:nonFraction unitRef="shares" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMy0xLTEtMA_dd11c54c-e81e-465d-a07a-529ba0be19ba">10,623</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:68.785%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMi01LTEtMS0w_e37a4a1e-ecf5-4455-ad46-0b1a0d812967">8,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMi03LTEtMS0w_9a5f20f7-4220-4e16-ae00-13711e6ee3d5">3,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNS01LTEtMS0w_58a57be1-2b56-4aae-892a-16f0644842a4">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNS03LTEtMS0w_fdceb774-e0e4-40b1-a3ed-9c7f3820467c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNi01LTEtMS0w_1daf7af2-53da-4401-bc38-a9663b015e9c">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNi03LTEtMS0w_8430ba0c-0932-4e55-8a93-6db97e0dfc27">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfOC01LTEtMS0w_f532fbe1-8ee5-4f76-afab-06758467bfdb">8,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfOC03LTEtMS0w_62998b9d-2cd2-49f2-a1cf-b7b85d9a738c">3,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTAtNS0xLTEtMA_245f126a-2b4f-4c2e-b96a-23c4a3967e55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTAtNy0xLTEtMA_d373c5fd-0602-4bed-afee-8dfa67508537">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTItNS0xLTEtMA_7e0fc752-7fb5-4ab0-ae34-777b33837ecd">8,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTItNy0xLTEtMA_b64896f2-5b9d-4a01-a8cd-adce906ee94d">3,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:22.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38fe760abf524b1f9fc7025d34a428f2_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMS0xLTEtMA_4ee05dba-5e33-4986-8a2c-04f7ab09f21b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fe760abf524b1f9fc7025d34a428f2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMy0xLTEtMA_e0570821-05f9-4730-a3ca-3e716815378b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41bb661c1032422799be713e40ad8635_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtNS0xLTEtMA_17436ea6-0e93-4524-b23e-ac3eca1ab0d7">19,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41bb661c1032422799be713e40ad8635_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtNy0xLTEtMA_22331c95-d2f3-4b62-9a7a-65acad59586b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia525a7cd4cf8438fb5f3cba58bc350cd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtOS0xLTEtMA_7b49a1b7-174b-451d-b9f8-b3a3676e51f7">458,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32a9ade1a1d14e93b37b75e67f601a91_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTEtMS0xLTA_670361c6-f307-4924-9028-2331d475aeee">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id072402eb2074150a1eb3fdd22afd12c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTMtMS0xLTA_c2b0dbe9-3ce5-4d4b-a596-9aff675b2fb2">425,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i589da21b9cd3494bb5d59a64f84a8c12_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTUtMS0xLTA_8c91b238-1e80-4aa4-aa57-c96e4a353dc5">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcea2fbb21824e578b12c0844d468746_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTctMS0xLTA_7b6ff348-4c7e-4aae-887c-cab134cf48a9">32,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe02162890344d1fbf90456b0bead153_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTktMS0xLTA_5d4f8c4a-4d37-460c-9023-aded9b710b7d">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMjEtMS0xLTA_324606c5-fbb4-4942-a038-1312c550df0f">32,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd907497bf9499ab23f6889b68495e5_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMTMtMS0xLTA_4b1b34bd-77f1-4869-8183-4a04a7810abf">8,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMTctMS0xLTA_62866713-2434-4e31-bd00-542b2ef8936d">8,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5533fa9fbc549e3ae2bdac8c681fe78_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMTktMS0xLTA_150ff8ec-2346-4b9e-9d5a-2a81fd747866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMjEtMS0xLTA_3581056a-8bcd-43b6-ab30-09962d4d49be">8,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i788bbf0e008d40dfa6fd131e136a8984_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTYtMTEtMS0xLTA_e418e59f-66ec-4c90-ac2c-ebf33054cc0a">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTYtMTctMS0xLTA_0a222ae0-683f-45e9-85bc-d2daa331441f">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTYtMjEtMS0xLTA_8620f92c-de45-44cd-945d-d7a0aa4ade0f">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctNS0xLTEtMA_13adb75f-f4a4-4fa1-b113-a5a354ef1eb2">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctOS0xLTEtMA_7e860a2c-555e-43e7-9178-e0a348cad143">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctMTctMS0xLTA_61b33eec-99ce-42cd-97a8-d92e1b305bca">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctMjEtMS0xLTA_3a2bbd9a-844d-4e6f-8bef-34935203c0f9">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtNS0xLTEtMA_811a6548-aa56-47c3-8c9f-62a5f639f0ef">39,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtNy0xLTEtMA_608eb615-8baf-4dc3-902b-01bfa9962f85">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtOS0xLTEtMA_247f5c77-9bd2-47c5-96f7-a18b8776b6e8">85,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtMTctMS0xLTA_05b8f04c-90d2-41ec-b840-9225e14016f1">85,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtMjEtMS0xLTA_f8438c97-0f07-476e-adc7-750b5d4927aa">85,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktNS0xLTEtMA_f5cbec43-1da1-4a7e-af33-3eb66878893e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktOS0xLTEtNTMw_8734845f-effd-4df2-b917-e1650e074914">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktMTctMS0xLTA_4fbddb10-7ae8-4763-aeec-78d6a1b71f22">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktMjEtMS0xLTA_ab683bd7-62e7-47f4-84ef-980530f0cd54">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1c094ccaf714cea8477934f4b218fbf_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMS0xLTEtMA_872d79e0-ea28-4b0e-b661-213d9ec243de">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c094ccaf714cea8477934f4b218fbf_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMy0xLTEtMA_e7af85b2-34d8-4b7f-bba0-f7c5245c8feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a2fea10ae844d2097b54a25c64f6e32_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtNS0xLTEtMA_eaddb5ec-0365-4785-a4c0-31d9be9f4661">59,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2fea10ae844d2097b54a25c64f6e32_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtNy0xLTEtMA_7a09fc63-e2c0-4cda-90ad-14946e7f212d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e16651f8d7949d58de041929b8d2de2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtOS0xLTEtMA_971abb01-aba2-43a0-bad8-ea5d6f05a911">544,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife0548a2ff6f4f1b99d092c805f2a489_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTEtMS0xLTA_1e8974f1-16bb-4e7c-b977-cb4c644edf7a">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ccb52a1055149e9b884edffba7b0c9f_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTMtMS0xLTA_b8ace1d6-93a4-45c7-8b7f-9e4ed9d42fd9">433,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0867f814915348b5bdb4e08faea3ba19_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTUtMS0xLTA_5d575eae-60e3-4234-abe0-037c38dc441c">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f7c29d762741c784b2f2e5280bba2b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTctMS0xLTA_127d2f4b-0aca-4c0d-824b-58ad2c4675a6">110,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24a7731dee2e425cadcef9131a3f1611_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTktMS0xLTA_6f93e6c2-8e0e-49e5-82cd-25864e9bf212">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMjEtMS0xLTA_294a76cf-d60f-458a-998f-2f795db23a86">110,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:22.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i232ac432d803493e882af56dc9654ec2_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMS0xLTEtMA_5e6b6aa0-e172-4720-8cc9-1d5965c7728e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232ac432d803493e882af56dc9654ec2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMy0xLTEtMA_d3b93c6f-4e3e-44a0-a97c-50beb7a4bb39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf6a615e6ae547058117f5e18a5dba6d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtNS0xLTEtMA_47004e59-b027-45c6-8ccb-707df1433dab">10,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6a615e6ae547058117f5e18a5dba6d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtNy0xLTEtMA_f60bdf57-b22e-4b67-b8c9-5895fdea2cfa">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588195ddb3e14a50b4ad59be6d72d358_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtOS0xLTEtMA_4f5a7d47-5fa3-4634-95f0-f67205a828d6">438,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97509a62a4a4419bb9b6e60ac0a55a5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTEtMS0xLTA_0044f295-d93d-4d56-99e1-951d8e52fd18">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef01373193f4f92b43d3255e62c34e9_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTMtMS0xLTA_ba90fafb-1178-4b21-a90b-4dff6f5c11ef">417,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e147676a9d347cdb2e16b52523ff885_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTUtMS0xLTA_206e8590-6f64-407f-81fd-0f7cbee14277">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0536559cd0b54911a2cea21fc56aed37_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTctMS0xLTA_668e5d40-3069-4520-bb9a-cc6ce1ee7089">20,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c07dd6e75a243069a60c6bf7db68018_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTktMS0xLTA_af8b1412-6cfc-4c47-837b-6d6ea1ae9bcc">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3d95bdf08242159f078fb83657a19d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMjEtMS0xLTA_8c07bb74-5662-4936-99ea-77942eb62003">20,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ea27c84c39b4c3ca91f6aaa91387695_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMTMtMS0xLTA_622f9746-84b7-4e6b-be81-6087f18c640a">3,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMTctMS0xLTA_e5efa92d-87af-4dc3-a64d-d6c302289f41">3,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebefcd2c95f49fdb51cf02aeec47cce_D20200101-20200331" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMTktMS0xLTA_883f6945-898f-44a9-9b5e-2b101409ca34">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMjEtMS0xLTA_1614e110-dabc-45fb-924a-bd1b0fa57db7">3,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe4eeca0cde7433db812f696fe9f6f5b_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTYtMTEtMS0xLTA_5f1dcdf3-c9e1-45c2-9805-f9d7c16ed81c">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTYtMTctMS0xLTA_93a866da-937e-42a2-95e7-68d1b9bb8802">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTYtMjEtMS0xLTA_d876af24-eeba-4f88-a415-725118054b44">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d385d56f17c46bba3c7db051eabde22_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctNS0xLTEtMA_71dd9703-cd6b-4449-a52e-e9e7cbc60372">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f829607cf341adad7ed6ed97c8e4b9_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctOS0xLTEtMA_f7bffc65-d756-485a-ab2e-eb5e482ab587">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctMTctMS0xLTA_5293b707-3e9b-43ad-9e21-6d880e3b6619">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctMjEtMS0xLTA_12b5d91e-4696-496f-a1e2-b70d203789d1">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25f1c3ec495342668f144f3ae1f669b6_I20200331" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMS0xLTEtMA_cbbe42cf-088a-4d85-813e-c14bad326c9b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f1c3ec495342668f144f3ae1f669b6_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMy0xLTEtMA_32e0aeda-f2d4-447d-b9e1-c4ff67e1ee30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia15c0e3aae5c4517a60ff1bf682aa1ab_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtNS0xLTEtMA_0341bec0-6d0d-4eb1-9c46-bb3c008a8dd2">10,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15c0e3aae5c4517a60ff1bf682aa1ab_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtNy0xLTEtMA_396b7b5d-7b5b-45b5-8c59-1774e1554f3c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17df6bc95b14a6a91bd4d7107a927f7_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtOS0xLTEtMA_0bfa5a27-7cc5-4f62-8d0c-8e38c2fad4d3">439,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ecb9460cf04d2b971feeef71d2b6e7_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTEtMS0xLTA_1d74ae62-795f-4ba8-9f49-4aedcebbf696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic47c3d63fff74ae6a6360be7e478b1be_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTMtMS0xLTA_79849689-0fbd-4374-895b-b60b7ea2bdad">421,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic572abd8348545418bc389f5eda0860b_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTUtMS0xLTA_9fb5ba33-90f7-4741-b490-416136689c08">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d643ab02b0d434e8d777c9ea8ed75d8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTctMS0xLTA_761c64dd-697f-40e6-b85f-dbaf7aafc9a9">17,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd979cbd8b84bbb887c9f1f556f8f9e_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTktMS0xLTA_96096bac-d9f1-4007-a113-fffe02da4ba7">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264a67c0128540ff86e03277435eec08_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMjEtMS0xLTA_c78a0d60-dc85-4a66-b67a-598a99c400f4">16,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMy0xLTEtMS0w_b4226d97-3a30-4940-8ef6-60a6d2025a84">8,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMy0zLTEtMS0w_4f8e02d7-7969-4f9c-803f-26d1ad5e150f">3,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNS0xLTEtMS0w_1726db03-33a1-4cf7-83e4-e7efeaaf6ac4">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNS0zLTEtMS0w_b6be021f-0ff5-4797-8c29-64ab56820c85">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNi0xLTEtMS0w_cc311b4d-d12a-4af7-beb3-9449d1f79b3e">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNi0zLTEtMS0w_75257900-41e7-4bc4-98f2-fadfba406ea8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfOS0xLTEtMS0w_2acc15fb-a895-4775-a30f-43dba1ba2677">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfOS0zLTEtMS0w_cadd47d1-5ae6-4dd2-986c-60ac5e2cf956">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTEtMS0xLTEtMA_6bf1c351-2381-4556-a8d3-e0abe9be1330">1,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTEtMy0xLTEtMA_53fede75-2d65-4a64-af5a-75016a231670">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTItMS0xLTEtMA_209337e2-ca9a-4d58-942b-286f7b5e17e1">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTItMy0xLTEtMA_61e28391-cb9b-4401-9f39-a75136c5b265">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTMtMS0xLTEtMA_fe3f4b86-3693-480e-a80d-4527ebdbb93f">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTMtMy0xLTEtMA_5cfc6acb-bfae-46cd-911b-7423a5480c51">1,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTQtMS0xLTEtMA_55d47302-c464-4b5b-977b-75768cc6d4af">7,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTQtMy0xLTEtMA_059f9474-b69b-4b52-b8ed-7805189207ba">4,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTYtMS0xLTEtMA_f45d5e73-3cc4-46f1-9699-1fe8bd155a5d">75,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTYtMy0xLTEtMA_a313fd09-18d3-4dbc-bb0f-53406072b094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTctMS0xLTEtMA_7522838e-8d82-4063-95c4-1f6c8b6b0eed">10,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTctMy0xLTEtMA_1bf77231-ecdf-4019-8ff6-131d5e4d38d7">11,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTgtMS0xLTEtMA_6b45bb08-97d8-461b-b69f-8e5803c067bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTgtMy0xLTEtMA_69d00542-7c6b-4ddb-8358-207c30461259">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTktMS0xLTEtMA_d35ad3a9-7553-4e85-a951-cfeb4fbf0ff5">65,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTktMy0xLTEtMA_9b84a8c8-9dfd-4813-a4c3-0f94bbb6e8e4">11,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjEtMS0xLTEtMA_ac8eb878-3323-4b98-8fbf-4d334d7cf61f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjEtMy0xLTEtMA_4f006d2e-2dc4-430d-9eef-a2b06292fe1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjItMS0xLTEtMA_afd0a0cf-8fe4-4d46-8df5-8725227ab143">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjItMy0xLTEtMA_87e9c4c5-661f-4a8a-bd9d-f692b84623cd">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjMtMS0xLTEtMA_91ad30c2-88e7-431e-8190-16116562d541">85,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjMtMy0xLTEtMA_b18c3b43-7d41-475e-b36d-172b88de7381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjUtMS0xLTEtMA_bd028cc9-546f-4f30-a9c5-46df9ccab533">85,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjUtMy0xLTEtMA_ba3d6af8-4d9c-4274-a547-ad92779fb91d">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjYtMS0xLTEtMA_10722c29-2e97-437b-83a3-d0b5194c4203">12,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjYtMy0xLTEtMA_3f98ba66-741f-4c03-b75c-525b1e88f9ed">6,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjctMS0xLTEtMA_e3099261-422f-45b7-a4ab-67c6d8c2cf3d">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3d95bdf08242159f078fb83657a19d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjctMy0xLTEtMA_d19a916f-c43c-41e2-9dff-049e1563e206">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjgtMS0xLTEtMA_49f6a35f-42e5-496b-bf35-614e828c4604">28,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264a67c0128540ff86e03277435eec08_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjgtMy0xLTEtMA_b2b8d01c-8292-4f9d-a3bc-06a9a28fc59a">20,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="clbs:BusinessTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMTE5NTQ_413f9ec7-bdb4-4313-adfe-8d97dfec80bb" continuedAt="i32168d059887447395f0f75223b42dc3" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="i32168d059887447395f0f75223b42dc3" continuedAt="ie77d5b31e01248fab943f993ac8677a1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; "our," &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b (FREEDOM) study in the U.S. for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease based on the results of an ongoing clinical trial and recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration ("FDA") for Buerger's disease; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis diabetic kidney disease (&#8220;DKD&#8221;) and OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS14), a Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designated Phase 3 ready therapy for treatment of no-option refractory disabling angina (&#8220;NORDA&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34 Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a stem cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is a stem cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34+ cells, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology including but not limited to CLI, CMD, DKD and NORDA.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's randomized and open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI has shown strong results to date. The initial responses observed in the subjects who have reached an endpoint in this open label study are consistent with a positive therapeutic effect and safety profile as reported by previously published clinical trials in Japan. The study's enrollment continues to be slowed by the COVID-19 pandemic's impact in Japan, however, the Company is encouraged by the patient pre-screening pipeline and continues to make progress towards study completion, the exact date of which is impossible to predict given the continuing impact of COVID-19 on clinical trials like ours in Japan. While the final outcome of the trial will depend on all data from all subjects, data, to date, are very encouraging.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS16 for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $<ix:nonFraction unitRef="usd" contextRef="icdcbdf98a7ca4a708730bbebd3ba7714_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM0Mw_ac316321-7daf-49dd-8306-1e895f478ea8">1.9</ix:nonFraction>&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for CLBS16 for the treatment of CMD, a disease that afflicts millions of patients with no current targeted treatment options. That study, the ESCaPE-CMD trial, was a Phase 2a proof-of-concept study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. That data set showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Questionnaire score, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM trial of CLBS16 as a therapy for CMD. The first patient in the study was subsequently treated in January 2021 at The Christ Hospital Health Network in Cincinnati, Ohio. This 105-patient double-blind randomized and placebo-controlled </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><ix:continuation id="ie77d5b31e01248fab943f993ac8677a1" continuedAt="i68f78c232d1e4925a4328d43df8bcb0e"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial (FREEDOM Trial) is designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. To the Company's knowledge, this is the first controlled regenerative medicine trial in CMD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared an initial development plan for the clinical study of CLBS201, a CD34+ investigational product for administration into the renal arteries to slow the deterioration or reverse the decline of renal function in patients with diabetic kidney disease ("DKD") who, although at a pre-dialysis stage, exhibit rapidly progressive disease. Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. A Phase 2 proof of concept, randomized, placebo-controlled study is planned for initiation in the second half of 2021. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of No Option Refractory Disabling Angina</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired the rights to data and regulatory filings for a CD34+ cell therapy program for refractory angina that had been advanced to Phase 3 by a previous sponsor.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the clinical evidence from the completed studies that a single administration of OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, this product received Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation from the FDA. The Company continues to seek an agreement with the FDA on the design of a Phase 3 study of appropriate and practical size and scope which, in combination with previously filed Phase 1, 2 and 3 data, will be considered for the registration of OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notably, the RMAT designation affords the product a 6-month review time for a biologics license application ("BLA"), once submitted. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot be reasonably estimated at this time. In response to the pandemic, the Company has implemented universal work from home as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan has experienced significant delays in enrollment due to the &#8220;State of Emergency&#8221; that was in effect for most of 2020 in response to COVID-19, and which was re-implemented on January 7, 2021 through March 21, 2021, and again on April 25, 2021 through May 11, 2021 covering Tokyo and other regions.  This most recent reinstatement of the &#8220;State of Emergency&#8221; continues negatively to impact enrollment of the on-going clinical trial. </span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM1Ng_bb65aa71-18d2-4755-94bb-2e2489207dc4" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2021, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2020 and 2019 included in our 2020 Form 10-K. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><ix:continuation id="i68f78c232d1e4925a4328d43df8bcb0e"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM1Nw_5bd75421-7ab6-4650-a14e-b91578b01335" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM1OA_3ba16252-86a2-4604-b9ca-0a4641e3407e" continuedAt="ibfd185c92a524458858c5b05b7434142" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibfd185c92a524458858c5b05b7434142">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA0OQ_9afe24e4-831c-4046-becf-5fd6fe1b22d8" continuedAt="i4249a2f5ef43491b96da78775abe7188" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i4249a2f5ef43491b96da78775abe7188"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2020 Form 10-K. There were no changes to these policies during the three months ended March&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA0MQ_eecbf0c3-b59a-47c2-a2a3-27392313a58f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA0Mg_9098c289-5e71-4a77-addb-b4826cbb6d15" continuedAt="ib241feb784f1497785e5374eef632519" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></ix:nonNumeric></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib241feb784f1497785e5374eef632519">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.</ix:continuation> </span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA1MQ_9653f0f1-cb80-4550-8739-357a07c9d40e" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses, which will require companies to present assets held at amortized cost and available for sale debt securities net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. The guidance was effective for fiscal years and interim periods beginning after December 15, 2019 and adopted January 1, 2020. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company determined that the adoption of this new accounting guidance did not have a material impact on its consolidated financial statements and footnote disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjM4_3c2a691b-9b72-4734-89de-bc4283f4e688" continuedAt="ic363413087ed4439b18286e7bc68dd60" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="ic363413087ed4439b18286e7bc68dd60"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjMz_3bfebec0-0ec4-4594-ac95-4de53dc2d875" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xLTEtMS0w_6b20f5d4-76d9-4069-9925-f863acc21973">59,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0zLTEtMS0w_240ffe9b-b8b1-42e7-bd48-721f35151a18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy01LTEtMS0w_287ee465-3e9d-4ece-a782-f6dbb7f33b93">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy03LTEtMS0w_f239dc34-507e-4215-b9be-ff7c3f0c01c3">59,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy05LTEtMS0w_3cd392d6-c182-4ae9-b6ff-77c4bc946f95">8,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xMS0xLTEtMA_b5ad5fae-84d1-43fc-9913-b455b0a06de3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xMy0xLTEtMA_5e5e84b1-ebe6-4cce-8f6e-b15cb816f86c">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xNS0xLTEtMA_7461db66-ec33-444d-8ccb-51f655d6716e">8,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xLTEtMS0w_43b425d3-438b-4fa5-a871-60708218d47b">18,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0zLTEtMS0w_75e7c1ef-f19f-437e-9060-c06fcf40a562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC01LTEtMS0w_49c44727-9e0f-46ae-b4b2-5127084aa8a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC03LTEtMS0w_88e59384-e863-4561-b3d3-6e1a3cdc5e07">18,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC05LTEtMS0w_07de9124-68f1-4164-946e-6e6b74c56abb">7,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xMS0xLTEtMA_e3f26116-1a5e-4304-9368-18a04761ddb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xMy0xLTEtMA_d23c5ee5-07e0-4dd2-9ab0-c0006e3f4bc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xNS0xLTEtMA_842fb8be-e346-4e76-87f6-a67ef47edd51">7,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xLTEtMS0w_1f1b3c92-4114-4beb-a085-336661aadb2a">29,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0zLTEtMS0w_45ab07fc-af8f-4c9e-9ec3-f2f49345314f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS01LTEtMS0w_0e7d4766-879a-462f-9a95-42f5e30ec199">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS03LTEtMS0w_9c6ad385-2786-41c8-a2ee-2f2cad8018ab">29,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS05LTEtMS0w_6ffd6a7a-d1f2-4a54-9591-2805ec5325bf">14,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xMS0xLTEtMA_6fc0e4b3-c825-41f4-8794-f4bd2aa48014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xMy0xLTEtMA_9247c421-c4fe-418f-a825-ecd66f11dffc">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xNS0xLTEtMA_b8cf9664-8d68-4b77-aadd-d61123f756c2">14,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xLTEtMS0w_6bb7a8a5-d086-4709-869d-e23704f49714">106,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0zLTEtMS0w_77f1a5df-68b4-43d1-903c-ad7d2e6555dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy01LTEtMS0w_d5adae8c-865b-4c53-ba30-d8452b8235fa">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy03LTEtMS0w_267ae3d3-5e0d-4e94-9036-ff8519951fcb">106,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy05LTEtMS0w_81c31b8c-a86d-4d21-8167-ee0ad42ac2bb">30,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xMS0xLTEtMA_9e0f5dfa-d4ce-4131-a597-8f1853db8d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xMy0xLTEtMA_15442427-5ca4-44da-b25b-1db172b5fad7">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xNS0xLTEtMA_823d0d36-96d8-4c1f-a0a4-041244994e50">30,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjQw_56717076-1ab7-420d-8228-d3bb123833e4" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMS0xLTEtMS0w_9021d163-7159-46bf-9abc-3a216b75c71b">24,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMS0zLTEtMS0w_46adbe8e-b87a-414f-9b12-7aba0ef44b7c">12,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMi0xLTEtMS0w_457ab04d-3b3d-4769-b7f6-c4671c2686ff">82,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMi0zLTEtMS0w_c87b93a8-25dc-4e03-8821-f46791b2797d">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMy0xLTEtMS0w_7c40408e-755a-46df-9266-8802a0e6710f">106,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMy0zLTEtMS0w_45803ad6-300f-45ae-a112-bbee1ad38960">30,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjM2_444f6433-c287-4084-b872-85b6d958cf52" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMi0xLTEtMS0w_534b3e62-3eb1-4f33-94ff-7f123ef9f84e">106,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMi0zLTEtMS0w_fc84d239-3a00-4ffa-a820-08845050b74e">106,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMy0xLTEtMS0w_0492e532-00d1-4f84-9fbd-306c86d9ea40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMy0zLTEtMS0w_98a2fa6c-84e5-41ef-8666-a1b830629b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfNC0xLTEtMS0w_907c8b1a-a019-4e35-8567-5c1366232768">106,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfNC0zLTEtMS0w_9a788a17-0037-4249-b007-0d8544201256">106,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_46"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RleHRyZWdpb246Yjg3MDFmZjg1MWU0NDQyYzk1NThlNDAwNWFkNTk4YjRfMzI5_9987b041-e53b-48f6-894a-7614c8ef8578" continuedAt="i8a76039b4c1d41d58abea056a9a5826d" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="i8a76039b4c1d41d58abea056a9a5826d"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March&#160;31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive.  <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RleHRyZWdpb246Yjg3MDFmZjg1MWU0NDQyYzk1NThlNDAwNWFkNTk4YjRfMzIz_11d0bd0e-762a-4aa4-ade4-00912dbb288f" continuedAt="ifcbaad97c18b470ca79583be35d0b17b" escape="true">At March&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ifcbaad97c18b470ca79583be35d0b17b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i499338433b98478ba449207f9bded52e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMi0xLTEtMS0w_7d46d379-b9c6-4c84-a049-9a1423cc1ded">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i777bc9631ae24b4aa509c6ab60a91a57_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMi0zLTEtMS0w_27cfc6ab-7a46-46a1-b7a7-2252c2986b06">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24b54c799369442588b92ab156347688_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMy0xLTEtMS0w_52a74fdb-3506-475a-9491-70d265ba08aa">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa3f2806d8764f13bec22b3ff8cf87ed_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMy0zLTEtMS0w_088196a5-1867-426a-9e84-085cf0c54df8">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccdb907e20cf4c1b9603607b2905156a_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfNS0xLTEtMS0w_eac6bec1-0e16-4719-81d8-69c5a70d644f">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i132ae7e2b40f4aacbfb45d310a8825e2_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfNS0zLTEtMS0w_53bdbaef-8c75-43de-b37b-ade7248a89de">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4b25ca7d61014564ad831413af96ade6_49"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RleHRyZWdpb246OWNiZDkzNDQxMzA5NDgyZTk0M2I1ODVkYzBjNGMwZTdfMTQ4MA_c2fa7981-85b1-4f34-9afd-346745e42e4a" continuedAt="if5880aece5724b7eb1dbac686fb1196a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="if5880aece5724b7eb1dbac686fb1196a" continuedAt="id52a3f6f7dd94f2da92569565efc87fb"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><ix:continuation id="id52a3f6f7dd94f2da92569565efc87fb"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RleHRyZWdpb246OWNiZDkzNDQxMzA5NDgyZTk0M2I1ODVkYzBjNGMwZTdfMTQ3OQ_2c934a49-b241-4f1e-9e99-4b644975de18" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of March&#160;31, 2021, and December&#160;31, 2020 (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:115.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffea5c40fbc940929f1156d78435b50f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0yLTEtMS0w_75c5309c-4c44-475b-b6cb-bb749d10609f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9f9eb3437d453dbe79a9bff47d7f5f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy00LTEtMS0w_1cc2e1f2-61c1-4222-bb6b-7a3e70d9e89e">82,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bdf6d06fccf49ae9869c434a423e19b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy02LTEtMS0w_faf662b5-6766-42f5-8340-7b2b4b6ea999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4537dc4974b74981b566969155de0b54_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy04LTEtMS0w_a623f33e-6d04-4912-b191-a13b813925be">82,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25ae7a16882454a89235836a00c085e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xMC0xLTEtMA_32285f74-382b-42ad-bef7-7bcc4cab39d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0034e259507451381d712e51c59a110_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xMi0xLTEtMA_7e60c333-e43b-404d-8590-22fcd537db3d">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17695a58a11c417395bec355c88d7fdf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xNC0xLTEtMA_324ae6e7-812c-4b23-988f-e6cfcaeb162e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad507469e2c44e1c81b999fe3754c26f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xNi0xLTEtMA_f5903afd-aaca-42df-8a67-01cbb271f75f">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffea5c40fbc940929f1156d78435b50f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0yLTEtMS0w_15e0b763-2264-46bd-9e75-d98de1f65bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9f9eb3437d453dbe79a9bff47d7f5f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC00LTEtMS0w_97e2f185-ea07-4b84-9797-db188f4fe4b2">82,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bdf6d06fccf49ae9869c434a423e19b_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC02LTEtMS0w_9a8ca122-2055-4789-b312-5eb0b3dc3790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4537dc4974b74981b566969155de0b54_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC04LTEtMS0w_e49a98c1-be15-493c-b4d5-90489e7fa0a1">82,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25ae7a16882454a89235836a00c085e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xMC0xLTEtMA_9d053b38-e675-4379-ba89-e9aa94191a56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0034e259507451381d712e51c59a110_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xMi0xLTEtMA_d48bbfa1-829e-47a9-b7f2-5dd99d3c0d5c">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17695a58a11c417395bec355c88d7fdf_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xNC0xLTEtMA_107e79d5-b5f0-4ebf-8d2d-2c94b271b7f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad507469e2c44e1c81b999fe3754c26f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xNi0xLTEtMA_4cf1c444-ab54-4232-8223-1f150d785fef">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6&#160;&#8211;&#160;<ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RleHRyZWdpb246YTNhN2JkOWQ1ZjI2NDc4YjgyOGM5OTQyMTRhZWZjMmFfMTEy_b36dacd7-964b-453a-b7b3-d42ada1ad2f9" continuedAt="ib352cafbcacb463f9f2302083c78a44a" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="ib352cafbcacb463f9f2302083c78a44a"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RleHRyZWdpb246YTNhN2JkOWQ1ZjI2NDc4YjgyOGM5OTQyMTRhZWZjMmFfMTA5_a4e9579d-426b-43b7-bb19-bcac54fa8df4" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMS0xLTEtMS0w_86a3282f-2006-4fae-8247-47333011aa55">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMS0zLTEtMS0w_f867340d-bb14-4f2e-89c4-366a89a1bc31">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMi0xLTEtMS0w_4b39aad6-5731-474f-9bf5-c64779838458">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMi0zLTEtMS0w_98b180b6-cc27-4465-b9b0-e0a75d938d6d">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNC0xLTEtMS0w_e27359e7-cb2a-40f2-9d9b-1f737a1fba37">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNC0zLTEtMS0w_e22e7ffe-ad1e-4c15-af3c-24622ee499ca">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNS0xLTEtMS0w_7e27e4c5-8e98-4c47-8322-62056c939aef">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNS0zLTEtMS0w_0144c040-52e1-4b49-aafb-6316ee762168">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7&#160;&#8211;&#160;<ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTE2Ng_0bd4d968-f171-4d01-b333-13357d6c48a3" continuedAt="i6d9d3aa7365048d6b5a2f7bfcf3a0d23" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="i6d9d3aa7365048d6b5a2f7bfcf3a0d23" continuedAt="ia673b5c311b34302bca677735b56ee7a"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for <ix:nonFraction unitRef="office" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="clbs:NumberOfOfficesUnderOperatingLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfNzA_c0a023f1-3410-45c2-9388-0370e44cefe8">two</ix:nonFraction> offices with terms that expire in 2022 and 2023. The Company estimates its incremental borrowing rate, at lease commencement, to determine the present value of lease payments, since most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases include options for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTE3MA_c9670a3e-f503-4c11-8b69-22bac041456d" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9e8e338fc54edf89217db73847c29b_I20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMi0xLTEtMS0w_831d37f2-bac1-4acc-80ff-c2561f0894f0">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a96d4091904e6b919d8e86339a5d99_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMi0zLTEtMS0w_e504fa11-e47e-4420-8eba-71c0bd2ac665">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMy0xLTEtMS0w_17151964-699c-425a-90a5-f39bf6cbf533">492</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMy0zLTEtMS0w_593939c1-3656-4e6b-8199-4e7c43e6c0bd">574</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ced2f706c534f1d91b7bc6ba399fe9f_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNi0xLTEtMS0w_f7ab5bd9-cce9-435b-81fc-57e1a208be5c">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b76807e468541f4b8af73ed9c91b2fd_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNi0zLTEtMS0w_4462307c-a878-4f1d-a7e8-f743dab354fd">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e538a949044dd7ac2e7157cd069c22_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNy0xLTEtMS0w_e16e5780-b2fc-4cb6-a1bd-e91a8dcc6bb6">155</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa95386fd914df2ab6e70d41a0648dc_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNy0zLTEtMS0w_30c90d75-f152-4857-a689-6a9d51b584ff">254</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfOC0xLTEtMS0w_1d564fa0-61a3-4b37-bd6e-6a3f87ce5537">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfOC0zLTEtMS0w_2c3c114b-7726-4e31-9e18-efd6d84deec5">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the weighted average remaining lease term for our operating leases was <ix:nonNumeric contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfOTg4_b5569f45-7a31-45f8-8536-39ed4d81b871">1.6</ix:nonNumeric> years, and the weighted average discount rate for our operating leases was <ix:nonFraction unitRef="number" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTA2MA_e316d6f6-01b5-422c-91f4-115a2af043d5">9.625</ix:nonFraction>%. <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTE2NQ_960c4365-ab2c-40d1-acf2-df0e1a532294" continuedAt="i94b298dcd7894ec9abf1cf202a0e5106" escape="true">Future minimum lease payments under the lease agreements as of March&#160;31, 2021 were as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="ia673b5c311b34302bca677735b56ee7a"><ix:continuation id="i94b298dcd7894ec9abf1cf202a0e5106"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfMy0xLTEtMS0w_f91808d5-667f-43b8-9488-2b778d325156">312</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNC0xLTEtMS0w_58b3dfcb-ae1e-4b16-8dc4-369c26857ff4">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNS0xLTEtMS0w_e840811b-2e33-4100-bb43-35d9d0bd3c98">27</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNi0xLTEtMS0w_adb2927c-2191-484e-bc28-98e892aaec2e">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNy0xLTEtMS0w_9a863c2b-f62f-4e0a-b7c7-38f457a147f9">42</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfOC0xLTEtMS0w_2b1fdaf5-5c97-4376-91c8-feec518aace0">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_58"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTEwNQ_bb0c9b07-2a81-4f57-ab83-2452318effcc" continuedAt="ie29eee6995944667bb94230c6316abc8" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ie29eee6995944667bb94230c6316abc8" continuedAt="i93eb95b91537424691db98d5919b0a1c"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="-5" format="ixt:numdotdecimal" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDMw_95bdfe17-a4d8-4325-9178-4df2f6502086">26.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional <ix:nonFraction unitRef="shares" contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331" decimals="INF" format="ixt:numdotdecimal" name="clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNjQy_36c06b2c-6804-4c46-ac0f-5d87599c0acf">181,510</ix:nonFraction> shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, Lincoln Park purchased <ix:nonFraction unitRef="shares" contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNzUx_5f7a4a98-cf4d-4490-9589-e02da2e385d8">250,000</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNzky_6545f8d8-f03f-4bb6-8e2e-cc4ccbd6b08d">4.00</ix:nonFraction> per share, for a total gross purchase price of $<ix:nonFraction unitRef="usd" contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfODQy_f0a591be-5f09-4324-b019-d2fb221c1c4f">1.0</ix:nonFraction> million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the <ix:nonNumeric contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331" format="ixt-sec:durmonth" name="clbs:TermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTAyMA_83ce69db-8f4b-49f5-916d-4d35bf487c7e">36</ix:nonNumeric>-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to <ix:nonFraction unitRef="shares" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="INF" format="ixt:numdotdecimal" name="clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTIwNQ_8202e7ca-d850-4b79-a23a-62d316997471">100,000</ix:nonFraction> shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $<ix:nonFraction unitRef="usd" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="-5" format="ixt:numdotdecimal" name="clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTM5OQ_7e104d7a-f46b-41bb-bd25-ab15844c4046">2.5</ix:nonFraction> million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTk0NA_de9c4cf6-6129-4a09-b694-44fd88aba1b7">300</ix:nonFraction>% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMjAzMw_5fe4689e-62eb-4cf8-96b6-ca87420e8741">30</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than <ix:nonFraction unitRef="number" contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331" decimals="4" name="clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMjkzNQ_eb60c461-aed3-4638-b3fd-d65fe94db757">9.99</ix:nonFraction>% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the <ix:nonNumeric contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331" format="ixt-sec:durmonth" name="clbs:TermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMzM0NA_83ce69db-8f4b-49f5-916d-4d35bf487c7e">36</ix:nonNumeric> months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Sales Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright&#160;&amp; Co., LLC ("HCW") as sales agent, which was subsequently amended in August 2018 (the "Sales Agreement"), in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock having an aggregate offering price of not more than $<ix:nonFraction unitRef="usd" contextRef="i1a98eb81842e4748b436585c87156f1a_I20180831" decimals="-5" format="ixt:numdotdecimal" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDA1OQ_1b38bd11-5b1f-49a0-98c3-7bbc1c27d2a1">25.0</ix:nonFraction> million.&#160;In&#160;March&#160;2019, subsequent to the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"), the aggregate market value of its </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><ix:continuation id="i93eb95b91537424691db98d5919b0a1c" continuedAt="i142f6bcbb6de46a685b75f80282479b5"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding common stock held by non-affiliates was approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ic03c497fe3a647068aff689400691742_I20190331" decimals="-5" format="ixt:numdotdecimal" name="clbs:AggregateMarketValueOfCommonStockNonAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDMwNQ_af103c7e-19b4-4e7b-8834-f6f0fa143784">52.8</ix:nonFraction> million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below&#160;$75.0 million at the time of its 2018 Form 10-K filing, the aggregate amount of securities that the Company was permitted to offer and sell at such time was reduced to $<ix:nonFraction unitRef="usd" contextRef="i253f4e81f39240bfa1478bea971064bb_I20190331" decimals="-5" format="ixt:numdotdecimal" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDYwNw_83ae2bcb-533a-4a4f-9a83-c68c1819b5da">17.6</ix:nonFraction> million (or a maximum of <ix:nonFraction unitRef="shares" contextRef="i253f4e81f39240bfa1478bea971064bb_I20190331" decimals="-5" format="ixt:numdotdecimal" name="clbs:SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTQxMA_9f50ecee-bb78-4d93-b025-de07f977087a">4.8</ix:nonFraction>&#160;million shares), which was equal to one-third of the aggregate market value of its common stock held by non-affiliates at such time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Sales Agreement, HCW will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon the Company's instructions, including any price, time or size limits specified by the Company. The Company has provided HCW with customary indemnification rights, and HCW will be entitled to a commission at a fixed commission rate equal to <ix:nonFraction unitRef="number" contextRef="i47215ddbef4645acbdcebd547430280c_D20180801-20180831" decimals="INF" name="clbs:SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNTE4Mg_b1aac8ca-2e0e-48dc-8c54-1bb7fb629ff4">3.0</ix:nonFraction>% of the gross proceeds per share sold. The Company has no obligation to sell any of the shares and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement. The Sales Agreement will terminate upon the sale of all of the shares under the Sales Agreement unless terminated earlier by either party as permitted under the Sales Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the Company suspended the use of the at-the-market transactions facility (the &#8220;ATM&#8221;) and terminated the continuous offering pursuant to the Common Stock Sales Agreement (&#8220;Sales Agreement&#8221;) entered into in February 2018 with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;). The Company will no longer make any sales of its common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of February 12, 2021, the Company had sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0bb45e4366f343b387c5ac5a70b7d93c_D20180201-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTA5OTUxMTYzODIxOQ_743c18e0-1a7a-427a-8255-6e349fbdddfc">3,784,912</ix:nonFraction> shares of its common stock pursuant to the Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0bb45e4366f343b387c5ac5a70b7d93c_D20180201-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTA5OTUxMTYzODMxNA_52a629a6-03fd-42c9-bcd3-e5277dabb974">9.5</ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2021, the Company had not issued any shares under the Sales Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registered Direct Offerings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Securities Purchase Agreement (the &#8220;Institutional Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Institutional Purchasers&#8221;). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of <ix:nonFraction unitRef="shares" contextRef="i14d5d5e90b62441eb1838b078677e72b_D20210201-20210228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTEzMg_0a88d037-9a3e-4b95-9e98-964f36bf627d">24,906,134</ix:nonFraction> shares of its common stock and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTEzNg_cd7c27c3-4a73-488b-8cf5-c2a498b1bf96">12,453,067</ix:nonFraction> shares of its common stock at a combined purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE0MA_6ed97e6f-2d26-4b07-8fcd-39abdf67be3c">2.45</ix:nonFraction> per share and associated warrant. Each warrant features an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE0NA_d7628e70-b6fa-42d6-b6d7-ca3e24067f8a">2.90</ix:nonFraction> per share, is exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE0OA_df55220d-dc49-4848-9389-5dad6dba8778">five years</ix:nonNumeric> from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the &#8220;Additional Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Additional Purchasers&#8221;). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5a8d0caecfc8478a9763718f92a1c601_D20210201-20210228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE1Mg_11c54233-4275-4e22-8183-599f5d5ae619">1,632,652</ix:nonFraction> shares of its common stock and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE1Ng_e55ef510-42f0-4140-aa11-3262e08c3088">816,326</ix:nonFraction> shares of its common stock at a combined purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE2MA_e7427f05-37d7-4dfe-8ca6-96fd6f1a7c49">2.45</ix:nonFraction> per share and associated warrant. Each warrant features an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE2NA_2889cb6b-6071-4054-ac05-ddfbce652154">2.90</ix:nonFraction> per share, is exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE2OA_a4740c97-1500-4c4f-a98f-630b398190d9">five years</ix:nonNumeric> from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="iaf4ed15255a740ccbc038f0987ef5f67_D20210201-20210228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE5OQ_4cd393d2-469e-4cc2-b7e6-fe4959d02fdc">65.0</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a securities purchase agreement (the &#8220;January Private Placement&#8221;) with certain investors (the &#8220;January Purchasers&#8221;). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5885d9e0c6b24703a32d31ff18fa6628_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTIzMQ_a9813351-e47a-4832-9d05-d5f1d9e099b9">12,500,000</ix:nonFraction> shares of its common stock at a purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTIzNQ_3223d088-3111-4841-940f-33cb0795d181">2.00</ix:nonFraction> per share, along with warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTIzOQ_64c08b44-ed23-4e0a-92bf-ae0d98ae3170">6,250,000</ix:nonFraction> shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5885d9e0c6b24703a32d31ff18fa6628_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTI0Mw_f3f6d06c-3c98-42a6-8484-dd83de8e8c80">25.0</ix:nonFraction> million. Each warrant is exercisable for <ix:nonFraction unitRef="shares" contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMjE5OTAyMzI4MTI5Mw_eaffa646-4ff2-42d4-a4f8-a905de534af2">one</ix:nonFraction> share of common stock and features an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTI1NA_3ccccdb8-a571-4c1f-bea2-1bebc5c192cc">2.90</ix:nonFraction> per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Exercises</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i7f840f3881574b5db5784970c5024047_D20210101-20210131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTMxMQ_d6acce42-cf1b-4fec-8342-599db90f1359">801,148</ix:nonFraction> shares of common stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7f840f3881574b5db5784970c5024047_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTMxNQ_46b0a821-e8cc-4e10-b412-d09e3ee8d1fd">1.8</ix:nonFraction> million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="i142f6bcbb6de46a685b75f80282479b5" continuedAt="ibf3183e230f14bae81fe67733e6696b8"><div style="margin-bottom:8pt;text-align:justify;text-indent:14.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTExMQ_a1b75155-c450-4fa1-a8c1-83bc5526b6c0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94c77a9975714e5bb66f65c196bcb6f9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0yLTEtMS0w_371316d3-bdc6-4bbb-90ab-c577866d57f9">963,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94c77a9975714e5bb66f65c196bcb6f9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi00LTEtMS0w_dce56923-f0d2-45d5-a7ac-4dd233e608da">14.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd25e43236aa4b5696a0696badf143fe_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi02LTEtMS0w_b2e6e69f-1cc0-4253-a313-d268b143ad40">5.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c77a9975714e5bb66f65c196bcb6f9_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi04LTEtMS0w_39aa9537-9251-4606-b2ff-1f2b65c0a20b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="INF" format="ixt:numdotdecimal" name="clbs:CommonStockWarrantsShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xMC0xLTEtMA_6e0fef69-87ce-49fa-b32a-081c8db503a4">2,638,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xMi0xLTEtMA_f88ff3cb-cce1-4eb6-bae8-0ee0597536c1">2.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if48a0e1d6f4147ebb6edcba9191e4ea5_D20200101-20200930" format="ixt-sec:duryear" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xNC0xLTEtMA_11c7c830-d1d4-49fb-9c8b-2838f8537694">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-3" format="ixt:zerodash" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xNi0xLTEtMA_48c67620-f97d-4d5d-aef6-c4fd3e139a01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS0yLTEtMS0w_7b01fba7-fd4c-467c-84dc-9948041ec623">155,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS00LTEtMS0w_1bf64067-726a-4ced-8960-d6bd609d6590">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="clbs:WarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS0xMC0xLTEtMA_98d0ff3d-92f6-4ab6-91de-54d7c42413b4">19,519,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS0xMi0xLTEtMA_75d044c8-6250-4037-85ba-c4569515204d">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi0yLTEtMS0w_ff508286-1679-429b-97b0-1352c392c621">7,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi00LTEtMS0w_082e797f-b597-4e5a-8ac0-7bf988367e30">3.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="clbs:WarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi0xMC0xLTEtMA_22f7184c-65be-4d42-8edf-4595dc788a4c">801,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi0xMi0xLTEtMA_ccdbb1c6-5900-4a1d-b942-38d39a507ac0">2.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy0yLTEtMS0w_8940b4cf-ffc4-4d0b-b994-42fd276eb7c3">7,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy00LTEtMS0w_cdc87b7e-1780-442f-bfa3-2effbdb5dc98">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="clbs:WarrantsCanceled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy0xMC0xLTEtMA_cb7ec573-7f9f-4303-b7f2-b2f080256b15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="2" format="ixt:zerodash" name="clbs:WeightedAverageExercisePriceWarrantsCanceled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy0xMi0xLTEtMA_f73b58c2-15eb-440f-b7d6-84176b1d41c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC0yLTEtMS0w_cd36951e-4d2b-4014-82fc-3203c4148165">82,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC00LTEtMS0w_5bc93522-9c7b-41c4-8184-730de12ff2e9">6.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="clbs:WarrantsExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC0xMC0xLTEtMA_c2587a7d-b668-47dd-bcd7-837b475ed7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="2" format="ixt:zerodash" name="clbs:WeightedAverageExercisePriceWarrantsExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC0xMi0xLTEtMA_310ad7be-a6c2-4f52-84fe-840a8110d253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0yLTEtMS0w_6d10354f-3d80-43ae-99f5-9fa7fb5838dc">1,022,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS00LTEtMS0w_c34e646a-1e85-4128-8509-ba79c8179a48">13.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS02LTEtMS0w_35476f8c-85fc-4aa2-a1b2-73bd4e184601">6.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS04LTEtMS0w_a2dd9348-86c4-4914-8280-c55c29a74e56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="clbs:CommonStockWarrantsShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xMC0xLTEtMA_70b74795-e94f-4b8c-a43e-aff562315c91">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xMi0xLTEtMA_eaa444a8-b1f5-41b5-b5aa-341344c0349b">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:duryear" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xNC0xLTEtMA_3cace20c-194e-4c43-ac12-528a594d0a6a">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xNi0xLTEtMA_1bf052d2-987f-4bf6-ba98-b826bb755033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMi0xLTEtMA_1c9ddccd-5149-495c-8a4b-e7cfd2ed6539">996,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtNC0xLTEtMA_6e1e23ba-2e6a-4b36-84f1-0e2d98074520">13.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtNi0xLTEtMA_e2b5d8a2-ed09-48ea-982d-31af87726662">6.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtOC0xLTEtMA_98e68e4f-267e-4813-b192-dc6ca9ad1645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="clbs:Sharesvestedandexpectedtovest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTAtMS0xLTA_e5b3f7c1-3052-44f3-896f-cf223dee6409">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTItMS0xLTA_d19c6967-089d-47a5-a32f-3091dfd2919e">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:duryear" name="clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTQtMS0xLTA_6c07569d-fd31-4072-b46e-9794156461ea">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTYtMS0xLTA_89885cb7-8b68-442e-8276-6b6c36aff54c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMi0xLTEtMA_4c429a52-e3a1-4d7a-a676-e39a69bc6711">765,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtNC0xLTEtMA_560c3277-4a76-4ddc-80e5-284d527f8cb6">17.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331" format="ixt-sec:duryear" name="clbs:OptionsVestedweightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtNi0xLTEtMA_172dd6a9-02fc-4dd7-a3b4-3eb08f35faa6">5.87</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtOC0xLTEtMA_e7ccc809-fd4b-479f-ae72-1935683e4850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="clbs:WarrantsVested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTAtMS0xLTA_2a5b82b2-39a0-4ef1-847d-4175bc82d7fc">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTItMS0xLTA_59fdb5ac-79f6-49ab-950c-245b00838354">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" format="ixt-sec:duryear" name="clbs:WeightedAverageRemainingContractualTermwarrantsvested" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTQtMS0xLTA_01c8c605-e02f-4b07-b5de-7ade0611aefa">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-3" format="ixt:zerodash" name="clbs:AggregateIntrinsicValueWarrantsvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTYtMS0xLTA_bd6c8add-cab7-4da9-9653-cda38a437992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTEwMA_953148b4-044b-4422-b4b6-ab1dfe8ad101" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMi0yLTEtMS0w_d8f7fce9-c277-4c41-ba76-db5b203a2ef3">300,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMi00LTEtMS0w_0751786b-48d0-4ac8-8834-fa38d1de9f10">156,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMy0yLTEtMS0w_a66fa4e6-c5bb-4b1f-99a8-149e6ce3b068">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMy00LTEtMS0w_1b6846ed-d947-490d-97b7-d5f6836e5edf">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTEwOA_2a55c60b-c9cb-4a64-9b9c-b508145317c1" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMi0xLTEtMS0w_211f0f28-5777-422b-b50c-b88a7a946ae4">458,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b7bf07503274c4ba141b5cbc1970f3f_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMi0zLTEtMS0w_4c1092ae-b74a-4252-a44c-52385b7d3294">195,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMy0xLTEtMS0w_e3b13631-9a46-4425-a54e-775ce0240293">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7bf07503274c4ba141b5cbc1970f3f_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMy0zLTEtMS0w_f3d8715c-4386-45f5-b03f-7302b5e3848c">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf3183e230f14bae81fe67733e6696b8">The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfODgwNA_70f88544-9759-4a28-81de-5e6e34f2da0f">1.59</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfODgxMQ_eabb3258-1070-455c-ad12-a2d377b83e6f">3.19</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNzE0NjgyNTYwMjE1Ng_0c31fc1b-9c94-449e-a978-63a5bfb25ab8">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones.</ix:continuation> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_64"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTEyOA_8bb24770-e7d2-4235-a97c-c66b65893420" continuedAt="iae5bca60c71c4db3a25805d94b51c66c" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="iae5bca60c71c4db3a25805d94b51c66c" continuedAt="ic561fd8f4e5c4310b21db83f057fcb84"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;<ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTE0NA_14bf722a-89d3-4a76-80db-c4ee68559da9" continuedAt="i57311aa7f59248b8bc6dd715dfd0fe5d" escape="true">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><ix:continuation id="ic561fd8f4e5c4310b21db83f057fcb84"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i57311aa7f59248b8bc6dd715dfd0fe5d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.490%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe5f0e3fd7141d6b7317b9c81f7225c_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMi01LTEtMS0w_e46a6b67-08d5-4c60-ac80-8999ad22d7e0">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb173d03e633477ead116cda9d9948a3_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMi03LTEtMS0w_a9097cd5-07f6-4ee0-9726-a99831c8271b">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eab163f6b9e41e5b784b249926dbd6e_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMy01LTEtMS0w_78572bf9-95cf-46fc-a8dd-53f824607730">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c54fa8f52bb4465a41b34646f8ffcce_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMy03LTEtMS0w_f25e15e4-5514-4fb9-bf80-6a8c91e973da">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfNC01LTEtMS0w_e2ff7a78-ab93-47f1-bcc4-2dfd4ceaa3e9">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfNC03LTEtMS0w_ac991d77-b17c-4eb2-afb6-f9e20aa7b10c">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTEzMw_afb40865-f55b-49c4-bb4e-ae28874cc5a5" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59d2dafdc848809ac87c686c29886a_I20210331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMS0xLTEtMS0w_f6ff72e7-0c86-452f-9664-d5eb19e95ae6">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e73ba2637749b6bbc62bc908b6e954_I20210331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMS0zLTEtMS0w_73a01229-de6c-4d75-acbc-f069a41f6159">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e428d7942a045c8984c14fda8656fa5_I20210331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMS01LTEtMS0w_a4e4f4db-6a8c-4655-8806-117fe6b98b42">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMi0xLTEtMS0w_0eccb091-bbae-4351-ab7d-6324292d78ea">1.82</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMi0zLTEtMS0w_a0867eef-9263-4738-8499-c9a6a4c8e9bf">1.39</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMi01LTEtMS0w_0eebd7bb-d84f-47a2-9094-f10a5e1ca92d">2.21</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTE1MQ_07eea1aa-77d9-4a91-a086-73d0fbddbf1e" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfMy0xLTEtMS0w_94964291-449a-44f4-b650-0cd356f21e46">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id723fbccd73440de8762bc38568bf063_D20200101-20200331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfMy0zLTEtMS0w_a3aa133a-a904-4ef1-a00a-0753c786e512">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfNC0xLTEtMS0w_15697a6a-9bd6-4189-862c-4294f81e71cc">1.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id723fbccd73440de8762bc38568bf063_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfNC0zLTEtMS0w_aa76bb64-d90d-46ae-9148-c8c421525dfc">2.16</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_67"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10&#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfMTM4Ng_fdea2e26-afea-4a1f-93f3-876d31a98556" continuedAt="i0ee2dadea45f4549b8dfac6c3448a6dd" escape="true">Research Funding</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i0ee2dadea45f4549b8dfac6c3448a6dd" continuedAt="ie6498fedd86548798b8b83494d1073bc">California Institute of Regenerative Medicine Grant Award</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie6498fedd86548798b8b83494d1073bc">In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded the Company funds of up to $<ix:nonFraction unitRef="usd" contextRef="ie43284901a884f78a402755fd3b41aaa_I20170228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfMjA0_20c54310-e55e-4d9e-afc2-3a80f15b88bd">12.2</ix:nonFraction> million to support the T-Rex Study. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $<ix:nonFraction unitRef="usd" contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNTM4_9aaeb504-395a-47f7-9f11-157bffb8f3c9">8.6</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="ib1905a146945439d89ff1228516dc50e_D20170501-20200930" decimals="-5" format="ixt:numdotdecimal" name="clbs:FundingOfGrantAwardCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNTUx_1ea07c99-d9b4-4a96-86b1-2002e600f11e">8.2</ix:nonFraction> million has been received through the grant project period completion. The Company received $<ix:nonFraction unitRef="usd" contextRef="iffe95d09252c410489923fdd656451ce_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="clbs:FundingOfGrantAwardCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNjM4_14bff649-b5d7-4da5-9a61-1951db8272c8">5.7</ix:nonFraction> million in initial funding in May 2017, a $<ix:nonFraction unitRef="usd" contextRef="i64d49bafd16540ef92725c78f1429358_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="clbs:MilestonePaymentOnGrantAwardCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNjc1_281b8172-e64c-41fc-958a-d9b24ff98281">1.9</ix:nonFraction> million milestone payment in December 2017, a $<ix:nonFraction unitRef="usd" contextRef="i7c059030f14c498b9bf58d821d59c031_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="clbs:ProgressPaymentOnGrantAwardCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNzE2_11c9511e-5b81-4907-8260-07f8605f743a">0.3</ix:nonFraction> million progress payment in March 2018, and a $<ix:nonFraction unitRef="usd" contextRef="icc32f1fee1574a39a7e75cd277331948_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNzU3_07dbb53d-a983-498d-b9a0-5436e16b2c3f">0.2</ix:nonFraction>&#160;million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $<ix:nonFraction unitRef="usd" contextRef="i619b7221c8b6420b9d72d12bbca2851d_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfOTcy_e7232224-4fec-40c6-b117-c6e93b327b85">46</ix:nonFraction>&#160;thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the three months ended March&#160;31, 2021 and March&#160;31, 2020, the Company amortized and recognized $<ix:nonFraction unitRef="usd" contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNDM5ODA0NjUxMzAwOQ_77762afa-61b3-4e97-8bbe-007d302222cf">0.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNDM5ODA0NjUxMzAxNw_e76f9f8a-ff47-4ee8-a180-e604501dbcf9">0.7</ix:nonFraction>&#160;million in credits, respectively, to research and development related to CIRM funds received.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_70"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfMzMyOQ_895637cd-60b7-46db-b044-00a88065890a" continuedAt="i2d7a540684674a419e07c3ff17636335" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i2d7a540684674a419e07c3ff17636335" continuedAt="ied893814cc6f493294755ad23d41f1f3"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i0023b178cff546c5a4ed4572f1675a89_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNTQ1Ng_31c54dd0-1588-44ce-beaf-8035c495b99f">264</ix:nonFraction>&#160;million of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;As of December&#160;31, 2020, the Company had State NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="i64fbc9ce8d824790bfc3e917a2bd92b9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNjA0Mg_1ad1242c-c1c1-4442-8d95-161b2ad8cfdf">99</ix:nonFraction>&#160;million, California of $<ix:nonFraction unitRef="usd" contextRef="ib20ab50a11fb4b0f89cb676e7cf79d61_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNjA2MA_88e390dc-ca15-41c0-90fb-0f65ee3864db">70</ix:nonFraction>&#160;million, and New York City of $<ix:nonFraction unitRef="usd" contextRef="i448dfa4c0bd046df85903ca8cc449d02_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNjA3OA_6e249e75-1413-46eb-90ab-ff405b54cc21">13</ix:nonFraction>&#160;million to offset future taxable income expiring from 2030 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><ix:continuation id="ied893814cc6f493294755ad23d41f1f3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2040. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an analysis and determined that they did not have an ownership change of greater than 50% over a 3-year testing period. The last ownership change was determined to be on June 3, 2015. Based on a market capitalization of $<ix:nonFraction unitRef="usd" contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231" decimals="-5" format="ixt:numdotdecimal" name="clbs:MarketCapitalizationUsedInNetOperatingLossAnalysis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNzE0NjgyNTU5MzY5OA_bcd26bd4-1b61-4fb9-b749-8de23bb9a448">125</ix:nonFraction>&#160;million and using an applicable federal rate of 2.5%, the annual limitation would be approximately $<ix:nonFraction unitRef="usd" contextRef="i60f0f64709a44444b6515aa9f4cba303_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="clbs:NetOperatingLossAnalysisAnnualLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNzE0NjgyNTU5MzY4NA_17992835-f4b2-4bba-a366-92d78a5fc373">3.0</ix:nonFraction>&#160;million. Post change losses generated after June 3, 2015 would not be subject to 382 limitations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2017, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_73"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83My9mcmFnOjE4NjMzMGJhN2E5NzQ0ZjNhNDJjOTljMjNmOWI1ZTAzL3RleHRyZWdpb246MTg2MzMwYmE3YTk3NDRmM2E0MmM5OWMyM2Y5YjVlMDNfNDM0_c6816782-8db7-4cbe-a903-cf4b18ea8a2a" continuedAt="i56b25cfa307f4c9a863c91447045dad1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i56b25cfa307f4c9a863c91447045dad1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2020 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2020 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; "our," &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. We are developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Our technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical development experience. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. Our current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b (FREEDOM) study in the U.S. for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease based on the results of an ongoing clinical trial and recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration ("FDA") for Buerger's disease; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis diabetic kidney disease (&#8220;DKD&#8221;) and OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS14), a Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designated Phase 3 ready therapy for treatment of  no-option refractory disabling angina (&#8220;NORDA&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34 Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a stem cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is a stem cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology including but not limited to CLI, CMD, DKD and NORDA.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our randomized and open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI has shown strong results to date. The initial responses observed in the subjects who have reached an endpoint in this open label study are consistent with a positive therapeutic effect and safety profile as reported by previously published clinical trials in Japan. The study's enrollment continues to be been slowed by the COVID-19 pandemic's impact in Japan, however, we are encouraged by the patient pre-screening pipeline and continue to make progress towards study completion, the exact date of which is impossible to predict given the continuing impact of COVID-19 on clinical trials like ours in Japan. While the final outcome of the trial will depend on all data from all subjects, data, to date, are very encouraging.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS16 for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $1.9 million grant from the National Institutes of Health (Award Number R44HL135889), we initiated our program for CLBS16 for the treatment of CMD, a disease that afflicts millions of patients with no current targeted treatment options. That study, the ESCaPE-CMD trial, was a Phase 2a proof-of-concept study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. That data set showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Questionnaire score, as well as an acceptable safety profile. The full data set </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio.  In December 2020, we commenced enrollment in our Phase 2b FREEDOM trial of CLBS16 as a therapy for CMD. The first patient in the study was subsequently treated in January 2021 at The Christ Hospital Health Network in Cincinnati, Ohio. This 105-patient double-blind randomized and placebo-controlled clinical trial (FREEDOM Trial) is designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. To our knowledge, this is the first controlled regenerative medicine trial in CMD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared an initial development plan for the clinical study of CLBS201, a CD34+ investigational product for administration into the renal arteries to slow the deterioration or reverse the decline of renal function in patients with diabetic kidney disease ("DKD") who, although at a pre-dialysis stage, exhibit rapidly progressive disease. Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. A Phase 2 proof of concept, randomized, placebo-controlled study is planned for initiation in the second half of 2021. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of No Option Refractory Disabling Angina</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the rights to data and regulatory filings for a CD34+ cell therapy program for refractory angina that had been advanced to Phase 3 by a previous sponsor.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the clinical evidence from the completed studies that a single administration of OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, this product received Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation from the FDA. We continue to seek an agreement with the FDA on the design of a Phase 3 study of appropriate and practical size and scope which, in combination with previously filed Phase 1, 2 and 3 data, will be considered for the registration of OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notably, the RMAT designation affords the product a 6-month review time for a biologics license application ("BLA"), once submitted. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot be reasonably estimated at this time. In response to the pandemic, we have implemented universal work from home as well as stringent social distancing and other hygiene policies for employees when they must be in the office. Our clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan has experienced significant delays in enrollment due to the &#8220;State of Emergency&#8221; in effect in Japan for most of 2020 and re-implemented in Japan on January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to increased number of COVID-19 patients. Due to recently reported large increases in COVID-19 cases in Japan, a renewed &#8220;State of Emergency&#8221; has been implemented again on April 25, 2021 through May 11, 2021. This newly reinstated &#8220;State of Emergency&#8221; continues negatively to impact enrollment of the on-going clinical trial.</span></div><div id="i4b25ca7d61014564ad831413af96ade6_82"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2021 Compared to Three Months Ended March&#160;31, 2020 </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $8.1 million for the three months ended March&#160;31, 2021, compared to net loss of $4.0 million for the three months ended March&#160;31, 2020. </span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021, operating expenses totaled $8.1 million compared to $4.1 million for the three months ended March&#160;31, 2020, representing an increase of 99%.  Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were approximately $5.1 million for the three months ended March&#160;31, 2021, compared to $1.5 million for the three months ended March&#160;31, 2020, representing an increase of $3.6&#160;million or 239%.  Research and development in both periods focused on the advancement of our ischemic repair platform and related to:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ongoing registration-eligible study expenses for HONEDRA&#174; in critical limb ischemia in Japan, whereby we continue to focus spending on our patient enrollment. We have experienced significant delays in enrollment in that study due to the &#8220;State of Emergency&#8221; in effect in Japan for most of 2020 and re-implemented in Japan on January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to increased number of COVID-19 patients as well as a severe shortage of beds in intensive care units (and other hospital beds) affecting all of our clinical sites. We continue to make progress towards study completion;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the proof-of-concept study for CLBS16 in coronary microvascular dysfunction, whereby study enrollment was completed in the second quarter of 2019 and full results reported in May 2020 and continuing efforts to advance our CLBS16 Phase 2b study (the FREEDOM study) which commenced in the fourth quarter of 2020 with the first patient in the study treated in January 2021; and</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the preparation of our filing of an IND for the clinical study of CLBS201 for Treatment of Diabetic Kidney Disease.  A Phase 2 proof of concept, randomized, placebo-controlled study is planned for initiation in the second half of 2021.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $3.0 million for the three months ended March&#160;31, 2021, compared to $2.6 million for the three months ended March&#160;31, 2020, representing an increase of 18%. Our general and administrative expenses focus on general corporate-related activities.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income is primarily comprised of investment income on cash, cash equivalents and marketable securities. </span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March&#160;31, 2021, we had cash, cash equivalents and marketable securities of approximately $111.5 million, working capital of approximately $109.6 million, and stockholders&#8217; equity of approximately $110.3 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;During the three months ended March&#160;31, 2021, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,241)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2021 was $8.0 million, which is comprised of (i) our net loss of $8.1 million, adjusted for non-cash expenses totaling $0.9 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $0.8 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2020 was $4.2 million, which is comprised of (i) our net loss of $4.0 million, adjusted for non-cash expenses totaling $0.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $0.9 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities during the three months ended March&#160;31, 2021 totaled $65.1 million and was primarily due to net purchases of marketable securities (net of sales of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the three months ended March&#160;31, 2020 totaled $11.1 million and was primarily due to net proceeds from sales of marketable securities (net of purchases of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the three months ended March&#160;31, 2021 primarily consisted of (i) net proceeds of $23.1 million through the issuance of common shares and warrants in our January 2021 private placement, (ii) net proceeds of $1.8 million in connection with warrant exercises, (iii) net proceeds of $60.6 million through the issuance of common shares and warrants in both of our February 2021 registered direct offerings, which was partially offset by tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the three months ended March&#160;31, 2020 consisted of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of biopharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements considering the assumption that any initiation of an OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 3 study is contingent on reaching agreement with the FDA on a study design of appropriate and practical size and scope.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we entered into a Securities Purchase Agreement (the &#8220;Institutional Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Institutional Purchasers&#8221;). Pursuant to the terms of the Institutional Purchase Agreement, we sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of our common stock and warrants to purchase an aggregate of 12,453,067 shares of our common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, we entered into a Securities Purchase Agreement (the &#8220;Additional Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Additional Purchasers&#8221;). Pursuant to the terms of the Additional Purchase Agreement, we sold to the Additional Purchasers an aggregate of 1,632,652 shares of our common stock and warrants to purchase an aggregate of 816,326 shares of our common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. The closing of the offerings occurred on February 17, 2021. In connection with the registered direct offerings, we received gross proceeds of approximately $65.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we suspended the use of the at-the-market transactions facility (the &#8220;ATM&#8221;) and terminated the continuous offering pursuant to the Common Stock Sales Agreement (&#8220;Sales Agreement&#8221;) entered into in February 2018 with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;). As of February 12, 2021, we had sold an aggregate of 3,784,912 shares of our common stock pursuant to the Sales Agreement for aggregate gross proceeds of $9.5&#160;million. We will no longer make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with certain institutional and accredited investors (the &#8220;January Purchasers&#8221;), pursuant to which the Company issued and sold to the January Purchasers in a private placement an aggregate of (i) 12,500,000 shares of common stock, and (ii) warrants exercisable for up to an aggregate of 6,250,000 shares of common stock at a combined offering price of $2.00 per share of common stock and associated warrant. The warrants have an exercise price of $2.90 per share. Each warrant will be immediately exercisable and will expire five and one-half years from the issuance date.  The closing of the offering occurred on January 25, 2021. We received gross proceeds of $25.0&#160;million in connection with the private placement, before deducting placement agent fees and related offering expenses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, we and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we have the right to sell to Lincoln Park shares of our common stock having an aggregate value of up to $26.0&#160;million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, we issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares. Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, we have the right, from time to time, at our sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $2,500,000, unless we and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;). If we direct Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, we may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of our common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, we may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day. As of March&#160;31, 2021, we had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that our operations are seasonal in nature.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2021, compared to those reported in our 2020 Form 10-K.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_91"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_94"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are the controls and other procedures we have designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Compliance Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Compliance Officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Chief Executive Officer and Chief Compliance Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer and Chief Compliance Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material changes to the disclosures previously reported in our 2020 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_103"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously reported in our 2020 Form 10-K. See the risk factors set forth in our 2020 Annual Report on Form 10-K under the caption "Item 1 A - Risk Factors."</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_106"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_109"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_112"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_115"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i4b25ca7d61014564ad831413af96ade6_118"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CALADRIUS BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:   President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Principal Financial Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div id="i4b25ca7d61014564ad831413af96ade6_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4b25ca7d61014564ad831413af96ade6_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:457.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000060/pipe20200710ex101.htm">10.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement, dated as of January 21, 2021, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K filed on January 25, 2021).</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000060/pipe20200710ex102.htm">10.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Registration Rights Agreement, dated as of January 21, 2021, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Form 8-K filed on January 25, 2021).</span></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000032/exhibit10120210212.htm">10.3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Institutional Securities Purchase Agreement, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K filed on February 16, 2021).</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000032/exhibit10220210212.htm">10.4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Institutional Additional Securities Purchase Agreement, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Form 8-K filed on February 16, 2021).</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex311_20210331xq1.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex32_20210331q1.htm">32</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:16.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:502.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>clbs-ex311_20210331xq1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3e34a63872b64a188a5490a74fff6b1f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>clbs-ex32_20210331q1.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i708d601035904ab3aefd55395ba67073_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2021 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;May&#160;6, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>clbs-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d9eba1cb-e72d-43c9-86c5-dbb9216f38d8,g:166abcdb-ccb3-45de-adfb-a1da6bb60890-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:clbs="http://www.caladrius.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20210331">
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>2101101 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessNarrativeDetails" roleURI="http://www.caladrius.com/role/TheBusinessNarrativeDetails">
        <link:definition>2402401 - Disclosure - The Business - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>2105103 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>2306301 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>2407402 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>2408403 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>2409404 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>2110104 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>2311302 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>2412405 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>2113105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>2314303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2415406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>2116106 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>2317304 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>2418407 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>2119107 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>2320305 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>2421408 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>2422409 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>2124108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>2325306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>2426411 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>2427412 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>2428413 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>2129109 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>2330307 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2431414 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>2432415 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>2433416 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchFunding" roleURI="http://www.caladrius.com/role/ResearchFunding">
        <link:definition>2134110 - Disclosure - Research Funding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchFundingDetails" roleURI="http://www.caladrius.com/role/ResearchFundingDetails">
        <link:definition>2435417 - Disclosure - Research Funding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>2136111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetOperatingLossCarryForwardDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails">
        <link:definition>2437418 - Disclosure - Income Taxes - Net Operating Loss Carry Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>2138112 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="clbs_IschemicRepairCD34CellTechnologyMember" abstract="true" name="IschemicRepairCD34CellTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_StockOptionsActivityAxis" abstract="true" name="StockOptionsActivityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="clbs_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" abstract="false" name="SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_PreferredStockSharesDesignated" abstract="false" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_NumberOfOfficesUnderOperatingLeases" abstract="false" name="NumberOfOfficesUnderOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="clbs_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" abstract="false" name="RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" abstract="false" name="AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_LincolnParkAgreementMember" abstract="true" name="LincolnParkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" abstract="false" name="SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_AggregateMarketValueOfCommonStockNonAffiliates" abstract="false" name="AggregateMarketValueOfCommonStockNonAffiliates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_January2021PurchaseAgreementMember" abstract="true" name="January2021PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" abstract="false" name="SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="clbs_ProgressPaymentOnGrantAwardCashReceived" abstract="false" name="ProgressPaymentOnGrantAwardCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_InstitutionalPurchaseAgreementMember" abstract="true" name="InstitutionalPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_PreferredStockLiquidationPreferenceShare" abstract="false" name="PreferredStockLiquidationPreferenceShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_StockOptionsActivityDomain" abstract="true" name="StockOptionsActivityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AdditionalPurchaseAgreementMember" abstract="true" name="AdditionalPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MilestonePaymentOnGrantAwardCashReceived" abstract="false" name="MilestonePaymentOnGrantAwardCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" abstract="false" name="StockIssuedDuringPeriodSharesIssuedAsConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_OptionsVestedweightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedweightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="clbs_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" abstract="false" name="MarketCapitalizationUsedInNetOperatingLossAnalysis" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_FundingOfGrantAwardCashReceived" abstract="false" name="FundingOfGrantAwardCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="clbs_NetOperatingLossAnalysisAnnualLimitation" abstract="false" name="NetOperatingLossAnalysisAnnualLimitation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" abstract="false" name="SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_H.C.WainwrightSalesAmendedAgreementMember" abstract="true" name="H.C.WainwrightSalesAmendedAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_UsEquityPlanMember" abstract="true" name="UsEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>clbs-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d9eba1cb-e72d-43c9-86c5-dbb9216f38d8,g:166abcdb-ccb3-45de-adfb-a1da6bb60890-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20210331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c6c93cc-4143-4f31-a924-6ba78e61f553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0edb30ab-95ab-4f19-b90e-914170053863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c6c93cc-4143-4f31-a924-6ba78e61f553" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0edb30ab-95ab-4f19-b90e-914170053863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_831a6c19-8c19-48d4-b36f-08729204da81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c6c93cc-4143-4f31-a924-6ba78e61f553" xlink:to="loc_us-gaap_CommitmentsAndContingencies_831a6c19-8c19-48d4-b36f-08729204da81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a4ede445-fdd5-422f-939f-c1b983224406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c6c93cc-4143-4f31-a924-6ba78e61f553" xlink:to="loc_us-gaap_Liabilities_a4ede445-fdd5-422f-939f-c1b983224406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d1a97a72-5c76-44d8-98cd-b0e7bb5047cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:to="loc_us-gaap_PreferredStockValue_d1a97a72-5c76-44d8-98cd-b0e7bb5047cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4cb2220b-82fb-4542-a219-6f1a8a58ea83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:to="loc_us-gaap_CommonStockValue_4cb2220b-82fb-4542-a219-6f1a8a58ea83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_021da273-8c74-420d-ad84-585f903b6f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:to="loc_us-gaap_AdditionalPaidInCapital_021da273-8c74-420d-ad84-585f903b6f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a91216f1-4877-407e-a168-90c57946880b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:to="loc_us-gaap_TreasuryStockValue_a91216f1-4877-407e-a168-90c57946880b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c29f102c-22d7-45f8-b5be-d42f1ff5ce78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c29f102c-22d7-45f8-b5be-d42f1ff5ce78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3facb6ec-563d-4393-a7ee-a4211cfbe2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_43fd7ce0-6e32-463e-8c04-c50b43b8b569" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3facb6ec-563d-4393-a7ee-a4211cfbe2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9c241bf-d267-4a2e-9ab6-a649df2b7d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2bb9c3b-de99-4f59-9089-6cb7b7b1e99e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c241bf-d267-4a2e-9ab6-a649df2b7d72" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2bb9c3b-de99-4f59-9089-6cb7b7b1e99e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_a2a1ba7e-938a-451d-b7ad-945047204ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c241bf-d267-4a2e-9ab6-a649df2b7d72" xlink:to="loc_us-gaap_MarketableSecurities_a2a1ba7e-938a-451d-b7ad-945047204ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8dda4ea3-5abd-40cb-90f9-76472c34d466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9c241bf-d267-4a2e-9ab6-a649df2b7d72" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8dda4ea3-5abd-40cb-90f9-76472c34d466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8fca04f6-6512-4b75-aabd-39f0f0b4b6be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_95c695c9-82b3-40f1-9f21-a8d438203b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8fca04f6-6512-4b75-aabd-39f0f0b4b6be" xlink:to="loc_us-gaap_AccountsPayableCurrent_95c695c9-82b3-40f1-9f21-a8d438203b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03786fb7-29c9-413e-9aec-9acf97ac4ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8fca04f6-6512-4b75-aabd-39f0f0b4b6be" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_03786fb7-29c9-413e-9aec-9acf97ac4ad3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b07be4d-3e42-4782-9e1d-e2b55ff4cbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b91f87fa-d2a7-435c-ad8a-236c83aaf038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b07be4d-3e42-4782-9e1d-e2b55ff4cbf9" xlink:to="loc_us-gaap_StockholdersEquity_b91f87fa-d2a7-435c-ad8a-236c83aaf038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_009710e5-0041-42a3-8bf8-ddef16dfc08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1b07be4d-3e42-4782-9e1d-e2b55ff4cbf9" xlink:to="loc_us-gaap_MinorityInterest_009710e5-0041-42a3-8bf8-ddef16dfc08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2b2a5ed-5eee-4ff7-9b3f-7be0f66e67a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1aa9564f-c608-4fcd-9736-04e659936ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c2b2a5ed-5eee-4ff7-9b3f-7be0f66e67a9" xlink:to="loc_us-gaap_LiabilitiesCurrent_1aa9564f-c608-4fcd-9736-04e659936ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_90cf2abb-76a2-4872-a7fb-9a0beecda7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c2b2a5ed-5eee-4ff7-9b3f-7be0f66e67a9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_90cf2abb-76a2-4872-a7fb-9a0beecda7fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0736ae5d-ab80-49a9-a2c9-66c74ea26d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73269a04-e53c-4621-a8ba-c6f2173e89f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0736ae5d-ab80-49a9-a2c9-66c74ea26d6e" xlink:to="loc_us-gaap_AssetsCurrent_73269a04-e53c-4621-a8ba-c6f2173e89f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_afa064b1-b581-456e-900e-153430d0b924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0736ae5d-ab80-49a9-a2c9-66c74ea26d6e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_afa064b1-b581-456e-900e-153430d0b924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3b544259-d921-4fd5-ab0e-b07a1762ce92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0736ae5d-ab80-49a9-a2c9-66c74ea26d6e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3b544259-d921-4fd5-ab0e-b07a1762ce92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0b00334c-49e6-4abc-904b-a11851b2718d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_70e6ee6a-1eac-4985-9108-5a92468afe22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0b00334c-49e6-4abc-904b-a11851b2718d" xlink:to="loc_us-gaap_OperatingExpenses_70e6ee6a-1eac-4985-9108-5a92468afe22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b1c84af3-a5d4-4619-a037-87b137a89958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e788a910-8ffd-474d-ad2f-07b686ce3663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b1c84af3-a5d4-4619-a037-87b137a89958" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e788a910-8ffd-474d-ad2f-07b686ce3663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_236348fc-f111-45b2-9295-87ed0b28c492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_71cb7c88-8d01-4dc4-b963-da0437626652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_236348fc-f111-45b2-9295-87ed0b28c492" xlink:to="loc_us-gaap_ProfitLoss_71cb7c88-8d01-4dc4-b963-da0437626652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_deffe55c-ae44-4489-a30a-fa7c7eb3d398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_236348fc-f111-45b2-9295-87ed0b28c492" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_deffe55c-ae44-4489-a30a-fa7c7eb3d398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fae28b7e-820c-43e6-bbda-84a19e124d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3193b36f-7bc4-47c5-9da1-b53258342f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fae28b7e-820c-43e6-bbda-84a19e124d39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3193b36f-7bc4-47c5-9da1-b53258342f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b966afd2-5602-45fe-85b7-f8755936d0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fae28b7e-820c-43e6-bbda-84a19e124d39" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b966afd2-5602-45fe-85b7-f8755936d0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ba145979-a820-49b9-813b-aaf42a81b3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_614b3670-a7c8-4ec5-a37d-59f9ae4b7d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ba145979-a820-49b9-813b-aaf42a81b3dd" xlink:to="loc_us-gaap_OperatingIncomeLoss_614b3670-a7c8-4ec5-a37d-59f9ae4b7d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_faf97f5a-ba69-4565-a3e4-1b5a920b53cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ba145979-a820-49b9-813b-aaf42a81b3dd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_faf97f5a-ba69-4565-a3e4-1b5a920b53cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_41f31b7d-8db3-4534-9d6e-d0033e0298c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_65e5bd8b-4c4c-4e7d-9246-79bb0f6cbead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_41f31b7d-8db3-4534-9d6e-d0033e0298c6" xlink:to="loc_us-gaap_ProfitLoss_65e5bd8b-4c4c-4e7d-9246-79bb0f6cbead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3ba00a7a-19b7-4ce7-9cd0-a375aaafb92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_41f31b7d-8db3-4534-9d6e-d0033e0298c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3ba00a7a-19b7-4ce7-9cd0-a375aaafb92f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c6dbcbb4-bdc1-48c4-a5e2-e5df510c224d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_34acb584-2181-41b6-9af6-b2aca5ba8e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c6dbcbb4-bdc1-48c4-a5e2-e5df510c224d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_34acb584-2181-41b6-9af6-b2aca5ba8e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb532e81-4118-43c0-aee9-f5d0ec48ba36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_079d3a54-0ca7-4a6c-9aa1-fecd29aeb64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb532e81-4118-43c0-aee9-f5d0ec48ba36" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_079d3a54-0ca7-4a6c-9aa1-fecd29aeb64f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a480f4ad-b82d-4060-b81d-13b87582d8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bb532e81-4118-43c0-aee9-f5d0ec48ba36" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a480f4ad-b82d-4060-b81d-13b87582d8c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c5e54d1-05a0-4dfa-a9dd-539a4dd5540c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1dc35a21-1970-4c74-9c39-555415cbb30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c5e54d1-05a0-4dfa-a9dd-539a4dd5540c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1dc35a21-1970-4c74-9c39-555415cbb30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b2e7db5f-518e-4dee-9512-e7c9db16d031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c5e54d1-05a0-4dfa-a9dd-539a4dd5540c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b2e7db5f-518e-4dee-9512-e7c9db16d031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_477169b0-6ae3-4ccc-ac67-04a1dd35e532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c5e54d1-05a0-4dfa-a9dd-539a4dd5540c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_477169b0-6ae3-4ccc-ac67-04a1dd35e532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68bca7bc-85b2-43c8-9540-ead87a5518d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37d4ad6b-ab48-4bbd-87b3-93f04f132ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68bca7bc-85b2-43c8-9540-ead87a5518d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37d4ad6b-ab48-4bbd-87b3-93f04f132ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e99ec8fb-0cf9-4a38-925d-c6ecf6230a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68bca7bc-85b2-43c8-9540-ead87a5518d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e99ec8fb-0cf9-4a38-925d-c6ecf6230a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cab8a257-04dd-4328-bf23-0b93b4c3638e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68bca7bc-85b2-43c8-9540-ead87a5518d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cab8a257-04dd-4328-bf23-0b93b4c3638e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0442545e-2ab8-47b2-ba2e-506566f1b063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_us-gaap_ProfitLoss_0442545e-2ab8-47b2-ba2e-506566f1b063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1126d142-0750-42b6-8ed4-c068e57149d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1126d142-0750-42b6-8ed4-c068e57149d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8a3431f5-3e39-4ea0-b207-8c4b7cba99eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_us-gaap_DepreciationAndAmortization_8a3431f5-3e39-4ea0-b207-8c4b7cba99eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aac67f6a-46c4-4577-a009-7ab9d2721731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aac67f6a-46c4-4577-a009-7ab9d2721731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eb449016-d96d-4179-9040-86da1722eb3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eb449016-d96d-4179-9040-86da1722eb3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51c8ea67-6587-460c-99be-9f8dd7e463bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51c8ea67-6587-460c-99be-9f8dd7e463bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_76fc00cc-9ee1-4411-9c7c-366c4f98511a" xlink:href="clbs-20210331.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4aa4ff57-007d-470f-8fc2-3dccc0606bfb" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_76fc00cc-9ee1-4411-9c7c-366c4f98511a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_564aab3f-6e22-47e5-8205-c7c2f9b6579a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5ab9e7c0-1c1a-4d96-9693-5d162d91a601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_564aab3f-6e22-47e5-8205-c7c2f9b6579a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5ab9e7c0-1c1a-4d96-9693-5d162d91a601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2a43858b-41ad-4198-91ee-0657baca2038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_564aab3f-6e22-47e5-8205-c7c2f9b6579a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2a43858b-41ad-4198-91ee-0657baca2038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_65d4d155-661a-4dbe-8b88-7ecbd05de80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_564aab3f-6e22-47e5-8205-c7c2f9b6579a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_65d4d155-661a-4dbe-8b88-7ecbd05de80b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20210331.xsd#TheBusiness"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessNarrativeDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#TheBusinessNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/TheBusinessNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecurities"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec367d34-a30b-4c71-8653-1d417713960a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b14975c-1ca4-4c97-82bd-1baf242ffa22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec367d34-a30b-4c71-8653-1d417713960a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b14975c-1ca4-4c97-82bd-1baf242ffa22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c255e758-82fd-419b-9c19-848769fa4824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec367d34-a30b-4c71-8653-1d417713960a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c255e758-82fd-419b-9c19-848769fa4824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_51b90df0-a3fa-4212-a518-8032ba3a736d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec367d34-a30b-4c71-8653-1d417713960a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_51b90df0-a3fa-4212-a518-8032ba3a736d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_02286061-370c-4096-9e9b-0f3b6eccc7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_1a1e358c-d3a4-45ff-bf99-5958a768073e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_02286061-370c-4096-9e9b-0f3b6eccc7cc" xlink:to="loc_us-gaap_Cash_1a1e358c-d3a4-45ff-bf99-5958a768073e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_ed4af303-b425-4b7e-aba2-2db29f01af6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_02286061-370c-4096-9e9b-0f3b6eccc7cc" xlink:to="loc_us-gaap_MarketableSecurities_ed4af303-b425-4b7e-aba2-2db29f01af6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1ed0ed3-719d-4fe5-a2dc-24e14fbd1299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_62f9cf49-c6a8-4b91-ae4f-b4a790ed32c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1ed0ed3-719d-4fe5-a2dc-24e14fbd1299" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_62f9cf49-c6a8-4b91-ae4f-b4a790ed32c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_06c43869-cd8b-42c9-ac43-924afabe3e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1ed0ed3-719d-4fe5-a2dc-24e14fbd1299" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_06c43869-cd8b-42c9-ac43-924afabe3e0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9143dd25-9229-499c-84c6-02ef351b5f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_d9f209fc-1d13-44ed-9684-64d7e20307e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9143dd25-9229-499c-84c6-02ef351b5f9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_d9f209fc-1d13-44ed-9684-64d7e20307e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_11121388-27b0-4fe0-b963-f861b688d4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9143dd25-9229-499c-84c6-02ef351b5f9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_11121388-27b0-4fe0-b963-f861b688d4e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShare"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_af3a9f68-966a-4c33-8370-9523141b7ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_82cf616e-44da-48ee-a0f4-baa92b8f9863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_af3a9f68-966a-4c33-8370-9523141b7ce3" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_82cf616e-44da-48ee-a0f4-baa92b8f9863" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilities"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_77b61f24-625d-4aec-a38c-9370f1ff548a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9288447c-5a57-43a7-971a-9762d3c0279b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_77b61f24-625d-4aec-a38c-9370f1ff548a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9288447c-5a57-43a7-971a-9762d3c0279b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4014753e-e970-4e10-be01-c7332f10d742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_77b61f24-625d-4aec-a38c-9370f1ff548a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4014753e-e970-4e10-be01-c7332f10d742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_caffa3d2-8da3-45f2-a6c0-b0470037e3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_77b61f24-625d-4aec-a38c-9370f1ff548a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_caffa3d2-8da3-45f2-a6c0-b0470037e3f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeases"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_decc744c-0657-44b7-b0bd-2d36a46a7b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7a307725-ab3f-4ccd-ac6f-0135a2c8be9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_decc744c-0657-44b7-b0bd-2d36a46a7b5a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7a307725-ab3f-4ccd-ac6f-0135a2c8be9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4a743d8f-3823-40d8-ac37-3e809c4dfc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_decc744c-0657-44b7-b0bd-2d36a46a7b5a" xlink:to="loc_us-gaap_OperatingLeaseLiability_4a743d8f-3823-40d8-ac37-3e809c4dfc4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1fdf6f8d-1e24-4079-ab77-d0e382b6ee4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_aa3577ed-577f-491d-91ae-b68f6084a29a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1fdf6f8d-1e24-4079-ab77-d0e382b6ee4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_aa3577ed-577f-491d-91ae-b68f6084a29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_73df774c-e87d-4b62-bebe-98ebfc50a7f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1fdf6f8d-1e24-4079-ab77-d0e382b6ee4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_73df774c-e87d-4b62-bebe-98ebfc50a7f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3892f824-5970-4da6-aadd-6ce86db86e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1fdf6f8d-1e24-4079-ab77-d0e382b6ee4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3892f824-5970-4da6-aadd-6ce86db86e85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFunding" xlink:type="simple" xlink:href="clbs-20210331.xsd#ResearchFunding"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ResearchFunding" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ResearchFundingDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeTaxesNetOperatingLossCarryForwardDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20210331.xsd#Contingencies"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>clbs-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d9eba1cb-e72d-43c9-86c5-dbb9216f38d8,g:166abcdb-ccb3-45de-adfb-a1da6bb60890-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20210331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended" id="i2a64f5c08c04436fa4750afda9742486_Cover"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i3c5c2d4870384cfea7b487082812e90d_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended" id="icade6eb4b7804fac80b5989df7cd7316_ConsolidatedBalanceSheetsParentheticals"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="ibe4f601fabd5419c9f3c6f265bcf3f59_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="ic42679099fff419eb9d7c84cf8a212bd_ConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="icd20974727924d67a0363e523d12fd16_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c7a6796d-b90f-406a-ac95-fe3c45021aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c7a6796d-b90f-406a-ac95-fe3c45021aa0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9b3985b3-6ed1-432c-b260-dea7862f87e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_SharesOutstanding_9b3985b3-6ed1-432c-b260-dea7862f87e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0017bdeb-9b14-40c3-866f-88e356dd6fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0017bdeb-9b14-40c3-866f-88e356dd6fbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_345721a5-34c2-41b0-823a-b716069b169a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_ProfitLoss_345721a5-34c2-41b0-823a-b716069b169a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_428d9035-938d-4f0f-b15a-5085d41bdaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_428d9035-938d-4f0f-b15a-5085d41bdaa9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d840b2e0-e1ef-4c47-8ce8-6cedc504f5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d840b2e0-e1ef-4c47-8ce8-6cedc504f5d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1325a85f-8926-41e4-ae5a-975a9c3ac72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1325a85f-8926-41e4-ae5a-975a9c3ac72f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_434097e7-7560-482b-95a9-1e96935a2b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_434097e7-7560-482b-95a9-1e96935a2b80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b6dfd77-9d31-496b-b442-930129faca11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b6dfd77-9d31-496b-b442-930129faca11" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e50733b-c5f8-4b9e-bf9a-3127f236bf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e50733b-c5f8-4b9e-bf9a-3127f236bf1a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8996671e-cab7-4fe0-8e96-72ae6d614421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8996671e-cab7-4fe0-8e96-72ae6d614421" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dbfaeca6-e1fb-42e1-831c-07a72a70d984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cedbfe63-0e94-4aec-bd99-f2860d26482d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c7a6796d-b90f-406a-ac95-fe3c45021aa0" xlink:to="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5b72aa57-03bb-458b-90b1-89a83dd427d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:to="loc_us-gaap_EquityComponentDomain_5b72aa57-03bb-458b-90b1-89a83dd427d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:to="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:to="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ef7f6c54-46fb-4f2e-821a-c73537386f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_PreferredStockMember_ef7f6c54-46fb-4f2e-821a-c73537386f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d5cd1191-18c7-4319-a684-0ca503711ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_CommonStockMember_d5cd1191-18c7-4319-a684-0ca503711ff8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c3771c61-6464-4d65-983c-3cba15210018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c3771c61-6464-4d65-983c-3cba15210018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_62e3832e-5140-4203-a969-48461c296585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_62e3832e-5140-4203-a969-48461c296585" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c85eef9b-2ac6-47c0-bfdc-fb6b61974ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_RetainedEarningsMember_c85eef9b-2ac6-47c0-bfdc-fb6b61974ed2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e55e9ed3-ed84-4493-8728-7df3cfcfda99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_TreasuryStockMember_e55e9ed3-ed84-4493-8728-7df3cfcfda99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9db7c422-e12a-4bed-a7d8-578824fadd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9db7c422-e12a-4bed-a7d8-578824fadd30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i3770f1cff172444089fb59e1267ff0e7_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20210331.xsd#TheBusiness"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended" id="i75cac7103b6c4b54be325032a0f96740_TheBusiness"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessNarrativeDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#TheBusinessNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TheBusinessNarrativeDetails" xlink:type="extended" id="i814dc8c389e549faaae6379565d750d9_TheBusinessNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ed29838e-87d3-4d42-8c18-eef6feb71165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_d5d2b11d-96e8-4ef2-9515-500edc3398d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ed29838e-87d3-4d42-8c18-eef6feb71165" xlink:to="loc_us-gaap_GrantsReceivable_d5d2b11d-96e8-4ef2-9515-500edc3398d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ed29838e-87d3-4d42-8c18-eef6feb71165" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_adb0ed84-ae64-4872-adef-d9136e92aef1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:to="loc_us-gaap_ProjectMember_adb0ed84-ae64-4872-adef-d9136e92aef1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c32b5b2d-4e42-4129-aba5-eba66dcf8e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:to="loc_us-gaap_ProjectMember_c32b5b2d-4e42-4129-aba5-eba66dcf8e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IschemicRepairCD34CellTechnologyMember_d5f2e0ae-c4f2-4777-8b4a-dcb3911c677a" xlink:href="clbs-20210331.xsd#clbs_IschemicRepairCD34CellTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_c32b5b2d-4e42-4129-aba5-eba66dcf8e36" xlink:to="loc_clbs_IschemicRepairCD34CellTechnologyMember_d5f2e0ae-c4f2-4777-8b4a-dcb3911c677a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ia265bebcbff14bc5b350ce2cade64476_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i08296d5a343647c49602a7c57bf2939f_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecurities"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended" id="i0e550fc1fbf248b889c3d30748ee6287_AvailableforSaleSecurities"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended" id="i8a5c6a9c8a1347b394c1c575999a2544_AvailableforSaleSecuritiesTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended" id="iaa43cd47a3f648f786ab0cfab582b802_AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5f4d7928-5f4d-4853-88cb-1222835cbb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5f4d7928-5f4d-4853-88cb-1222835cbb69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d848594d-e496-41a5-957d-10cce8b5983e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d848594d-e496-41a5-957d-10cce8b5983e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40ccf591-dfa7-46e5-a5ad-cca0e46bbc0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40ccf591-dfa7-46e5-a5ad-cca0e46bbc0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_801065e9-120f-4e67-82f5-76ab1b97cb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_801065e9-120f-4e67-82f5-76ab1b97cb7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c04c5239-add0-4392-89a5-9e8b380f3a5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c04c5239-add0-4392-89a5-9e8b380f3a5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c0879cb1-67c7-4af1-bb58-f273ed70eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c0879cb1-67c7-4af1-bb58-f273ed70eb4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_439b04e2-82dc-4e09-a1ad-989bdec6d1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_439b04e2-82dc-4e09-a1ad-989bdec6d1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_5a32b0ea-38df-48ed-ad1a-008d948240d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_5a32b0ea-38df-48ed-ad1a-008d948240d3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i8349e2083cbb4e6a9e1589ddaa06346a_AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended" id="ife4b66ca186940dbbdd2a7a1a2ea6487_AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShare"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended" id="i2bb3ac6f2dc744ee8ff8ff0a3de52250_IncomeLossPerShare"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended" id="i2e5c61a7e076496288ae5bd984426ae0_IncomeLossPerShareTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended" id="id1651203279d4b3e8fcb7cd18ba3f006_IncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_649f1904-1a79-436c-aaa5-23e41fbd8d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9369b51a-ffb5-4d8f-8f12-9025c4f2b954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_649f1904-1a79-436c-aaa5-23e41fbd8d5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9369b51a-ffb5-4d8f-8f12-9025c4f2b954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_649f1904-1a79-436c-aaa5-23e41fbd8d5a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fdcfd022-4ce2-4efd-a96a-d94c4414b193_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fdcfd022-4ce2-4efd-a96a-d94c4414b193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5d9ba097-39bc-422f-833d-0d760353b10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5d9ba097-39bc-422f-833d-0d760353b10c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6dbf613c-31b2-4bab-b83d-e5f688b704ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:to="loc_us-gaap_WarrantMember_6dbf613c-31b2-4bab-b83d-e5f688b704ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1717a702-10d3-4635-b3b3-f4167a7a6b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1717a702-10d3-4635-b3b3-f4167a7a6b9e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended" id="i343dd2f8d62f4422af3311dc6eaff341_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i29902668a9aa400a92ee5103c8831a4f_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="ie8fef869db674f948e0ba17e14b5d0a9_FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8dfee2a2-8bcb-4766-bc17-74284b3fd7c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8dfee2a2-8bcb-4766-bc17-74284b3fd7c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_98166d9d-228c-476a-a6c7-84b45346baf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_98166d9d-228c-476a-a6c7-84b45346baf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93192da3-3885-4879-9d87-d6c98cb47c37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93192da3-3885-4879-9d87-d6c98cb47c37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d7d9c7e9-60d8-4adf-974f-167e87dec01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d7d9c7e9-60d8-4adf-974f-167e87dec01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0c21f79d-66f3-4321-a851-22eb236a6cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0c21f79d-66f3-4321-a851-22eb236a6cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_474d556c-a200-4569-94ab-e0f6b2cac9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_474d556c-a200-4569-94ab-e0f6b2cac9da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b21ed0c9-e522-4bc5-864d-0193163c9d94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b21ed0c9-e522-4bc5-864d-0193163c9d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd250e7c-bdca-4e5e-8bde-1c92ba891430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd250e7c-bdca-4e5e-8bde-1c92ba891430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1c85b937-6e1a-4a16-a210-c6ce5c1ced68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd250e7c-bdca-4e5e-8bde-1c92ba891430" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1c85b937-6e1a-4a16-a210-c6ce5c1ced68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilities"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended" id="id0dc1fd2307347dfbcb2e44548e948cf_AccruedLiabilities"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended" id="i2b63805c3b314fc7a94ab4db31ae3de7_AccruedLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended" id="ibea78721fad240d48f501b01733b82ab_AccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeases"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended" id="i3087c399ebd740d585e8ca5f51964b54_OperatingLeases"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended" id="i7499613581774488a68078deb853ddf7_OperatingLeasesTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended" id="i9804755a40b9474d944da3683747984f_OperatingLeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended" id="i3a70c6144b534fc18edc14be0408ece7_OperatingLeasesBalanceSheetPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ca23117-b12d-4d25-bb69-996ef3ffaf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ca23117-b12d-4d25-bb69-996ef3ffaf8b" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_abf67673-e080-4d39-a0c6-d971e3ca31e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_abf67673-e080-4d39-a0c6-d971e3ca31e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a5c331af-a4f1-45ad-8bf5-7d7b8b3dd01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a5c331af-a4f1-45ad-8bf5-7d7b8b3dd01c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7285c1fd-888a-4583-bb28-401698b909de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7285c1fd-888a-4583-bb28-401698b909de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cc28d859-66eb-4097-8b01-20c4c760621a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseLiability_cc28d859-66eb-4097-8b01-20c4c760621a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ca23117-b12d-4d25-bb69-996ef3ffaf8b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c006a88e-0a8d-4ad1-a12d-0a50d3381131_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c006a88e-0a8d-4ad1-a12d-0a50d3381131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_bbe16ea0-139f-46c8-bbd3-80fb8e0bd1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:to="loc_us-gaap_OtherAssetsMember_bbe16ea0-139f-46c8-bbd3-80fb8e0bd1fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6e8ad395-67a4-43fc-94f1-a8b4b00be5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_6e8ad395-67a4-43fc-94f1-a8b4b00be5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_90a3cc9d-9f6f-4866-b04b-27683f18deb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_90a3cc9d-9f6f-4866-b04b-27683f18deb2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="i461114e7cda44288a597131c79cb79f1_OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended" id="i6e65588efa44446eb2ace19563f1baa8_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended" id="i3d3339a01d5a4471a0c1e1f444e74a32_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended" id="i953b93e6f1f944978f0b87482b0cbff5_StockholdersEquityEquityIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_966e17e7-10fe-48f4-973b-c2465eb1f48c" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_966e17e7-10fe-48f4-973b-c2465eb1f48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_0997346f-281c-41ac-96d9-8d4c34e41b95" xlink:href="clbs-20210331.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_0997346f-281c-41ac-96d9-8d4c34e41b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4666d144-ff67-4eb5-8ce6-56d35c70bca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4666d144-ff67-4eb5-8ce6-56d35c70bca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0ba1ffc6-e9d3-43c0-abdb-14cbb955a6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0ba1ffc6-e9d3-43c0-abdb-14cbb955a6f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fa62f0e3-1f07-4a1f-a20c-b84c2f27e545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fa62f0e3-1f07-4a1f-a20c-b84c2f27e545" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_9ccd58a7-3fea-4558-8855-d999ebe95dd6" xlink:href="clbs-20210331.xsd#clbs_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_TermOfAgreement_9ccd58a7-3fea-4558-8855-d999ebe95dd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_dfbbcedc-a919-444a-94d2-3e41c749e318" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_dfbbcedc-a919-444a-94d2-3e41c749e318" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_34d961a8-62e1-47aa-b7b6-bc14cfc328e8" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_34d961a8-62e1-47aa-b7b6-bc14cfc328e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_4a01d440-5b00-4739-bbbb-ff054ddfdc0f" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_4a01d440-5b00-4739-bbbb-ff054ddfdc0f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_fe692522-7c89-4c36-abd8-145e12109aa2" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_fe692522-7c89-4c36-abd8-145e12109aa2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_2b3eb709-549e-4929-9440-da38f779e544" xlink:href="clbs-20210331.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_2b3eb709-549e-4929-9440-da38f779e544" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateMarketValueOfCommonStockNonAffiliates_a5c0797c-bccf-49c5-a4eb-3114a06298d0" xlink:href="clbs-20210331.xsd#clbs_AggregateMarketValueOfCommonStockNonAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_AggregateMarketValueOfCommonStockNonAffiliates_a5c0797c-bccf-49c5-a4eb-3114a06298d0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_e61c78ec-91aa-46be-be08-425250a0ba28" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_e61c78ec-91aa-46be-be08-425250a0ba28" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_00b710f0-3325-432c-8a23-d0b7193c3c05" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_00b710f0-3325-432c-8a23-d0b7193c3c05" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9fd92a14-ec0e-4a09-a997-74bbf62b01c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9fd92a14-ec0e-4a09-a997-74bbf62b01c1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5e8aac-87e0-40d9-84b5-a5343e2e9b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5e8aac-87e0-40d9-84b5-a5343e2e9b20" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48e9882e-3419-4768-9ca5-98e7db6f3f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48e9882e-3419-4768-9ca5-98e7db6f3f5f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e84cbb7a-06dc-4a62-84eb-6aa9b2a4d920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e84cbb7a-06dc-4a62-84eb-6aa9b2a4d920" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1d223882-4baa-4d0a-9553-4be9fd1ad826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1d223882-4baa-4d0a-9553-4be9fd1ad826" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_964766e9-091d-49aa-b54c-cbaa4571c7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_964766e9-091d-49aa-b54c-cbaa4571c7dd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_3f0182d4-82d7-4903-8412-f4b9a6a33257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_3f0182d4-82d7-4903-8412-f4b9a6a33257" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_381d26f0-4e43-4286-9a37-30cbc2a95a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_381d26f0-4e43-4286-9a37-30cbc2a95a92" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_622b21ed-e930-4c67-b722-4ef982352bd9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_622b21ed-e930-4c67-b722-4ef982352bd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_406e471e-95fe-4676-a02d-7aa9af9ede77" xlink:href="clbs-20210331.xsd#clbs_LincolnParkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_LincolnParkAgreementMember_406e471e-95fe-4676-a02d-7aa9af9ede77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_2dcc13d1-1139-4811-a88c-0c96ba32db5a" xlink:href="clbs-20210331.xsd#clbs_H.C.WainwrightSalesAmendedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_2dcc13d1-1139-4811-a88c-0c96ba32db5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_InstitutionalPurchaseAgreementMember_afec6677-1053-4b4d-9dec-9594e0059cd9" xlink:href="clbs-20210331.xsd#clbs_InstitutionalPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_InstitutionalPurchaseAgreementMember_afec6677-1053-4b4d-9dec-9594e0059cd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AdditionalPurchaseAgreementMember_8bd84964-fccb-4425-8fc9-ebb81d2d8944" xlink:href="clbs-20210331.xsd#clbs_AdditionalPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_AdditionalPurchaseAgreementMember_8bd84964-fccb-4425-8fc9-ebb81d2d8944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_January2021PurchaseAgreementMember_0d3624c4-72b4-4d98-93ac-e1d58a13c8e4" xlink:href="clbs-20210331.xsd#clbs_January2021PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_January2021PurchaseAgreementMember_0d3624c4-72b4-4d98-93ac-e1d58a13c8e4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended" id="i5ccf6e5edabe49c7b5f81cd8b2e6ab9d_StockholdersEquityStockOptionsandWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_599f6ee9-c5c6-414e-80ef-285f3ba942a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_599f6ee9-c5c6-414e-80ef-285f3ba942a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3c7b0325-41ca-4001-b370-17132055302e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3c7b0325-41ca-4001-b370-17132055302e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_faf34f4e-6e55-4d0e-bb19-41182f17dad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_faf34f4e-6e55-4d0e-bb19-41182f17dad6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9a165247-6bba-472a-bec8-e61e6590c41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9a165247-6bba-472a-bec8-e61e6590c41b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_774669cc-12c3-4f39-bc8d-733f4bfe247f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_774669cc-12c3-4f39-bc8d-733f4bfe247f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_772b11ae-545b-4fcd-838d-875be1543f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fbf2b77c-0f1e-4708-b4fc-f28611237768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fbf2b77c-0f1e-4708-b4fc-f28611237768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5da066d1-d004-4f6b-a884-beb46600efb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5da066d1-d004-4f6b-a884-beb46600efb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8d73dc1e-7d71-4cf0-af47-4998dffc5474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8d73dc1e-7d71-4cf0-af47-4998dffc5474" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d259a86c-95e5-4b7d-81d0-b08f242792ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d259a86c-95e5-4b7d-81d0-b08f242792ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_811c1196-7cbe-4aeb-9c45-94e72c00f58c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_811c1196-7cbe-4aeb-9c45-94e72c00f58c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_531155c2-619c-4fe3-b7eb-fb98b53f6333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6c1ad860-df41-409f-9fc2-45780dd3ac59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6c1ad860-df41-409f-9fc2-45780dd3ac59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3be51dad-0a57-4df2-8e99-72d57d59c995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3be51dad-0a57-4df2-8e99-72d57d59c995" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_334e06ef-9929-4b7c-ad1a-f65cf16a7c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_334e06ef-9929-4b7c-ad1a-f65cf16a7c59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e1132747-c0ef-4cd3-9120-9ccc4b187cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e1132747-c0ef-4cd3-9120-9ccc4b187cd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_499730e8-858a-4a1d-a493-b537972d5931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_499730e8-858a-4a1d-a493-b537972d5931" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1410c3ad-2891-4ae5-b5cf-8925a3f26793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1410c3ad-2891-4ae5-b5cf-8925a3f26793" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c94d02b3-e956-4b13-9677-999dc019b52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c94d02b3-e956-4b13-9677-999dc019b52e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c2a2bc50-f432-4291-a5e2-b77b6bb8d89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c2a2bc50-f432-4291-a5e2-b77b6bb8d89a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_1d3bd50f-007a-4f54-836a-13d3c475b964" xlink:href="clbs-20210331.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_1d3bd50f-007a-4f54-836a-13d3c475b964" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a227f4fa-f666-4562-a575-c368c3693bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a227f4fa-f666-4562-a575-c368c3693bee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_ffcb7b3f-e1f2-4c2d-9793-52428014405a" xlink:href="clbs-20210331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_CommonStockWarrantsShares_ffcb7b3f-e1f2-4c2d-9793-52428014405a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted_24b8d279-9ad7-46b3-b392-7f190231ac95" xlink:href="clbs-20210331.xsd#clbs_WarrantsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsGranted_24b8d279-9ad7-46b3-b392-7f190231ac95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised_28c9eff1-df77-4f2c-a184-062bca602fcb" xlink:href="clbs-20210331.xsd#clbs_WarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsExercised_28c9eff1-df77-4f2c-a184-062bca602fcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled_d6b7d40c-c9fd-402c-a4c9-dd0e31ef89b2" xlink:href="clbs-20210331.xsd#clbs_WarrantsCanceled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsCanceled_d6b7d40c-c9fd-402c-a4c9-dd0e31ef89b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired_7781f993-1a64-4b17-8067-f62b857e1268" xlink:href="clbs-20210331.xsd#clbs_WarrantsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsExpired_7781f993-1a64-4b17-8067-f62b857e1268" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_04c43720-5ee6-4fd6-8da2-b4013fd7fc24" xlink:href="clbs-20210331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:href="clbs-20210331.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_e7462d70-319a-4e69-aa86-2f5e89411bc8" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_e7462d70-319a-4e69-aa86-2f5e89411bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_668ee830-320d-402a-84ad-a3a416e9d458" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_668ee830-320d-402a-84ad-a3a416e9d458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_62fd1954-eb0b-4500-bb43-2205204d1784" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_62fd1954-eb0b-4500-bb43-2205204d1784" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_8e5cfaf4-feb5-4110-b72f-16fde3bec63d" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_8e5cfaf4-feb5-4110-b72f-16fde3bec63d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_e97d77b0-d3b9-407e-8e47-a9aff3d6123f" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_e97d77b0-d3b9-407e-8e47-a9aff3d6123f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_ef1714ff-1ca6-456f-91b3-7913d01a9fba" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_66eab7e3-1068-490a-8a5b-de4a8fee6a55" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_66eab7e3-1068-490a-8a5b-de4a8fee6a55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_674b9d74-9c49-4e14-b266-5a9c32e28a87" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_674b9d74-9c49-4e14-b266-5a9c32e28a87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest_6734850f-3ef9-4100-9c65-94a2cc332862" xlink:href="clbs-20210331.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_Sharesvestedandexpectedtovest_6734850f-3ef9-4100-9c65-94a2cc332862" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_13b82242-252a-4b04-a012-b2899b346190" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_13b82242-252a-4b04-a012-b2899b346190" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_686dd71d-15ea-4a0f-a743-e5357ee73cf1" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_686dd71d-15ea-4a0f-a743-e5357ee73cf1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_6c6a2e42-65be-4ef6-81ee-19582548cbb0" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_6c6a2e42-65be-4ef6-81ee-19582548cbb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested_1acd0f6a-728f-4c73-902b-926f5d92882d" xlink:href="clbs-20210331.xsd#clbs_WarrantsVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WarrantsVested_1acd0f6a-728f-4c73-902b-926f5d92882d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_6057ad03-fee6-4f26-bb7d-ac843c56e8e9" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_6057ad03-fee6-4f26-bb7d-ac843c56e8e9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_52d8db26-8559-4a3c-a185-7269200b850c" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_52d8db26-8559-4a3c-a185-7269200b850c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested_9d2d8541-0602-49ec-afcc-bc5f008005d0" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvested_9d2d8541-0602-49ec-afcc-bc5f008005d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:to="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityDomain_76b40a3e-d1db-4896-9430-534734645b24_default" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:to="loc_clbs_StockOptionsActivityDomain_76b40a3e-d1db-4896-9430-534734645b24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityDomain_3ffee9bd-c62a-4552-a71e-f568905e891e" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:to="loc_clbs_StockOptionsActivityDomain_3ffee9bd-c62a-4552-a71e-f568905e891e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UsEquityPlanMember_53ff5676-8148-4acf-978b-b18c9e9b5751" xlink:href="clbs-20210331.xsd#clbs_UsEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_StockOptionsActivityDomain_3ffee9bd-c62a-4552-a71e-f568905e891e" xlink:to="loc_clbs_UsEquityPlanMember_53ff5676-8148-4acf-978b-b18c9e9b5751" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="i80d7374260684a20ad4ed97c52a5114c_StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_8cd4adf5-15c0-469b-8458-0e8960fd5703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_8cd4adf5-15c0-469b-8458-0e8960fd5703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c18eedbf-55ef-44f3-9baf-2ad608f67dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c18eedbf-55ef-44f3-9baf-2ad608f67dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_afaaa04a-bc2a-4682-9dac-91bd581d9aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_afaaa04a-bc2a-4682-9dac-91bd581d9aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_469a2bc7-c11a-45ff-8ce8-f4a4dbc0148a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_469a2bc7-c11a-45ff-8ce8-f4a4dbc0148a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:to="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ccc29a4-5136-489b-9c89-0042c358bff5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ccc29a4-5136-489b-9c89-0042c358bff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_74eec890-b61d-44de-87c4-fe137f142cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:to="loc_us-gaap_RestrictedStockMember_74eec890-b61d-44de-87c4-fe137f142cb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_602db703-5665-4d69-93a4-edc573165c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_602db703-5665-4d69-93a4-edc573165c46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended" id="ic17d6d4df01247bd8e3e101fc720b778_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i576ee1082e7d44d1808b81d282c28f70_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i7d4fa0c3fb4f4f919cb10090234831a4_ShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dfa2945-cc19-4239-9feb-8adb8401e0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c7e141d-2e31-4298-afc3-8fdd875bf258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dfa2945-cc19-4239-9feb-8adb8401e0ea" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c7e141d-2e31-4298-afc3-8fdd875bf258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dfa2945-cc19-4239-9feb-8adb8401e0ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fe9033f-cb4c-4465-98cd-beb50413ba14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fe9033f-cb4c-4465-98cd-beb50413ba14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d251d06-aae0-4815-a615-2dde2b726515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d251d06-aae0-4815-a615-2dde2b726515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_88cd23d2-1d51-4b6f-9460-e03bc2767cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_88cd23d2-1d51-4b6f-9460-e03bc2767cef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended" id="i3bd13af86db04be098dfc5e36b050da4_ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c0ec6b4-7cd6-43d8-9575-a5e94337e9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c0ec6b4-7cd6-43d8-9575-a5e94337e9e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46150e8f-15b4-4233-bb98-64c6604379ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46150e8f-15b4-4233-bb98-64c6604379ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:to="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9170ae0-5fc4-4d84-9cee-d1108bd6515c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9170ae0-5fc4-4d84-9cee-d1108bd6515c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53e922f9-457d-4813-94e1-208dd450bc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53e922f9-457d-4813-94e1-208dd450bc1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_283ca5e3-ddaa-49df-a9a5-d710b64aa5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_283ca5e3-ddaa-49df-a9a5-d710b64aa5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_972f2f1d-6e65-4761-a804-02ca0e410e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:to="loc_us-gaap_RestrictedStockMember_972f2f1d-6e65-4761-a804-02ca0e410e06" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended" id="i9f50e3f04c0f4675a7676d02c3a7a021_ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_093f61c2-3662-41e9-a989-6c8f767b1dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_093f61c2-3662-41e9-a989-6c8f767b1dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b996c4b3-364f-4dd3-9734-cbf7eddb1d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b996c4b3-364f-4dd3-9734-cbf7eddb1d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:to="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5efa8211-478a-437f-a737-8c8b5c12698f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5efa8211-478a-437f-a737-8c8b5c12698f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d3fb85-eba8-41c6-ae43-8c4230f8d1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d3fb85-eba8-41c6-ae43-8c4230f8d1e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_83e74190-2218-4fb1-9445-2212c6d6287f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d3fb85-eba8-41c6-ae43-8c4230f8d1e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_83e74190-2218-4fb1-9445-2212c6d6287f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFunding" xlink:type="simple" xlink:href="clbs-20210331.xsd#ResearchFunding"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchFunding" xlink:type="extended" id="i06a6db1bc50e45d489a57b60d413c3ec_ResearchFunding"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ResearchFundingDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="extended" id="i1dd5575df52d47ab85b579099a170da3_ResearchFundingDetails"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended" id="i001684673e1b494195e84843c2b83d41_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeTaxesNetOperatingLossCarryForwardDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails" xlink:type="extended" id="i7936d34cb5524c9ca4eff8d2856c38cb_IncomeTaxesNetOperatingLossCarryForwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7b0fe363-bbb0-4221-8b7e-e2562f660033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7b0fe363-bbb0-4221-8b7e-e2562f660033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_0ace8e34-c566-4e1b-a32b-897c33c03612" xlink:href="clbs-20210331.xsd#clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_0ace8e34-c566-4e1b-a32b-897c33c03612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetOperatingLossAnalysisAnnualLimitation_c740d563-4f4f-4996-9188-32eb34a3f00b" xlink:href="clbs-20210331.xsd#clbs_NetOperatingLossAnalysisAnnualLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_clbs_NetOperatingLossAnalysisAnnualLimitation_c740d563-4f4f-4996-9188-32eb34a3f00b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6d80901b-61bc-41c5-a389-420e3c8a2715_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6d80901b-61bc-41c5-a389-420e3c8a2715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3b8e6a81-002b-428d-a19e-ef72305f2f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:to="loc_us-gaap_DomesticCountryMember_3b8e6a81-002b-428d-a19e-ef72305f2f96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_41ab5ac6-7f4f-4c19-add2-e9426a548ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_41ab5ac6-7f4f-4c19-add2-e9426a548ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0974b5e1-6d5c-4da5-b773-7310b1ded025_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0974b5e1-6d5c-4da5-b773-7310b1ded025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_601296a9-f315-4c18-ba35-8deadaa16b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_601296a9-f315-4c18-ba35-8deadaa16b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_cfb074c6-3190-48b1-9b21-7f783cf745bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_cfb074c6-3190-48b1-9b21-7f783cf745bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_773d8af3-746e-4999-b431-77681919c1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_773d8af3-746e-4999-b431-77681919c1d5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20210331.xsd#Contingencies"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended" id="iecc03158bf9d4c5b992ff2ccf140a112_Contingencies"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>clbs-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d9eba1cb-e72d-43c9-86c5-dbb9216f38d8,g:166abcdb-ccb3-45de-adfb-a1da6bb60890-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_696d1c51-7966-4a5a-b7e2-dc448e0c9dad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d4324aa5-23fb-4503-ba69-a2955169b4d7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9975e932-ffa2-4495-a936-832b76d28304_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_133d103d-6d4f-458d-b894-e95d8f4d4789_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6e236222-62ad-46d4-8b76-1a7715101db3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_94e0d749-3862-4902-9f6a-73b6c0d8cb37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_df06dfc9-9063-4724-8ec5-447a12b197ad_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a8ded8a1-4edd-4d3e-a242-09aaa1d3074f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ec7da45a-cfe3-4717-a059-314d3580ca4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_846e473e-348b-490a-b5cc-84b84784086a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1c06a13-4a04-4380-bf86-14d9fe6caaab_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3338c028-9579-4308-aee6-97a9b3671436_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ec11fd84-5041-40f2-a733-9711b031e316_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_eba24662-f82d-4ee1-8d52-870c941b39a8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_866c4ba8-ce20-4087-82d9-0da3b0fc8f66_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_fe9a0224-8357-4ed1-b554-9ac7f8680d36_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_26790f3b-8088-481f-922b-ed5cc5593b88_terseLabel_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest" xlink:href="clbs-20210331.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_Sharesvestedandexpectedtovest" xlink:to="lab_clbs_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d10d5a8-98b1-4fc4-b855-86f42aff5f41_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_fdffee1d-2f03-4876-a29f-7258589622c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a557b73f-525f-429c-b876-be23eeb8148c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_74da657e-ff2b-4c9e-b0ff-9b7733cccaee_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_110690d7-ebe3-43c9-b71d-3f8b19a1bdb9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0c91e327-d76f-4ebe-8f1d-bec3dfe2bc87_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_106a75a4-3c86-43b9-a093-e74b2ff886b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ec475769-d32c-470b-b8ce-42227cfa5d03_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_da4e191c-3921-44e4-b41f-691c5e211364_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_512348b0-3a5b-429a-9ebd-e6592b94f722_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_98218401-2d52-4b13-a9d4-3a5188952c9d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_362873ab-b294-43dc-93fc-2c02df74dd72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_76e8a5cf-2dd2-4c7f-829d-f3a1ed0f3144_terseLabel_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:href="clbs-20210331.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:to="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_StockOptionsActivityDomain_c03ce424-6662-4f79-8675-09f714c258b7_terseLabel_en-US" xlink:label="lab_clbs_StockOptionsActivityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Activity [Domain]</link:label>
    <link:label id="lab_clbs_StockOptionsActivityDomain_label_en-US" xlink:label="lab_clbs_StockOptionsActivityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Activity [Domain]</link:label>
    <link:label id="lab_clbs_StockOptionsActivityDomain_documentation_en-US" xlink:label="lab_clbs_StockOptionsActivityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Activity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityDomain" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_StockOptionsActivityDomain" xlink:to="lab_clbs_StockOptionsActivityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb673470-733c-4e2a-b458-d5c90deec6c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8e800884-a239-4ffc-9679-29646e0af2e4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExpired_8eecce6d-192f-4d99-a2ba-362ce0dc8587_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExpired_label_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_clbs_WarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired" xlink:href="clbs-20210331.xsd#clbs_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExpired" xlink:to="lab_clbs_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_965ef0e1-9e66-430f-9a7f-5be35f6ce27f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6d9dbc2e-253d-42df-b4e8-a530754241da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e3c74cc3-d4a9-4d56-bac8-a75cf343f3ba_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2f1ad7b8-2ac3-41bb-9833-b71029c3c048_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ea2163e7-cf5d-4d8f-a0c7-b96582290525_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a3b57a93-092d-4863-b493-6636c214e09f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExercised_65e7c25f-79c2-4036-bb7f-c4489b1ba932_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExercised_label_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_clbs_WarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised" xlink:href="clbs-20210331.xsd#clbs_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExercised" xlink:to="lab_clbs_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50b63337-ff14-43fe-bc80-28220fccccf3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d00be5e2-029a-46e6-b848-b3490d7f2541_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8139bc67-7fba-40f5-8f62-106e7a6786e8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e6d87d83-03b6-400b-af9b-e890f2054ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ecdd39e4-4453-4931-8580-0f0e2625808c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6cd0e300-f446-4529-8056-add8d1d2d1a1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c2892809-31d8-4e3e-b864-ba634620cb3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4b87549e-6572-429a-a14a-e7af19340b4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f7e77996-88e0-4155-97e3-2a0d01623acc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_af8b345d-050f-41f7-b0e3-3769f9fad951_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1d2704da-1dc1-42ba-84cf-74d64095f439_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_d6a9714e-2ddc-42f0-b29a-076385e49456_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5beb7563-b1b7-46f0-8cf4-776cd75b5cac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_53d697f7-7490-40fa-9769-4a01903670b5_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91a16792-9b4d-43c4-8fe3-b43e6a7f4b7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting terms (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_32a67694-94f5-416c-a2d6-b06459d82b92_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c7259470-72c1-4f8f-a14a-0c727afa34c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c8dc07db-c1ef-4fae-8f3a-06a8e5bafb1a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d120b84e-6bf2-4ec1-b5be-0a05a7f87304_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_7078fe5f-5a38-4064-af85-5e16bf3bca7c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Warrants [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_afbef1b2-a92b-4cba-bb6c-a6758fe176a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_723cbacb-ed3e-4443-abd3-a3bdcfcf9a54_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d5264ea5-eb01-4973-8533-fb0b5064e971_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a272235b-a45e-4364-8c20-cf93eac8be21_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_c243f8a6-183a-45e1-8f8a-e7f0c6f84ad2_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares allowable to direct for Regular Purchase (in shares)</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsVested_6262fc15-50ec-4065-9d4c-8e6faae57896_terseLabel_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsVested_label_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_clbs_WarrantsVested_documentation_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested" xlink:href="clbs-20210331.xsd#clbs_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsVested" xlink:to="lab_clbs_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f29abc9b-ec60-4c82-8a6d-6519f56b6d45_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0d79a918-c2b8-40ba-8cf4-2d1cf6e517b3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_aa68cbe2-c5b8-4176-9e22-6bea809cc71c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7997a589-d5fc-4cfd-aa09-875ef35aab6e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_46da2aef-d946-4282-86a2-be5ff2ea3445_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_14a960e7-4204-485a-8a4a-23d97745f062_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_98cd0b26-2086-4f23-9e54-598e4442caf9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_76a5931a-e38a-4ee4-afa3-4c490a8ec8b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5ae5fd2c-56e5-4415-ba1f-9b6e67123cd5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2ee2bb7f-e03e-4cd4-a114-b338fa95d4e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_BusinessTextBlock_796fddda-c6fd-4f6e-a91b-17dc614a0c09_terseLabel_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_label_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_documentation_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock" xlink:href="clbs-20210331.xsd#clbs_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_BusinessTextBlock" xlink:to="lab_clbs_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_42bc1164-7491-438a-a8ca-596821b5ee61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_d4d32349-c786-488b-97b9-b7cbdcb1fc3f_terseLabel_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum beneficial ownership allowable per agreement (percent)</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_label_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_documentation_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:href="clbs-20210331.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:to="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7a2ca50d-82ab-4753-8d4b-2bb27d3c8001_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_aa66349d-7f04-4a0e-a351-f4ccd358654b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_4e197a6f-4da8-4055-abea-fd9c678b64db_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fc3480f6-0e70-47f4-a890-ab9648352384_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_98dc288e-272a-462c-a2a0-f74c5a4baa63_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum obligation per directed purchase transaction for Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_776b146d-9b22-471b-8f84-c6aaba24117f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_e5ca85fa-e0ff-46e6-bba2-13369120a83f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_4bf9b6b8-9e03-49c8-add8-0c7ecdf16fbd_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_c523a66e-ed71-4731-b189-9c4d032cec6b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_2c03be17-35da-40d3-8240-9efd40e9ea2c_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1374a60e-4f9e-4c81-9e7f-527af015c648_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ba780991-75b7-49cb-a448-0b60bdc48016_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_11fea26f-4114-43e2-a8f2-ee8ec1ff8252_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_12715285-bab4-486c-ab1c-1f1259273765_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_90ac05c4-fa22-4e89-885e-c5928c14ffdd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_be9e79b7-7446-4509-9680-3a1c0ba5e7c9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_60b9ae63-48e3-4d89-a855-37068807a4a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_5cd7928d-fd92-4c89-aac9-96383c54648e_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_506eabb8-c091-46db-a4f6-65b3afc0dc98_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1641ae16-811c-4ecd-8ade-e729f53a3198_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_eeb9aa9d-0a7e-4a2a-af9e-9f9d9e93303a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Stock Options and warrants [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_26765a5b-978f-46ff-a873-11f089c6b80d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_83eb48be-4e93-487a-80ba-c5c917d90969_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6c10b839-058e-495a-b256-c00696e8f66c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_1aeed65d-a0c4-4ccd-a718-ee6736cb6191_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c42527a-0d9a-485a-b5a9-20b32a1d2b3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5691b465-102b-47a5-8977-4646ce7ab20e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_dc7f242c-a9b5-4f6a-8b08-f882b589a390_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3242c02a-f418-44f2-9757-4b994dc8a144_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fdde3c8c-ecf9-4a1d-8b77-e9ac1aa5d5af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68f51fd8-840c-46a9-8922-ca705281ef63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e10c3f1d-7c0d-4956-9838-0851cd9a431a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4d9ce697-5425-43e1-9f17-a34e3ab08b23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_2bb0c79a-773e-4dbf-94ea-ba99e492b6f2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e4219191-7cc5-42f4-a5a2-3fa7c9893d80_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d8770de9-ae9f-46c7-b6d6-5fbc1c78b5d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7bb8f6c9-738f-4328-a092-448909b8ac44_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_4a012690-5d7d-47a1-8098-8379118aeed1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b7549f3c-287a-4b9e-8fdc-a295d52569ec_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AdditionalPurchaseAgreementMember_25b06bcf-9644-4e82-8d9c-02ed33afbe25_terseLabel_en-US" xlink:label="lab_clbs_AdditionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Purchase Agreement</link:label>
    <link:label id="lab_clbs_AdditionalPurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_AdditionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_AdditionalPurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_AdditionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AdditionalPurchaseAgreementMember" xlink:href="clbs-20210331.xsd#clbs_AdditionalPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AdditionalPurchaseAgreementMember" xlink:to="lab_clbs_AdditionalPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f2607443-f1b3-4f41-aefa-6aa226e4f905_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_60f6d5f1-9fa3-4874-b613-297f2e00e238_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares authorized per agreement (in shares)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" xlink:to="lab_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_19b1c18a-3bc4-404f-b625-7b0877f18ecd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3b1e0bb3-96fd-4f24-afc9-e69f157cf31c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f14e2189-6ab5-4983-927b-0a77abae2d16_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d6f29bf7-f1da-46da-a858-bad81fc8b431_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_b5e39e75-13f5-420d-b75c-b71f24d12a69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a3b01c6e-a128-4c66-b0fe-cfdf246d6f70_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5d60ff7d-e2ae-4f20-8cb0-0865da8fa5ce_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_2b93e935-dd44-4dcf-8cce-437223a868f4_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_0f5d33d4-6729-4189-a7b7-4b27688b6d1c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f0fec632-37bd-41c3-99d0-e3fa6a5a515a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5a0c6f91-bb45-4edf-b9a9-c1d88ecc6bf7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,510,038 and 19,389,413 shares at March 31, 2021 and December 31, 2020, respectively; and outstanding, 59,498,958 and 19,378,333 shares at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_TermOfAgreement_52d63c1f-ad06-4252-8b11-7bf282717664_terseLabel_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in months)</link:label>
    <link:label id="lab_clbs_TermOfAgreement_label_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_clbs_TermOfAgreement_documentation_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement" xlink:href="clbs-20210331.xsd#clbs_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_TermOfAgreement" xlink:to="lab_clbs_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_dac657f0-7026-4ab6-8090-af2c31524e08_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less - net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_301f53a7-1acf-4e67-bd0e-219f8a9b1241_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b49a7be1-a962-4d16-8a37-b7e4e9f82b92_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_814658de-8a5e-4407-a817-4e32d4bbcdfa_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_0d2bd61f-bdab-4c18-a29f-70c1c657541e_terseLabel_en-US" xlink:label="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of accrued grant funding to offset expense</link:label>
    <link:label id="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_label_en-US" xlink:label="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Accrued Grant Funding Liability To Offset Expense</link:label>
    <link:label id="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_documentation_en-US" xlink:label="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Accrued Grant Funding Liability To Offset Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:href="clbs-20210331.xsd#clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:to="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_40ab9181-8f96-4355-bd91-a2c741b181e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_FundingOfGrantAwardCashReceived_329ae01a-4de6-4704-9ddb-5ae64e55b6b0_terseLabel_en-US" xlink:label="lab_clbs_FundingOfGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding of grant award</link:label>
    <link:label id="lab_clbs_FundingOfGrantAwardCashReceived_label_en-US" xlink:label="lab_clbs_FundingOfGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Of Grant Award, Cash Received</link:label>
    <link:label id="lab_clbs_FundingOfGrantAwardCashReceived_documentation_en-US" xlink:label="lab_clbs_FundingOfGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Of Grant Award, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FundingOfGrantAwardCashReceived" xlink:href="clbs-20210331.xsd#clbs_FundingOfGrantAwardCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_FundingOfGrantAwardCashReceived" xlink:to="lab_clbs_FundingOfGrantAwardCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsCanceled_b3ea75ee-44ff-4439-ab55-ce73bf8a63da_negatedLabel_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_label_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled" xlink:href="clbs-20210331.xsd#clbs_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsCanceled" xlink:to="lab_clbs_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember_47188e0a-087e-442d-9682-45ffe473c65d_terseLabel_en-US" xlink:label="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H.C. Wainwright Sales Amended Agreement</link:label>
    <link:label id="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember_label_en-US" xlink:label="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H.C. Wainwright Sales Amended Agreement [Member]</link:label>
    <link:label id="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember_documentation_en-US" xlink:label="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H.C. Wainwright Sales Amended Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:href="clbs-20210331.xsd#clbs_H.C.WainwrightSalesAmendedAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:to="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_043188c2-116f-4491-8cb7-4846f62ff6ad_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9f52fd2b-9b9f-4aca-88eb-cba3819ee6e9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_e1a72500-b8c5-4f89-9048-9cc744d924a9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates_667ead7e-25e4-4fd5-9c9a-b38932964f9b_terseLabel_en-US" xlink:label="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate market of common stock held by non-affiliates</link:label>
    <link:label id="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates_label_en-US" xlink:label="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Market Value Of Common Stock, Non-Affiliates</link:label>
    <link:label id="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates_documentation_en-US" xlink:label="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Market Value Of Common Stock, Non-Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateMarketValueOfCommonStockNonAffiliates" xlink:href="clbs-20210331.xsd#clbs_AggregateMarketValueOfCommonStockNonAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateMarketValueOfCommonStockNonAffiliates" xlink:to="lab_clbs_AggregateMarketValueOfCommonStockNonAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a69970-972c-443e-b6a4-ff974e4b955e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_UsEquityPlanMember_543af8fe-8a00-4cab-b717-aa167f41fd7c_terseLabel_en-US" xlink:label="lab_clbs_UsEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Equity Plan [Member]</link:label>
    <link:label id="lab_clbs_UsEquityPlanMember_label_en-US" xlink:label="lab_clbs_UsEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Equity Plan [Member]</link:label>
    <link:label id="lab_clbs_UsEquityPlanMember_documentation_en-US" xlink:label="lab_clbs_UsEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Equity Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UsEquityPlanMember" xlink:href="clbs-20210331.xsd#clbs_UsEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_UsEquityPlanMember" xlink:to="lab_clbs_UsEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4985c809-d349-4411-bf63-17aac6893795_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7cfc68f7-66be-4b78-b3a6-ae2911e4e5cc_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f45b739b-1fab-4f06-89f2-4c7b0b7c250f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dea0957f-621f-4eda-805d-685b6ea481c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2f4dac02-849a-4a47-ad0a-4aff9fb6c3a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2cd3a338-a9d0-40c3-b4a8-a7e1207aae63_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_b4535392-8fae-4919-a337-c31610546a93_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_801a3ef6-4cc5-41d9-b662-945bece53c86_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d70ef9aa-8111-49a3-b4ef-95ce5c713641_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52bfac1c-1803-47f1-9949-349b00623bd5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of restricted stock issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_088e51c1-2c4d-4ad0-b3fd-86324dd19e0a_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b6b6334b-7bfc-41c6-8c05-a5da20ab4b96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84d797ba-4ea6-463c-9bdd-af62c3ce71d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_691cb866-183e-4043-97b2-b0a22c309a93_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_619c2bbc-7f26-4a13-ad30-2ae53b12ed24_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d0b6eb29-3dc9-4ec7-8917-ecc507e76ccd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_f23abe79-0f7f-47e6-b518-835d44bd442e_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_476e6ffc-6963-45ee-abef-e845e176db5e_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_628a8a4b-4b50-4993-9a79-6def96f5e777_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_67c371f1-ee2d-4a01-8ef0-9f04eba771f2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0ed1d430-9580-4920-a2b1-fc29fd85f291_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecee29af-b08c-417d-a09e-b09fd3e6858c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7f0072f2-f9e1-479a-9a26-0299342d114a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_200ba5d3-92e2-4711-99e5-dc1bf4a3c16f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_2896b0aa-eda3-4823-b626-4429ae8460eb_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e2a9971-7f4d-40f1-a068-9575eb375290_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_90292121-27b7-40cb-93cc-ef8f4337600f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7f9bba5e-6406-4db8-b6cd-8ab7896ac4fa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Caladrius Biosciences, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_303709bd-2ab8-4013-84ee-b8d763624fa9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProgressPaymentOnGrantAwardCashReceived_c684130e-0242-4cc2-afac-7726cf1621d3_terseLabel_en-US" xlink:label="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress payment received on grant award</link:label>
    <link:label id="lab_clbs_ProgressPaymentOnGrantAwardCashReceived_label_en-US" xlink:label="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress Payment On Grant Award, Cash Received</link:label>
    <link:label id="lab_clbs_ProgressPaymentOnGrantAwardCashReceived_documentation_en-US" xlink:label="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress Payment On Grant Award, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:href="clbs-20210331.xsd#clbs_ProgressPaymentOnGrantAwardCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:to="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_228d6fe0-5f1a-4f66-a629-e5b07fe575eb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity, Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NetOperatingLossAnalysisAnnualLimitation_dea7872b-e90a-47e3-9f7f-8f09c6a30c3d_terseLabel_en-US" xlink:label="lab_clbs_NetOperatingLossAnalysisAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual limitation on usage of net operating losses</link:label>
    <link:label id="lab_clbs_NetOperatingLossAnalysisAnnualLimitation_label_en-US" xlink:label="lab_clbs_NetOperatingLossAnalysisAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Analysis, Annual Limitation</link:label>
    <link:label id="lab_clbs_NetOperatingLossAnalysisAnnualLimitation_documentation_en-US" xlink:label="lab_clbs_NetOperatingLossAnalysisAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Analysis, Annual Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetOperatingLossAnalysisAnnualLimitation" xlink:href="clbs-20210331.xsd#clbs_NetOperatingLossAnalysisAnnualLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NetOperatingLossAnalysisAnnualLimitation" xlink:to="lab_clbs_NetOperatingLossAnalysisAnnualLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_57e406d2-410a-432a-85e3-30ea5eb417fe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7edd2cff-7cf5-4cac-b4e1-4d50b7c98c4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3038ca30-e860-4258-9232-1ae75df5d2d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_eb7bb61d-fa7c-427f-b6b6-e3b136342c1c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_792d356a-f8a6-45b6-93d4-7e1caf802274_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0f099ee0-46f0-43ec-94cf-170c235cd119_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_ec952c11-9c7f-4a63-be28-d60b82e9a4f6_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants awarded</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_eda076a0-6f91-4dd1-8f4b-b12fa208fcae_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_dc5af50f-c6f5-4d3a-a5ad-64eeb84768fc_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Caladrius Biosciences, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_7464b26c-a70d-42c5-b1b0-a16210948a8e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Captions</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_3ec1cc46-778f-4d04-8695-2eb8beee0695_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1a237850-6698-4478-ae1f-fe63fc9ecd00_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_179f7c99-dacf-4485-8ab1-d21a24b56008_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cdf4169d-764f-46ca-a652-d5ac8eab2160_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6eefde9-ffb7-47c4-aaa5-6d7a4e66776a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da8f7dfa-c145-47b0-9d3d-f57d161cc6d8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_57b7cc34-0527-4402-9ad1-7dd97c3173f4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_b3bda148-db30-43aa-87f5-6edf118dc5b8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsGranted_c9ac27e3-aea1-4e11-83ce-224ea634fbf4_terseLabel_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsGranted_label_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_clbs_WarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted" xlink:href="clbs-20210331.xsd#clbs_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsGranted" xlink:to="lab_clbs_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_380e8eb3-42fd-4b21-9483-b37810b2245a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_e34d8582-cace-4580-b060-8eff90aad67f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_80be6d32-58ec-4839-afc5-1db7fd763663_terseLabel_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="clbs-20210331.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a13c655e-4ace-444c-8a84-dfb21bb06c1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_027df033-b6d7-4408-a769-af920217f3b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b4bfdb24-f829-4242-ae7f-9bcceb037628_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7864a668-81a2-4044-8edc-e2a225d02f1a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_82276056-349c-405c-982c-ee4ff026bba4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f9b74af2-b9a7-4846-8ba3-a6fc50e67080_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ab52aa95-51e5-4890-a696-06c7cff69ce9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4a23761c-ae4d-4b4c-862d-e1666e5f0341_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_8f2581ab-1a75-4b93-accb-dff656f50735_periodStartLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_cac2ce8f-79e2-4217-850a-342b8baf66e0_periodEndLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18ba2161-a662-46c6-95f1-67b3e1372c2e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_30179f3f-2a41-4bb4-8f87-f7bbaf377f3f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_a4c00692-3222-4dae-88b2-7d0d3e76e9c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_affcb8f6-c2de-423c-8f98-04e885d45223_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d4bdd69f-b36d-427b-8740-fae4665ca296_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_3e5a9065-2090-49df-8f32-107578feb52a_terseLabel_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="clbs-20210331.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_abff198b-eddc-4012-864a-5b9e3cacc0a6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiration term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_6a8725e0-37fb-4a61-8592-52111216c822_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3f0e975-b094-40da-9dcb-0857e30789ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c676a22e-8263-4475-82f2-733b15c82d98_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Caladrius Biosciences, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_82880e7c-e51b-4de9-b67d-e23c6a426bd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d7817887-2477-494d-bfd7-004270580f6f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b4af7011-a538-4572-90b2-6465869f6e8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8a095fe9-c726-4add-a857-45f92a971f1d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_18c33697-39f7-407f-88a7-78172e0f0f6b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_38d5968a-7a48-45aa-bd0a-82052a5269dc_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a5e0edfb-145e-4e8e-88da-7e57fed17b31_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e782094f-54b4-41cd-9f28-bfc5967d22a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0c294885-1073-47f2-8da6-3a0c8234e157_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a252021e-fde3-4f9f-b398-b0033b0a429d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7a678fe3-9791-4452-9246-1150070843b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_IschemicRepairCD34CellTechnologyMember_441c83f6-e8cb-43bc-bc18-52d242e388e0_terseLabel_en-US" xlink:label="lab_clbs_IschemicRepairCD34CellTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CD34 cell technology</link:label>
    <link:label id="lab_clbs_IschemicRepairCD34CellTechnologyMember_label_en-US" xlink:label="lab_clbs_IschemicRepairCD34CellTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ischemic Repair CD34 Cell Technology [Member]</link:label>
    <link:label id="lab_clbs_IschemicRepairCD34CellTechnologyMember_documentation_en-US" xlink:label="lab_clbs_IschemicRepairCD34CellTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ischemic Repair CD34 Cell Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IschemicRepairCD34CellTechnologyMember" xlink:href="clbs-20210331.xsd#clbs_IschemicRepairCD34CellTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_IschemicRepairCD34CellTechnologyMember" xlink:to="lab_clbs_IschemicRepairCD34CellTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a8a80968-618e-459f-981f-f4e2959beb62_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b257a891-8bde-45ad-8c28-5094083d0428_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fd5d0697-a71f-4d87-ad7c-adad5d222d7f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_a3187d7b-230e-407e-9ac6-82af2859027a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5fc52702-a185-4011-bf3f-d47321a8d998_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a6f77e05-83ff-43fb-8f50-525a86a502cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_92234954-94d1-40fa-9664-667965910c70_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_66051348-704d-4202-8b39-69a74b2284c8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8fe9c36e-4c81-41b3-a766-4709cd551272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f75a1e25-d77d-458f-a7af-aedf861b8a16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities - net unrealized loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9afb857-4755-489b-90e8-25a141805eba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a06e8cd4-d466-41a3-911e-68d197b6620b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d084488-f22e-4d9a-b91a-ad6b3c3bef17_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants issued</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6a3fd583-9f1e-4f04-86bf-810e30de5c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_daeaa00b-bd42-456e-a34e-227b623c4af3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_94a0325e-f9df-43eb-b7f4-1926c2457cac_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_6e6ed32e-4ff9-40c9-8c27-c3a1781c8d77_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_53ed2fd8-b82c-48ed-bae9-fa35ac154b13_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of restricted stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4eb0ebc5-e987-47c2-be7d-a00f049c6c44_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross price for stock transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LincolnParkAgreementMember_9a480457-601a-4d4c-b2e2-9d9222df3234_terseLabel_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_label_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_documentation_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember" xlink:href="clbs-20210331.xsd#clbs_LincolnParkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LincolnParkAgreementMember" xlink:to="lab_clbs_LincolnParkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a93b92fa-54d7-45e7-9e17-37c865e5a0d0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_601cfff2-f5bf-4b85-ad27-9606f08b19d0_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_89d1b34e-9572-4861-937a-4c7522314a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_870f4658-0b2e-4d91-888c-db08d62b90ec_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_aef31496-a1fb-49f0-97d8-d89941304f74_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c4c63205-0d36-4963-9dbf-e34382b57c20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5933b5bd-6e12-420a-9b9d-f2e38d8498bb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a47f9523-54df-4424-87a4-f3ad08a46a9b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8132c18d-ceb4-4948-b3ff-f534b01d40e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_356df6d2-4373-4972-9860-e5877ce2ab4b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76cb6b6d-c3f9-4d44-9f8b-37f5d4b42429_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_76040d6f-8a10-473a-83b9-75285d897dd5_terseLabel_en-US" xlink:label="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market capitalization used in net operating loss analysis</link:label>
    <link:label id="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_label_en-US" xlink:label="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Capitalization Used In Net Operating Loss Analysis</link:label>
    <link:label id="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_documentation_en-US" xlink:label="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Capitalization Used In Net Operating Loss Analysis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" xlink:href="clbs-20210331.xsd#clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" xlink:to="lab_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f2e2919c-ea5b-47f8-834c-52cbca363dbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_a384fa8b-5a9d-49ea-a406-3b4b704a82e5_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_f90d23d9-f62d-4154-8946-3facfc86c4a6_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_45988736-6265-4dfc-8eac-bc4c84560d59_terseLabel_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment shares issued as consideration per agreement (in shares)</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_label_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_documentation_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:href="clbs-20210331.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:to="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_98890415-b8c9-477e-ba6c-fd7b1551fa63_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b75ebde2-77e2-436f-a1a5-587b6e1c2722_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4c4070d7-accf-483f-ba55-555dc32b4d39_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7d7d8b49-22f4-4858-bbb1-1b39c92201ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_640acfcb-684a-41ae-8b3f-44c1b9c19e1d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_fa36b39b-1ea6-400d-bc9b-6fbcb936331f_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission on gross proceeds due to third party (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_label_en-US" xlink:label="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent</link:label>
    <link:label id="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_documentation_en-US" xlink:label="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:to="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f482bfbf-e4d5-40b3-9643-944012a0b0f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a7511edd-fc76-44a6-985f-e1d8db26fd86_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_14e6225a-f884-44ae-a4b6-87d759f6bd1a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_30a1f335-5d5b-496b-aac2-ded3108b5c82_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bff80055-e9b6-4c56-ab99-ece803b013a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d54a605c-63ef-42cf-b630-2259a155fafb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_db919228-3671-405d-b901-0f157a7f427d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d05ff9c3-3f98-4a57-899e-a97c22a6287b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d64a0733-e7e3-4287-8571-acba18d262b2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f3012a34-ba5f-4295-bdeb-a44c95e299bf_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_83b10e09-b34a-4b69-a47d-4a34d5a227aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_41529a1a-a777-4025-8f73-bbdf1c5b8f85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4bcdb207-e563-4144-a94f-f984e36cae0f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3569188e-8a83-4663-b51a-04a86505201b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8a85fd52-883a-4364-a848-4555b350a374_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CommonStockWarrantsShares_b89920cc-519f-4ecc-aa3b-827202137e69_periodStartLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_08e0e616-17ec-43d5-8c9f-2f3ebcbdc2ce_periodEndLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_label_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares" xlink:href="clbs-20210331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CommonStockWarrantsShares" xlink:to="lab_clbs_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_037f69df-b8b1-45cb-a80b-db434e0f749e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_047168bb-9c34-4e5e-b2ea-39e0bc28b3c2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dc5a4c7b-e8c9-463c-8d2f-ad02f64a0906_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_StockOptionsActivityAxis_68f3f994-ea74-4957-9d83-4e234e4cba0e_terseLabel_en-US" xlink:label="lab_clbs_StockOptionsActivityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Activity [Axis]</link:label>
    <link:label id="lab_clbs_StockOptionsActivityAxis_label_en-US" xlink:label="lab_clbs_StockOptionsActivityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Activity [Axis]</link:label>
    <link:label id="lab_clbs_StockOptionsActivityAxis_documentation_en-US" xlink:label="lab_clbs_StockOptionsActivityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityAxis" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_StockOptionsActivityAxis" xlink:to="lab_clbs_StockOptionsActivityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_InstitutionalPurchaseAgreementMember_33928ee6-6cb0-46af-a43e-c31b525565ff_terseLabel_en-US" xlink:label="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Institutional Purchase Agreement</link:label>
    <link:label id="lab_clbs_InstitutionalPurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Institutional Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_InstitutionalPurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Institutional Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_InstitutionalPurchaseAgreementMember" xlink:href="clbs-20210331.xsd#clbs_InstitutionalPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_InstitutionalPurchaseAgreementMember" xlink:to="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1e22725f-185d-4bd3-bd50-f186a1d9af7a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1f4a8da-60f5-4d0a-a279-eb0aae9d28c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_e349be75-4529-4b73-bc42-63e818f08960_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_3889d4b6-db79-407c-9373-184902c0e2db_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca6b1dc3-7306-4f40-aadd-3bcbafee13f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_85c95f34-5489-41ad-86f9-0d4551145940_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f1d5984b-2421-466f-90ca-ed6c66498309_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8124bd7b-8d80-431f-9664-8aa9a6ab5773_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b51d9018-5dee-4c11-9517-f46b5ad0d09a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b95b5163-e525-4800-946f-7e4e4ebc634f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_709a3708-e0a9-4491-ab58-7bf238e4c59e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_db8290f5-e00a-4654-9fc0-0913ec8f4771_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e723de9-5748-4051-bea7-fd6cb444ddf5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_17ea0df8-c60f-41c5-aa14-daf2d0776517_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_598f90ea-8255-4352-8ef2-bd6401818f50_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d640389a-c8d4-404e-a06a-6b8833a8a39f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_24e63690-74c6-4448-9341-db2cb02b4d24_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f3a944e4-cc4f-4ef4-9293-98eb577c5795_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_16672ef5-4eab-4a46-8e20-bbeba472508a_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_13996ebc-6d27-412c-9e9d-22408a8d6dcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b354616d-fedb-48fd-8add-1e0f464c3696_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7380840-a40b-40d5-a7fe-d57380daf9bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fe4edc93-0013-4b7a-9bec-22aebf760877_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_ec0c7772-9e8a-42df-86e0-4c210f236c25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a3e2f0cf-b625-4814-888f-1dae3af2ee92_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e394daa3-64ca-49e5-9725-b90d2c91c40e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a4f5d6b5-f839-4cd1-9bcb-5e9bf97c153b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_870cea84-fb93-4692-984e-ddd28a514547_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5b3e2ae5-75ea-4cba-b1b2-44e5003e6a92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_22adbe00-122a-429c-bb27-d47d2ff02737_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation value</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_label_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_documentation_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:href="clbs-20210331.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:to="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MilestonePaymentOnGrantAwardCashReceived_1911365a-4692-4333-a006-e63809942a4d_terseLabel_en-US" xlink:label="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received on grant award</link:label>
    <link:label id="lab_clbs_MilestonePaymentOnGrantAwardCashReceived_label_en-US" xlink:label="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment On Grant Award, Cash Received</link:label>
    <link:label id="lab_clbs_MilestonePaymentOnGrantAwardCashReceived_documentation_en-US" xlink:label="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment On Grant Award, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:href="clbs-20210331.xsd#clbs_MilestonePaymentOnGrantAwardCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:to="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3d443e10-99f9-46d3-9c7e-7fd298ed4946_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a6617e0f-dcee-410e-a3b8-47c21a9d5369_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_cff2b7a1-05b2-4e7c-a273-fd0bf2c51755_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_92ff765b-99ba-4c74-bcb3-0429e35a0895_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b4b556d6-46d7-4700-814e-9ee1fae2edb0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d5cba948-5c97-4a62-88a9-ca4682c38edf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2a34fac7-27bc-4883-a1ae-1851a2fdcadb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_6bf408dd-5bf5-4f96-86ba-22989d9e5d38_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_51807ac8-e044-4617-943b-ac3f2bb92745_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b1b220b4-03c1-4af4-8ded-01e8e25a7898_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_23b6c29a-e89a-4a96-a5dd-173238ae9254_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_daacce39-2389-4d3f-9093-0dd00ac276aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b3859137-8f55-4be0-93ba-5fa795c5f8f7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e689476f-3d83-4295-a4b7-626a00bd5256_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_a0689ef9-a04e-4a08-bf83-8eca2bc24be9_terseLabel_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offices under operating leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_label_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_documentation_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:href="clbs-20210331.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:to="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b613804c-50ec-4598-ba06-da8c0c26506b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dd4baa87-3597-4af1-9be4-de51bd49d989_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d8036596-7cc9-4a7c-94ac-db4e7da260cc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5ab4920d-dc23-4570-9998-79a58da70020_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c9243e7f-6cf1-4ef8-a58a-94644c8a92ff_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_e49bbebe-b585-4a88-9ad6-90907739f721_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4ac5e5e7-4f98-486b-97d0-a0f79ac58fcd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_41e413fb-a4ca-43ff-b464-5d509520508f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ac717d8b-5977-46f0-894d-d18f298188b4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_ebf34ca0-2c94-4e7c-be74-8f1714b80fb2_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_label_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_documentation_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated" xlink:href="clbs-20210331.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockSharesDesignated" xlink:to="lab_clbs_PreferredStockSharesDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_eca2f342-1c05-4cd6-9d19-c6cdcdd29d9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3cfcc016-7970-4e09-985c-50e478e3ec81_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc405fb6-1c0c-4e7a-856c-464777fa9bf4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7421705e-7d32-42a5-9c75-2918d32bf930_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_11fd3df2-c7ec-4ef1-ae58-86f86ceea509_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_5f9991fd-fc30-4ce9-a89f-0cb972a18b15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_39f8974c-ee8a-4fd6-999e-03537ce9f822_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_982411fb-61f1-4d07-be2a-eb4bb453cf55_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_688eb68a-b500-48d6-865f-da60414e80b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_27dbfb13-676d-4fdf-80ae-fc5aedcb5c6d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bea354d5-7bc4-46e9-bc92-ea0f291180a2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_9f7ae7df-d722-4358-8a74-51d343d6af11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_January2021PurchaseAgreementMember_8895b722-707e-4954-bf9a-85408835f7d4_terseLabel_en-US" xlink:label="lab_clbs_January2021PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Private Placement</link:label>
    <link:label id="lab_clbs_January2021PurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_January2021PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_January2021PurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_January2021PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_January2021PurchaseAgreementMember" xlink:href="clbs-20210331.xsd#clbs_January2021PurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_January2021PurchaseAgreementMember" xlink:to="lab_clbs_January2021PurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_13b6e76b-4ed4-43e1-8e8c-0744268a296d_terseLabel_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="clbs-20210331.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_170d3c03-2941-460d-855c-6b660a48f157_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 11,080 shares at March 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_edae3dbd-f7a8-4f68-a61c-120fa8e3aca3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_b5e31f70-820a-4eb7-a61c-f0de97e801d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0af8da87-4503-48b5-9382-9afcef818c3b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_f2742d3f-9b93-4fd9-ad95-d5549be1973c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b3e8220f-2a5c-4d86-bc8e-08a3b39f1e4f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af331368-cf44-4a75-9e27-877e79b7c1c3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_99527535-5cc6-4fd8-8a70-5de8f1e110a2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_df11f13e-bbe8-4826-aacd-79c0026c0a7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ea28f5b8-6715-4dd5-bca8-8158de198667_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_379587b8-796b-4221-ad36-6c77b0d84c78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9c34d942-f631-4c46-a9ea-eba98a58ad3e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_01c6897d-d871-49e6-b0b7-2c18482a1394_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>clbs-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d9eba1cb-e72d-43c9-86c5-dbb9216f38d8,g:166abcdb-ccb3-45de-adfb-a1da6bb60890-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20210331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a66705a9-bb9f-4e6a-b7ec-132488e3114d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_DocumentType_a66705a9-bb9f-4e6a-b7ec-132488e3114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fe21ce25-dc34-4c59-9249-2d8749c7fd94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_DocumentQuarterlyReport_fe21ce25-dc34-4c59-9249-2d8749c7fd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a7b964e0-5c88-4f1c-b4f0-2465ccf9f74b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_DocumentPeriodEndDate_a7b964e0-5c88-4f1c-b4f0-2465ccf9f74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_93323736-dd09-4c35-a8c1-a25d8e873a65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_DocumentTransitionReport_93323736-dd09-4c35-a8c1-a25d8e873a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2877950f-48f8-4d74-80f7-d118ec9cf1be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityFileNumber_2877950f-48f8-4d74-80f7-d118ec9cf1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ccbb428f-2118-4c7b-a634-0ed8fafed113" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityRegistrantName_ccbb428f-2118-4c7b-a634-0ed8fafed113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b10a2831-6eda-4833-8b2e-dfe428d62aab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b10a2831-6eda-4833-8b2e-dfe428d62aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_63b5aa34-c869-42ed-9a15-82e459e3d210" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityTaxIdentificationNumber_63b5aa34-c869-42ed-9a15-82e459e3d210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_44f79fe1-79ec-4a5f-8daf-f2ce48528917" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityAddressAddressLine1_44f79fe1-79ec-4a5f-8daf-f2ce48528917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e0b4bedb-2021-4045-b3be-8b3e855f9db1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityAddressCityOrTown_e0b4bedb-2021-4045-b3be-8b3e855f9db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_17290c0a-0745-4496-89e4-de7747db89b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityAddressStateOrProvince_17290c0a-0745-4496-89e4-de7747db89b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_15c3e212-1572-4eb3-a0e0-a2e8af0102a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityAddressPostalZipCode_15c3e212-1572-4eb3-a0e0-a2e8af0102a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d937af23-c8c9-4b40-8051-9583f6576c3b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_CityAreaCode_d937af23-c8c9-4b40-8051-9583f6576c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e5ba0e21-6e3a-4ddb-b297-b424edcce12b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_LocalPhoneNumber_e5ba0e21-6e3a-4ddb-b297-b424edcce12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f16dea13-a38a-498c-8aa8-697fcb49881c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_Security12bTitle_f16dea13-a38a-498c-8aa8-697fcb49881c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f5b72695-76d0-4430-bacf-5dce1d85be82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_TradingSymbol_f5b72695-76d0-4430-bacf-5dce1d85be82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_142610f2-9e6a-4ad3-b5a5-6a9b40801321" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_SecurityExchangeName_142610f2-9e6a-4ad3-b5a5-6a9b40801321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_45509cb0-7da7-428b-a480-daf2dc1d4721" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityCurrentReportingStatus_45509cb0-7da7-428b-a480-daf2dc1d4721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fe5cfcfe-091d-4619-8a48-cd098508577d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityInteractiveDataCurrent_fe5cfcfe-091d-4619-8a48-cd098508577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7347682d-8d80-4afe-ac5f-9d095673e0db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityFilerCategory_7347682d-8d80-4afe-ac5f-9d095673e0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e6bef8b2-0a57-40fd-bda6-daab07462c78" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntitySmallBusiness_e6bef8b2-0a57-40fd-bda6-daab07462c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_113c3d41-b1ef-448d-9542-0e342a27b719" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityEmergingGrowthCompany_113c3d41-b1ef-448d-9542-0e342a27b719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_94e59e38-2fa4-46fd-9983-277393cd7d80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityShellCompany_94e59e38-2fa4-46fd-9983-277393cd7d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1e97b373-f06d-4d49-8c8d-024e4013daef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityCentralIndexKey_1e97b373-f06d-4d49-8c8d-024e4013daef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_daefb920-5f0c-4ac9-899e-8bed0f215d87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_CurrentFiscalYearEndDate_daefb920-5f0c-4ac9-899e-8bed0f215d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e5c58c46-d96a-4db4-81b1-274a4fd4efa2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_DocumentFiscalYearFocus_e5c58c46-d96a-4db4-81b1-274a4fd4efa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5758e35d-9692-43b5-80a3-76695a2c0f60" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5758e35d-9692-43b5-80a3-76695a2c0f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fbda5a83-39d3-4a85-b79d-f03c85c20777" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_AmendmentFlag_fbda5a83-39d3-4a85-b79d-f03c85c20777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d5a222f1-d56e-4e99-a57e-cb1b045aa0a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8c3a32a8-44ab-4639-a01b-a0f8c39f8fb6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d5a222f1-d56e-4e99-a57e-cb1b045aa0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fbfad721-f3d7-4b61-8f4f-e4785e3bc321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fbfad721-f3d7-4b61-8f4f-e4785e3bc321" xlink:to="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2616fcb-ae96-447e-80cb-fb97609a5dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f2616fcb-ae96-447e-80cb-fb97609a5dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_e653d25b-b136-47a3-9533-ced99ab4e3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_MarketableSecurities_e653d25b-b136-47a3-9533-ced99ab4e3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be9a5e39-169a-4f7d-8b8d-7b8b9a566cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be9a5e39-169a-4f7d-8b8d-7b8b9a566cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cb00f420-5c5a-47c2-9bff-42954615db6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_AssetsCurrent_cb00f420-5c5a-47c2-9bff-42954615db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1797acad-6678-48c9-a6aa-e7ea24e5089f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1797acad-6678-48c9-a6aa-e7ea24e5089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dcb75571-187e-4625-9ab1-a0971a8d5818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dcb75571-187e-4625-9ab1-a0971a8d5818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d103cef9-61de-4d70-9835-e4a5e385a072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cc2934e-6cf3-4e16-8d00-99fa8865564a" xlink:to="loc_us-gaap_Assets_d103cef9-61de-4d70-9835-e4a5e385a072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1fcc12bc-5848-400b-b070-bb6508a4dda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fbfad721-f3d7-4b61-8f4f-e4785e3bc321" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1fcc12bc-5848-400b-b070-bb6508a4dda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1fcc12bc-5848-400b-b070-bb6508a4dda6" xlink:to="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3b1a70b0-3610-4401-9c78-dc97ed64dbe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:to="loc_us-gaap_AccountsPayableCurrent_3b1a70b0-3610-4401-9c78-dc97ed64dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4dce0274-d8f1-4751-93f6-5c0b0bb0fa0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4dce0274-d8f1-4751-93f6-5c0b0bb0fa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1214d977-5bfa-4c36-bf31-062108536458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:to="loc_us-gaap_LiabilitiesCurrent_1214d977-5bfa-4c36-bf31-062108536458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_553ee12a-0970-49e3-b0a8-67de8248af3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_553ee12a-0970-49e3-b0a8-67de8248af3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eba4a8ad-d105-4043-8c2f-240353c0ed58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d85696c3-26df-4177-a55a-bae11523c6b1" xlink:to="loc_us-gaap_Liabilities_eba4a8ad-d105-4043-8c2f-240353c0ed58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0f8caa3d-766b-43fb-abaa-239ea2fc6076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1fcc12bc-5848-400b-b070-bb6508a4dda6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0f8caa3d-766b-43fb-abaa-239ea2fc6076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1fcc12bc-5848-400b-b070-bb6508a4dda6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2a4cf8f8-328f-448c-94d0-4642d87df058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_PreferredStockValue_2a4cf8f8-328f-448c-94d0-4642d87df058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_69cd5480-624b-4dd9-9a32-f938b1a6b1cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_CommonStockValue_69cd5480-624b-4dd9-9a32-f938b1a6b1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f5a7db90-1143-49b8-84c8-f6dac7f8e0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f5a7db90-1143-49b8-84c8-f6dac7f8e0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_2e908c61-6c6e-43f1-b4e0-188bb7163c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_TreasuryStockValue_2e908c61-6c6e-43f1-b4e0-188bb7163c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ada429c2-0b70-4e3a-b093-03e964cfb5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ada429c2-0b70-4e3a-b093-03e964cfb5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_607d8856-cadc-45ae-8a14-7d7b0502aea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_607d8856-cadc-45ae-8a14-7d7b0502aea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f7aabb73-0b8b-452d-806b-7f5728624b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_StockholdersEquity_f7aabb73-0b8b-452d-806b-7f5728624b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5f5e9d31-e000-4c1b-8616-292ea5fad0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_MinorityInterest_5f5e9d31-e000-4c1b-8616-292ea5fad0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c57f899-745e-4383-8703-70fde9ab105c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473722d-05b9-49ac-af9c-9d9b4eeb4b05" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c57f899-745e-4383-8703-70fde9ab105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c762da58-c5be-4448-a12d-1a8e213cf97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1fcc12bc-5848-400b-b070-bb6508a4dda6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c762da58-c5be-4448-a12d-1a8e213cf97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8f874d1d-896f-420e-ab48-8d2a6c0b545c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8f874d1d-896f-420e-ab48-8d2a6c0b545c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare_070f0964-e37d-4fbd-a4e2-c69042a44930" xlink:href="clbs-20210331.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_clbs_PreferredStockLiquidationPreferenceShare_070f0964-e37d-4fbd-a4e2-c69042a44930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dd3e3b1b-7d87-4dcf-a729-e42795a3ac53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_dd3e3b1b-7d87-4dcf-a729-e42795a3ac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated_106b05a1-eec9-4dcd-9641-af450f72e76d" xlink:href="clbs-20210331.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_clbs_PreferredStockSharesDesignated_106b05a1-eec9-4dcd-9641-af450f72e76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ea4cde93-34ce-4157-bc7e-1e397f816c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ea4cde93-34ce-4157-bc7e-1e397f816c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7d08f822-1c35-4e84-81c3-50d3c233f751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7d08f822-1c35-4e84-81c3-50d3c233f751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6177b073-7289-49df-b3b6-a1ad9e590969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6177b073-7289-49df-b3b6-a1ad9e590969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f5484940-6402-4469-ae69-0f9b09ab0f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f5484940-6402-4469-ae69-0f9b09ab0f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e1887578-5da2-4442-8801-d2265834fca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_CommonStockSharesIssued_e1887578-5da2-4442-8801-d2265834fca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_36fdbccd-25db-4642-8904-8187b1fc3e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_36fdbccd-25db-4642-8904-8187b1fc3e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_ec94bb2a-7a62-42ce-b43c-d8e0166bcfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f4d1056c-25bf-4ddc-b27c-eda2a18e9ebd" xlink:to="loc_us-gaap_TreasuryStockShares_ec94bb2a-7a62-42ce-b43c-d8e0166bcfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_86283922-1dd7-4318-9525-6f75d123b7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_OperatingExpensesAbstract_86283922-1dd7-4318-9525-6f75d123b7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_140951c4-b87c-4d63-b9ef-13d33e596e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_86283922-1dd7-4318-9525-6f75d123b7f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_140951c4-b87c-4d63-b9ef-13d33e596e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c5dc4dc9-f18d-4ab9-8681-bbb7b0f55aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_86283922-1dd7-4318-9525-6f75d123b7f5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c5dc4dc9-f18d-4ab9-8681-bbb7b0f55aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_35351d85-b8e0-41d4-82ba-7d8854c043c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_86283922-1dd7-4318-9525-6f75d123b7f5" xlink:to="loc_us-gaap_OperatingExpenses_35351d85-b8e0-41d4-82ba-7d8854c043c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_41041001-221f-4c01-99ee-02355dfafd7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_OperatingIncomeLoss_41041001-221f-4c01-99ee-02355dfafd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a9f80330-09d2-4e0b-96bd-1de7cbe96e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a9f80330-09d2-4e0b-96bd-1de7cbe96e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3b707093-c259-4970-94e7-d1caa9e81d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a9f80330-09d2-4e0b-96bd-1de7cbe96e4f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3b707093-c259-4970-94e7-d1caa9e81d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2543ead6-7c79-48a5-be59-bb7e4f2886a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a9f80330-09d2-4e0b-96bd-1de7cbe96e4f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2543ead6-7c79-48a5-be59-bb7e4f2886a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ab5b5603-3847-4cd8-8e2f-301bc1a5c67f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_ProfitLoss_ab5b5603-3847-4cd8-8e2f-301bc1a5c67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_cfff877b-3ab1-467b-9614-df71a6dadfd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_cfff877b-3ab1-467b-9614-df71a6dadfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46d2949a-e80f-420f-b88b-b46c7b11e72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_NetIncomeLoss_46d2949a-e80f-420f-b88b-b46c7b11e72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_3e197f86-b9c6-4de9-a0b2-6834bcdbbefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_3e197f86-b9c6-4de9-a0b2-6834bcdbbefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78d0aeb4-d6a9-4f0b-a0cb-98a062368c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_3e197f86-b9c6-4de9-a0b2-6834bcdbbefa" xlink:to="loc_us-gaap_EarningsPerShareBasic_78d0aeb4-d6a9-4f0b-a0cb-98a062368c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6c546e07-9b6a-4a55-9458-24970218526d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_3e197f86-b9c6-4de9-a0b2-6834bcdbbefa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6c546e07-9b6a-4a55-9458-24970218526d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20cb85cc-7929-41e3-bb60-48fb219b5c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4638dba2-0bfc-4ae1-81c2-109a8b962c55" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20cb85cc-7929-41e3-bb60-48fb219b5c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f79bbc3-bcf9-48fc-abd9-ccedd4212f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20cb85cc-7929-41e3-bb60-48fb219b5c90" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f79bbc3-bcf9-48fc-abd9-ccedd4212f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19251977-8579-4443-8995-3e82aad51b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20cb85cc-7929-41e3-bb60-48fb219b5c90" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_19251977-8579-4443-8995-3e82aad51b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_10f94595-96be-4c6d-a6c1-ee5db7e2836b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:to="loc_us-gaap_ProfitLoss_10f94595-96be-4c6d-a6c1-ee5db7e2836b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_08e8b1e3-d2c3-4de1-8a72-efbc51b35f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_08e8b1e3-d2c3-4de1-8a72-efbc51b35f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2ffad96-982b-4b30-b31e-47259a65a978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2ffad96-982b-4b30-b31e-47259a65a978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_43a98f85-f7a5-4ea5-aaa6-193dddcc3520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_43a98f85-f7a5-4ea5-aaa6-193dddcc3520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f8bee0fe-774b-4700-b6c3-e73ea9403c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f8bee0fe-774b-4700-b6c3-e73ea9403c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f557406-f23c-46c6-9b22-3d2646cef240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6813480d-6722-4647-9bad-6ffaeeb359df" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f557406-f23c-46c6-9b22-3d2646cef240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ccd5cf53-998d-42ed-966b-1cc75708daba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ccd5cf53-998d-42ed-966b-1cc75708daba" xlink:to="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5b72aa57-03bb-458b-90b1-89a83dd427d1" xlink:to="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:to="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ef7f6c54-46fb-4f2e-821a-c73537386f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_PreferredStockMember_ef7f6c54-46fb-4f2e-821a-c73537386f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d5cd1191-18c7-4319-a684-0ca503711ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_CommonStockMember_d5cd1191-18c7-4319-a684-0ca503711ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c3771c61-6464-4d65-983c-3cba15210018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c3771c61-6464-4d65-983c-3cba15210018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_62e3832e-5140-4203-a969-48461c296585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_62e3832e-5140-4203-a969-48461c296585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c85eef9b-2ac6-47c0-bfdc-fb6b61974ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_RetainedEarningsMember_c85eef9b-2ac6-47c0-bfdc-fb6b61974ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e55e9ed3-ed84-4493-8728-7df3cfcfda99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_51d2db38-5c47-47ba-84ba-6dd9142614d5" xlink:to="loc_us-gaap_TreasuryStockMember_e55e9ed3-ed84-4493-8728-7df3cfcfda99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9db7c422-e12a-4bed-a7d8-578824fadd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_00dbb3d2-7425-4832-98fa-541ad468f26d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9db7c422-e12a-4bed-a7d8-578824fadd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c7a6796d-b90f-406a-ac95-fe3c45021aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4170a12b-68cd-4ae7-9a67-92422378fce3" xlink:to="loc_us-gaap_StatementLineItems_c7a6796d-b90f-406a-ac95-fe3c45021aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c7a6796d-b90f-406a-ac95-fe3c45021aa0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9b3985b3-6ed1-432c-b260-dea7862f87e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_SharesOutstanding_9b3985b3-6ed1-432c-b260-dea7862f87e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0017bdeb-9b14-40c3-866f-88e356dd6fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0017bdeb-9b14-40c3-866f-88e356dd6fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_345721a5-34c2-41b0-823a-b716069b169a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_ProfitLoss_345721a5-34c2-41b0-823a-b716069b169a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_428d9035-938d-4f0f-b15a-5085d41bdaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_428d9035-938d-4f0f-b15a-5085d41bdaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d840b2e0-e1ef-4c47-8ce8-6cedc504f5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d840b2e0-e1ef-4c47-8ce8-6cedc504f5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1325a85f-8926-41e4-ae5a-975a9c3ac72f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1325a85f-8926-41e4-ae5a-975a9c3ac72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_434097e7-7560-482b-95a9-1e96935a2b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_434097e7-7560-482b-95a9-1e96935a2b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b6dfd77-9d31-496b-b442-930129faca11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b6dfd77-9d31-496b-b442-930129faca11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e50733b-c5f8-4b9e-bf9a-3127f236bf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e50733b-c5f8-4b9e-bf9a-3127f236bf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8996671e-cab7-4fe0-8e96-72ae6d614421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8996671e-cab7-4fe0-8e96-72ae6d614421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dbfaeca6-e1fb-42e1-831c-07a72a70d984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_SharesOutstanding_dbfaeca6-e1fb-42e1-831c-07a72a70d984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cedbfe63-0e94-4aec-bd99-f2860d26482d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3334a033-2d21-4fbc-9c9d-cc62641794a4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cedbfe63-0e94-4aec-bd99-f2860d26482d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20210331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2e07c07-e073-4535-ae03-04a22682b1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2e07c07-e073-4535-ae03-04a22682b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_682b8c0f-512a-4389-bce3-9acbc530ccbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2e07c07-e073-4535-ae03-04a22682b1c3" xlink:to="loc_us-gaap_ProfitLoss_682b8c0f-512a-4389-bce3-9acbc530ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecc2f25b-2b39-42f4-873c-dd914c75dbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2e07c07-e073-4535-ae03-04a22682b1c3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecc2f25b-2b39-42f4-873c-dd914c75dbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_91804ca3-8e72-42b6-a4cc-487b372151b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecc2f25b-2b39-42f4-873c-dd914c75dbbb" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_91804ca3-8e72-42b6-a4cc-487b372151b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_711a2bb9-54f9-4d01-ba21-6d42507600bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecc2f25b-2b39-42f4-873c-dd914c75dbbb" xlink:to="loc_us-gaap_DepreciationAndAmortization_711a2bb9-54f9-4d01-ba21-6d42507600bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_914cef87-c635-46d1-8b40-83064be51576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecc2f25b-2b39-42f4-873c-dd914c75dbbb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_914cef87-c635-46d1-8b40-83064be51576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c044b2f-8778-4d85-9af1-750d199e2778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2e07c07-e073-4535-ae03-04a22682b1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c044b2f-8778-4d85-9af1-750d199e2778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e514bcad-8cf8-4a97-a9d4-a2ec52a74c91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c044b2f-8778-4d85-9af1-750d199e2778" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e514bcad-8cf8-4a97-a9d4-a2ec52a74c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1f3593f0-aa58-40fb-a156-01728fcae509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c044b2f-8778-4d85-9af1-750d199e2778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1f3593f0-aa58-40fb-a156-01728fcae509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_b2b0999f-b516-4084-9be2-72e42c80a7d4" xlink:href="clbs-20210331.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c044b2f-8778-4d85-9af1-750d199e2778" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_b2b0999f-b516-4084-9be2-72e42c80a7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9ec71c7-2200-46a9-8f5b-9552e456295a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f2e07c07-e073-4535-ae03-04a22682b1c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c9ec71c7-2200-46a9-8f5b-9552e456295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70a8fd1b-9a5d-4b38-8f13-6ce1499a7a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70a8fd1b-9a5d-4b38-8f13-6ce1499a7a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4338d52d-7f6e-49e5-9dcc-12f0c740aa67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70a8fd1b-9a5d-4b38-8f13-6ce1499a7a62" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4338d52d-7f6e-49e5-9dcc-12f0c740aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_bfc468df-cd0b-4587-b3b2-18fa8dfb9983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70a8fd1b-9a5d-4b38-8f13-6ce1499a7a62" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_bfc468df-cd0b-4587-b3b2-18fa8dfb9983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2320716d-8510-4b76-b5e0-3897076cbac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70a8fd1b-9a5d-4b38-8f13-6ce1499a7a62" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2320716d-8510-4b76-b5e0-3897076cbac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eee503bb-ed0a-49ac-95b6-112008891230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_70a8fd1b-9a5d-4b38-8f13-6ce1499a7a62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eee503bb-ed0a-49ac-95b6-112008891230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5e16bdd9-425e-4143-9968-0b42be2fca45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5e16bdd9-425e-4143-9968-0b42be2fca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_88405901-3fc8-4edd-8268-267b0c57befa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5e16bdd9-425e-4143-9968-0b42be2fca45" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_88405901-3fc8-4edd-8268-267b0c57befa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a523a349-e416-4569-a043-fa56803e964e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5e16bdd9-425e-4143-9968-0b42be2fca45" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a523a349-e416-4569-a043-fa56803e964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d43075b-cbf8-4919-ad97-cf108529e162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5e16bdd9-425e-4143-9968-0b42be2fca45" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d43075b-cbf8-4919-ad97-cf108529e162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45fb5206-4f9b-46df-9fbb-e102ac19de65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5e16bdd9-425e-4143-9968-0b42be2fca45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45fb5206-4f9b-46df-9fbb-e102ac19de65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6124de5-c652-4691-99f2-16b12316d8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6124de5-c652-4691-99f2-16b12316d8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14cfd144-55ad-49e5-9e94-67b640693432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14cfd144-55ad-49e5-9e94-67b640693432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_19dddc18-9c1c-477a-ad6a-307757560bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9c51bec9-407b-4193-bfe5-b40e2ab79ab9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_19dddc18-9c1c-477a-ad6a-307757560bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20210331.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7acb2eee-f1b4-4ba5-bbc2-65e67e3fb31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock_3a3e3f06-1fac-4210-8882-c08c22c0f679" xlink:href="clbs-20210331.xsd#clbs_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7acb2eee-f1b4-4ba5-bbc2-65e67e3fb31b" xlink:to="loc_clbs_BusinessTextBlock_3a3e3f06-1fac-4210-8882-c08c22c0f679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessNarrativeDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#TheBusinessNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15080d09-d182-4b36-930a-cb0367001ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15080d09-d182-4b36-930a-cb0367001ec9" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c32b5b2d-4e42-4129-aba5-eba66dcf8e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_adb0ed84-ae64-4872-adef-d9136e92aef1" xlink:to="loc_us-gaap_ProjectMember_c32b5b2d-4e42-4129-aba5-eba66dcf8e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IschemicRepairCD34CellTechnologyMember_d5f2e0ae-c4f2-4777-8b4a-dcb3911c677a" xlink:href="clbs-20210331.xsd#clbs_IschemicRepairCD34CellTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_c32b5b2d-4e42-4129-aba5-eba66dcf8e36" xlink:to="loc_clbs_IschemicRepairCD34CellTechnologyMember_d5f2e0ae-c4f2-4777-8b4a-dcb3911c677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ed29838e-87d3-4d42-8c18-eef6feb71165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f97cb986-cd43-41d1-b0be-430f6e652dc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ed29838e-87d3-4d42-8c18-eef6feb71165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_d5d2b11d-96e8-4ef2-9515-500edc3398d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ed29838e-87d3-4d42-8c18-eef6feb71165" xlink:to="loc_us-gaap_GrantsReceivable_d5d2b11d-96e8-4ef2-9515-500edc3398d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7be25c85-389f-409d-bc07-62cfc49b30d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bb36e822-795d-4771-88e0-cb20e96dee19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7be25c85-389f-409d-bc07-62cfc49b30d8" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bb36e822-795d-4771-88e0-cb20e96dee19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5a9985cc-5bad-48b0-9d00-f1532554a07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5a9985cc-5bad-48b0-9d00-f1532554a07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a4a23c9b-4c07-4fa0-ac32-231afb075353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:to="loc_us-gaap_UseOfEstimates_a4a23c9b-4c07-4fa0-ac32-231afb075353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d8d44ab8-5245-458e-af5b-3ea55828fedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d8d44ab8-5245-458e-af5b-3ea55828fedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_f0be8dc4-04c6-40c7-9f70-2496ea16f6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_f0be8dc4-04c6-40c7-9f70-2496ea16f6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6cc494c4-d80f-4b76-a7e8-cf5e772fb28e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6cc494c4-d80f-4b76-a7e8-cf5e772fb28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f4f8685f-2416-4c66-9946-8b17fadf0e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61278827-3860-4b9d-9b31-1e0c549286d9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f4f8685f-2416-4c66-9946-8b17fadf0e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_555f6727-057e-4062-aed0-c80283dbe706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8b92bb2b-233b-44fc-920f-cac485c16008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_555f6727-057e-4062-aed0-c80283dbe706" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_8b92bb2b-233b-44fc-920f-cac485c16008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1b1597ef-b7c2-4cb4-aa88-75f17e53bf2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_316bcdd2-cbf0-41dd-91c9-eb481248f6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1b1597ef-b7c2-4cb4-aa88-75f17e53bf2c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_316bcdd2-cbf0-41dd-91c9-eb481248f6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_6b6fecbb-2ebe-4a23-b312-67922d2fee62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1b1597ef-b7c2-4cb4-aa88-75f17e53bf2c" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_6b6fecbb-2ebe-4a23-b312-67922d2fee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_12eb3834-5ce7-46fa-a363-0daa30738afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1b1597ef-b7c2-4cb4-aa88-75f17e53bf2c" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_12eb3834-5ce7-46fa-a363-0daa30738afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_aa7fba3d-d8eb-4bde-87d9-43b4f5d9440a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_aa7fba3d-d8eb-4bde-87d9-43b4f5d9440a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c04c5239-add0-4392-89a5-9e8b380f3a5b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c0879cb1-67c7-4af1-bb58-f273ed70eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c0879cb1-67c7-4af1-bb58-f273ed70eb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_439b04e2-82dc-4e09-a1ad-989bdec6d1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_439b04e2-82dc-4e09-a1ad-989bdec6d1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_5a32b0ea-38df-48ed-ad1a-008d948240d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da7a5696-e699-43c7-b934-2311aa47282f" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_5a32b0ea-38df-48ed-ad1a-008d948240d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21e4d622-fc6d-4d26-9e2b-84b8d417bf99" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5f4d7928-5f4d-4853-88cb-1222835cbb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5f4d7928-5f4d-4853-88cb-1222835cbb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d848594d-e496-41a5-957d-10cce8b5983e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d848594d-e496-41a5-957d-10cce8b5983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40ccf591-dfa7-46e5-a5ad-cca0e46bbc0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40ccf591-dfa7-46e5-a5ad-cca0e46bbc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_801065e9-120f-4e67-82f5-76ab1b97cb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d27af90d-f6d8-4656-85ef-5e6337fe4d45" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_801065e9-120f-4e67-82f5-76ab1b97cb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_37f2142e-e86c-4def-9dfa-768b57a64a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_fcf03e9d-bc93-45fb-92d1-ace7810b2ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_37f2142e-e86c-4def-9dfa-768b57a64a32" xlink:to="loc_us-gaap_Cash_fcf03e9d-bc93-45fb-92d1-ace7810b2ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_d618eecc-d341-4454-8f9a-19a34eb71934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_37f2142e-e86c-4def-9dfa-768b57a64a32" xlink:to="loc_us-gaap_MarketableSecurities_d618eecc-d341-4454-8f9a-19a34eb71934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8717dda4-aa84-47c3-8ac4-73eb59dd798b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_37f2142e-e86c-4def-9dfa-768b57a64a32" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8717dda4-aa84-47c3-8ac4-73eb59dd798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f5434209-d4dd-42da-8cc9-b58da2741b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a6d4aede-c548-4938-93b1-12161c7cc949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f5434209-d4dd-42da-8cc9-b58da2741b78" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a6d4aede-c548-4938-93b1-12161c7cc949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_bde301f8-2f52-411c-a732-169be389db1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a6d4aede-c548-4938-93b1-12161c7cc949" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_bde301f8-2f52-411c-a732-169be389db1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_68c0cad4-9ad8-4c0d-9ed7-34d9a5c0c3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a6d4aede-c548-4938-93b1-12161c7cc949" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_68c0cad4-9ad8-4c0d-9ed7-34d9a5c0c3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_234c71fb-132a-42c0-b251-73008d90949d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a6d4aede-c548-4938-93b1-12161c7cc949" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_234c71fb-132a-42c0-b251-73008d90949d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1562eef2-bbce-4985-b8af-87e3e2436dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f5434209-d4dd-42da-8cc9-b58da2741b78" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1562eef2-bbce-4985-b8af-87e3e2436dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_41118d4e-2427-4420-9acd-828aeea02232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1562eef2-bbce-4985-b8af-87e3e2436dc0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_41118d4e-2427-4420-9acd-828aeea02232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_de139d20-c2bb-4a11-a6ef-1e5347786f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1562eef2-bbce-4985-b8af-87e3e2436dc0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_de139d20-c2bb-4a11-a6ef-1e5347786f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ac87a46c-9753-4005-af2e-b83df4585c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_1562eef2-bbce-4985-b8af-87e3e2436dc0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ac87a46c-9753-4005-af2e-b83df4585c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c3ff0722-771b-4ad2-b04b-3b6b6899ef25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1a499d9b-388d-44eb-9f8b-4d49d6c8e44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3ff0722-771b-4ad2-b04b-3b6b6899ef25" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1a499d9b-388d-44eb-9f8b-4d49d6c8e44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b77c28b0-c567-4c93-952f-e0b8a143152f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1bc44e11-312a-4e5f-ae6c-b40bf986367e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b77c28b0-c567-4c93-952f-e0b8a143152f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1bc44e11-312a-4e5f-ae6c-b40bf986367e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_257481cb-74bb-4617-9729-d0f508cf8648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_257481cb-74bb-4617-9729-d0f508cf8648" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fdcfd022-4ce2-4efd-a96a-d94c4414b193" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5d9ba097-39bc-422f-833d-0d760353b10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5d9ba097-39bc-422f-833d-0d760353b10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6dbf613c-31b2-4bab-b83d-e5f688b704ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:to="loc_us-gaap_WarrantMember_6dbf613c-31b2-4bab-b83d-e5f688b704ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1717a702-10d3-4635-b3b3-f4167a7a6b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75c9cdec-554a-44c4-87ee-1bb583331ab7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1717a702-10d3-4635-b3b3-f4167a7a6b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_649f1904-1a79-436c-aaa5-23e41fbd8d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_80afcc09-e34e-4fbc-99a6-33e7d4883c35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_649f1904-1a79-436c-aaa5-23e41fbd8d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9369b51a-ffb5-4d8f-8f12-9025c4f2b954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_649f1904-1a79-436c-aaa5-23e41fbd8d5a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9369b51a-ffb5-4d8f-8f12-9025c4f2b954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c5a3e89c-1267-4b0b-8790-cfcf16b1ef01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_49d5825a-2b25-4e13-8d7d-485170df6b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c5a3e89c-1267-4b0b-8790-cfcf16b1ef01" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_49d5825a-2b25-4e13-8d7d-485170df6b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_28180b44-cfd0-48ec-af14-a027b482afac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e48193e0-2e73-4c93-b2fe-c63f6e2d9f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_28180b44-cfd0-48ec-af14-a027b482afac" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e48193e0-2e73-4c93-b2fe-c63f6e2d9f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bb3920f1-5701-4c3b-818e-3f84fddc09fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bb3920f1-5701-4c3b-818e-3f84fddc09fd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93192da3-3885-4879-9d87-d6c98cb47c37" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d7d9c7e9-60d8-4adf-974f-167e87dec01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d7d9c7e9-60d8-4adf-974f-167e87dec01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0c21f79d-66f3-4321-a851-22eb236a6cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0c21f79d-66f3-4321-a851-22eb236a6cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_474d556c-a200-4569-94ab-e0f6b2cac9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55cff199-0a40-4495-b13e-c37a49d75819" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_474d556c-a200-4569-94ab-e0f6b2cac9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd250e7c-bdca-4e5e-8bde-1c92ba891430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b21ed0c9-e522-4bc5-864d-0193163c9d94" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd250e7c-bdca-4e5e-8bde-1c92ba891430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1c85b937-6e1a-4a16-a210-c6ce5c1ced68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd250e7c-bdca-4e5e-8bde-1c92ba891430" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1c85b937-6e1a-4a16-a210-c6ce5c1ced68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_825cabd1-908b-41f8-b60c-1caaaf730f18" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8dfee2a2-8bcb-4766-bc17-74284b3fd7c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8dfee2a2-8bcb-4766-bc17-74284b3fd7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_98166d9d-228c-476a-a6c7-84b45346baf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be8b2d6c-fd5c-4c73-8f0b-b99a55260648" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_98166d9d-228c-476a-a6c7-84b45346baf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8bd92785-c0ef-4b66-9d42-fc5a1227f7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4e23cb50-00d9-491e-9a30-fd1e53391d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8bd92785-c0ef-4b66-9d42-fc5a1227f7e6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_4e23cb50-00d9-491e-9a30-fd1e53391d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_5b1aacd9-529e-4cfb-b48a-a9c1dd1ba29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_759d7047-53dd-44be-ae01-14e2c169bf1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_5b1aacd9-529e-4cfb-b48a-a9c1dd1ba29d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_759d7047-53dd-44be-ae01-14e2c169bf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8eb4eb5a-efd4-47af-bcdd-de5e926537a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b780433b-d1c5-497c-a060-05a5abdbe53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8eb4eb5a-efd4-47af-bcdd-de5e926537a8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b780433b-d1c5-497c-a060-05a5abdbe53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c2282e8-fc86-489d-b7ce-b32c4e1897fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8eb4eb5a-efd4-47af-bcdd-de5e926537a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c2282e8-fc86-489d-b7ce-b32c4e1897fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4fc5d504-aa82-4f82-8a7a-3829e34092fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8eb4eb5a-efd4-47af-bcdd-de5e926537a8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4fc5d504-aa82-4f82-8a7a-3829e34092fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e967c33e-8247-4acb-a472-41bdbcc5754a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8eb4eb5a-efd4-47af-bcdd-de5e926537a8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e967c33e-8247-4acb-a472-41bdbcc5754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_941a00c7-6099-40e4-995a-ffafb1a5261c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_41a238fc-7493-47c8-b0b1-90a576fd879e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_941a00c7-6099-40e4-995a-ffafb1a5261c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_41a238fc-7493-47c8-b0b1-90a576fd879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2480fd08-2649-42c8-8774-c451a8e3bcee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_db170d09-52fe-47d9-b2b4-6e5ebcd32d59" xlink:href="clbs-20210331.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2480fd08-2649-42c8-8774-c451a8e3bcee" xlink:to="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_db170d09-52fe-47d9-b2b4-6e5ebcd32d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f8864abc-07fe-408c-ac4a-22ee8d1244d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2480fd08-2649-42c8-8774-c451a8e3bcee" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f8864abc-07fe-408c-ac4a-22ee8d1244d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1aaba2a8-dc61-425c-b370-1436dac0c04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases_0eb30eea-73af-4d25-9467-0ab7e858bfc1" xlink:href="clbs-20210331.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1aaba2a8-dc61-425c-b370-1436dac0c04b" xlink:to="loc_clbs_NumberOfOfficesUnderOperatingLeases_0eb30eea-73af-4d25-9467-0ab7e858bfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ce7a5142-f237-4d18-ac8f-8d9014d985aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1aaba2a8-dc61-425c-b370-1436dac0c04b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ce7a5142-f237-4d18-ac8f-8d9014d985aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1d111c9a-747b-45b6-a28b-06f73d4eec71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1aaba2a8-dc61-425c-b370-1436dac0c04b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1d111c9a-747b-45b6-a28b-06f73d4eec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c0b6423b-d513-4335-b260-a7cb8d65c579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0b6423b-d513-4335-b260-a7cb8d65c579" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c006a88e-0a8d-4ad1-a12d-0a50d3381131" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_bbe16ea0-139f-46c8-bbd3-80fb8e0bd1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:to="loc_us-gaap_OtherAssetsMember_bbe16ea0-139f-46c8-bbd3-80fb8e0bd1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_6e8ad395-67a4-43fc-94f1-a8b4b00be5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_6e8ad395-67a4-43fc-94f1-a8b4b00be5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_90a3cc9d-9f6f-4866-b04b-27683f18deb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_baf8667c-95aa-4d4d-8dd5-318a91580dd2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_90a3cc9d-9f6f-4866-b04b-27683f18deb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ca23117-b12d-4d25-bb69-996ef3ffaf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cbe48d34-c4b6-4acf-8c48-68e03a6975f3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ca23117-b12d-4d25-bb69-996ef3ffaf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8ca23117-b12d-4d25-bb69-996ef3ffaf8b" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_abf67673-e080-4d39-a0c6-d971e3ca31e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_abf67673-e080-4d39-a0c6-d971e3ca31e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a5c331af-a4f1-45ad-8bf5-7d7b8b3dd01c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a5c331af-a4f1-45ad-8bf5-7d7b8b3dd01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7285c1fd-888a-4583-bb28-401698b909de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7285c1fd-888a-4583-bb28-401698b909de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cc28d859-66eb-4097-8b01-20c4c760621a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_1878d955-c006-48e9-ab9f-60e6c067b61f" xlink:to="loc_us-gaap_OperatingLeaseLiability_cc28d859-66eb-4097-8b01-20c4c760621a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bec90015-f936-443e-8803-26ae463b74b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bec90015-f936-443e-8803-26ae463b74b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_10b209eb-b4ea-44ab-b969-988fc37d6ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_10b209eb-b4ea-44ab-b969-988fc37d6ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_293be99e-7318-4d7b-a3f2-7f5976e44317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_293be99e-7318-4d7b-a3f2-7f5976e44317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d1f66d5-5e37-4734-8850-ed1b5f3d7763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d1f66d5-5e37-4734-8850-ed1b5f3d7763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b53db7ab-2fe5-4cdf-9291-f83d74cb7c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b53db7ab-2fe5-4cdf-9291-f83d74cb7c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_99fa5087-10c2-409e-a751-85062b58288c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_99fa5087-10c2-409e-a751-85062b58288c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ab1cbd8f-45f6-4070-9226-d0f98db9ce8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_182dcd80-a9bd-4bb1-8354-fdf17bf13940" xlink:to="loc_us-gaap_OperatingLeaseLiability_ab1cbd8f-45f6-4070-9226-d0f98db9ce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20210331.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cb694d67-a30b-411b-af44-70a45818fe0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ba3303b4-1439-4e50-a0d2-6df9256416dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cb694d67-a30b-411b-af44-70a45818fe0f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ba3303b4-1439-4e50-a0d2-6df9256416dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2deaad6-fa50-4507-9b61-20c045e1facc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_de787b6b-48cd-4976-96c9-fc674b828707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2deaad6-fa50-4507-9b61-20c045e1facc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_de787b6b-48cd-4976-96c9-fc674b828707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6a500376-5357-41a5-b079-7018f04c6d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2deaad6-fa50-4507-9b61-20c045e1facc" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6a500376-5357-41a5-b079-7018f04c6d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e7039d06-cba9-41a1-935f-55f5680b601b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2deaad6-fa50-4507-9b61-20c045e1facc" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e7039d06-cba9-41a1-935f-55f5680b601b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8179bb9b-b40e-4d2b-bcc0-442bb770f25e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8179bb9b-b40e-4d2b-bcc0-442bb770f25e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_622b21ed-e930-4c67-b722-4ef982352bd9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_406e471e-95fe-4676-a02d-7aa9af9ede77" xlink:href="clbs-20210331.xsd#clbs_LincolnParkAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_LincolnParkAgreementMember_406e471e-95fe-4676-a02d-7aa9af9ede77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_2dcc13d1-1139-4811-a88c-0c96ba32db5a" xlink:href="clbs-20210331.xsd#clbs_H.C.WainwrightSalesAmendedAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_2dcc13d1-1139-4811-a88c-0c96ba32db5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_InstitutionalPurchaseAgreementMember_afec6677-1053-4b4d-9dec-9594e0059cd9" xlink:href="clbs-20210331.xsd#clbs_InstitutionalPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_InstitutionalPurchaseAgreementMember_afec6677-1053-4b4d-9dec-9594e0059cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AdditionalPurchaseAgreementMember_8bd84964-fccb-4425-8fc9-ebb81d2d8944" xlink:href="clbs-20210331.xsd#clbs_AdditionalPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_AdditionalPurchaseAgreementMember_8bd84964-fccb-4425-8fc9-ebb81d2d8944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_January2021PurchaseAgreementMember_0d3624c4-72b4-4d98-93ac-e1d58a13c8e4" xlink:href="clbs-20210331.xsd#clbs_January2021PurchaseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63cb3c85-51e8-44b9-a4f8-c5738f2700a1" xlink:to="loc_clbs_January2021PurchaseAgreementMember_0d3624c4-72b4-4d98-93ac-e1d58a13c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a0468951-eedc-4c04-a75f-dc09846f1e10" xlink:to="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_966e17e7-10fe-48f4-973b-c2465eb1f48c" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_966e17e7-10fe-48f4-973b-c2465eb1f48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_0997346f-281c-41ac-96d9-8d4c34e41b95" xlink:href="clbs-20210331.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_0997346f-281c-41ac-96d9-8d4c34e41b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4666d144-ff67-4eb5-8ce6-56d35c70bca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4666d144-ff67-4eb5-8ce6-56d35c70bca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0ba1ffc6-e9d3-43c0-abdb-14cbb955a6f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0ba1ffc6-e9d3-43c0-abdb-14cbb955a6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fa62f0e3-1f07-4a1f-a20c-b84c2f27e545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fa62f0e3-1f07-4a1f-a20c-b84c2f27e545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_9ccd58a7-3fea-4558-8855-d999ebe95dd6" xlink:href="clbs-20210331.xsd#clbs_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_TermOfAgreement_9ccd58a7-3fea-4558-8855-d999ebe95dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_dfbbcedc-a919-444a-94d2-3e41c749e318" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_dfbbcedc-a919-444a-94d2-3e41c749e318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_34d961a8-62e1-47aa-b7b6-bc14cfc328e8" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_34d961a8-62e1-47aa-b7b6-bc14cfc328e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_4a01d440-5b00-4739-bbbb-ff054ddfdc0f" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_4a01d440-5b00-4739-bbbb-ff054ddfdc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_fe692522-7c89-4c36-abd8-145e12109aa2" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_fe692522-7c89-4c36-abd8-145e12109aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_2b3eb709-549e-4929-9440-da38f779e544" xlink:href="clbs-20210331.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_2b3eb709-549e-4929-9440-da38f779e544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateMarketValueOfCommonStockNonAffiliates_a5c0797c-bccf-49c5-a4eb-3114a06298d0" xlink:href="clbs-20210331.xsd#clbs_AggregateMarketValueOfCommonStockNonAffiliates"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_AggregateMarketValueOfCommonStockNonAffiliates_a5c0797c-bccf-49c5-a4eb-3114a06298d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_e61c78ec-91aa-46be-be08-425250a0ba28" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement_e61c78ec-91aa-46be-be08-425250a0ba28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_00b710f0-3325-432c-8a23-d0b7193c3c05" xlink:href="clbs-20210331.xsd#clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_00b710f0-3325-432c-8a23-d0b7193c3c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9fd92a14-ec0e-4a09-a997-74bbf62b01c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9fd92a14-ec0e-4a09-a997-74bbf62b01c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5e8aac-87e0-40d9-84b5-a5343e2e9b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5e8aac-87e0-40d9-84b5-a5343e2e9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48e9882e-3419-4768-9ca5-98e7db6f3f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48e9882e-3419-4768-9ca5-98e7db6f3f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e84cbb7a-06dc-4a62-84eb-6aa9b2a4d920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e84cbb7a-06dc-4a62-84eb-6aa9b2a4d920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1d223882-4baa-4d0a-9553-4be9fd1ad826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1d223882-4baa-4d0a-9553-4be9fd1ad826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_964766e9-091d-49aa-b54c-cbaa4571c7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_964766e9-091d-49aa-b54c-cbaa4571c7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_3f0182d4-82d7-4903-8412-f4b9a6a33257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_3f0182d4-82d7-4903-8412-f4b9a6a33257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_381d26f0-4e43-4286-9a37-30cbc2a95a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd8e448e-a17d-442e-940f-1f6e103b71cb" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_381d26f0-4e43-4286-9a37-30cbc2a95a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_df7b664d-ac0d-4fc2-8be9-f48e736442ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_df7b664d-ac0d-4fc2-8be9-f48e736442ea" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:to="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockOptionsActivityDomain_3ffee9bd-c62a-4552-a71e-f568905e891e" xlink:href="clbs-20210331.xsd#clbs_StockOptionsActivityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_StockOptionsActivityAxis_76b40a3e-d1db-4896-9430-534734645b24" xlink:to="loc_clbs_StockOptionsActivityDomain_3ffee9bd-c62a-4552-a71e-f568905e891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UsEquityPlanMember_53ff5676-8148-4acf-978b-b18c9e9b5751" xlink:href="clbs-20210331.xsd#clbs_UsEquityPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_StockOptionsActivityDomain_3ffee9bd-c62a-4552-a71e-f568905e891e" xlink:to="loc_clbs_UsEquityPlanMember_53ff5676-8148-4acf-978b-b18c9e9b5751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f72199b1-9928-4e69-9784-b3cb08a57d46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_599f6ee9-c5c6-414e-80ef-285f3ba942a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_599f6ee9-c5c6-414e-80ef-285f3ba942a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3c7b0325-41ca-4001-b370-17132055302e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3c7b0325-41ca-4001-b370-17132055302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_faf34f4e-6e55-4d0e-bb19-41182f17dad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_faf34f4e-6e55-4d0e-bb19-41182f17dad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9a165247-6bba-472a-bec8-e61e6590c41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9a165247-6bba-472a-bec8-e61e6590c41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_774669cc-12c3-4f39-bc8d-733f4bfe247f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_774669cc-12c3-4f39-bc8d-733f4bfe247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_772b11ae-545b-4fcd-838d-875be1543f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35364874-5d5a-4bb5-945c-c3c837cb8885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_772b11ae-545b-4fcd-838d-875be1543f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fbf2b77c-0f1e-4708-b4fc-f28611237768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fbf2b77c-0f1e-4708-b4fc-f28611237768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5da066d1-d004-4f6b-a884-beb46600efb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5da066d1-d004-4f6b-a884-beb46600efb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8d73dc1e-7d71-4cf0-af47-4998dffc5474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8d73dc1e-7d71-4cf0-af47-4998dffc5474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d259a86c-95e5-4b7d-81d0-b08f242792ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d259a86c-95e5-4b7d-81d0-b08f242792ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_811c1196-7cbe-4aeb-9c45-94e72c00f58c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_811c1196-7cbe-4aeb-9c45-94e72c00f58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_531155c2-619c-4fe3-b7eb-fb98b53f6333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f2461c94-113e-4186-ab5a-3d44c68c3cfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_531155c2-619c-4fe3-b7eb-fb98b53f6333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6c1ad860-df41-409f-9fc2-45780dd3ac59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6c1ad860-df41-409f-9fc2-45780dd3ac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3be51dad-0a57-4df2-8e99-72d57d59c995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3be51dad-0a57-4df2-8e99-72d57d59c995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_334e06ef-9929-4b7c-ad1a-f65cf16a7c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_334e06ef-9929-4b7c-ad1a-f65cf16a7c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e1132747-c0ef-4cd3-9120-9ccc4b187cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e1132747-c0ef-4cd3-9120-9ccc4b187cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_499730e8-858a-4a1d-a493-b537972d5931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_499730e8-858a-4a1d-a493-b537972d5931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1410c3ad-2891-4ae5-b5cf-8925a3f26793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1410c3ad-2891-4ae5-b5cf-8925a3f26793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c94d02b3-e956-4b13-9677-999dc019b52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c94d02b3-e956-4b13-9677-999dc019b52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c2a2bc50-f432-4291-a5e2-b77b6bb8d89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c2a2bc50-f432-4291-a5e2-b77b6bb8d89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_1d3bd50f-007a-4f54-836a-13d3c475b964" xlink:href="clbs-20210331.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_1d3bd50f-007a-4f54-836a-13d3c475b964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a227f4fa-f666-4562-a575-c368c3693bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a3705b77-f5e4-4788-8e98-323760eb7a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a227f4fa-f666-4562-a575-c368c3693bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cee20078-1922-445c-b6e2-e591d72b3384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_ffcb7b3f-e1f2-4c2d-9793-52428014405a" xlink:href="clbs-20210331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_CommonStockWarrantsShares_ffcb7b3f-e1f2-4c2d-9793-52428014405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted_24b8d279-9ad7-46b3-b392-7f190231ac95" xlink:href="clbs-20210331.xsd#clbs_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsGranted_24b8d279-9ad7-46b3-b392-7f190231ac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised_28c9eff1-df77-4f2c-a184-062bca602fcb" xlink:href="clbs-20210331.xsd#clbs_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsExercised_28c9eff1-df77-4f2c-a184-062bca602fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled_d6b7d40c-c9fd-402c-a4c9-dd0e31ef89b2" xlink:href="clbs-20210331.xsd#clbs_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsCanceled_d6b7d40c-c9fd-402c-a4c9-dd0e31ef89b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired_7781f993-1a64-4b17-8067-f62b857e1268" xlink:href="clbs-20210331.xsd#clbs_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_WarrantsExpired_7781f993-1a64-4b17-8067-f62b857e1268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_04c43720-5ee6-4fd6-8da2-b4013fd7fc24" xlink:href="clbs-20210331.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6b9ffaf9-d18f-4ba8-a3ad-ce22a0a6c2df" xlink:to="loc_clbs_CommonStockWarrantsShares_04c43720-5ee6-4fd6-8da2-b4013fd7fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:href="clbs-20210331.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_e7462d70-319a-4e69-aa86-2f5e89411bc8" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_e7462d70-319a-4e69-aa86-2f5e89411bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_668ee830-320d-402a-84ad-a3a416e9d458" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_668ee830-320d-402a-84ad-a3a416e9d458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_62fd1954-eb0b-4500-bb43-2205204d1784" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_62fd1954-eb0b-4500-bb43-2205204d1784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_8e5cfaf4-feb5-4110-b72f-16fde3bec63d" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_8e5cfaf4-feb5-4110-b72f-16fde3bec63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_e97d77b0-d3b9-407e-8e47-a9aff3d6123f" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_e97d77b0-d3b9-407e-8e47-a9aff3d6123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_ef1714ff-1ca6-456f-91b3-7913d01a9fba" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_44443b23-7fb2-40c6-9902-817800b27297" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_ef1714ff-1ca6-456f-91b3-7913d01a9fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_66eab7e3-1068-490a-8a5b-de4a8fee6a55" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_66eab7e3-1068-490a-8a5b-de4a8fee6a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_674b9d74-9c49-4e14-b266-5a9c32e28a87" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_674b9d74-9c49-4e14-b266-5a9c32e28a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest_6734850f-3ef9-4100-9c65-94a2cc332862" xlink:href="clbs-20210331.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_Sharesvestedandexpectedtovest_6734850f-3ef9-4100-9c65-94a2cc332862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_13b82242-252a-4b04-a012-b2899b346190" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_13b82242-252a-4b04-a012-b2899b346190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_686dd71d-15ea-4a0f-a743-e5357ee73cf1" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_686dd71d-15ea-4a0f-a743-e5357ee73cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_6c6a2e42-65be-4ef6-81ee-19582548cbb0" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_6c6a2e42-65be-4ef6-81ee-19582548cbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested_1acd0f6a-728f-4c73-902b-926f5d92882d" xlink:href="clbs-20210331.xsd#clbs_WarrantsVested"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WarrantsVested_1acd0f6a-728f-4c73-902b-926f5d92882d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_6057ad03-fee6-4f26-bb7d-ac843c56e8e9" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_6057ad03-fee6-4f26-bb7d-ac843c56e8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_52d8db26-8559-4a3c-a185-7269200b850c" xlink:href="clbs-20210331.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_52d8db26-8559-4a3c-a185-7269200b850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested_9d2d8541-0602-49ec-afcc-bc5f008005d0" xlink:href="clbs-20210331.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_fd84e8ef-c3b7-42bf-8c5f-cb8823674e7e" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvested_9d2d8541-0602-49ec-afcc-bc5f008005d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_372901b9-4f58-407b-860b-e8794b1194bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_372901b9-4f58-407b-860b-e8794b1194bf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:to="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5ccc29a4-5136-489b-9c89-0042c358bff5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_74eec890-b61d-44de-87c4-fe137f142cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:to="loc_us-gaap_RestrictedStockMember_74eec890-b61d-44de-87c4-fe137f142cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_602db703-5665-4d69-93a4-edc573165c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8407d2f-543a-46e5-bbe0-bda5e9b6f364" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_602db703-5665-4d69-93a4-edc573165c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f07ab30-2ef9-4505-b790-0524f57d62d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_8cd4adf5-15c0-469b-8458-0e8960fd5703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_8cd4adf5-15c0-469b-8458-0e8960fd5703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c18eedbf-55ef-44f3-9baf-2ad608f67dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c18eedbf-55ef-44f3-9baf-2ad608f67dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_afaaa04a-bc2a-4682-9dac-91bd581d9aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_afaaa04a-bc2a-4682-9dac-91bd581d9aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_469a2bc7-c11a-45ff-8ce8-f4a4dbc0148a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8c43d16-f837-4290-b411-bfc00ee73ddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_469a2bc7-c11a-45ff-8ce8-f4a4dbc0148a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_d4aee2ab-8c44-4d76-be33-ccf33001b664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5f93fd7c-0b69-42bf-ae04-e58e83d161d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d4aee2ab-8c44-4d76-be33-ccf33001b664" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5f93fd7c-0b69-42bf-ae04-e58e83d161d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_272baa12-eeb0-42a2-90f5-bb41d7749520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fabcd925-58f4-45eb-a466-cb6f642608bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_272baa12-eeb0-42a2-90f5-bb41d7749520" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_fabcd925-58f4-45eb-a466-cb6f642608bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_05d7b871-3d72-42ce-8c3f-80bd462d8891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_272baa12-eeb0-42a2-90f5-bb41d7749520" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_05d7b871-3d72-42ce-8c3f-80bd462d8891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e5adae21-0c93-4aec-a795-464df2d18106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_272baa12-eeb0-42a2-90f5-bb41d7749520" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e5adae21-0c93-4aec-a795-464df2d18106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_6262cc6a-7f00-4c56-950f-327eba7d0713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_6262cc6a-7f00-4c56-950f-327eba7d0713" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5fe9033f-cb4c-4465-98cd-beb50413ba14" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d251d06-aae0-4815-a615-2dde2b726515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2d251d06-aae0-4815-a615-2dde2b726515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_88cd23d2-1d51-4b6f-9460-e03bc2767cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7720b1b7-dfc4-479b-9827-b3c4d55bc6ce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_88cd23d2-1d51-4b6f-9460-e03bc2767cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dfa2945-cc19-4239-9feb-8adb8401e0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5431b145-dd63-4d69-a747-5bffc8f9dac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dfa2945-cc19-4239-9feb-8adb8401e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c7e141d-2e31-4298-afc3-8fdd875bf258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dfa2945-cc19-4239-9feb-8adb8401e0ea" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c7e141d-2e31-4298-afc3-8fdd875bf258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_8e278895-fee7-431f-9c72-64b78d9e6555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_8e278895-fee7-431f-9c72-64b78d9e6555" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:to="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d9170ae0-5fc4-4d84-9cee-d1108bd6515c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_53e922f9-457d-4813-94e1-208dd450bc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:to="loc_us-gaap_EmployeeStockOptionMember_53e922f9-457d-4813-94e1-208dd450bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_283ca5e3-ddaa-49df-a9a5-d710b64aa5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_283ca5e3-ddaa-49df-a9a5-d710b64aa5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_972f2f1d-6e65-4761-a804-02ca0e410e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a331e610-b83a-403b-b7f8-1fae67c57d06" xlink:to="loc_us-gaap_RestrictedStockMember_972f2f1d-6e65-4761-a804-02ca0e410e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0c673c04-5762-48ab-b478-c5b8287a5b23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c0ec6b4-7cd6-43d8-9575-a5e94337e9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6c0ec6b4-7cd6-43d8-9575-a5e94337e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46150e8f-15b4-4233-bb98-64c6604379ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3a7de057-6db9-45fd-bd50-90303d1f90ef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_46150e8f-15b4-4233-bb98-64c6604379ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47cfc529-abfd-4356-96a0-c73112cfe3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47cfc529-abfd-4356-96a0-c73112cfe3cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:to="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d3fb85-eba8-41c6-ae43-8c4230f8d1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5efa8211-478a-437f-a737-8c8b5c12698f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d3fb85-eba8-41c6-ae43-8c4230f8d1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_83e74190-2218-4fb1-9445-2212c6d6287f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d3fb85-eba8-41c6-ae43-8c4230f8d1e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_83e74190-2218-4fb1-9445-2212c6d6287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8497bf1-6e2e-4724-ac63-f832bb1650c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_093f61c2-3662-41e9-a989-6c8f767b1dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_093f61c2-3662-41e9-a989-6c8f767b1dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b996c4b3-364f-4dd3-9734-cbf7eddb1d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4104d0d3-895f-4353-bf63-3a573078be54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b996c4b3-364f-4dd3-9734-cbf7eddb1d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFunding" xlink:type="simple" xlink:href="clbs-20210331.xsd#ResearchFunding"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchFunding" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_2aed9b47-6fa5-4727-8b43-028077afdcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_28e94fe9-1434-4d85-aeda-1fca66187719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_2aed9b47-6fa5-4727-8b43-028077afdcd3" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_28e94fe9-1434-4d85-aeda-1fca66187719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#ResearchFundingDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_17e05979-5a35-4382-ad14-b3d5b8215d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:to="loc_us-gaap_GrantsReceivable_17e05979-5a35-4382-ad14-b3d5b8215d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FundingOfGrantAwardCashReceived_6c98d2dd-2793-48c5-8bba-fbf06ecbd41d" xlink:href="clbs-20210331.xsd#clbs_FundingOfGrantAwardCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:to="loc_clbs_FundingOfGrantAwardCashReceived_6c98d2dd-2793-48c5-8bba-fbf06ecbd41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MilestonePaymentOnGrantAwardCashReceived_dbb32ffd-3eaf-4f47-ad78-9878fafc098e" xlink:href="clbs-20210331.xsd#clbs_MilestonePaymentOnGrantAwardCashReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:to="loc_clbs_MilestonePaymentOnGrantAwardCashReceived_dbb32ffd-3eaf-4f47-ad78-9878fafc098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProgressPaymentOnGrantAwardCashReceived_bf350ec4-392e-4a5d-8a5f-bc5b68baa128" xlink:href="clbs-20210331.xsd#clbs_ProgressPaymentOnGrantAwardCashReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:to="loc_clbs_ProgressPaymentOnGrantAwardCashReceived_bf350ec4-392e-4a5d-8a5f-bc5b68baa128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_07c9bb9e-a4e4-4621-af55-969f4035f413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_07c9bb9e-a4e4-4621-af55-969f4035f413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_9878e432-7f3a-4d3f-82d3-8fec1c526a77" xlink:href="clbs-20210331.xsd#clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0b485100-b0bc-4fe0-bd5c-2108118def17" xlink:to="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_9878e432-7f3a-4d3f-82d3-8fec1c526a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7fd73670-2c6b-469b-b33f-feb6fd23b215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f32f7c94-852a-4044-b068-d04fb059454a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7fd73670-2c6b-469b-b33f-feb6fd23b215" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f32f7c94-852a-4044-b068-d04fb059454a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails" xlink:type="simple" xlink:href="clbs-20210331.xsd#IncomeTaxesNetOperatingLossCarryForwardDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2dbaa12f-9e38-4a5d-9115-fbd1ec464247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2dbaa12f-9e38-4a5d-9115-fbd1ec464247" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6d80901b-61bc-41c5-a389-420e3c8a2715" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3b8e6a81-002b-428d-a19e-ef72305f2f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:to="loc_us-gaap_DomesticCountryMember_3b8e6a81-002b-428d-a19e-ef72305f2f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_41ab5ac6-7f4f-4c19-add2-e9426a548ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a7b47af6-c684-4f9d-90bd-b3ef6834eea1" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_41ab5ac6-7f4f-4c19-add2-e9426a548ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0974b5e1-6d5c-4da5-b773-7310b1ded025" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_601296a9-f315-4c18-ba35-8deadaa16b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_601296a9-f315-4c18-ba35-8deadaa16b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_cfb074c6-3190-48b1-9b21-7f783cf745bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_cfb074c6-3190-48b1-9b21-7f783cf745bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_773d8af3-746e-4999-b431-77681919c1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_5e6119b4-5e3b-446b-befe-0e1251e8e55d" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_773d8af3-746e-4999-b431-77681919c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_093551ee-b949-43fd-a563-2ecac7e82e4f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7b0fe363-bbb0-4221-8b7e-e2562f660033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7b0fe363-bbb0-4221-8b7e-e2562f660033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_0ace8e34-c566-4e1b-a32b-897c33c03612" xlink:href="clbs-20210331.xsd#clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis_0ace8e34-c566-4e1b-a32b-897c33c03612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetOperatingLossAnalysisAnnualLimitation_c740d563-4f4f-4996-9188-32eb34a3f00b" xlink:href="clbs-20210331.xsd#clbs_NetOperatingLossAnalysisAnnualLimitation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8dc2571d-8358-4021-b3ce-90c61fb3c08e" xlink:to="loc_clbs_NetOperatingLossAnalysisAnnualLimitation_c740d563-4f4f-4996-9188-32eb34a3f00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20210331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8799765-2980-4452-82be-ad776064d6e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c5d987ee-acc1-4082-a3da-7768d8cf6b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8799765-2980-4452-82be-ad776064d6e9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c5d987ee-acc1-4082-a3da-7768d8cf6b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>clbs-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clbs="http://www.caladrius.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clbs-20210331.xsd" xlink:type="simple"/>
    <context id="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5b23b6c1a5fe4d4c8bdb981ced74fa45_I20210506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i38fe760abf524b1f9fc7025d34a428f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41bb661c1032422799be713e40ad8635_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia525a7cd4cf8438fb5f3cba58bc350cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32a9ade1a1d14e93b37b75e67f601a91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id072402eb2074150a1eb3fdd22afd12c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i589da21b9cd3494bb5d59a64f84a8c12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcea2fbb21824e578b12c0844d468746_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe02162890344d1fbf90456b0bead153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabd907497bf9499ab23f6889b68495e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98213f01318841c58e971c61065d059b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5533fa9fbc549e3ae2bdac8c681fe78_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i788bbf0e008d40dfa6fd131e136a8984_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia1c094ccaf714cea8477934f4b218fbf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8a2fea10ae844d2097b54a25c64f6e32_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3e16651f8d7949d58de041929b8d2de2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ife0548a2ff6f4f1b99d092c805f2a489_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9ccb52a1055149e9b884edffba7b0c9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0867f814915348b5bdb4e08faea3ba19_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i35f7c29d762741c784b2f2e5280bba2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i24a7731dee2e425cadcef9131a3f1611_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i232ac432d803493e882af56dc9654ec2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf6a615e6ae547058117f5e18a5dba6d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i588195ddb3e14a50b4ad59be6d72d358_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id97509a62a4a4419bb9b6e60ac0a55a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ef01373193f4f92b43d3255e62c34e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e147676a9d347cdb2e16b52523ff885_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0536559cd0b54911a2cea21fc56aed37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c07dd6e75a243069a60c6bf7db68018_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c3d95bdf08242159f078fb83657a19d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ea27c84c39b4c3ca91f6aaa91387695_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ebefcd2c95f49fdb51cf02aeec47cce_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe4eeca0cde7433db812f696fe9f6f5b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d385d56f17c46bba3c7db051eabde22_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i61f829607cf341adad7ed6ed97c8e4b9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i25f1c3ec495342668f144f3ae1f669b6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia15c0e3aae5c4517a60ff1bf682aa1ab_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie17df6bc95b14a6a91bd4d7107a927f7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i59ecb9460cf04d2b971feeef71d2b6e7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic47c3d63fff74ae6a6360be7e478b1be_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic572abd8348545418bc389f5eda0860b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6d643ab02b0d434e8d777c9ea8ed75d8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iebd979cbd8b84bbb887c9f1f556f8f9e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i264a67c0128540ff86e03277435eec08_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icdcbdf98a7ca4a708730bbebd3ba7714_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">clbs:IschemicRepairCD34CellTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic3bc96434426403a9bd2301ded3b4994_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i115a0e9999e14fdcb9279eee27425491_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib5a759825b1a41819d598d7d7e1af92d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic89c436a48cc48ef91082d25c26d3752_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i499338433b98478ba449207f9bded52e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i777bc9631ae24b4aa509c6ab60a91a57_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i24b54c799369442588b92ab156347688_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa3f2806d8764f13bec22b3ff8cf87ed_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iccdb907e20cf4c1b9603607b2905156a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i132ae7e2b40f4aacbfb45d310a8825e2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iffea5c40fbc940929f1156d78435b50f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc9f9eb3437d453dbe79a9bff47d7f5f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4bdf6d06fccf49ae9869c434a423e19b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4537dc4974b74981b566969155de0b54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic25ae7a16882454a89235836a00c085e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0034e259507451381d712e51c59a110_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17695a58a11c417395bec355c88d7fdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad507469e2c44e1c81b999fe3754c26f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad9e8e338fc54edf89217db73847c29b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i26a96d4091904e6b919d8e86339a5d99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ced2f706c534f1d91b7bc6ba399fe9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8b76807e468541f4b8af73ed9c91b2fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37e538a949044dd7ac2e7157cd069c22_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieaa95386fd914df2ab6e70d41a0648dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if63681e7fe174b76af8b5ab1341d9fa0_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1a98eb81842e4748b436585c87156f1a_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="ic03c497fe3a647068aff689400691742_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i253f4e81f39240bfa1478bea971064bb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i47215ddbef4645acbdcebd547430280c_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i0bb45e4366f343b387c5ac5a70b7d93c_D20180201-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i14d5d5e90b62441eb1838b078677e72b_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="icec9ddeca5314500aed87a027edc3fbe_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i5a8d0caecfc8478a9763718f92a1c601_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="iaf4ed15255a740ccbc038f0987ef5f67_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i5885d9e0c6b24703a32d31ff18fa6628_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i7f840f3881574b5db5784970c5024047_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i94c77a9975714e5bb66f65c196bcb6f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd25e43236aa4b5696a0696badf143fe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if48a0e1d6f4147ebb6edcba9191e4ea5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d54f54529cf4daea43de35b41341f98_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="clbs:StockOptionsActivityAxis">clbs:UsEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i759214c1bb7f4003972143f129ebe638_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0b7bf07503274c4ba141b5cbc1970f3f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icbe5f0e3fd7141d6b7317b9c81f7225c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb173d03e633477ead116cda9d9948a3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4eab163f6b9e41e5b784b249926dbd6e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3c54fa8f52bb4465a41b34646f8ffcce_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5a59d2dafdc848809ac87c686c29886a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i81e73ba2637749b6bbc62bc908b6e954_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9e428d7942a045c8984c14fda8656fa5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id723fbccd73440de8762bc38568bf063_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie43284901a884f78a402755fd3b41aaa_I20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="ib1905a146945439d89ff1228516dc50e_D20170501-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffe95d09252c410489923fdd656451ce_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i64d49bafd16540ef92725c78f1429358_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7c059030f14c498b9bf58d821d59c031_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="icc32f1fee1574a39a7e75cd277331948_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i619b7221c8b6420b9d72d12bbca2851d_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0023b178cff546c5a4ed4572f1675a89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64fbc9ce8d824790bfc3e917a2bd92b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib20ab50a11fb4b0f89cb676e7cf79d61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i448dfa4c0bd046df85903ca8cc449d02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60f0f64709a44444b6515aa9f4cba303_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="office">
        <measure>clbs:office</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN18zLTEtMS0xLTA_a0a2008d-f0fa-4bbc-af04-1a99f1a48bcf">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN180LTEtMS0xLTA_839e699b-1369-4bd4-9b4d-9bdec2d10a89">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN181LTEtMS0xLTA_bda56b26-7fda-49bf-b2b3-3d3c8d2368d2">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN182LTEtMS0xLTA_37baddaa-61b1-4831-87c0-fef45d91e010">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80L2ZyYWc6NGU3ZThjYTI0YzQ4NGNkM2ExZGZmOTg4YWJmZDE4NTEvdGFibGU6NzQ2ZTMyYWNhZTM4NDkxMTllODk1NDc1NGI1OWE0MzcvdGFibGVyYW5nZTo3NDZlMzJhY2FlMzg0OTExOWU4OTU0NzU0YjU5YTQzN183LTEtMS0xLTA_5faa75af-b2b2-4cf1-9ec4-d2fc7bfe2e93">false</dei:AmendmentFlag>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82MS9mcmFnOmNkMWFiMjVlMjkzZjQyNmNhNmRjMmUwMjFiNzI3MTc5L3RleHRyZWdpb246Y2QxYWIyNWUyOTNmNDI2Y2E2ZGMyZTAyMWI3MjcxNzlfMzU_09f095b6-0fdd-404b-b968-c07397e03a0b">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDMx_08ccdbab-73e0-4fde-b1e1-5ba026613115">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWZhNWYxMmRmZWJhNDIzMjg1ZTc1MGJiOTk4YWI2NGQvdGFibGVyYW5nZToxZmE1ZjEyZGZlYmE0MjMyODVlNzUwYmI5OThhYjY0ZF8wLTAtMS0xLTA_760fe0d1-719b-4d82-bb23-1d8561c6fd77">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8xMjY_32218f7b-2087-4be5-89b0-1ec03b2ad2fc">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6OWY0ZTZhNThmNWJlNGMyZDg5MmFiMjJiZGIzMmYxYzcvdGFibGVyYW5nZTo5ZjRlNmE1OGY1YmU0YzJkODkyYWIyMmJkYjMyZjFjN18wLTAtMS0xLTA_7207ac75-9917-4997-af40-add4f9f720e4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM3_824237fa-4482-4e67-89ce-1ac4a89700d3">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDMy_e0a72439-1f6f-465b-90c5-bd8a5286fc11">CALADRIUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8wLTAtMS0xLTA_d9ea0d86-6c00-43f1-beaa-0b6d9fa091c1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8wLTEtMS0xLTA_c216a6b7-c23b-4300-9225-f0407c78db34">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjowMDg3MGZiY2Y5OTg0M2RjYjQ0YzZkN2QyZDUzY2ZjYV80_5b5d80bf-fe74-44b1-9932-714e4e5bac60">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjowMDg3MGZiY2Y5OTg0M2RjYjQ0YzZkN2QyZDUzY2ZjYV84_d90d21ff-0ceb-4aa6-b438-bd0c33b607d1">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjowMDg3MGZiY2Y5OTg0M2RjYjQ0YzZkN2QyZDUzY2ZjYV8xMg_1c32f831-6146-4f3d-b66a-56b1778df138">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MWFiOGUxMTkzMGQ4NDQxMmE3YzIzZGQ3NGQwYWNhYjkvdGFibGVyYW5nZToxYWI4ZTExOTMwZDg0NDEyYTdjMjNkZDc0ZDBhY2FiOV8zLTEtMS0xLTA_3e1f3d80-0652-416a-a335-68e7c690bebc">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDMz_1979834b-c222-4b38-8410-efee56ba0771">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM4_cfccc28e-86fb-4654-9847-2349190e5d5e">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MzRiNjcwZjQ2YjE2NDQxZmIyNWJjNzM4NTcyZmUxZDMvdGFibGVyYW5nZTozNGI2NzBmNDZiMTY0NDFmYjI1YmM3Mzg1NzJmZTFkM18yLTAtMS0xLTA_9b58dae7-737f-4c2d-88b9-5504de2af08e">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MzRiNjcwZjQ2YjE2NDQxZmIyNWJjNzM4NTcyZmUxZDMvdGFibGVyYW5nZTozNGI2NzBmNDZiMTY0NDFmYjI1YmM3Mzg1NzJmZTFkM18yLTEtMS0xLTA_7c9dadd2-26b5-4e25-a0e8-75fdda582879">CLBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6MzRiNjcwZjQ2YjE2NDQxZmIyNWJjNzM4NTcyZmUxZDMvdGFibGVyYW5nZTozNGI2NzBmNDZiMTY0NDFmYjI1YmM3Mzg1NzJmZTFkM18yLTItMS0xLTAvdGV4dHJlZ2lvbjo1OTIzYzFhZWJiNzQ0MjU3YWEwM2NmZjQ1ZjM3NGQ3N184_4f878843-fdb4-4815-9ef1-d4c326608496">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM0_053f5ff6-b08a-4db3-9c57-06365d81e2f7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDQw_0b99fc94-a7d3-494b-95ef-7f1d2db8d237">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6YjMxMDFiMTI0NzExNGNlZmI4Y2ExZWIwMjZkOTA3OTUvdGFibGVyYW5nZTpiMzEwMWIxMjQ3MTE0Y2VmYjhjYTFlYjAyNmQ5MDc5NV8xLTAtMS0xLTA_15f9a1b6-f9a5-492e-9ce0-080241e69cd6">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6YjMxMDFiMTI0NzExNGNlZmI4Y2ExZWIwMjZkOTA3OTUvdGFibGVyYW5nZTpiMzEwMWIxMjQ3MTE0Y2VmYjhjYTFlYjAyNmQ5MDc5NV8xLTQtMS0xLTA_43e7bc4e-10dd-4b4d-b357-e1c96425e5d5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6YjMxMDFiMTI0NzExNGNlZmI4Y2ExZWIwMjZkOTA3OTUvdGFibGVyYW5nZTpiMzEwMWIxMjQ3MTE0Y2VmYjhjYTFlYjAyNmQ5MDc5NV8yLTQtMS0xLTA_a8adc0d2-640f-45e0-b6e8-58973b9c30a8">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGV4dHJlZ2lvbjo3YmQzODRkYzU5YjU0MDIxYTlmOGM2YzU5YWJkZDZlNF8yMDM2_5c776158-affb-4d0c-99ca-eeb414a2aaf4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5b23b6c1a5fe4d4c8bdb981ced74fa45_I20210506"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xL2ZyYWc6N2JkMzg0ZGM1OWI1NDAyMWE5ZjhjNmM1OWFiZGQ2ZTQvdGFibGU6OTA0YjVhNThmYWQyNDAyOThhMTA0OWFkOTM5YjNlMmMvdGFibGVyYW5nZTo5MDRiNWE1OGZhZDI0MDI5OGExMDQ5YWQ5MzliM2UyY18xLTEtMS0xLTA_65d0ea44-0a88-4778-8768-7fb6a57331d2"
      unitRef="shares">59498958</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMi0xLTEtMS0w_bad68ca7-b8c2-4d21-bd96-4a77d26c861e"
      unitRef="usd">28744000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMi0zLTEtMS0w_6ad2f137-2cd4-49e6-ab8d-723e72629a8d"
      unitRef="usd">16512000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMy0xLTEtMS0w_51924661-0f9b-4a15-9ab4-328a3e53b3d1"
      unitRef="usd">82767000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMy0zLTEtMS0w_e14d9c46-625c-44ab-a21d-ab2d37379557"
      unitRef="usd">18061000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNC0xLTEtMS0w_eaaa1ba7-4098-4518-afcb-a6f369740ed1"
      unitRef="usd">2522000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNC0zLTEtMS0w_3bc18985-bde6-4c38-97c8-109250f48fe0"
      unitRef="usd">758000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNS0xLTEtMS0w_53412836-0e92-4b26-8f59-83a75c39ef37"
      unitRef="usd">114033000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNS0zLTEtMS0w_e204490f-8066-4bbe-a6fb-065301855b4d"
      unitRef="usd">35331000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNi0xLTEtMS0w_d004a40a-7191-409f-9e49-06ae75535fad"
      unitRef="usd">41000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNi0zLTEtMS0w_93f130cb-2614-446c-93a0-d22f4722c0e8"
      unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNy0xLTEtMS0w_ad9a2323-fd37-4921-882e-7475d986b567"
      unitRef="usd">533000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfNy0zLTEtMS0w_bb7e558a-81ef-46de-b66e-594160c874ce"
      unitRef="usd">614000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfOC0xLTEtMS0w_f1ee2d8a-db73-4b75-adf9-72d6eafc7ffd"
      unitRef="usd">114607000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfOC0zLTEtMS0w_36cceda4-0f4b-4862-bd5d-46641a89aa0f"
      unitRef="usd">36002000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTItMS0xLTEtMA_88a1993c-b7d4-49e3-ae1f-77bcf5122195"
      unitRef="usd">2315000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTItMy0xLTEtMA_ad7603c8-4273-4fd3-a67e-16c6ea0a6418"
      unitRef="usd">1020000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTMtMS0xLTEtMA_713dea0b-2e3a-40a2-b421-4fbf851244b1"
      unitRef="usd">2123000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTMtMy0xLTEtMA_39c99051-f811-447f-a8d4-6f61380becb3"
      unitRef="usd">2486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTQtMS0xLTEtMA_d8614cab-03e2-42f2-9c69-e3da2c976712"
      unitRef="usd">4438000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTQtMy0xLTEtMA_6650435b-7019-42a8-adaa-4e7db668ce9b"
      unitRef="usd">3506000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTUtMS0xLTEtMA_d05c12b4-0113-4e5c-962d-b10df7458365"
      unitRef="usd">155000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTUtMy0xLTEtMA_45539a00-c2f8-4b93-a9f7-9464c0b0a64c"
      unitRef="usd">254000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTYtMS0xLTEtMA_9506461b-cb2c-4265-b949-7db090139534"
      unitRef="usd">4593000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTYtMy0xLTEtMA_7dc35cf1-e160-472c-83cf-14f9ab1fffaf"
      unitRef="usd">3760000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTctMS0xLTEtMA_cea340e0-fd0d-4682-abba-d6d92b3f2eda"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMTctMy0xLTEtMA_91b24375-a159-466e-a7c1-7b5c411f360d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzM0_132343b0-4765-4ecd-a6b5-08395487cdf1"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzM0_eedec326-3a3b-40d1-9a48-f673564094f6"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzExMQ_89e52f7f-fc3e-4a9b-9bf9-d9c73c671813"
      unitRef="shares">0.001</clbs:PreferredStockLiquidationPreferenceShare>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzExMQ_a301d552-57a4-4e0c-b318-2b0d503f9024"
      unitRef="shares">0.001</clbs:PreferredStockLiquidationPreferenceShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzEzNw_aed5007d-0a17-47cc-a3b9-9e400441d35b"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzEzNw_e7fd06c8-30f8-4ead-952a-9204e0ec55ca"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <clbs:PreferredStockSharesDesignated
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE1MQ_104ee782-880b-4350-a40b-6c92a55b7dc6"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <clbs:PreferredStockSharesDesignated
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE1MQ_4bc3f02c-8e5d-4af1-aadb-a1319a8fc870"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_3a8ee107-fa4f-4755-a638-d9f816e4b39b"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_5abeb93c-18de-4b3f-b5ef-6053f81e53d6"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_c605c64e-550d-4897-b0f8-daa2de8256a2"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2MTNiZWZiNDk5ZjQwZmE4Y2YyNjQzYTZiMmNmMGQ4XzE5Nw_f976c298-0eab-4274-bee7-5c7b6f7b35f8"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMS0xLTEtMA_3c81211b-298b-4f55-a81c-fb5f474ffe2a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjAtMy0xLTEtMA_dd6f1ba4-3f68-4d8d-b32f-d23e7a4b94d7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzE5_8514cc1b-f012-4b4c-a2fb-b8b707c0033e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzE5_a8cf19ee-3b2b-44d2-abcb-4254b2823233"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzQ0_42f65ed7-c64f-4b13-bb21-1a67e0f3b22b"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzQ0_d20d351a-ddb0-4596-a449-c423c344de05"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzc5_449bf20e-d1ad-47a5-84e4-ca581c8f1101"
      unitRef="shares">59510038</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzg2_4ecf81a9-ee18-4437-8d8c-0f9ac11b7f96"
      unitRef="shares">19389413</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzEwOTk1MTE2MjgyMDE_cb51f5fd-3010-4bcf-80f2-3b0602453edb"
      unitRef="shares">59498958</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NjA2MmI2NjcyYzRjMDBiYmYyZDk1ODQ5NzVkZWJkXzEwOTk1MTE2MjgyMTY_11030c7a-f0f9-42ce-addf-882ee522f8ca"
      unitRef="shares">19378333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMS0xLTEtMA_7fa4d182-f374-49a1-bbab-4bda65849792"
      unitRef="usd">60000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjEtMy0xLTEtMA_4370155d-bb08-4ec2-a76b-8c9bb91ce7c9"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjItMS0xLTEtMA_76a89eaf-e605-4091-8a0f-d18de6814a09"
      unitRef="usd">544601000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjItMy0xLTEtMA_cb871620-2550-4dec-a6b6-825583e11347"
      unitRef="usd">458748000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOjAwZmVlZWUxNDZhZTRmZDc4OWQwNDE1NzQzZjBiNmExXzI5_213a90da-3a91-4f11-9020-beed2cd806f8"
      unitRef="shares">11080</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOjAwZmVlZWUxNDZhZTRmZDc4OWQwNDE1NzQzZjBiNmExXzI5_a592f757-ec27-4ec9-81bb-fe97f01f0b73"
      unitRef="shares">11080</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMS0xLTEtMA_fa19dfef-d421-477f-83c9-2c9111fbc71e"
      unitRef="usd">708000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjMtMy0xLTEtMA_9a32b772-1a80-4af8-8766-b3476d4ffa59"
      unitRef="usd">708000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjQtMS0xLTEtMA_caec4086-bdba-4ff7-836f-67362ceca51c"
      unitRef="usd">-433613000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjQtMy0xLTEtMA_6d556aa0-e9c1-426e-976d-0c92a0f29bb1"
      unitRef="usd">-425550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjUtMS0xLTEtMA_56d5a488-f9cf-4e10-a839-d6a0a71d24d8"
      unitRef="usd">-72000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjUtMy0xLTEtMA_cd179134-43ba-4c10-b24b-d240e957b4b2"
      unitRef="usd">-13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjYtMS0xLTEtMA_9742e598-5bdc-41a8-9f29-6fcfb58ea43e"
      unitRef="usd">110268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjYtMy0xLTEtMA_ea0713ff-44a7-40de-889f-35fc30ed6e13"
      unitRef="usd">32496000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjctMS0xLTEtMA_23f39d7d-d90c-45f8-a605-1951d114887b"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjctMy0xLTEtMA_52590729-1280-4c78-a932-1d28740c8eb7"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjgtMS0xLTEtMA_370bc4b0-82aa-4e60-b710-5f4683754dda"
      unitRef="usd">110014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjgtMy0xLTEtMA_7da7e0a4-3cfb-46c7-9495-381176d3e845"
      unitRef="usd">32242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjktMS0xLTEtMA_934f0fb5-57ad-470c-bb63-d299fb9dcade"
      unitRef="usd">114607000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xNi9mcmFnOmIzOTFiMjc4M2EzNTQ5NTViNjNhODRjNmE5Mjc3NTljL3RhYmxlOjI5MjUxOTgyOWY0NzQyZDViYzMzNTY4N2VmOTM0ZTgxL3RhYmxlcmFuZ2U6MjkyNTE5ODI5ZjQ3NDJkNWJjMzM1Njg3ZWY5MzRlODFfMjktMy0xLTEtMA_a9405a8b-9f99-494d-897c-601054918b2c"
      unitRef="usd">36002000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMy0xLTEtMS0w_4f6b39de-1b2b-4aeb-ae70-87f8430689d5"
      unitRef="usd">5076000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMy0zLTEtMS0w_25c1b72c-d3bf-4a43-a1ad-21306a72b249"
      unitRef="usd">1499000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNC0xLTEtMS0w_7a9f2cf5-bd08-492d-a025-d43596f8504d"
      unitRef="usd">3010000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNC0zLTEtMS0w_08a0e8c4-ac56-4570-8e15-4e3de36b475d"
      unitRef="usd">2558000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNS0xLTEtMS0w_477f0ff1-cf88-4198-bf80-d875651dd145"
      unitRef="usd">8086000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNS0zLTEtMS0w_ae7159ce-ca45-4d3a-a2af-3f1ce3c7dc1d"
      unitRef="usd">4057000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNy0xLTEtMS0w_c11c1786-a8f8-4004-85bd-7573511e3001"
      unitRef="usd">-8086000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfNy0zLTEtMS0w_06fddd37-e5c5-4f6a-b890-fa3b7dcff5e5"
      unitRef="usd">-4057000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTAtMS0xLTEtMA_accd1e0d-53b5-4c95-bc02-954c37f672bc"
      unitRef="usd">23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTAtMy0xLTEtMA_e8321a25-a9b2-4106-96c2-36e8e2703dd0"
      unitRef="usd">71000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTItMS0xLTEtMA_577630c3-112d-4f77-8eb3-67631b443026"
      unitRef="usd">23000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTItMy0xLTEtMA_2c07a4d0-d759-4e3f-9bc5-d042046647cc"
      unitRef="usd">71000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTYtMS0xLTEtMA_b46f02ad-86e4-4c24-981f-6117100bada3"
      unitRef="usd">-8063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTYtMy0xLTEtMA_f636c29f-28c0-4467-b7f5-ed5b7d73e528"
      unitRef="usd">-3986000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTctMS0xLTEtMA_b1784c45-9ba9-4904-9b58-e233d17355d2"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTctMy0xLTEtMA_c54d3d86-15b7-4762-91dc-3b5313e391c5"
      unitRef="usd">4000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTgtMS0xLTEtMA_5d2a495d-a24d-42b1-a30c-80958463662d"
      unitRef="usd">-8063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMTgtMy0xLTEtMA_5d5b0b3e-7b81-4948-943f-6126d5f796a8"
      unitRef="usd">-3990000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMS0xLTEtMA_15692c7e-6113-492c-93ee-b1f32a8906a2"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMS0xLTEtMA_ed8f5158-d879-448f-ba7e-c5cdbd3f4f31"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMy0xLTEtMA_14155284-4c90-4467-94ab-21a5b8e0cc39"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjItMy0xLTEtMA_6348faec-cc9f-4ef1-ae23-cbbb722c8cdd"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMS0xLTEtMA_085230ae-4a1f-4875-9614-2f739b0cf210"
      unitRef="shares">42117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMS0xLTEtMA_9fcbc3ce-8063-4746-b3d6-2493f8463fe3"
      unitRef="shares">42117000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMy0xLTEtMA_0b1fae9e-e3a9-4946-85f8-717bb4ae1ccf"
      unitRef="shares">10623000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8xOS9mcmFnOjEwN2E5NDc3NDk4MTQxZDdiMzVhYmI1Y2QyYTQ0NzllL3RhYmxlOmYwNDhhOGFiYTZjNTQ5MDViMDNkZmU0ZTQ5NjJjNGU0L3RhYmxlcmFuZ2U6ZjA0OGE4YWJhNmM1NDkwNWIwM2RmZTRlNDk2MmM0ZTRfMjUtMy0xLTEtMA_dd11c54c-e81e-465d-a07a-529ba0be19ba"
      unitRef="shares">10623000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMi01LTEtMS0w_e37a4a1e-ecf5-4455-ad46-0b1a0d812967"
      unitRef="usd">-8063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMi03LTEtMS0w_9a5f20f7-4220-4e16-ae00-13711e6ee3d5"
      unitRef="usd">-3986000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNS01LTEtMS0w_58a57be1-2b56-4aae-892a-16f0644842a4"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNS03LTEtMS0w_fdceb774-e0e4-40b1-a3ed-9c7f3820467c"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNi01LTEtMS0w_1daf7af2-53da-4401-bc38-a9663b015e9c"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfNi03LTEtMS0w_8430ba0c-0932-4e55-8a93-6db97e0dfc27"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfOC01LTEtMS0w_f532fbe1-8ee5-4f76-afab-06758467bfdb"
      unitRef="usd">-8122000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfOC03LTEtMS0w_62998b9d-2cd2-49f2-a1cf-b7b85d9a738c"
      unitRef="usd">-3988000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTAtNS0xLTEtMA_245f126a-2b4f-4c2e-b96a-23c4a3967e55"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTAtNy0xLTEtMA_d373c5fd-0602-4bed-afee-8dfa67508537"
      unitRef="usd">4000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTItNS0xLTEtMA_7e0fc752-7fb5-4ab0-ae34-777b33837ecd"
      unitRef="usd">-8122000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yMi9mcmFnOmE4OThlZGFjMjNkMzQ1YTI4MTE5ZTYwNjAyOTgyZjIwL3RhYmxlOmNmMTJhYjIxMmY0MDRkZDc5ZTM3MjczMTFiMTZjODdjL3RhYmxlcmFuZ2U6Y2YxMmFiMjEyZjQwNGRkNzllMzcyNzMxMWIxNmM4N2NfMTItNy0xLTEtMA_b64896f2-5b9d-4a01-a8cd-adce906ee94d"
      unitRef="usd">-3992000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i38fe760abf524b1f9fc7025d34a428f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMS0xLTEtMA_4ee05dba-5e33-4986-8a2c-04f7ab09f21b"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38fe760abf524b1f9fc7025d34a428f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMy0xLTEtMA_e0570821-05f9-4730-a3ca-3e716815378b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i41bb661c1032422799be713e40ad8635_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtNS0xLTEtMA_17436ea6-0e93-4524-b23e-ac3eca1ab0d7"
      unitRef="shares">19389000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41bb661c1032422799be713e40ad8635_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtNy0xLTEtMA_22331c95-d2f3-4b62-9a7a-65acad59586b"
      unitRef="usd">19000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia525a7cd4cf8438fb5f3cba58bc350cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtOS0xLTEtMA_7b49a1b7-174b-451d-b9f8-b3a3676e51f7"
      unitRef="usd">458748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32a9ade1a1d14e93b37b75e67f601a91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTEtMS0xLTA_670361c6-f307-4924-9028-2331d475aeee"
      unitRef="usd">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id072402eb2074150a1eb3fdd22afd12c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTMtMS0xLTA_c2b0dbe9-3ce5-4d4b-a596-9aff675b2fb2"
      unitRef="usd">-425550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i589da21b9cd3494bb5d59a64f84a8c12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTUtMS0xLTA_8c91b238-1e80-4aa4-aa57-c96e4a353dc5"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcea2fbb21824e578b12c0844d468746_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTctMS0xLTA_7b6ff348-4c7e-4aae-887c-cab134cf48a9"
      unitRef="usd">32496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe02162890344d1fbf90456b0bead153_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMTktMS0xLTA_5d4f8c4a-4d37-460c-9023-aded9b710b7d"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTMtMjEtMS0xLTA_324606c5-fbb4-4942-a038-1312c550df0f"
      unitRef="usd">32242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iabd907497bf9499ab23f6889b68495e5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMTMtMS0xLTA_4b1b34bd-77f1-4869-8183-4a04a7810abf"
      unitRef="usd">-8063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMTctMS0xLTA_62866713-2434-4e31-bd00-542b2ef8936d"
      unitRef="usd">-8063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic5533fa9fbc549e3ae2bdac8c681fe78_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMTktMS0xLTA_150ff8ec-2346-4b9e-9d5a-2a81fd747866"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTUtMjEtMS0xLTA_3581056a-8bcd-43b6-ab30-09962d4d49be"
      unitRef="usd">-8063000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i788bbf0e008d40dfa6fd131e136a8984_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTYtMTEtMS0xLTA_e418e59f-66ec-4c90-ac2c-ebf33054cc0a"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTYtMTctMS0xLTA_0a222ae0-683f-45e9-85bc-d2daa331441f"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTYtMjEtMS0xLTA_8620f92c-de45-44cd-945d-d7a0aa4ade0f"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctNS0xLTEtMA_13adb75f-f4a4-4fa1-b113-a5a354ef1eb2"
      unitRef="shares">273000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctOS0xLTEtMA_7e860a2c-555e-43e7-9178-e0a348cad143"
      unitRef="usd">413000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctMTctMS0xLTA_61b33eec-99ce-42cd-97a8-d92e1b305bca"
      unitRef="usd">413000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTctMjEtMS0xLTA_3a2bbd9a-844d-4e6f-8bef-34935203c0f9"
      unitRef="usd">413000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtNS0xLTEtMA_811a6548-aa56-47c3-8c9f-62a5f639f0ef"
      unitRef="shares">39841000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtNy0xLTEtMA_608eb615-8baf-4dc3-902b-01bfa9962f85"
      unitRef="usd">41000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtOS0xLTEtMA_247f5c77-9bd2-47c5-96f7-a18b8776b6e8"
      unitRef="usd">85416000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtMTctMS0xLTA_05b8f04c-90d2-41ec-b840-9225e14016f1"
      unitRef="usd">85457000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTgtMjEtMS0xLTA_f8438c97-0f07-476e-adc7-750b5d4927aa"
      unitRef="usd">85457000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3939df11fd8d4c4f8a80c601304f4d8d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktNS0xLTEtMA_f5cbec43-1da1-4a7e-af33-3eb66878893e"
      unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id4867f16779c49f793d71bb479fb08f5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktOS0xLTEtNTMw_8734845f-effd-4df2-b917-e1650e074914"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i98213f01318841c58e971c61065d059b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktMTctMS0xLTA_4fbddb10-7ae8-4763-aeec-78d6a1b71f22"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMTktMjEtMS0xLTA_ab683bd7-62e7-47f4-84ef-980530f0cd54"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesOutstanding
      contextRef="ia1c094ccaf714cea8477934f4b218fbf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMS0xLTEtMA_872d79e0-ea28-4b0e-b661-213d9ec243de"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1c094ccaf714cea8477934f4b218fbf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMy0xLTEtMA_e7af85b2-34d8-4b7f-bba0-f7c5245c8feb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i8a2fea10ae844d2097b54a25c64f6e32_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtNS0xLTEtMA_eaddb5ec-0365-4785-a4c0-31d9be9f4661"
      unitRef="shares">59510000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a2fea10ae844d2097b54a25c64f6e32_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtNy0xLTEtMA_7a09fc63-e2c0-4cda-90ad-14946e7f212d"
      unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e16651f8d7949d58de041929b8d2de2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtOS0xLTEtMA_971abb01-aba2-43a0-bad8-ea5d6f05a911"
      unitRef="usd">544601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife0548a2ff6f4f1b99d092c805f2a489_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTEtMS0xLTA_1e8974f1-16bb-4e7c-b977-cb4c644edf7a"
      unitRef="usd">-72000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ccb52a1055149e9b884edffba7b0c9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTMtMS0xLTA_b8ace1d6-93a4-45c7-8b7f-9e4ed9d42fd9"
      unitRef="usd">-433613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0867f814915348b5bdb4e08faea3ba19_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTUtMS0xLTA_5d575eae-60e3-4234-abe0-037c38dc441c"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35f7c29d762741c784b2f2e5280bba2b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTctMS0xLTA_127d2f4b-0aca-4c0d-824b-58ad2c4675a6"
      unitRef="usd">110268000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24a7731dee2e425cadcef9131a3f1611_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMTktMS0xLTA_6f93e6c2-8e0e-49e5-82cd-25864e9bf212"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjc5MWNkNjU1OGRjNDQxZTliZjVkMjdiN2Y4OTI4NGQ3L3RhYmxlcmFuZ2U6NzkxY2Q2NTU4ZGM0NDFlOWJmNWQyN2I3Zjg5Mjg0ZDdfMjEtMjEtMS0xLTA_294a76cf-d60f-458a-998f-2f795db23a86"
      unitRef="usd">110014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i232ac432d803493e882af56dc9654ec2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMS0xLTEtMA_5e6b6aa0-e172-4720-8cc9-1d5965c7728e"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i232ac432d803493e882af56dc9654ec2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMy0xLTEtMA_d3b93c6f-4e3e-44a0-a97c-50beb7a4bb39"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="idf6a615e6ae547058117f5e18a5dba6d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtNS0xLTEtMA_47004e59-b027-45c6-8ccb-707df1433dab"
      unitRef="shares">10529000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf6a615e6ae547058117f5e18a5dba6d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtNy0xLTEtMA_f60bdf57-b22e-4b67-b8c9-5895fdea2cfa"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i588195ddb3e14a50b4ad59be6d72d358_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtOS0xLTEtMA_4f5a7d47-5fa3-4634-95f0-f67205a828d6"
      unitRef="usd">438911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id97509a62a4a4419bb9b6e60ac0a55a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTEtMS0xLTA_0044f295-d93d-4d56-99e1-951d8e52fd18"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ef01373193f4f92b43d3255e62c34e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTMtMS0xLTA_ba90fafb-1178-4b21-a90b-4dff6f5c11ef"
      unitRef="usd">-417400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e147676a9d347cdb2e16b52523ff885_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTUtMS0xLTA_206e8590-6f64-407f-81fd-0f7cbee14277"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0536559cd0b54911a2cea21fc56aed37_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTctMS0xLTA_668e5d40-3069-4520-bb9a-cc6ce1ee7089"
      unitRef="usd">20816000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c07dd6e75a243069a60c6bf7db68018_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMTktMS0xLTA_af8b1412-6cfc-4c47-837b-6d6ea1ae9bcc"
      unitRef="usd">-263000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c3d95bdf08242159f078fb83657a19d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTMtMjEtMS0xLTA_8c07bb74-5662-4936-99ea-77942eb62003"
      unitRef="usd">20553000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i5ea27c84c39b4c3ca91f6aaa91387695_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMTMtMS0xLTA_622f9746-84b7-4e6b-be81-6087f18c640a"
      unitRef="usd">-3990000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMTctMS0xLTA_e5efa92d-87af-4dc3-a64d-d6c302289f41"
      unitRef="usd">-3990000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ebefcd2c95f49fdb51cf02aeec47cce_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMTktMS0xLTA_883f6945-898f-44a9-9b5e-2b101409ca34"
      unitRef="usd">4000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTUtMjEtMS0xLTA_1614e110-dabc-45fb-924a-bd1b0fa57db7"
      unitRef="usd">-3986000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibe4eeca0cde7433db812f696fe9f6f5b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTYtMTEtMS0xLTA_5f1dcdf3-c9e1-45c2-9805-f9d7c16ed81c"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTYtMTctMS0xLTA_93a866da-937e-42a2-95e7-68d1b9bb8802"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTYtMjEtMS0xLTA_d876af24-eeba-4f88-a415-725118054b44"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6d385d56f17c46bba3c7db051eabde22_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctNS0xLTEtMA_71dd9703-cd6b-4449-a52e-e9e7cbc60372"
      unitRef="shares">110000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i61f829607cf341adad7ed6ed97c8e4b9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctOS0xLTEtMA_f7bffc65-d756-485a-ab2e-eb5e482ab587"
      unitRef="usd">419000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5de4de1937724a35a9bc8417e5b0ff61_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctMTctMS0xLTA_5293b707-3e9b-43ad-9e21-6d880e3b6619"
      unitRef="usd">419000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMTctMjEtMS0xLTA_12b5d91e-4696-496f-a1e2-b70d203789d1"
      unitRef="usd">419000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i25f1c3ec495342668f144f3ae1f669b6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMS0xLTEtMA_cbbe42cf-088a-4d85-813e-c14bad326c9b"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25f1c3ec495342668f144f3ae1f669b6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMy0xLTEtMA_32e0aeda-f2d4-447d-b9e1-c4ff67e1ee30"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia15c0e3aae5c4517a60ff1bf682aa1ab_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtNS0xLTEtMA_0341bec0-6d0d-4eb1-9c46-bb3c008a8dd2"
      unitRef="shares">10639000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia15c0e3aae5c4517a60ff1bf682aa1ab_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtNy0xLTEtMA_396b7b5d-7b5b-45b5-8c59-1774e1554f3c"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie17df6bc95b14a6a91bd4d7107a927f7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtOS0xLTEtMA_0bfa5a27-7cc5-4f62-8d0c-8e38c2fad4d3"
      unitRef="usd">439330000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59ecb9460cf04d2b971feeef71d2b6e7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTEtMS0xLTA_1d74ae62-795f-4ba8-9f49-4aedcebbf696"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic47c3d63fff74ae6a6360be7e478b1be_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTMtMS0xLTA_79849689-0fbd-4374-895b-b60b7ea2bdad"
      unitRef="usd">-421390000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic572abd8348545418bc389f5eda0860b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTUtMS0xLTA_9fb5ba33-90f7-4741-b490-416136689c08"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d643ab02b0d434e8d777c9ea8ed75d8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTctMS0xLTA_761c64dd-697f-40e6-b85f-dbaf7aafc9a9"
      unitRef="usd">17243000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebd979cbd8b84bbb887c9f1f556f8f9e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMTktMS0xLTA_96096bac-d9f1-4007-a113-fffe02da4ba7"
      unitRef="usd">-259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i264a67c0128540ff86e03277435eec08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yNS9mcmFnOmU4NjBhMGVjNDk4OTQ1ZjRiOWFkZDhjMjQxNjIwYmU4L3RhYmxlOjYyMmMzZWMzNjg4YTQxM2JiMzQyNWVkMmE0ZDc1NzcxL3RhYmxlcmFuZ2U6NjIyYzNlYzM2ODhhNDEzYmIzNDI1ZWQyYTRkNzU3NzFfMjEtMjEtMS0xLTA_c78a0d60-dc85-4a66-b67a-598a99c400f4"
      unitRef="usd">16984000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMy0xLTEtMS0w_b4226d97-3a30-4940-8ef6-60a6d2025a84"
      unitRef="usd">-8063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMy0zLTEtMS0w_4f8e02d7-7969-4f9c-803f-26d1ad5e150f"
      unitRef="usd">-3986000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNS0xLTEtMS0w_1726db03-33a1-4cf7-83e4-e7efeaaf6ac4"
      unitRef="usd">597000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNS0zLTEtMS0w_b6be021f-0ff5-4797-8c29-64ab56820c85"
      unitRef="usd">567000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNi0xLTEtMS0w_cc311b4d-d12a-4af7-beb3-9449d1f79b3e"
      unitRef="usd">16000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfNi0zLTEtMS0w_75257900-41e7-4bc4-98f2-fadfba406ea8"
      unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfOS0xLTEtMS0w_2acc15fb-a895-4775-a30f-43dba1ba2677"
      unitRef="usd">-323000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfOS0zLTEtMS0w_cadd47d1-5ae6-4dd2-986c-60ac5e2cf956"
      unitRef="usd">-19000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTEtMS0xLTEtMA_6bf1c351-2381-4556-a8d3-e0abe9be1330"
      unitRef="usd">1763000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTEtMy0xLTEtMA_53fede75-2d65-4a64-af5a-75016a231670"
      unitRef="usd">-354000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTItMS0xLTEtMA_209337e2-ca9a-4d58-942b-286f7b5e17e1"
      unitRef="usd">-81000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTItMy0xLTEtMA_61e28391-cb9b-4401-9f39-a75136c5b265"
      unitRef="usd">-233000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTMtMS0xLTEtMA_fe3f4b86-3693-480e-a80d-4527ebdbb93f"
      unitRef="usd">834000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTMtMy0xLTEtMA_5cfc6acb-bfae-46cd-911b-7423a5480c51"
      unitRef="usd">-1443000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTQtMS0xLTEtMA_55d47302-c464-4b5b-977b-75768cc6d4af"
      unitRef="usd">-7975000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTQtMy0xLTEtMA_059f9474-b69b-4b52-b8ed-7805189207ba"
      unitRef="usd">-4241000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTYtMS0xLTEtMA_f45d5e73-3cc4-46f1-9699-1fe8bd155a5d"
      unitRef="usd">75911000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTYtMy0xLTEtMA_a313fd09-18d3-4dbc-bb0f-53406072b094"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTctMS0xLTEtMA_7522838e-8d82-4063-95c4-1f6c8b6b0eed"
      unitRef="usd">10821000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTctMy0xLTEtMA_1bf77231-ecdf-4019-8ff6-131d5e4d38d7"
      unitRef="usd">11104000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTgtMS0xLTEtMA_6b45bb08-97d8-461b-b69f-8e5803c067bb"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTgtMy0xLTEtMA_69d00542-7c6b-4ddb-8358-207c30461259"
      unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTktMS0xLTEtMA_d35ad3a9-7553-4e85-a951-cfeb4fbf0ff5"
      unitRef="usd">-65090000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMTktMy0xLTEtMA_9b84a8c8-9dfd-4813-a4c3-0f94bbb6e8e4"
      unitRef="usd">11102000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjEtMS0xLTEtMA_ac8eb878-3323-4b98-8fbf-4d334d7cf61f"
      unitRef="usd">24000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjEtMy0xLTEtMA_4f006d2e-2dc4-430d-9eef-a2b06292fe1a"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjItMS0xLTEtMA_afd0a0cf-8fe4-4d46-8df5-8725227ab143"
      unitRef="usd">184000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjItMy0xLTEtMA_87e9c4c5-661f-4a8a-bd9d-f692b84623cd"
      unitRef="usd">148000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjMtMS0xLTEtMA_91ad30c2-88e7-431e-8190-16116562d541"
      unitRef="usd">85457000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjMtMy0xLTEtMA_b18c3b43-7d41-475e-b36d-172b88de7381"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjUtMS0xLTEtMA_bd028cc9-546f-4f30-a9c5-46df9ccab533"
      unitRef="usd">85297000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjUtMy0xLTEtMA_ba3d6af8-4d9c-4274-a547-ad92779fb91d"
      unitRef="usd">-148000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjYtMS0xLTEtMA_10722c29-2e97-437b-83a3-d0b5194c4203"
      unitRef="usd">12232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjYtMy0xLTEtMA_3f98ba66-741f-4c03-b75c-525b1e88f9ed"
      unitRef="usd">6713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjctMS0xLTEtMA_e3099261-422f-45b7-a4ab-67c6d8c2cf3d"
      unitRef="usd">16512000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7c3d95bdf08242159f078fb83657a19d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjctMy0xLTEtMA_d19a916f-c43c-41e2-9dff-049e1563e206"
      unitRef="usd">14032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjgtMS0xLTEtMA_49f6a35f-42e5-496b-bf35-614e828c4604"
      unitRef="usd">28744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i264a67c0128540ff86e03277435eec08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8yOC9mcmFnOmIwNDVjYTJjMDBlYjRlOGE4ZDI3MmFhZGQ1OTMyNmIwL3RhYmxlOjQ0NWUxODM3NmY0MTQ2ODM5NjI3ODU5MzY1NGU0Yzc2L3RhYmxlcmFuZ2U6NDQ1ZTE4Mzc2ZjQxNDY4Mzk2Mjc4NTkzNjU0ZTRjNzZfMjgtMy0xLTEtMA_b2b8d01c-8292-4f9d-a3bc-06a9a28fc59a"
      unitRef="usd">20745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <clbs:BusinessTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMTE5NTQ_413f9ec7-bdb4-4313-adfe-8d97dfec80bb">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Caladrius Biosciences, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; "our," &#x201c;Caladrius&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#x2019;s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b (FREEDOM) study in the U.S. for the treatment of coronary microvascular dysfunction (&#x201c;CMD&#x201d;); HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#x201c;CLI&#x201d;) and Buerger&#x2019;s disease based on the results of an ongoing clinical trial and recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration ("FDA") for Buerger's disease; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis diabetic kidney disease (&#x201c;DKD&#x201d;) and OLOGO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CLBS14), a Regenerative Medicine Advanced Therapy (&#x201c;RMAT&#x201d;) designated Phase 3 ready therapy for treatment of no-option refractory disabling angina (&#x201c;NORDA&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ischemic Repair (CD34 Cell Technology)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CD34+ cell was discovered as a result of the deliberate search for a stem cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is a stem cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's proprietary cell technology using autologous (a patient&#x2019;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34+ cells, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology including but not limited to CLI, CMD, DKD and NORDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; for Treatment of Critical Limb Ischemia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's randomized and open-label, registration-eligible study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan for the treatment of CLI has shown strong results to date. The initial responses observed in the subjects who have reached an endpoint in this open label study are consistent with a positive therapeutic effect and safety profile as reported by previously published clinical trials in Japan. The study's enrollment continues to be slowed by the COVID-19 pandemic's impact in Japan, however, the Company is encouraged by the patient pre-screening pipeline and continues to make progress towards study completion, the exact date of which is impossible to predict given the continuing impact of COVID-19 on clinical trials like ours in Japan. While the final outcome of the trial will depend on all data from all subjects, data, to date, are very encouraging.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CLBS16 for Treatment of Coronary Microvascular Dysfunction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for CLBS16 for the treatment of CMD, a disease that afflicts millions of patients with no current targeted treatment options. That study, the ESCaPE-CMD trial, was a Phase 2a proof-of-concept study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. That data set showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Questionnaire score, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM trial of CLBS16 as a therapy for CMD. The first patient in the study was subsequently treated in January 2021 at The Christ Hospital Health Network in Cincinnati, Ohio. This 105-patient double-blind randomized and placebo-controlled &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical trial (FREEDOM Trial) is designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. To the Company's knowledge, this is the first controlled regenerative medicine trial in CMD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CLBS201 for Treatment of Diabetic Kidney Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared an initial development plan for the clinical study of CLBS201, a CD34+ investigational product for administration into the renal arteries to slow the deterioration or reverse the decline of renal function in patients with diabetic kidney disease ("DKD") who, although at a pre-dialysis stage, exhibit rapidly progressive disease. Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. A Phase 2 proof of concept, randomized, placebo-controlled study is planned for initiation in the second half of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;OLOGO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; for Treatment of No Option Refractory Disabling Angina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired the rights to data and regulatory filings for a CD34+ cell therapy program for refractory angina that had been advanced to Phase 3 by a previous sponsor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the clinical evidence from the completed studies that a single administration of OLOGO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, this product received Regenerative Medicine Advanced Therapy (&#x201c;RMAT&#x201d;) designation from the FDA. The Company continues to seek an agreement with the FDA on the design of a Phase 3 study of appropriate and practical size and scope which, in combination with previously filed Phase 1, 2 and 3 data, will be considered for the registration of OLOGO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Notably, the RMAT designation affords the product a 6-month review time for a biologics license application ("BLA"), once submitted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Out-licensing Opportunities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot be reasonably estimated at this time. In response to the pandemic, the Company has implemented universal work from home as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan has experienced significant delays in enrollment due to the &#x201c;State of Emergency&#x201d; that was in effect for most of 2020 in response to COVID-19, and which was re-implemented on January 7, 2021 through March 21, 2021, and again on April 25, 2021 through May 11, 2021 covering Tokyo and other regions.  This most recent reinstatement of the &#x201c;State of Emergency&#x201d; continues negatively to impact enrollment of the on-going clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2021, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2020 and 2019 included in our 2020 Form 10-K. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</clbs:BusinessTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="icdcbdf98a7ca4a708730bbebd3ba7714_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM0Mw_ac316321-7daf-49dd-8306-1e895f478ea8"
      unitRef="usd">1900000</us-gaap:GrantsReceivable>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM1Ng_bb65aa71-18d2-4755-94bb-2e2489207dc4">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2021, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2020 and 2019 included in our 2020 Form 10-K. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM1Nw_5bd75421-7ab6-4650-a14e-b91578b01335">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNC9mcmFnOjE3NjBiMGUxMjY0NjQ4OTc5ODY2NGUyMDNhZDI2OTY4L3RleHRyZWdpb246MTc2MGIwZTEyNjQ2NDg5Nzk4NjY0ZTIwM2FkMjY5NjhfMjE5OTAyMzMyMDM1OA_3ba16252-86a2-4604-b9ca-0a4641e3407e">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA0OQ_9afe24e4-831c-4046-becf-5fd6fe1b22d8">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2020 Form 10-K. There were no changes to these policies during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses, which will require companies to present assets held at amortized cost and available for sale debt securities net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. The guidance was effective for fiscal years and interim periods beginning after December 15, 2019 and adopted January 1, 2020. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company determined that the adoption of this new accounting guidance did not have a material impact on its consolidated financial statements and footnote disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA0MQ_eecbf0c3-b59a-47c2-a2a3-27392313a58f">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA0Mg_9098c289-5e71-4a77-addb-b4826cbb6d15">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl8zNy9mcmFnOmVkYjYwYjU5OTczNTRmNTZhNmE0NmUwODZkZTJhYzY5L3RleHRyZWdpb246ZWRiNjBiNTk5NzM1NGY1NmE2YTQ2ZTA4NmRlMmFjNjlfNDA1MQ_9653f0f1-cb80-4550-8739-357a07c9d40e">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#x2014;Credit Losses, which will require companies to present assets held at amortized cost and available for sale debt securities net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. The guidance was effective for fiscal years and interim periods beginning after December 15, 2019 and adopted January 1, 2020. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company determined that the adoption of this new accounting guidance did not have a material impact on its consolidated financial statements and footnote disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjM4_3c2a691b-9b72-4734-89de-bc4283f4e688">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjMz_3bfebec0-0ec4-4594-ac95-4de53dc2d875">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xLTEtMS0w_6b20f5d4-76d9-4069-9925-f863acc21973"
      unitRef="usd">59937000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0zLTEtMS0w_240ffe9b-b8b1-42e7-bd48-721f35151a18"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy01LTEtMS0w_287ee465-3e9d-4ece-a782-f6dbb7f33b93"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3bc96434426403a9bd2301ded3b4994_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy03LTEtMS0w_f239dc34-507e-4215-b9be-ff7c3f0c01c3"
      unitRef="usd">59876000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy05LTEtMS0w_3cd392d6-c182-4ae9-b6ff-77c4bc946f95"
      unitRef="usd">8406000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xMS0xLTEtMA_b5ad5fae-84d1-43fc-9913-b455b0a06de3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xMy0xLTEtMA_5e5e84b1-ebe6-4cce-8f6e-b15cb816f86c"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i115a0e9999e14fdcb9279eee27425491_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfMy0xNS0xLTEtMA_7461db66-ec33-444d-8ccb-51f655d6716e"
      unitRef="usd">8399000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xLTEtMS0w_43b425d3-438b-4fa5-a871-60708218d47b"
      unitRef="usd">18044000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0zLTEtMS0w_75e7c1ef-f19f-437e-9060-c06fcf40a562"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC01LTEtMS0w_49c44727-9e0f-46ae-b4b2-5127084aa8a6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c8bef8b2cc44b6fa8ff26d8e49874b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC03LTEtMS0w_88e59384-e863-4561-b3d3-6e1a3cdc5e07"
      unitRef="usd">18044000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC05LTEtMS0w_07de9124-68f1-4164-946e-6e6b74c56abb"
      unitRef="usd">7591000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xMS0xLTEtMA_e3f26116-1a5e-4304-9368-18a04761ddb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xMy0xLTEtMA_d23c5ee5-07e0-4dd2-9ab0-c0006e3f4bc2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5a759825b1a41819d598d7d7e1af92d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNC0xNS0xLTEtMA_842fb8be-e346-4e76-87f6-a67ef47edd51"
      unitRef="usd">7591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xLTEtMS0w_1f1b3c92-4114-4beb-a085-336661aadb2a"
      unitRef="usd">29016000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0zLTEtMS0w_45ab07fc-af8f-4c9e-9ec3-f2f49345314f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS01LTEtMS0w_0e7d4766-879a-462f-9a95-42f5e30ec199"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic89c436a48cc48ef91082d25c26d3752_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS03LTEtMS0w_9c6ad385-2786-41c8-a2ee-2f2cad8018ab"
      unitRef="usd">29004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS05LTEtMS0w_6ffd6a7a-d1f2-4a54-9591-2805ec5325bf"
      unitRef="usd">14753000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xMS0xLTEtMA_6fc0e4b3-c825-41f4-8794-f4bd2aa48014"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xMy0xLTEtMA_9247c421-c4fe-418f-a825-ecd66f11dffc"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d5b5d6a31d64a1f9b677e3d600d7850_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNS0xNS0xLTEtMA_b8cf9664-8d68-4b77-aadd-d61123f756c2"
      unitRef="usd">14747000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xLTEtMS0w_6bb7a8a5-d086-4709-869d-e23704f49714"
      unitRef="usd">106997000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0zLTEtMS0w_77f1a5df-68b4-43d1-903c-ad7d2e6555dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy01LTEtMS0w_d5adae8c-865b-4c53-ba30-d8452b8235fa"
      unitRef="usd">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy03LTEtMS0w_267ae3d3-5e0d-4e94-9036-ff8519951fcb"
      unitRef="usd">106924000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy05LTEtMS0w_81c31b8c-a86d-4d21-8167-ee0ad42ac2bb"
      unitRef="usd">30750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xMS0xLTEtMA_9e0f5dfa-d4ce-4131-a597-8f1853db8d00"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xMy0xLTEtMA_15442427-5ca4-44da-b25b-1db172b5fad7"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjdhZDFkOWFhOTZkYjQyMThhOWFmMjAwZjhhZGNhOWQ0L3RhYmxlcmFuZ2U6N2FkMWQ5YWE5NmRiNDIxOGE5YWYyMDBmOGFkY2E5ZDRfNy0xNS0xLTEtMA_823d0d36-96d8-4c1f-a0a4-041244994e50"
      unitRef="usd">30737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjQw_56717076-1ab7-420d-8228-d3bb123833e4">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:Cash
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMS0xLTEtMS0w_9021d163-7159-46bf-9abc-3a216b75c71b"
      unitRef="usd">24157000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMS0zLTEtMS0w_46adbe8e-b87a-414f-9b12-7aba0ef44b7c"
      unitRef="usd">12676000</us-gaap:Cash>
    <us-gaap:MarketableSecurities
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMi0xLTEtMS0w_457ab04d-3b3d-4769-b7f6-c4671c2686ff"
      unitRef="usd">82767000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMi0zLTEtMS0w_c87b93a8-25dc-4e03-8821-f46791b2797d"
      unitRef="usd">18061000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMy0xLTEtMS0w_7c40408e-755a-46df-9266-8802a0e6710f"
      unitRef="usd">106924000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOmJlMmQxYTk0NWQ4MjRjNWE4Y2IyYTM2OTVjYTk3Zjk3L3RhYmxlcmFuZ2U6YmUyZDFhOTQ1ZDgyNGM1YThjYjJhMzY5NWNhOTdmOTdfMy0zLTEtMS0w_45803ad6-300f-45ae-a112-bbee1ad38960"
      unitRef="usd">30737000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RleHRyZWdpb246NDMzYTQ5ZjQ1NDUyNDY1ZGJhMjczZjg3YzI2NmFjMThfNjM2_444f6433-c287-4084-b872-85b6d958cf52">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMi0xLTEtMS0w_534b3e62-3eb1-4f33-94ff-7f123ef9f84e"
      unitRef="usd">106997000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMi0zLTEtMS0w_fc84d239-3a00-4ffa-a820-08845050b74e"
      unitRef="usd">106924000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMy0xLTEtMS0w_0492e532-00d1-4f84-9fbd-306c86d9ea40"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfMy0zLTEtMS0w_98a2fa6c-84e5-41ef-8666-a1b830629b04"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfNC0xLTEtMS0w_907c8b1a-a019-4e35-8567-5c1366232768"
      unitRef="usd">106997000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80MC9mcmFnOjQzM2E0OWY0NTQ1MjQ2NWRiYTI3M2Y4N2MyNjZhYzE4L3RhYmxlOjJkMmRlZWI0ZjVmNjQ3MzliMzc4MDhjNDE4ZWEwMGY4L3RhYmxlcmFuZ2U6MmQyZGVlYjRmNWY2NDczOWIzNzgwOGM0MThlYTAwZjhfNC0zLTEtMS0w_9a788a17-0037-4249-b007-0d8544201256"
      unitRef="usd">106924000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RleHRyZWdpb246Yjg3MDFmZjg1MWU0NDQyYzk1NThlNDAwNWFkNTk4YjRfMzI5_9987b041-e53b-48f6-894a-7614c8ef8578">Income (Loss) Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the three months ended March&#160;31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive.  At March&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RleHRyZWdpb246Yjg3MDFmZjg1MWU0NDQyYzk1NThlNDAwNWFkNTk4YjRfMzIz_11d0bd0e-762a-4aa4-ade4-00912dbb288f">At March&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i499338433b98478ba449207f9bded52e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMi0xLTEtMS0w_7d46d379-b9c6-4c84-a049-9a1423cc1ded"
      unitRef="shares">1022000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i777bc9631ae24b4aa509c6ab60a91a57_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMi0zLTEtMS0w_27cfc6ab-7a46-46a1-b7a7-2252c2986b06"
      unitRef="shares">1280000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i24b54c799369442588b92ab156347688_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMy0xLTEtMS0w_52a74fdb-3506-475a-9491-70d265ba08aa"
      unitRef="shares">21357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifa3f2806d8764f13bec22b3ff8cf87ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfMy0zLTEtMS0w_088196a5-1867-426a-9e84-085cf0c54df8"
      unitRef="shares">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iccdb907e20cf4c1b9603607b2905156a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfNS0xLTEtMS0w_eac6bec1-0e16-4719-81d8-69c5a70d644f"
      unitRef="shares">798000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i132ae7e2b40f4aacbfb45d310a8825e2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80Ni9mcmFnOmI4NzAxZmY4NTFlNDQ0MmM5NTU4ZTQwMDVhZDU5OGI0L3RhYmxlOjlhYTM4NWQzYzlkZTQwZmU5NzA4MGVhOWEwYjI2ZTIyL3RhYmxlcmFuZ2U6OWFhMzg1ZDNjOWRlNDBmZTk3MDgwZWE5YTBiMjZlMjJfNS0zLTEtMS0w_53bdbaef-8c75-43de-b37b-ade7248a89de"
      unitRef="shares">313000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RleHRyZWdpb246OWNiZDkzNDQxMzA5NDgyZTk0M2I1ODVkYzBjNGMwZTdfMTQ4MA_c2fa7981-85b1-4f34-9afd-346745e42e4a">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of March&#160;31, 2021, and December&#160;31, 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:115.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RleHRyZWdpb246OWNiZDkzNDQxMzA5NDgyZTk0M2I1ODVkYzBjNGMwZTdfMTQ3OQ_2c934a49-b241-4f1e-9e99-4b644975de18">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of March&#160;31, 2021, and December&#160;31, 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:115.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iffea5c40fbc940929f1156d78435b50f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0yLTEtMS0w_75c5309c-4c44-475b-b6cb-bb749d10609f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibc9f9eb3437d453dbe79a9bff47d7f5f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy00LTEtMS0w_1cc2e1f2-61c1-4222-bb6b-7a3e70d9e89e"
      unitRef="usd">82767000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4bdf6d06fccf49ae9869c434a423e19b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy02LTEtMS0w_faf662b5-6766-42f5-8340-7b2b4b6ea999"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4537dc4974b74981b566969155de0b54_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy04LTEtMS0w_a623f33e-6d04-4912-b191-a13b813925be"
      unitRef="usd">82767000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic25ae7a16882454a89235836a00c085e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xMC0xLTEtMA_32285f74-382b-42ad-bef7-7bcc4cab39d7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia0034e259507451381d712e51c59a110_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xMi0xLTEtMA_7e60c333-e43b-404d-8590-22fcd537db3d"
      unitRef="usd">18061000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i17695a58a11c417395bec355c88d7fdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xNC0xLTEtMA_324ae6e7-812c-4b23-988f-e6cfcaeb162e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iad507469e2c44e1c81b999fe3754c26f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfMy0xNi0xLTEtMA_f5903afd-aaca-42df-8a67-01cbb271f75f"
      unitRef="usd">18061000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iffea5c40fbc940929f1156d78435b50f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0yLTEtMS0w_15e0b763-2264-46bd-9e75-d98de1f65bb2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc9f9eb3437d453dbe79a9bff47d7f5f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC00LTEtMS0w_97e2f185-ea07-4b84-9797-db188f4fe4b2"
      unitRef="usd">82767000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4bdf6d06fccf49ae9869c434a423e19b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC02LTEtMS0w_9a8ca122-2055-4789-b312-5eb0b3dc3790"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4537dc4974b74981b566969155de0b54_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC04LTEtMS0w_e49a98c1-be15-493c-b4d5-90489e7fa0a1"
      unitRef="usd">82767000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic25ae7a16882454a89235836a00c085e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xMC0xLTEtMA_9d053b38-e675-4379-ba89-e9aa94191a56"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia0034e259507451381d712e51c59a110_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xMi0xLTEtMA_d48bbfa1-829e-47a9-b7f2-5dd99d3c0d5c"
      unitRef="usd">18061000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i17695a58a11c417395bec355c88d7fdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xNC0xLTEtMA_107e79d5-b5f0-4ebf-8d2d-2c94b271b7f4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad507469e2c44e1c81b999fe3754c26f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl80OS9mcmFnOjljYmQ5MzQ0MTMwOTQ4MmU5NDNiNTg1ZGMwYzRjMGU3L3RhYmxlOjRmM2M0MjIxNzFhYzRjMWM4NmYyNTQ2OTg4ZTBiMzVkL3RhYmxlcmFuZ2U6NGYzYzQyMjE3MWFjNGMxYzg2ZjI1NDY5ODhlMGIzNWRfNC0xNi0xLTEtMA_4cf1c444-ab54-4232-8223-1f150d785fef"
      unitRef="usd">18061000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RleHRyZWdpb246YTNhN2JkOWQ1ZjI2NDc4YjgyOGM5OTQyMTRhZWZjMmFfMTEy_b36dacd7-964b-453a-b7b3-d42ada1ad2f9">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RleHRyZWdpb246YTNhN2JkOWQ1ZjI2NDc4YjgyOGM5OTQyMTRhZWZjMmFfMTA5_a4e9579d-426b-43b7-bb19-bcac54fa8df4">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMS0xLTEtMS0w_86a3282f-2006-4fae-8247-47333011aa55"
      unitRef="usd">1119000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMS0zLTEtMS0w_f867340d-bb14-4f2e-89c4-366a89a1bc31"
      unitRef="usd">1716000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMi0xLTEtMS0w_4b39aad6-5731-474f-9bf5-c64779838458"
      unitRef="usd">381000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfMi0zLTEtMS0w_98b180b6-cc27-4465-b9b0-e0a75d938d6d"
      unitRef="usd">370000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNC0xLTEtMS0w_e27359e7-cb2a-40f2-9d9b-1f737a1fba37"
      unitRef="usd">623000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNC0zLTEtMS0w_e22e7ffe-ad1e-4c15-af3c-24622ee499ca"
      unitRef="usd">400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNS0xLTEtMS0w_7e27e4c5-8e98-4c47-8322-62056c939aef"
      unitRef="usd">2123000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81Mi9mcmFnOmEzYTdiZDlkNWYyNjQ3OGI4MjhjOTk0MjE0YWVmYzJhL3RhYmxlOmJkYzYwM2ZkYmNmOTQ2NWJiMzdjNmRmY2NhNjAyNTUzL3RhYmxlcmFuZ2U6YmRjNjAzZmRiY2Y5NDY1YmIzN2M2ZGZjY2E2MDI1NTNfNS0zLTEtMS0w_0144c040-52e1-4b49-aafb-6316ee762168"
      unitRef="usd">2486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTE2Ng_0bd4d968-f171-4d01-b333-13357d6c48a3">Operating Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for two offices with terms that expire in 2022 and 2023. The Company estimates its incremental borrowing rate, at lease commencement, to determine the present value of lease payments, since most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases include options for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the weighted average remaining lease term for our operating leases was 1.6 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of March&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <clbs:NumberOfOfficesUnderOperatingLeases
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfNzA_c0a023f1-3410-45c2-9388-0370e44cefe8"
      unitRef="office">2</clbs:NumberOfOfficesUnderOperatingLeases>
    <clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTE3MA_c9670a3e-f503-4c11-8b69-22bac041456d">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iad9e8e338fc54edf89217db73847c29b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMi0xLTEtMS0w_831d37f2-bac1-4acc-80ff-c2561f0894f0"
      unitRef="usd">492000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i26a96d4091904e6b919d8e86339a5d99_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMi0zLTEtMS0w_e504fa11-e47e-4420-8eba-71c0bd2ac665"
      unitRef="usd">574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMy0xLTEtMS0w_17151964-699c-425a-90a5-f39bf6cbf533"
      unitRef="usd">492000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfMy0zLTEtMS0w_593939c1-3656-4e6b-8199-4e7c43e6c0bd"
      unitRef="usd">574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9ced2f706c534f1d91b7bc6ba399fe9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNi0xLTEtMS0w_f7ab5bd9-cce9-435b-81fc-57e1a208be5c"
      unitRef="usd">381000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8b76807e468541f4b8af73ed9c91b2fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNi0zLTEtMS0w_4462307c-a878-4f1d-a7e8-f743dab354fd"
      unitRef="usd">370000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i37e538a949044dd7ac2e7157cd069c22_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNy0xLTEtMS0w_e16e5780-b2fc-4cb6-a1bd-e91a8dcc6bb6"
      unitRef="usd">155000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieaa95386fd914df2ab6e70d41a0648dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfNy0zLTEtMS0w_30c90d75-f152-4857-a689-6a9d51b584ff"
      unitRef="usd">254000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfOC0xLTEtMS0w_1d564fa0-61a3-4b37-bd6e-6a3f87ce5537"
      unitRef="usd">536000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjI2MmUzYzE2MWQ5ZjQ2MzI4MTdlZThiYjU3YTBmMThiL3RhYmxlcmFuZ2U6MjYyZTNjMTYxZDlmNDYzMjgxN2VlOGJiNTdhMGYxOGJfOC0zLTEtMS0w_2c3c114b-7726-4e31-9e18-efd6d84deec5"
      unitRef="usd">624000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfOTg4_b5569f45-7a31-45f8-8536-39ed4d81b871">P1Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTA2MA_e316d6f6-01b5-422c-91f4-115a2af043d5"
      unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RleHRyZWdpb246ZWQ5YTZhMWRkZTRmNGVlZGE1OWEzOTRlMTk0ODIxZWRfMTE2NQ_960c4365-ab2c-40d1-acf2-df0e1a532294">Future minimum lease payments under the lease agreements as of March&#160;31, 2021 were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfMy0xLTEtMS0w_f91808d5-667f-43b8-9488-2b778d325156"
      unitRef="usd">312000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNC0xLTEtMS0w_58b3dfcb-ae1e-4b16-8dc4-369c26857ff4"
      unitRef="usd">239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNS0xLTEtMS0w_e840811b-2e33-4100-bb43-35d9d0bd3c98"
      unitRef="usd">27000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNi0xLTEtMS0w_adb2927c-2191-484e-bc28-98e892aaec2e"
      unitRef="usd">578000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfNy0xLTEtMS0w_9a863c2b-f62f-4e0a-b7c7-38f457a147f9"
      unitRef="usd">42000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81NS9mcmFnOmVkOWE2YTFkZGU0ZjRlZWRhNTlhMzk0ZTE5NDgyMWVkL3RhYmxlOjkyNTk1Y2IwNTkwZDRlNzlhNjNmYjI3MWQ4NjFkOWE5L3RhYmxlcmFuZ2U6OTI1OTVjYjA1OTBkNGU3OWE2M2ZiMjcxZDg2MWQ5YTlfOC0xLTEtMS0w_2b1fdaf5-5c97-4376-91c8-feec518aace0"
      unitRef="usd">536000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTEwNQ_bb0c9b07-2a81-4f57-ab83-2452318effcc">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#x2019;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#x201c;Offering&#x201d;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#x201c;Initial Purchase&#x201d;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#x2019;s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#x201c;Regular Purchase&#x201d;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#x201c;accelerated purchase&#x201d; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#x2019;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase Agreement does not limit the Company&#x2019;s ability to raise capital from other sources at the Company&#x2019;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright&#160;&amp;amp; Co., LLC ("HCW") as sales agent, which was subsequently amended in August 2018 (the "Sales Agreement"), in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock having an aggregate offering price of not more than $25.0 million.&#160;In&#160;March&#160;2019, subsequent to the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"), the aggregate market value of its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding common stock held by non-affiliates was approximately&#160;$52.8 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below&#160;$75.0 million at the time of its 2018 Form 10-K filing, the aggregate amount of securities that the Company was permitted to offer and sell at such time was reduced to $17.6 million (or a maximum of 4.8&#160;million shares), which was equal to one-third of the aggregate market value of its common stock held by non-affiliates at such time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms and conditions of the Sales Agreement, HCW will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon the Company's instructions, including any price, time or size limits specified by the Company. The Company has provided HCW with customary indemnification rights, and HCW will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. The Company has no obligation to sell any of the shares and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement. The Sales Agreement will terminate upon the sale of all of the shares under the Sales Agreement unless terminated earlier by either party as permitted under the Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, the Company suspended the use of the at-the-market transactions facility (the &#x201c;ATM&#x201d;) and terminated the continuous offering pursuant to the Common Stock Sales Agreement (&#x201c;Sales Agreement&#x201d;) entered into in February 2018 with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;HCW&#x201d;). The Company will no longer make any sales of its common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of February 12, 2021, the Company had sold an aggregate of 3,784,912 shares of its common stock pursuant to the Sales Agreement for net proceeds of $9.5&#160;million. During the three months ended March&#160;31, 2021, the Company had not issued any shares under the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Registered Direct Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into a Securities Purchase Agreement (the &#x201c;Institutional Purchase Agreement&#x201d;) with certain institutional investors (the &#x201c;Institutional Purchasers&#x201d;). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of its common stock and warrants to purchase an aggregate of 12,453,067 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the &#x201c;Additional Purchase Agreement&#x201d;) with certain accredited investors (the &#x201c;Additional Purchasers&#x201d;). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of 1,632,652 shares of its common stock and warrants to purchase an aggregate of 816,326 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $65.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a securities purchase agreement (the &#x201c;January Private Placement&#x201d;) with certain investors (the &#x201c;January Purchasers&#x201d;). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of 12,500,000 shares of its common stock at a purchase price equal to $2.00 per share, along with warrants to purchase an aggregate of 6,250,000 shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $25.0 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.90 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Exercises&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company issued 801,148 shares of common stock for net proceeds of $1.8 million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:14.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;963,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,638,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,519,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(801,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,022,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;br/&gt;&#160;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;996,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;765,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2021 and 2020 was $1.59 and $3.19 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDMw_95bdfe17-a4d8-4325-9178-4df2f6502086"
      unitRef="usd">26000000.0</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration
      contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNjQy_36c06b2c-6804-4c46-ac0f-5d87599c0acf"
      unitRef="shares">181510</clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNzUx_5f7a4a98-cf4d-4490-9589-e02da2e385d8"
      unitRef="shares">250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNzky_6545f8d8-f03f-4bb6-8e2e-cc4ccbd6b08d"
      unitRef="usdPerShare">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfODQy_f0a591be-5f09-4324-b019-d2fb221c1c4f"
      unitRef="usd">1000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <clbs:TermOfAgreement
      contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTAyMA_83ce69db-8f4b-49f5-916d-4d35bf487c7e">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTIwNQ_8202e7ca-d850-4b79-a23a-62d316997471"
      unitRef="shares">100000</clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTM5OQ_7e104d7a-f46b-41bb-bd25-ab15844c4046"
      unitRef="usd">2500000</clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTk0NA_de9c4cf6-6129-4a09-b694-44fd88aba1b7"
      unitRef="number">3</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMjAzMw_5fe4689e-62eb-4cf8-96b6-ca87420e8741"
      unitRef="number">0.30</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod>
    <clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty
      contextRef="if63681e7fe174b76af8b5ab1341d9fa0_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMjkzNQ_eb60c461-aed3-4638-b3fd-d65fe94db757"
      unitRef="number">0.0999</clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty>
    <clbs:TermOfAgreement
      contextRef="ic72d5330ed5a43abb6e14eca21ac396b_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMzM0NA_83ce69db-8f4b-49f5-916d-4d35bf487c7e">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="i1a98eb81842e4748b436585c87156f1a_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDA1OQ_1b38bd11-5b1f-49a0-98c3-7bbc1c27d2a1"
      unitRef="usd">25000000.0</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:AggregateMarketValueOfCommonStockNonAffiliates
      contextRef="ic03c497fe3a647068aff689400691742_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDMwNQ_af103c7e-19b4-4e7b-8834-f6f0fa143784"
      unitRef="usd">52800000</clbs:AggregateMarketValueOfCommonStockNonAffiliates>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="i253f4e81f39240bfa1478bea971064bb_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDYwNw_83ae2bcb-533a-4a4f-9a83-c68c1819b5da"
      unitRef="usd">17600000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement
      contextRef="i253f4e81f39240bfa1478bea971064bb_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTQxMA_9f50ecee-bb78-4d93-b025-de07f977087a"
      unitRef="shares">4800000</clbs:SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement>
    <clbs:SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent
      contextRef="i47215ddbef4645acbdcebd547430280c_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNTE4Mg_b1aac8ca-2e0e-48dc-8c54-1bb7fb629ff4"
      unitRef="number">0.030</clbs:SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0bb45e4366f343b387c5ac5a70b7d93c_D20180201-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTA5OTUxMTYzODIxOQ_743c18e0-1a7a-427a-8255-6e349fbdddfc"
      unitRef="shares">3784912</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0bb45e4366f343b387c5ac5a70b7d93c_D20180201-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMTA5OTUxMTYzODMxNA_52a629a6-03fd-42c9-bcd3-e5277dabb974"
      unitRef="usd">9500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i14d5d5e90b62441eb1838b078677e72b_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTEzMg_0a88d037-9a3e-4b95-9e98-964f36bf627d"
      unitRef="shares">24906134</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTEzNg_cd7c27c3-4a73-488b-8cf5-c2a498b1bf96"
      unitRef="shares">12453067</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE0MA_6ed97e6f-2d26-4b07-8fcd-39abdf67be3c"
      unitRef="usdPerShare">2.45</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE0NA_d7628e70-b6fa-42d6-b6d7-ca3e24067f8a"
      unitRef="usdPerShare">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="icec9ddeca5314500aed87a027edc3fbe_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE0OA_df55220d-dc49-4848-9389-5dad6dba8778">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5a8d0caecfc8478a9763718f92a1c601_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE1Mg_11c54233-4275-4e22-8183-599f5d5ae619"
      unitRef="shares">1632652</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE1Ng_e55ef510-42f0-4140-aa11-3262e08c3088"
      unitRef="shares">816326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE2MA_e7427f05-37d7-4dfe-8ca6-96fd6f1a7c49"
      unitRef="usdPerShare">2.45</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE2NA_2889cb6b-6071-4054-ac05-ddfbce652154"
      unitRef="usdPerShare">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i26d9ab027a9f41eb98c3e39e9e7125aa_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE2OA_a4740c97-1500-4c4f-a98f-630b398190d9">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iaf4ed15255a740ccbc038f0987ef5f67_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTE5OQ_4cd393d2-469e-4cc2-b7e6-fe4959d02fdc"
      unitRef="usd">65000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5885d9e0c6b24703a32d31ff18fa6628_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTIzMQ_a9813351-e47a-4832-9d05-d5f1d9e099b9"
      unitRef="shares">12500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTIzNQ_3223d088-3111-4841-940f-33cb0795d181"
      unitRef="usdPerShare">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTIzOQ_64c08b44-ed23-4e0a-92bf-ae0d98ae3170"
      unitRef="shares">6250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5885d9e0c6b24703a32d31ff18fa6628_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTI0Mw_f3f6d06c-3c98-42a6-8484-dd83de8e8c80"
      unitRef="usd">25000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfMjE5OTAyMzI4MTI5Mw_eaffa646-4ff2-42d4-a4f8-a905de534af2"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia81b7df5ebf54a24b5d58e6c8c96ed1f_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTI1NA_3ccccdb8-a571-4c1f-bea2-1bebc5c192cc"
      unitRef="usdPerShare">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i7f840f3881574b5db5784970c5024047_D20210101-20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTMxMQ_d6acce42-cf1b-4fec-8342-599db90f1359"
      unitRef="shares">801148</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i7f840f3881574b5db5784970c5024047_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNDM5ODA0NjUyOTMxNQ_46b0a821-e8cc-4e10-b412-d09e3ee8d1fd"
      unitRef="usd">1800000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTExMQ_a1b75155-c450-4fa1-a8c1-83bc5526b6c0">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;963,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,638,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,519,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(801,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,022,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;br/&gt;&#160;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;996,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;765,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i94c77a9975714e5bb66f65c196bcb6f9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0yLTEtMS0w_371316d3-bdc6-4bbb-90ab-c577866d57f9"
      unitRef="shares">963700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i94c77a9975714e5bb66f65c196bcb6f9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi00LTEtMS0w_dce56923-f0d2-45d5-a7ac-4dd233e608da"
      unitRef="usdPerShare">14.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idd25e43236aa4b5696a0696badf143fe_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi02LTEtMS0w_b2e6e69f-1cc0-4253-a313-d268b143ad40">P5Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i94c77a9975714e5bb66f65c196bcb6f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi04LTEtMS0w_39aa9537-9251-4606-b2ff-1f2b65c0a20b"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xMC0xLTEtMA_6e0fef69-87ce-49fa-b32a-081c8db503a4"
      unitRef="shares">2638355</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xMi0xLTEtMA_f88ff3cb-cce1-4eb6-bae8-0ee0597536c1"
      unitRef="usdPerShare">2.18</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="if48a0e1d6f4147ebb6edcba9191e4ea5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xNC0xLTEtMA_11c7c830-d1d4-49fb-9c8b-2838f8537694">P4Y11M23D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMi0xNi0xLTEtMA_48c67620-f97d-4d5d-aef6-c4fd3e139a01"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS0yLTEtMS0w_7b01fba7-fd4c-467c-84dc-9948041ec623"
      unitRef="shares">155150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS00LTEtMS0w_1bf64067-726a-4ced-8960-d6bd609d6590"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsGranted
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS0xMC0xLTEtMA_98d0ff3d-92f6-4ab6-91de-54d7c42413b4"
      unitRef="shares">19519393</clbs:WarrantsGranted>
    <clbs:WeightedAverageExercisePriceWarrantsGranted
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNS0xMi0xLTEtMA_75d044c8-6250-4037-85ba-c4569515204d"
      unitRef="usdPerShare">2.90</clbs:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi0yLTEtMS0w_ff508286-1679-429b-97b0-1352c392c621"
      unitRef="shares">7250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi00LTEtMS0w_082e797f-b597-4e5a-8ac0-7bf988367e30"
      unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExercised
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi0xMC0xLTEtMA_22f7184c-65be-4d42-8edf-4595dc788a4c"
      unitRef="shares">801148</clbs:WarrantsExercised>
    <clbs:WeightedAverageExercisePriceWarrantsExercised
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNi0xMi0xLTEtMA_ccdbb1c6-5900-4a1d-b942-38d39a507ac0"
      unitRef="usdPerShare">2.19</clbs:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy0yLTEtMS0w_8940b4cf-ffc4-4d0b-b994-42fd276eb7c3"
      unitRef="shares">7017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy00LTEtMS0w_cdc87b7e-1780-442f-bfa3-2effbdb5dc98"
      unitRef="usdPerShare">2.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsCanceled
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy0xMC0xLTEtMA_cb7ec573-7f9f-4303-b7f2-b2f080256b15"
      unitRef="shares">0</clbs:WarrantsCanceled>
    <clbs:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfNy0xMi0xLTEtMA_f73b58c2-15eb-440f-b7d6-84176b1d41c8"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC0yLTEtMS0w_cd36951e-4d2b-4014-82fc-3203c4148165"
      unitRef="shares">82359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC00LTEtMS0w_5bc93522-9c7b-41c4-8184-730de12ff2e9"
      unitRef="usdPerShare">6.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExpired
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC0xMC0xLTEtMA_c2587a7d-b668-47dd-bcd7-837b475ed7c0"
      unitRef="shares">0</clbs:WarrantsExpired>
    <clbs:WeightedAverageExercisePriceWarrantsExpired
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOC0xMi0xLTEtMA_310ad7be-a6c2-4f52-84fe-840a8110d253"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0yLTEtMS0w_6d10354f-3d80-43ae-99f5-9fa7fb5838dc"
      unitRef="shares">1022224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS00LTEtMS0w_c34e646a-1e85-4128-8509-ba79c8179a48"
      unitRef="usdPerShare">13.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS02LTEtMS0w_35476f8c-85fc-4aa2-a1b2-73bd4e184601">P6Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS04LTEtMS0w_a2dd9348-86c4-4914-8280-c55c29a74e56"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xMC0xLTEtMA_70b74795-e94f-4b8c-a43e-aff562315c91"
      unitRef="shares">21356600</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xMi0xLTEtMA_eaa444a8-b1f5-41b5-b5aa-341344c0349b"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xNC0xLTEtMA_3cace20c-194e-4c43-ac12-528a594d0a6a">P4Y11M23D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfOS0xNi0xLTEtMA_1bf052d2-987f-4bf6-ba98-b826bb755033"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMi0xLTEtMA_1c9ddccd-5149-495c-8a4b-e7cfd2ed6539"
      unitRef="shares">996573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtNC0xLTEtMA_6e1e23ba-2e6a-4b36-84f1-0e2d98074520"
      unitRef="usdPerShare">13.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtNi0xLTEtMA_e2b5d8a2-ed09-48ea-982d-31af87726662">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtOC0xLTEtMA_98e68e4f-267e-4813-b192-dc6ca9ad1645"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <clbs:Sharesvestedandexpectedtovest
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTAtMS0xLTA_e5b3f7c1-3052-44f3-896f-cf223dee6409"
      unitRef="shares">21356600</clbs:Sharesvestedandexpectedtovest>
    <clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTItMS0xLTA_d19c6967-089d-47a5-a32f-3091dfd2919e"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTQtMS0xLTA_6c07569d-fd31-4072-b46e-9794156461ea">P4Y11M23D</clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTAtMTYtMS0xLTA_89885cb7-8b68-442e-8276-6b6c36aff54c"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMi0xLTEtMA_4c429a52-e3a1-4d7a-a676-e39a69bc6711"
      unitRef="shares">765479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtNC0xLTEtMA_560c3277-4a76-4ddc-80e5-284d527f8cb6"
      unitRef="usdPerShare">17.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <clbs:OptionsVestedweightedAverageRemainingContractualTerm
      contextRef="ie9e01ed743284341b560ed9e922155e9_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtNi0xLTEtMA_172dd6a9-02fc-4dd7-a3b4-3eb08f35faa6">P5Y10M13D</clbs:OptionsVestedweightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i2d54f54529cf4daea43de35b41341f98_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtOC0xLTEtMA_e7ccc809-fd4b-479f-ae72-1935683e4850"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <clbs:WarrantsVested
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTAtMS0xLTA_2a5b82b2-39a0-4ef1-847d-4175bc82d7fc"
      unitRef="shares">21356600</clbs:WarrantsVested>
    <clbs:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTItMS0xLTA_59fdb5ac-79f6-49ab-950c-245b00838354"
      unitRef="usdPerShare">2.80</clbs:WeightedAverageExercisePriceWarrantsExercisable>
    <clbs:WeightedAverageRemainingContractualTermwarrantsvested
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTQtMS0xLTA_01c8c605-e02f-4b07-b5de-7ade0611aefa">P4Y11M23D</clbs:WeightedAverageRemainingContractualTermwarrantsvested>
    <clbs:AggregateIntrinsicValueWarrantsvested
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjBlZjdlMzI5YTk5YTRiMWQ5NmEyNzljY2U2NzY2YjU4L3RhYmxlcmFuZ2U6MGVmN2UzMjlhOTlhNGIxZDk2YTI3OWNjZTY3NjZiNThfMTEtMTYtMS0xLTA_bd6c8add-cab7-4da9-9653-cda38a437992"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTEwMA_953148b4-044b-4422-b4b6-ab1dfe8ad101">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMi0yLTEtMS0w_d8f7fce9-c277-4c41-ba76-db5b203a2ef3"
      unitRef="shares">300450</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMi00LTEtMS0w_0751786b-48d0-4ac8-8834-fa38d1de9f10"
      unitRef="shares">156184</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMy0yLTEtMS0w_a66fa4e6-c5bb-4b1f-99a8-149e6ce3b068"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjYyNTc2NmMyODgzMzQ1ZjM4OWM0N2VhNWY3NzdiYWU5L3RhYmxlcmFuZ2U6NjI1NzY2YzI4ODMzNDVmMzg5YzQ3ZWE1Zjc3N2JhZTlfMy00LTEtMS0w_1b6846ed-d947-490d-97b7-d5f6836e5edf"
      unitRef="usd">512000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfOTEwOA_2a55c60b-c9cb-4a64-9b9c-b508145317c1">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMi0xLTEtMS0w_211f0f28-5777-422b-b50c-b88a7a946ae4"
      unitRef="shares">458245</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i0b7bf07503274c4ba141b5cbc1970f3f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMi0zLTEtMS0w_4c1092ae-b74a-4252-a44c-52385b7d3294"
      unitRef="shares">195320</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMy0xLTEtMS0w_e3b13631-9a46-4425-a54e-775ce0240293"
      unitRef="usd">729000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i0b7bf07503274c4ba141b5cbc1970f3f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RhYmxlOjIwMjA0ZDdhNjhjYzQxMjM4MWM4ZjFiMDQ5ODE5NTEzL3RhYmxlcmFuZ2U6MjAyMDRkN2E2OGNjNDEyMzgxYzhmMWIwNDk4MTk1MTNfMy0zLTEtMS0w_f3d8715c-4386-45f5-b03f-7302b5e3848c"
      unitRef="usd">623000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfODgwNA_70f88544-9759-4a28-81de-5e6e34f2da0f"
      unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iadc5ba1f665f4a63b0c6f0900f8398bf_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfODgxMQ_eabb3258-1070-455c-ad12-a2d377b83e6f"
      unitRef="usdPerShare">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl81OC9mcmFnOjI2ZWY4NGIwNTU4NDQzYjg5ZjU2ZGNlZDRlMzlhNGMyL3RleHRyZWdpb246MjZlZjg0YjA1NTg0NDNiODlmNTZkY2VkNGUzOWE0YzJfNzE0NjgyNTYwMjE1Ng_0c31fc1b-9c94-449e-a978-63a5bfb25ab8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTEyOA_8bb24770-e7d2-4235-a97c-c66b65893420">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTE0NA_14bf722a-89d3-4a76-80db-c4ee68559da9">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icbe5f0e3fd7141d6b7317b9c81f7225c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMi01LTEtMS0w_e46a6b67-08d5-4c60-ac80-8999ad22d7e0"
      unitRef="usd">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb173d03e633477ead116cda9d9948a3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMi03LTEtMS0w_a9097cd5-07f6-4ee0-9726-a99831c8271b"
      unitRef="usd">125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4eab163f6b9e41e5b784b249926dbd6e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMy01LTEtMS0w_78572bf9-95cf-46fc-a8dd-53f824607730"
      unitRef="usd">501000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c54fa8f52bb4465a41b34646f8ffcce_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfMy03LTEtMS0w_f25e15e4-5514-4fb9-bf80-6a8c91e973da"
      unitRef="usd">442000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfNC01LTEtMS0w_e2ff7a78-ab93-47f1-bcc4-2dfd4ceaa3e9"
      unitRef="usd">597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmRlNmEzYWU1OTE5YzRlYTA4MTQzYTcxZmY5MzFjM2M4L3RhYmxlcmFuZ2U6ZGU2YTNhZTU5MTljNGVhMDgxNDNhNzFmZjkzMWMzYzhfNC03LTEtMS0w_ac991d77-b17c-4eb2-afb6-f9e20aa7b10c"
      unitRef="usd">567000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTEzMw_afb40865-f55b-49c4-bb4e-ae28874cc5a5">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5a59d2dafdc848809ac87c686c29886a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMS0xLTEtMS0w_f6ff72e7-0c86-452f-9664-d5eb19e95ae6"
      unitRef="usd">395000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i81e73ba2637749b6bbc62bc908b6e954_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMS0zLTEtMS0w_73a01229-de6c-4d75-acbc-f069a41f6159"
      unitRef="usd">537000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9e428d7942a045c8984c14fda8656fa5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMS01LTEtMS0w_a4e4f4db-6a8c-4655-8806-117fe6b98b42"
      unitRef="usd">575000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMi0xLTEtMS0w_0eccb091-bbae-4351-ab7d-6324292d78ea">P1Y9M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i759214c1bb7f4003972143f129ebe638_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMi0zLTEtMS0w_a0867eef-9263-4738-8499-c9a6a4c8e9bf">P1Y4M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOmJmMzJhNTg0M2Q5NzRmNjlhMTM4ZDM0MGFhZTc0ZmFkL3RhYmxlcmFuZ2U6YmYzMmE1ODQzZDk3NGY2OWExMzhkMzQwYWFlNzRmYWRfMi01LTEtMS0w_0eebd7bb-d84f-47a2-9094-f10a5e1ca92d">P2Y2M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RleHRyZWdpb246NDliOGVkZjJlZmNkNDA3ZmIyMDg1N2IxOGYxYjBhZWNfMTE1MQ_07eea1aa-77d9-4a91-a086-73d0fbddbf1e">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfMy0xLTEtMS0w_94964291-449a-44f4-b650-0cd356f21e46"
      unitRef="usd">397000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id723fbccd73440de8762bc38568bf063_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfMy0zLTEtMS0w_a3aa133a-a904-4ef1-a00a-0753c786e512"
      unitRef="usd">502000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfNC0xLTEtMS0w_15697a6a-9bd6-4189-862c-4294f81e71cc"
      unitRef="usdPerShare">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id723fbccd73440de8762bc38568bf063_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82NC9mcmFnOjQ5YjhlZGYyZWZjZDQwN2ZiMjA4NTdiMThmMWIwYWVjL3RhYmxlOjdjN2Q5ZjFlODY5MjRhZGI4M2Q5NjQwMzRiYTdkMTQ2L3RhYmxlcmFuZ2U6N2M3ZDlmMWU4NjkyNGFkYjgzZDk2NDAzNGJhN2QxNDZfNC0zLTEtMS0w_aa76bb64-d90d-46ae-9148-c8c421525dfc"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfMTM4Ng_fdea2e26-afea-4a1f-93f3-876d31a98556">Research FundingCalifornia Institute of Regenerative Medicine Grant AwardIn February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded the Company funds of up to $12.2 million to support the T-Rex Study. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $8.6&#160;million, of which $8.2 million has been received through the grant project period completion. The Company received $5.7 million in initial funding in May 2017, a $1.9 million milestone payment in December 2017, a $0.3 million progress payment in March 2018, and a $0.2&#160;million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $46&#160;thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the three months ended March&#160;31, 2021 and March&#160;31, 2020, the Company amortized and recognized $0.0&#160;million and $0.7&#160;million in credits, respectively, to research and development related to CIRM funds received.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="ie43284901a884f78a402755fd3b41aaa_I20170228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfMjA0_20c54310-e55e-4d9e-afc2-3a80f15b88bd"
      unitRef="usd">12200000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNTM4_9aaeb504-395a-47f7-9f11-157bffb8f3c9"
      unitRef="usd">8600000</us-gaap:GrantsReceivable>
    <clbs:FundingOfGrantAwardCashReceived
      contextRef="ib1905a146945439d89ff1228516dc50e_D20170501-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNTUx_1ea07c99-d9b4-4a96-86b1-2002e600f11e"
      unitRef="usd">8200000</clbs:FundingOfGrantAwardCashReceived>
    <clbs:FundingOfGrantAwardCashReceived
      contextRef="iffe95d09252c410489923fdd656451ce_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNjM4_14bff649-b5d7-4da5-9a61-1951db8272c8"
      unitRef="usd">5700000</clbs:FundingOfGrantAwardCashReceived>
    <clbs:MilestonePaymentOnGrantAwardCashReceived
      contextRef="i64d49bafd16540ef92725c78f1429358_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNjc1_281b8172-e64c-41fc-958a-d9b24ff98281"
      unitRef="usd">1900000</clbs:MilestonePaymentOnGrantAwardCashReceived>
    <clbs:ProgressPaymentOnGrantAwardCashReceived
      contextRef="i7c059030f14c498b9bf58d821d59c031_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNzE2_11c9511e-5b81-4907-8260-07f8605f743a"
      unitRef="usd">300000</clbs:ProgressPaymentOnGrantAwardCashReceived>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="icc32f1fee1574a39a7e75cd277331948_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNzU3_07dbb53d-a983-498d-b9a0-5436e16b2c3f"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="i619b7221c8b6420b9d72d12bbca2851d_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfOTcy_e7232224-4fec-40c6-b117-c6e93b327b85"
      unitRef="usd">46000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNDM5ODA0NjUxMzAwOQ_77762afa-61b3-4e97-8bbe-007d302222cf"
      unitRef="usd">0.0</clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense>
    <clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
      contextRef="iaba2dbefb7c541e5a095adbb2a7c222e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl82Ny9mcmFnOmU5MzE5MjBjOTQ4ODRmMTRiMmYxOTYyMDBmNDVhZDU2L3RleHRyZWdpb246ZTkzMTkyMGM5NDg4NGYxNGIyZjE5NjIwMGY0NWFkNTZfNDM5ODA0NjUxMzAxNw_e76f9f8a-ff47-4ee8-a180-e604501dbcf9"
      unitRef="usd">700000</clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfMzMyOQ_895637cd-60b7-46db-b044-00a88065890a">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company had approximately $264&#160;million of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;As of December&#160;31, 2020, the Company had State NOLs available in New Jersey of $99&#160;million, California of $70&#160;million, and New York City of $13&#160;million to offset future taxable income expiring from 2030 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;through 2040. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#x2019;s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an analysis and determined that they did not have an ownership change of greater than 50% over a 3-year testing period. The last ownership change was determined to be on June 3, 2015. Based on a market capitalization of $125&#160;million and using an applicable federal rate of 2.5%, the annual limitation would be approximately $3.0&#160;million. Post change losses generated after June 3, 2015 would not be subject to 382 limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2017, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from date of filing.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0023b178cff546c5a4ed4572f1675a89_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNTQ1Ng_31c54dd0-1588-44ce-beaf-8035c495b99f"
      unitRef="usd">264000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i64fbc9ce8d824790bfc3e917a2bd92b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNjA0Mg_1ad1242c-c1c1-4442-8d95-161b2ad8cfdf"
      unitRef="usd">99000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib20ab50a11fb4b0f89cb676e7cf79d61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNjA2MA_88e390dc-ca15-41c0-90fb-0f65ee3864db"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i448dfa4c0bd046df85903ca8cc449d02_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNDM5ODA0NjUxNjA3OA_6e249e75-1413-46eb-90ab-ff405b54cc21"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <clbs:MarketCapitalizationUsedInNetOperatingLossAnalysis
      contextRef="ifdc66b8dc5f24112b4be5bd7e1525084_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNzE0NjgyNTU5MzY5OA_bcd26bd4-1b61-4fb9-b749-8de23bb9a448"
      unitRef="usd">125000000</clbs:MarketCapitalizationUsedInNetOperatingLossAnalysis>
    <clbs:NetOperatingLossAnalysisAnnualLimitation
      contextRef="i60f0f64709a44444b6515aa9f4cba303_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83MC9mcmFnOjhlYWZmM2NjMWUyMDRiYWFhNjU5Yjc1NTNkYjcxZjIxL3RleHRyZWdpb246OGVhZmYzY2MxZTIwNGJhYWE2NTliNzU1M2RiNzFmMjFfNzE0NjgyNTU5MzY4NA_17992835-f4b2-4bba-a366-92d78a5fc373"
      unitRef="usd">3000000.0</clbs:NetOperatingLossAnalysisAnnualLimitation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiMjVjYTdkNjEwMTQ1NjRhZDgzMTQxM2FmOTZhZGU2L3NlYzo0YjI1Y2E3ZDYxMDE0NTY0YWQ4MzE0MTNhZjk2YWRlNl83My9mcmFnOjE4NjMzMGJhN2E5NzQ0ZjNhNDJjOTljMjNmOWI1ZTAzL3RleHRyZWdpb246MTg2MzMwYmE3YTk3NDRmM2E0MmM5OWMyM2Y5YjVlMDNfNDM0_c6816782-8db7-4cbe-a903-cf4b18ea8a2a">Contingencies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660097352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CALADRIUS BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,498,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152735101912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,744<span></span>
</td>
<td class="nump">$ 16,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">82,767<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">114,033<span></span>
</td>
<td class="nump">35,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">114,607<span></span>
</td>
<td class="nump">36,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,123<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,438<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,593<span></span>
</td>
<td class="nump">3,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,510,038 and 19,389,413 shares at March 31, 2021 and December 31, 2020, respectively; and outstanding, 59,498,958 and 19,378,333 shares at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">544,601<span></span>
</td>
<td class="nump">458,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 11,080 shares at March 31, 2021 and December 31, 2020</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(433,613)<span></span>
</td>
<td class="num">(425,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Caladrius Biosciences, Inc. stockholders' equity</a></td>
<td class="nump">110,268<span></span>
</td>
<td class="nump">32,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">110,014<span></span>
</td>
<td class="nump">32,242<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity, Total</a></td>
<td class="nump">$ 114,607<span></span>
</td>
<td class="nump">$ 36,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152734912312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreferredStockLiquidationPreferenceShare', window );">Preferred stock, liquidation value</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">59,510,038<span></span>
</td>
<td class="nump">19,389,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">59,498,958<span></span>
</td>
<td class="nump">19,378,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (shares)</a></td>
<td class="nump">11,080<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockLiquidationPreferenceShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockLiquidationPreferenceShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152741936216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,076<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,086<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(8,086)<span></span>
</td>
<td class="num">(4,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Investment income, net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(8,063)<span></span>
</td>
<td class="num">(3,986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less - net income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Caladrius Biosciences, Inc. common stockholders</a></td>
<td class="num">$ (8,063)<span></span>
</td>
<td class="num">$ (3,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares</a></td>
<td class="nump">42,117<span></span>
</td>
<td class="nump">10,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">42,117<span></span>
</td>
<td class="nump">10,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660452024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,063)<span></span>
</td>
<td class="num">$ (3,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized loss</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(8,122)<span></span>
</td>
<td class="num">(3,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</a></td>
<td class="num">$ (8,122)<span></span>
</td>
<td class="num">$ (3,992)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152663447560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Caladrius Biosciences, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,553<span></span>
</td>
<td class="nump">$ 20,816<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 438,911<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (417,400)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(3,986)<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">16,984<span></span>
</td>
<td class="nump">17,243<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">439,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(421,390)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">19,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">32,242<span></span>
</td>
<td class="nump">32,496<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">458,748<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(425,550)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(8,063)<span></span>
</td>
<td class="num">(8,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">85,457<span></span>
</td>
<td class="nump">85,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">85,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">59,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 110,014<span></span>
</td>
<td class="nump">$ 110,268<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 544,601<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
<td class="num">$ (433,613)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660254824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,063,000)<span></span>
</td>
<td class="num">$ (3,986,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">597,000<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion on marketable securities</a></td>
<td class="nump">323,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(1,763,000)<span></span>
</td>
<td class="nump">354,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="nump">834,000<span></span>
</td>
<td class="num">(1,443,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,975,000)<span></span>
</td>
<td class="num">(4,241,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(75,911,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">10,821,000<span></span>
</td>
<td class="nump">11,104,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(65,090,000)<span></span>
</td>
<td class="nump">11,102,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(184,000)<span></span>
</td>
<td class="num">(148,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">85,457,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">85,297,000<span></span>
</td>
<td class="num">(148,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">12,232,000<span></span>
</td>
<td class="nump">6,713,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,512,000<span></span>
</td>
<td class="nump">14,032,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 28,744,000<span></span>
</td>
<td class="nump">$ 20,745,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658443416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; "our," &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b (FREEDOM) study in the U.S. for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease based on the results of an ongoing clinical trial and recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration ("FDA") for Buerger's disease; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis diabetic kidney disease (&#8220;DKD&#8221;) and OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS14), a Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designated Phase 3 ready therapy for treatment of no-option refractory disabling angina (&#8220;NORDA&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34 Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a stem cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is a stem cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34+ cells, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology including but not limited to CLI, CMD, DKD and NORDA.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's randomized and open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI has shown strong results to date. The initial responses observed in the subjects who have reached an endpoint in this open label study are consistent with a positive therapeutic effect and safety profile as reported by previously published clinical trials in Japan. The study's enrollment continues to be slowed by the COVID-19 pandemic's impact in Japan, however, the Company is encouraged by the patient pre-screening pipeline and continues to make progress towards study completion, the exact date of which is impossible to predict given the continuing impact of COVID-19 on clinical trials like ours in Japan. While the final outcome of the trial will depend on all data from all subjects, data, to date, are very encouraging.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS16 for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for CLBS16 for the treatment of CMD, a disease that afflicts millions of patients with no current targeted treatment options. That study, the ESCaPE-CMD trial, was a Phase 2a proof-of-concept study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. That data set showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Questionnaire score, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM trial of CLBS16 as a therapy for CMD. The first patient in the study was subsequently treated in January 2021 at The Christ Hospital Health Network in Cincinnati, Ohio. This 105-patient double-blind randomized and placebo-controlled </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial (FREEDOM Trial) is designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. To the Company's knowledge, this is the first controlled regenerative medicine trial in CMD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared an initial development plan for the clinical study of CLBS201, a CD34+ investigational product for administration into the renal arteries to slow the deterioration or reverse the decline of renal function in patients with diabetic kidney disease ("DKD") who, although at a pre-dialysis stage, exhibit rapidly progressive disease. Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. A Phase 2 proof of concept, randomized, placebo-controlled study is planned for initiation in the second half of 2021. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of No Option Refractory Disabling Angina</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired the rights to data and regulatory filings for a CD34+ cell therapy program for refractory angina that had been advanced to Phase 3 by a previous sponsor.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the clinical evidence from the completed studies that a single administration of OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, this product received Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation from the FDA. The Company continues to seek an agreement with the FDA on the design of a Phase 3 study of appropriate and practical size and scope which, in combination with previously filed Phase 1, 2 and 3 data, will be considered for the registration of OLOGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notably, the RMAT designation affords the product a 6-month review time for a biologics license application ("BLA"), once submitted. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot be reasonably estimated at this time. In response to the pandemic, the Company has implemented universal work from home as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan has experienced significant delays in enrollment due to the &#8220;State of Emergency&#8221; that was in effect for most of 2020 in response to COVID-19, and which was re-implemented on January 7, 2021 through March 21, 2021, and again on April 25, 2021 through May 11, 2021 covering Tokyo and other regions.  This most recent reinstatement of the &#8220;State of Emergency&#8221; continues negatively to impact enrollment of the on-going clinical trial. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2021, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2020 and 2019 included in our 2020 Form 10-K. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658377064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2020 Form 10-K. There were no changes to these policies during the three months ended March&#160;31, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses, which will require companies to present assets held at amortized cost and available for sale debt securities net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. The guidance was effective for fiscal years and interim periods beginning after December 15, 2019 and adopted January 1, 2020. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company determined that the adoption of this new accounting guidance did not have a material impact on its consolidated financial statements and footnote disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658313640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658335656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March&#160;31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive.  At March&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658169560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of March&#160;31, 2021, and December&#160;31, 2020 (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:115.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152761799848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658219112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for two offices with terms that expire in 2022 and 2023. The Company estimates its incremental borrowing rate, at lease commencement, to determine the present value of lease payments, since most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases include options for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the weighted average remaining lease term for our operating leases was 1.6 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of March&#160;31, 2021 were as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152659940664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Sales Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright&#160;&amp; Co., LLC ("HCW") as sales agent, which was subsequently amended in August 2018 (the "Sales Agreement"), in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock having an aggregate offering price of not more than $25.0 million.&#160;In&#160;March&#160;2019, subsequent to the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"), the aggregate market value of its </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding common stock held by non-affiliates was approximately&#160;$52.8 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below&#160;$75.0 million at the time of its 2018 Form 10-K filing, the aggregate amount of securities that the Company was permitted to offer and sell at such time was reduced to $17.6 million (or a maximum of 4.8&#160;million shares), which was equal to one-third of the aggregate market value of its common stock held by non-affiliates at such time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Sales Agreement, HCW will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon the Company's instructions, including any price, time or size limits specified by the Company. The Company has provided HCW with customary indemnification rights, and HCW will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. The Company has no obligation to sell any of the shares and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement. The Sales Agreement will terminate upon the sale of all of the shares under the Sales Agreement unless terminated earlier by either party as permitted under the Sales Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the Company suspended the use of the at-the-market transactions facility (the &#8220;ATM&#8221;) and terminated the continuous offering pursuant to the Common Stock Sales Agreement (&#8220;Sales Agreement&#8221;) entered into in February 2018 with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;). The Company will no longer make any sales of its common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of February 12, 2021, the Company had sold an aggregate of 3,784,912 shares of its common stock pursuant to the Sales Agreement for net proceeds of $9.5&#160;million. During the three months ended March&#160;31, 2021, the Company had not issued any shares under the Sales Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registered Direct Offerings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Securities Purchase Agreement (the &#8220;Institutional Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Institutional Purchasers&#8221;). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of its common stock and warrants to purchase an aggregate of 12,453,067 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the &#8220;Additional Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Additional Purchasers&#8221;). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of 1,632,652 shares of its common stock and warrants to purchase an aggregate of 816,326 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $65.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a securities purchase agreement (the &#8220;January Private Placement&#8221;) with certain investors (the &#8220;January Purchasers&#8221;). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of 12,500,000 shares of its common stock at a purchase price equal to $2.00 per share, along with warrants to purchase an aggregate of 6,250,000 shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $25.0 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.90 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Exercises</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company issued 801,148 shares of common stock for net proceeds of $1.8 million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:14.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,638,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,519,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,022,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.48&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996,573&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.77&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.08&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2021 and 2020 was $1.59 and $3.19 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152659764456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:3.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658390296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Funding<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research Funding</a></td>
<td class="text">Research FundingCalifornia Institute of Regenerative Medicine Grant AwardIn February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded the Company funds of up to $12.2 million to support the T-Rex Study. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $8.6&#160;million, of which $8.2 million has been received through the grant project period completion. The Company received $5.7 million in initial funding in May 2017, a $1.9 million milestone payment in December 2017, a $0.3 million progress payment in March 2018, and a $0.2&#160;million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $46&#160;thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the three months ended March&#160;31, 2021 and March&#160;31, 2020, the Company amortized and recognized $0.0&#160;million and $0.7&#160;million in credits, respectively, to research and development related to CIRM funds received.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152659769624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company had approximately $264&#160;million of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;As of December&#160;31, 2020, the Company had State NOLs available in New Jersey of $99&#160;million, California of $70&#160;million, and New York City of $13&#160;million to offset future taxable income expiring from 2030 </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through 2040. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an analysis and determined that they did not have an ownership change of greater than 50% over a 3-year testing period. The last ownership change was determined to be on June 3, 2015. Based on a market capitalization of $125&#160;million and using an applicable federal rate of 2.5%, the annual limitation would be approximately $3.0&#160;million. Post change losses generated after June 3, 2015 would not be subject to 382 limitations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2017, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152659846056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660705064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2021, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2020 and 2019 included in our 2020 Form 10-K. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments&#8212;Credit Losses, which will require companies to present assets held at amortized cost and available for sale debt securities net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. The guidance was effective for fiscal years and interim periods beginning after December 15, 2019 and adopted January 1, 2020. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company determined that the adoption of this new accounting guidance did not have a material impact on its consolidated financial statements and footnote disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660511624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,997&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152659846056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At March&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152661147224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of March&#160;31, 2021, and December&#160;31, 2020 (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:115.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152659706696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660516968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text">Future minimum lease payments under the lease agreements as of March&#160;31, 2021 were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152661110296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,638,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,519,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,022,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.48&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996,573&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.77&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.08&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658366872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:3.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152661043416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_IschemicRepairCD34CellTechnologyMember', window );">CD34 cell technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_IschemicRepairCD34CellTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_IschemicRepairCD34CellTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660127496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 106,997<span></span>
</td>
<td class="nump">$ 30,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">106,924<span></span>
</td>
<td class="nump">30,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">59,937<span></span>
</td>
<td class="nump">8,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">59,876<span></span>
</td>
<td class="nump">8,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">18,044<span></span>
</td>
<td class="nump">7,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">18,044<span></span>
</td>
<td class="nump">7,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">29,016<span></span>
</td>
<td class="nump">14,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 29,004<span></span>
</td>
<td class="nump">$ 14,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152653527480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,157<span></span>
</td>
<td class="nump">$ 12,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">82,767<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 106,924<span></span>
</td>
<td class="nump">$ 30,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660455048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 106,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">106,997<span></span>
</td>
<td class="nump">$ 30,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">106,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total estimated fair value</a></td>
<td class="nump">$ 106,924<span></span>
</td>
<td class="nump">$ 30,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660531432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">21,357<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152662785192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">$ 82,767<span></span>
</td>
<td class="nump">$ 18,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">82,767<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">82,767<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">82,767<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152658300712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 1,119<span></span>
</td>
<td class="nump">$ 1,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="nump">$ 2,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660484008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>office</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_NumberOfOfficesUnderOperatingLeases', window );">Number of offices under operating leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NumberOfOfficesUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Offices Under Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NumberOfOfficesUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660102568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Balance Sheet Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Balance Sheet Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Balance Sheet Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Balance Sheet Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660755176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(42,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 536,000<span></span>
</td>
<td class="nump">$ 624,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152655341576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">38 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateMarketValueOfCommonStockNonAffiliates', window );">Aggregate market of common stock held by non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,457<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember', window );">Lincoln Park Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration', window );">Commitment shares issued as consideration per agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross price for stock transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_TermOfAgreement', window );">Term of agreement (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase', window );">Number of shares allowable to direct for Regular Purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase', window );">Maximum obligation per directed purchase transaction for Regular Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase', window );">Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod', window );">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty', window );">Maximum beneficial ownership allowable per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_H.C.WainwrightSalesAmendedAgreementMember', window );">H.C. Wainwright Sales Amended Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement', window );">Maximum number of shares authorized per agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent', window );">Commission on gross proceeds due to third party (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,784,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_InstitutionalPurchaseAgreementMember', window );">Institutional Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="nump">24,906,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants issued</a></td>
<td class="nump">12,453,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AdditionalPurchaseAgreementMember', window );">Additional Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="nump">1,632,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants issued</a></td>
<td class="nump">816,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_January2021PurchaseAgreementMember', window );">January 2021 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateMarketValueOfCommonStockNonAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Market Value Of Common Stock, Non-Affiliates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateMarketValueOfCommonStockNonAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_H.C.WainwrightSalesAmendedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_H.C.WainwrightSalesAmendedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_InstitutionalPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_InstitutionalPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AdditionalPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_AdditionalPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_January2021PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_January2021PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152654400552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">2,638,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="nump">19,519,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="num">(801,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="nump">2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="nump">2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</a></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_StockOptionsActivityAxis=clbs_UsEquityPlanMember', window );">US Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">963,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="nump">155,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="num">(7,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(82,359)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,022,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 14.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">$ 13.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 8 months 1 day<span></span>
</td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">996,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 13.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="nump">765,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 17.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OptionsVestedweightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_StockOptionsActivityAxis=clbs_UsEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_StockOptionsActivityAxis=clbs_UsEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660947160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock issued</a></td>
<td class="nump">300,450<span></span>
</td>
<td class="nump">156,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock issued</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of restricted stock issued</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock issued</a></td>
<td class="nump">458,245<span></span>
</td>
<td class="nump">195,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock issued</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152745871992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 501<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152735265752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 9 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 4 months 20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152660059912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152655323640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Funding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">41 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_FundingOfGrantAwardCashReceived', window );">Funding of grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MilestonePaymentOnGrantAwardCashReceived', window );">Milestone payment received on grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_ProgressPaymentOnGrantAwardCashReceived', window );">Progress payment received on grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense', window );">Amortization of accrued grant funding to offset expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Accrued Grant Funding Liability To Offset Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_FundingOfGrantAwardCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding Of Grant Award, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_FundingOfGrantAwardCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MilestonePaymentOnGrantAwardCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment On Grant Award, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MilestonePaymentOnGrantAwardCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProgressPaymentOnGrantAwardCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Progress Payment On Grant Award, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProgressPaymentOnGrantAwardCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140152735743912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net Operating Loss Carry Forward (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis', window );">Market capitalization used in net operating loss analysis</a></td>
<td class="nump">$ 125.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_NetOperatingLossAnalysisAnnualLimitation', window );">Annual limitation on usage of net operating losses</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">264.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | New Jersey Division of Taxation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California Franchise Tax Board</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | New York State Division of Taxation and Finance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 13.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market Capitalization Used In Net Operating Loss Analysis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NetOperatingLossAnalysisAnnualLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Analysis, Annual Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NetOperatingLossAnalysisAnnualLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW\#/RWQO+S]18IMMCRV%4B+*#C><^5SJ&^#[E1#J=*)_H-AA'?T'4$L#!!0
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M@X J)\!R8>2V&*+NI8&1K+A,86JFRAK \[64YF5AY[)Z#I__!U!+ P04
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MI<$.Q;UFV$2"L@;X_TY*\S*P'ZC;TM5_4$L#!!0    (  Z!IE(5DC:;#P,
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M&<V8- +P?2.$?GTQ$[1W?\O_ 5!+ P04    "  .@:92R4K:F#@4  "T,@
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MMA(4+2S/J'KU O8F5G2.AR<P-GLN'P5G =P;><I^VFPD5U JU-YMY,;4F16
M8/2.@]WC'\D?)&:W*8>4^0N2U#BZ.:+8K[DP<S5%IO6H:5_E#8(Z.^%#H:$!
MDTC&=^K/%,!>4!?ZFGQ;2_5PME:5JW$OG3I#5B@ZT+A"8^ZI#-S;$=,V#FZK
M#&*-$SEI4(0\&9V**<52,N6RLS[!0I!111H-PZA0*N<1-G;J3B)L'8*+8M8D
MOJ4R*I-!E(IG);408V$I%'#>3(]NV3GXC2,R6D12FP+=1AP,ES\\#7NU*0>V
M98JCH PD3_[]G)C9XU]_]6JU?/E]^"P-GLP-T5EN*>$T U3M.!C9?>3Z9_6
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MU$Z ^ NE[&[C#+1/O,E_4$L#!!0    (  Z!IE+-&NRCRP(  !P&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*5576_:,!3]*U=Y:B5&0D)7A@ )
MNDZKM&JHJ.O#M >3W!"KCIW:3H']^ET[(:720)/V@../<X_/L7TODZW2SZ9
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MWRVH?*-V %K/%1U8.W ;='\(LS]02P,$%     @ #H&F4K4'#S%S!   4@L
M !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULI5;;;MM&$/V5 5NT#N"*
M$N78AB,)\*5&"]2 D:3I0]&')3D4-U[NTKM+R?K[SBPODA)+?LB+M)>9,V>N
MW-G:V"=7(GIXJ91V\ZCTOKZ*8Y>56 DW,C5JNBF,K82GK5W&KK8H\J!4J3@9
MC\_C2D@=+6;A[-$N9J;Q2FI\M.":JA)V<X/*K.?1).H//LIEZ?D@7LQJL<1/
MZ/^N'RWMX@$EEQ5J)XT&B\4\NIY<W9RQ?!#X(G'M=M; GJ3&//'FSWP>C9D0
M*LP\(PCZ6^$M*L5 1..YPXP&DZRXN^[1[X/OY$LJ'-X:]8_,?3F/+B/(L1"-
M\A_-^@_L_'G/>)E1+OS"NI6=GD60-<Z;JE,F!I74[;]XZ>*PHW Y/J"0= I)
MX-T:"BSOA!>+F35KL"Q-:+P(K@9M(B<U)^63MW0K2<\O[H6T\$6H!N$!A6LL
M4L2]F\6>P%DDSCJ@FQ8H.0 TA0>C?>G@=YUCOJ\?$ZF!6=(SNTF. CX(.X+I
MY!22<3(Y@C<=/)T&O.G;GMY)ERG#SCKX]SIUWE)Q_'?$QME@XRS8./OQ:!X%
MXE:\<K7(<!Y1KSFT*XP.H</G$J'@NU6X,P444@N=2:% .(<D(G0.2HI4*NDE
M>>U+X4%8A!2E7D+5PN5!SF)MK.<-W5.!$S5:LPX"OF2ET$N$VLH,6YBU:51.
M0*28(;58#MX ]1T9UZU],!9J(<,%Q5J[ BV(@= &I&998W.T:M.*B+9K4_1K
M1$TE;Y\(J!;6RTS6@OTF+>9$5#0?J5Z(./%YM8T1Y,(CG."+]"WS=Z,0M5M3
M$139=T3^N9&V)9\IHBV+S6Y4J]V(DV6C0Z394&$4S3:.8T9FEL92A*_@+URA
M@@G)U@UG8#^8SXWA$ <R#DX:+?*OU.V8OPO!"+.J\\>1 0LR)\LRVZ:4SK[+
M*+-IT\=L6(&"6W:YZX--#HJ,K+I#@1IUW),#W+M30[J6[>IOO*%TJ(:& (TR
M7Y(W?22&HC,I5[1(%0;7 KG7G#H%E,%(3IG)/)4&!T+WNY[G] #/1N\8ZD2.
MVAO!_5N-PR:Z\I!DA3\(.=5"P*0B0.=!!5)4&\%DZS45F)-+34H9E6[H@_VF
MW<G!7FG^\M-E,KGXX (?YT*.NK+; F:A%$77'8T2MK=]S$Y?\@Z^-ODRG+"W
ME=B * J*<-!E-1%:L:_VO4ES*$RT)V&2K!5-L0#>5<,W&*5$*VQ6;MJXN=;[
M;4OYD#W7M8$O(>TDW\3SVRC^ZKX?B>WL0LHG=8-I-!<P5P>=[KI(S<B#K;&6
MV5"^)>>"77]@,\,7ZC3X?$<CL$JI8KOC,9P$BJ9Q=.UH[.QKO:+0=TO?@WV-
M?S:>R!^_O0ZN7;$1&AQ=Y(A[FY3?0*R$5$/?.4&+GR&46/*!5I?)Z<7YQ5M'
MD\O3\?GDK:,?Q7KM:QSOO',JM,OPFG,0LM<^>8;3X<%XW;Z3MN+M:Y,BM)3:
M42D5I#H>7;R/P+8ON';C31U>3:GQ] 8+RY(>O6A9@.X+0R.OV["!X1F]^!]0
M2P,$%     @ #H&F4AH[/.%U @  ?@4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&ULI53;;MLP#/T5PMC#!F3U+4NS( F0M!LV8$6+=I>'80^*3<="
M9<F3F*;]^U%RXJ5;&PS8BR52Y.$AY:/IUMA;5R,2W#=*NUE4$[63.'9%C8UP
M)Z9%S2>5L8T@-NTZ=JU%48:D1L59DHSB1D@=S:?!=V7G4[,A)35>67";IA'V
M88G*;&=1&NT=UW)=DW?$\VDKUGB#]*6]LFS%/4HI&]1.&@T6JUFT2"?+H8\/
M 5\E;MW!'GPG*V-NO?&QG$6))X0*"_((@I<[/$.E/!#3^+G#C/J2/O%POT=_
M'WKG7E;"X9E1WV1)]2P:1U!B)3:*KLWV ^[Z>>/Q"J-<^,*VB\VY8K%Q9)I=
M,MN-U-TJ[G=S.$@8)\\D9+N$+/#N"@66YX+$?&K-%JR/9C2_":V&;"8GM;^4
M&[)\*CF/YHNBL!LLX9,4*ZDD2733F!C8'\?%#F39@63/@.1P8335#M[I$LO'
M^3$3ZEEE>U;+["C@A; GD*<#R)(L/8*7]UWF 2__]R[A^V+ER/)?\>-(@6%?
M8!@*#/]OC$=!O/XFKA4%SB(6F$-[A]&3U/<^=> 3#DP%/+BB[B<'0I=PC@4V
M*[1[;P);M.CC*Z-8DPY>2@U4FXWC</=J\B?(WP W0@G+10> 3:O, R*L4&,E
MR862%I4@YD?BGIF]@'20IF_#>IJ.X+)%*TCJ-2AD/3WJXC7_\]:B)LC'*>2G
M"5Q2S:5'60[#)('/AH1BI&R0LL>OP_$(GKK ^$ 3#=IU4+Z#PFPT=?+HO?WC
MLN@T]3N\>YEX'FNI'=.M.#4Y.7T3@>W4WAEDVJ"PE2'6:]C6_$"B]0%\7AE#
M>\,7Z)_<^2]02P,$%     @ #H&F4HOU_O!]!   @@H  !D   !X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULI5;;;MM&$/V5 9&B"6"+$B7Y(D@&["1%"B2P
MX20MBJ(/*W(D+D)RV=VE:??K>V9)R9(OZD,?1'&Y,V?.7'?GK;$_7,[LZ;XL
M*K>(<N_K61R[-.=2N8&IN<+.RMA2>2SM.G:U994%I;*(D^'P)"Z5KJ*+>?AV
M8R_FIO&%KOC&DFO*4MF'*RY,NXA&T>;#K5[G7C[$%_-:K?DK^^_UC<4JWJ)D
MNN3*:5.1Y=4BNAS-KB8B'P1^T]RZG7<23Y;&_)#%K]DB&@HA+CCU@J#P=\?O
MN2@$"#3^[C&CK4E1W'W?H/\2?(<O2^7XO2E^UYG/%]%91!FO5%/X6]-^XMZ?
MJ>"EIG#A26TG.X)PVCAOREX9#$I==?_JOH_#CL+9\!6%I%=( N_.4&#Y07EU
M,;>F)2O20).7X&K0!CE=25*^>HM=#3U_<5VS55Y7:_K,<,[-8P]4V8O3'N&J
M0TA>01C3%U/YW-''*N-L7S\&FRVE9$/I*CD(^$79 8U'1Y0,D]$!O/'6Q7'
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MX[756K<DZV-CT_%WVA$JSG1,$O:49U318F)5?<'+_,14@;X0S%4_=+!-8-E
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MMZ,"W/ ,P#V% J-RMQ[P>#MS0BEQ-C'V,O8 L6?HA0U@4!2/NRITE0'T!4H
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M='O,ECW.'6U/OK0ZW]V,L1&@[<H,WJQ6>:QFH0QT06&3/.L:'Q^QST(DEUN
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MLL1G-#E>@/>%!<_;&P[0?YB?_@502P,$%     @ #H&F4IM24'>K @  [04
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MH-/)AY,,_#!<A@53FQIZ0RSC(7TV,H_1QP YKXEXOX@"XX1?_0902P,$%
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MHNIL"C4X*Q>&"AXLE1S5/JM+^ 4Q8?B861(E4EKYRX*;-.$9"23#/]?Y*@%
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M+7^F:J7B1!)$\.,U= ^P#0?!.>D@G!S2@=_YWRY0I>YUHDE6&V'JO_!VM7T
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M#5#?=XS)IX:^AC;_=EC]!U!+ P04    "  .@:92S)>MXV8"  #Q!0  &0
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M(ITF2FZ(LMD&S0[<VKAJHX8):^,2E7G+3!U.KT4J.9 /WZ36'\D"%%GF5)G
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MFEQ^/&5_T -L_\4+MV9"XR&N$!:<7Z!)U?:T=F)DX]K"4AIL,FY8X6\ E W
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MW\- F #]?<6Y>I^8D[ZZV<5_ %!+ P04    "  .@:92^6_BE7P"  #9!@
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MK:M!6FVL*OPL6BN+D\TO]_CM >T,\/U6*?NQ<>.M^9IE?P%02P,$%     @
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M(L?M206Z2/YI.@JLF!A[!R_F?OWX<?&8EYQL6NE8$2@V$V@7B.%OCN:X/:I
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M+IEF\ZD4>Y#&F]C,P*Z-15,TO#!IO-62OG+"Z?FM%JO[5&0)2O4<WGPON3[
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M#4:45EFU*M5$BZVM]DNAJ7>PPY3:.Y3&@;ZOA= /$_.#IF&<_P102P,$%
M  @ #H&F4DCKQ9W& @  L0@  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&ULS5;;3MM $/V5E<4#2 7?<B'(L90$VB(5*2+0/E1]V-B3V,+>=7<W,?Q]
M9]>.,2&Q^H+$B[V7.6?/S'AG')1</,D$0)'G/&-R;"5*%5>V+:,$<BHO> $,
M=U9<Y%3A5*QM60B@L0'EF>TYSL#.:<JL,#!K<Q$&?*.RE,%<$+G)<RI>II#Q
M<FRYUF[A/ETG2B_885#0-2Q /19S@3.[88G3')A,.2,"5F-KXE[-7$<#C,7/
M%$K9&A/MRI+S)SVYC<>6HQ5!!I'2%!1?6YA!EFDFU/&W)K6:,S6P/=ZQ?S7.
MHS-+*F'&LU]IK)*Q=6F1&%9TDZE[7GZ'VJ&^YHMX)LV3E+6M8Y%H(Q7/:S J
MR%-6O>ES'8@6 'D. [P:X.T#>D< ?@WPC:.5,N/6-54T# 0OB=#6R*8')C8&
MC=ZD3*=QH03NIHA3X2*A LZG&(B8S'B.7X>D)K[GY.C6S;,> SF]!D733)ZA
M\>/BFIR>G)$3DC+RD/"-I"R6@:U0HS[)CFH]TTJ/=T2/3^XX4XDD-RR&^"W>
M1M\:![V=@U.OD_".B@OBNU^(YWCN 3VS_X<['7+\)MZ^X?,[X[U\']2)$)2M
M 6^((LL7TK:;TQ>S/"FIB,GO'TA);A7D\D^'H%XCJ&<$]8X(>N"*9D2VCHO:
MLJ#*]:%$5KP#PZNKQ3;LCX:!O6T']X#-X-7FC>!^([C?*?@>)% 1)00_,+RP
M6ZQ$A0Y/1RP&#?7@<R1GV @:?E!R*MY^*_"CP5YNWINX7O]P;BX;O9>=>K\!
M X&*=6IHC.4JE4I07:@[@C%JR$>?(SNN\UH\G0_*3TW\YF8X[EZ&#ACU>MY>
MBNQ6\<]!K$U/E"ADPU15)IO5IN].3+?96Y_J?FR:RBM-U<RQ"*Y3)DD&*Z1T
M+H;XT8BJ/U83Q0O38I9<8<,RPP3_*4!H ]Q?<:YV$WU \Y<2_@-02P,$%
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M 8GG723R+$?,LD%/JR5HMYO0W(4OU4<3.2Y=5ZZMIJ><XNS@1*8J1_C$[M'
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M\)GFX)73@HNU,P_ ,%="Z<#8ZEHY$5BJ1P=';@:%;WD*+I5N8KL([N^L77X
M;&8@D O1"1P09YB,2FH,T_+:3IK%C?$)%+3CNW5I%2XT74>#"[)U:&XVR$SI
MC.DN3$0VILE(L!SD:+Y8PMVH,@30&%780<;I0DG::-AXM -+.V="W,)3\2/?
MXU[E.W7M0U5E-[2"VJ&C<1/@WV5SW+NTK^,-2OZ@S.?:;D<V<^@6=J-9SE?-
M?)5W C#V"&>G92G6GP1?R(*YS;\XX&1$-W[!4FG^:*-!J\RM@6D2/#!M^'S7
M\DO3\HZMS*:=5CFN>7"$FO]NGA=,,DW%KFC;^V\YRZ]6'%_^*\G-?Y5#P5Z-
M[5'WUD5>'(/(Y!A$'D%/QNF;U!BV1^/.^;MW^G;6 -YRQN0[O%.);=!@5G-A
MN&QG2YYE3#XYA"V]H3/[PKO';]=G+*>U,'<=.";;\3>6\;I(NU4WD(AVU7;\
M%;87)=TKEHW%9<96+)NV4[V8-</ #FS4]@*'0^2ZN?P(YN,P/P(8%@=3@/DX
M+RS._[2?(;H?AV':AEYDB/H,41_GY4.FS0>+X_=)[>7?:9K&<9)@&9U.O0JF
M6-Z2!+Y^-DP;>&!Q(-*?Y1JO-MXAS_<!5M/G.@3;*=Z)V$[Q7 /BSQMXI*F_
MVE@<\,"J@/4.Q/?'@9[R^\0Q5!73ACW!.)*F& *]Z._1)$&RD\#'7Q_L*8GC
M-/4C@/D5Q#&&P-.((Y@"T( A<=R<@P?G4;@YI\+MKT"3WU!+ P04    "  .
M@:92EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0    (  Z!IE(D2%N=XP,  "H>   /    >&PO=V]R:V)O;VLN>&ULQ9E+
M;]LX$(#_"J'+I@>OK4?2-J@+Y+%I Z1-4 >Y%@PUCHA0I)>DG*:_OJ1<HV.O
M,M@+HY,DZL%/0VH^DOKP9.SCO3&/[$>KM)MGC?>KX^G4B09:[OXV*]#AS-+8
MEOMP:!^F;F6!UZX!\*V:%K/9T;3E4F<?/VR?=6.G^,!X$%X:'0ICP9V$)_?G
M?#QD:^GDO532/\^S?E]!QEJI92M_0CW/9AESC7GZ;*S\:;3G:B&L46J>Y9L3
M=V"]%/\I7D3(6W[O^A+/[[_Q #+/CF;A@4MIG>^OZ)_/ ^,:PL6;H\Z;"ZD\
MV'/NX9,UW4KJA_B8\!93]!I]'+;;31"/[?\)HUDNI8!S([H6M-_$T8**@-HU
M<N4RIGD+\^S,K,'&]PD57-:;=_,!"D7*'LMPPE[6/5Y*%.V,DG6HO6:G7'$M
M@/4A= BP( "+T0#9P0U'D"4!6;XBY")"Q!L<,TMVO=IIZHJ K$:#/#/M"D$>
M$I"'HT'^\V\G$>01 7DT7B2Y:Q#D6P+R;5K(VP;8:>>D!H<_Y7<$T;NT1(NN
M;;E]CF%:R <MPVU<>W8BA.FTQVW[GH!\GQ;R9,VEXJ'*2;A]LN!A9P&BL])+
MP'',9U32GJ6%O-3"M, .KHQS;]@-V) 1N06,1SHEL50NN+3LCJL.V!?@KK.;
M[P/C44;)$RLE=#C;A2_W2O)^A++7L)1'\L0BB;8(I?J!787 [7)1ZL@3NV/A
MC7ALC*K!NK_Z3.R?,1MEC#RQ,OJN/SD-X:I[D8%V_468CY)%GM@6W\ !MZ)A
M%YVN0]-B+LH/>6)!_$XBM_S';C^C#)$G5D0P:^S]H,7>1TD9(4^L!-);WPL\
M3J:D4"26 FDN=H Q*3D4B>7P@KO8P6UDWYEUD-..Q))XP6%#F)0PBL3"&'#9
M%O$-9J3D4226Q[[4!@$I@Q2I#3)@MT%(2B-%8HV\I+G?H!B3LDKQBM,.-F%?
MN8UMOP[?]SEXC@?Y!26:(K%HZ&0YP9B4>HHQ9R,[ZBDI]91CJN=[B3$I]91C
MJ:?OF@IC4NHI1U+/A)TX!QYCDFM>8ZAG$\F=K%E2[BE?VSV[*0EC4@8J$QMH
M !.O=6),RD%E8@<-8%YT/G10]B6N[&-,RD%E8@<-^GRRW;G$F)2#RM3K8<.8
M?3&[Q@NR)>6@,O7T9Q@S3&N]E0*GHXIR4)7802^.CR9]EL>8E(.JQ XB,/=6
MX2O*055B!Q&844\8DW)0E=A!^VLK@P*JR)\NB06$5UFB?$(U*(L:C$D)J.H%
M--W^FZQA&4;8]==0A0OE@BMQ8UG<;%97J\.X8K+LE#H+9=?ZRO!Z^ZMS^YOV
MXR]02P,$%     @ #H&F4K@VQ-RI 0  +AL  !H   !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<\W9NV["0!"%X5=!?@"6F5EN$5"EH8UX 0N6BS#8\FX4
M>/L@*.!8*=*@/96UMCS^&W^RUK.O4)7I4)_C_M#$WN54G>.\V*?4?#@7U_MP
M*F._;L+Y=F5;MZ<RW9;MSC7E^ECN@M/!8.3:UQG%8O8ZL[>Z-N$_$^OM]K .
MG_7Z^Q3.Z8_![J=NCW$?0BIZJ[+=A30OW*5ZGH[N?I#^;7+16V[F1;O<2.%R
M!RD$:?X@@R#+'^0AR.</&D+0,'_0"()&^8/&$#3.'S2!H$G^H"D$3?,'R0!E
M'! D=; FT%J0:R'P6A!L(1!;D&PA,%L0;2%06Y!M(7!;$&XAD%N0;B&P6Q!O
M(=!;46\ET%M1;R706SL?VP1Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJ
MK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'I;9[.$0&]#O8U ;T.]C4!O0[V-0&]#
MO8U ;T.]C4!O0[V-0&^/>GL"O3WJ[0GT]JBW)]#;H]Z>0&_?V>PFT-NCWOZ=
M>L=TK4)\]CS6^/QW4IUN]X;GX^_+Q\G."W7'V<'OL<4O4$L#!!0    (  Z!
MIE)3V2LIL@$  %,;   3    6T-O;G1E;G1?5'EP97-=+GAM;,V9S6[",!"$
M7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W;4'C[.N%':D6C(BIU+K$2[\Z,O=)W
MR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4A)U<VUKY\&J7S*ATI9;$Q'@\8:EN
M/#5^Y%N-:#Y]HERM*S]XWH;/KM3-++)4N6CPN"]LO6:1,J8J4^7#/MLTV3>7
MT<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\;LK;,:+!0UK^H.E2Q;<6<WU7DXGZ)
M,QEUGI<I93I=UZ$E=L:2REQ!Y.LJWHL.^YU]N&':/_G5_IU,GV&H7%AM7)B8
MI<OMCB-INT<F")'U9?\13XY!^NKS43OMC+)?>H?K_=!VU<W#L6ZY_HZ_SOBD
M?V$. 9)#@N1(0'+<@.28@.2X!<EQ!Y+C'B0''Z,$02$J1T$J1V$J1X$J1Z$J
M1\$J1^$J1P$K1R&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K1"&K
M1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"%K@D+6!(6L"0I9$Q2R)BAD3?Z3
MK.]:K_[Z-T^[QK4JFZ,_Z_ZES3\!4$L! A0#%     @ #H&F4@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  .@:92'VY!7^X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  .@:92F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  Z!
MIE(AK5.@0 4  &T5   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  .@:92*D;:4=<%  #F%0  &
M        @(&##0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ #H&F4A)-5_,Y P  DPL  !@              ("!D!,  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  Z!IE+^BDGO(@0  *(.   8
M              " @?\6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  .@:92%9(VFP\#  #("   &               @(%7&P  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ #H&F4D\K1P$(!@
M&!L  !@              ("!G!X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    (  Z!IE*8J#DB,P4   <4   8              " @=HD
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  .@:92R4K:
MF#@4  "T,@  &               @(%#*@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ #H&F4N"8V]26!P  #!(  !@
M ("!L3X  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  Z!
MIE**-A2>XP,  .X)   9              " @7U&  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ #H&F4LT:[*/+ @  ' 8  !D
M         ("!ETH  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  .@:92M0</,7,$  !2"P  &0              @(&930  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  Z!IE(:.SSA=0(  'X%
M   9              " @4-2  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ #H&F4HOU_O!]!   @@H  !D              ("![U0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  .@:92BL\G
M[%,.  #N+@  &0              @(&C60  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    (  Z!IE+4+0JR1P0   T+   9
M  " @2UH  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M#H&F4BG:#=D<!   MPD  !D              ("!JVP  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  .@:92?EL#Y90&  "D#P  &0
M            @('^<   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    (  Z!IE*;4E!WJP(  .T%   9              " @<EW  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ #H&F4HP]KGXD"0
MP!@  !D              ("!JWH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  .@:92MS?AET $  !<"P  &0              @($&
MA   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  Z!IE(I
M/)/XD (  '4%   9              " @7V(  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ #H&F4A7)]O7< @  F08  !D
M     ("!1(L  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z!IE(I;(A9;0(  &D&   9              "
M@02=  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ #H&F
M4J^] I+8 P  @A   !D              ("!J)\  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  .@:92S)>MXV8"  #Q!0  &0
M        @(&WHP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   (  Z!IE))R1JNF0(  '<'   9              " @52F  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ #H&F4EBY:8'2 @  2 D
M !D              ("!)*D  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  .@:92MG<@J@L#  "+#   &0              @($MK
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  Z!IE(>)LL0
M> (  &0&   9              " @6^O  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ #H&F4GU>>6\\ @  4@4  !D
M ("!'K(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  .
M@:925(?7%,\"  #E"0  &0              @(&1M   >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  Z!IE+Y;^*5? (  -D&   9
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M970T,2YX;6Q02P$"% ,4    "  .@:92QJRY;P4#  "&"@  &0
M    @('>S@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M  Z!IE*7+T9YN@(  (P&   9              " @1K2  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ #H&F4HV6GJ*- P  (PP  !D
M             ("!"]4  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    "  .@:92(P!A_SP#  #D"@  &0              @('/V   >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  Z!IE*7^=^&( ,
M !(2   -              "  4+<  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     U #4 :@X  $KH      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Research Funding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchFunding</Role>
      <ShortName>Research Funding</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2138112 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Business - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusinessNarrativeDetails</Role>
      <ShortName>The Business - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Research Funding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchFundingDetails</Role>
      <ShortName>Research Funding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchFunding</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="clbs-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Income Taxes - Net Operating Loss Carry Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails</Role>
      <ShortName>Income Taxes - Net Operating Loss Carry Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="clbs-20210331.htm">clbs-20210331.htm</File>
    <File>clbs-20210331.xsd</File>
    <File>clbs-20210331_cal.xml</File>
    <File>clbs-20210331_def.xml</File>
    <File>clbs-20210331_lab.xml</File>
    <File>clbs-20210331_pre.xml</File>
    <File>clbs-ex311_20210331xq1.htm</File>
    <File>clbs-ex32_20210331q1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "clbs-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 12,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "clbs-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "clbs-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "clbs-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clbs-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clbs-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "clbs-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 6
   },
   "keyCustom": 44,
   "keyStandard": 266,
   "memberCustom": 7,
   "memberStandard": 29,
   "nsprefix": "clbs",
   "nsuri": "http://www.caladrius.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.caladrius.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Available-for-Sale-Securities",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "shortName": "Available-for-Sale-Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Income (Loss) Per Share",
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "shortName": "Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Fair Value Measurements",
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Accrued Liabilities",
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Operating Leases",
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Stockholders' Equity",
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Share-Based Compensation",
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Research Funding",
     "role": "http://www.caladrius.com/role/ResearchFunding",
     "shortName": "Research Funding",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Income Taxes",
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138112 - Disclosure - Contingencies",
     "role": "http://www.caladrius.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Available-for-Sale-Securities (Tables)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Income (Loss) Per Share (Tables)",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "shortName": "Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Business - Narrative (Details)",
     "role": "http://www.caladrius.com/role/TheBusinessNarrativeDetails",
     "shortName": "The Business - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "icdcbdf98a7ca4a708730bbebd3ba7714_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
     "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i499338433b98478ba449207f9bded52e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Income (Loss) Per Share (Details)",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "shortName": "Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i499338433b98478ba449207f9bded52e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i4537dc4974b74981b566969155de0b54_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i4537dc4974b74981b566969155de0b54_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Operating Leases - Narrative (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Operating Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ic03c497fe3a647068aff689400691742_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:AggregateMarketValueOfCommonStockNonAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ic03c497fe3a647068aff689400691742_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:AggregateMarketValueOfCommonStockNonAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ifdc66b8dc5f24112b4be5bd7e1525084_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:CommonStockWarrantsShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ifdc66b8dc5f24112b4be5bd7e1525084_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:CommonStockWarrantsShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i4a72bbc7a19a4308867ebcbccda93c14_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i5a59d2dafdc848809ac87c686c29886a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i5a59d2dafdc848809ac87c686c29886a_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ib6a4c616b7a941daba46e43fca86d58e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i7d33a4dfeca84deaa7206b25ce9ac65a_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Research Funding (Details)",
     "role": "http://www.caladrius.com/role/ResearchFundingDetails",
     "shortName": "Research Funding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "iffe95d09252c410489923fdd656451ce_D20170501-20170531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "clbs:FundingOfGrantAwardCashReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ifdc66b8dc5f24112b4be5bd7e1525084_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:MarketCapitalizationUsedInNetOperatingLossAnalysis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Income Taxes - Net Operating Loss Carry Forward (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails",
     "shortName": "Income Taxes - Net Operating Loss Carry Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "ifdc66b8dc5f24112b4be5bd7e1525084_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:MarketCapitalizationUsedInNetOperatingLossAnalysis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i232ac432d803493e882af56dc9654ec2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Equity",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i232ac432d803493e882af56dc9654ec2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Business",
     "role": "http://www.caladrius.com/role/TheBusiness",
     "shortName": "The Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20210331.htm",
      "contextRef": "i48f77d5409ba45b2b146e314fd08f2f4_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 38,
   "tag": {
    "clbs_AdditionalPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Purchase Agreement",
        "label": "Additional Purchase Agreement [Member]",
        "terseLabel": "Additional Purchase Agreement"
       }
      }
     },
     "localname": "AdditionalPurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateMarketValueOfCommonStockNonAffiliates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Market Value Of Common Stock, Non-Affiliates",
        "label": "Aggregate Market Value Of Common Stock, Non-Affiliates",
        "terseLabel": "Aggregate market of common stock held by non-affiliates"
       }
      }
     },
     "localname": "AggregateMarketValueOfCommonStockNonAffiliates",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Accrued Grant Funding Liability To Offset Expense",
        "label": "Amortization Of Accrued Grant Funding Liability To Offset Expense",
        "terseLabel": "Amortization of accrued grant funding to offset expense"
       }
      }
     },
     "localname": "AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_BusinessTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Business [Text Block]",
        "label": "The Business [Text Block]",
        "terseLabel": "The Business"
       }
      }
     },
     "localname": "BusinessTextBlock",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_CommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Shares",
        "label": "Common Stock Warrants, Shares",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "CommonStockWarrantsShares",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_FundingOfGrantAwardCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Of Grant Award, Cash Received",
        "label": "Funding Of Grant Award, Cash Received",
        "terseLabel": "Funding of grant award"
       }
      }
     },
     "localname": "FundingOfGrantAwardCashReceived",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_H.C.WainwrightSalesAmendedAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "H.C. Wainwright Sales Amended Agreement [Member]",
        "label": "H.C. Wainwright Sales Amended Agreement [Member]",
        "terseLabel": "H.C. Wainwright Sales Amended Agreement"
       }
      }
     },
     "localname": "H.C.WainwrightSalesAmendedAgreementMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_InstitutionalPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institutional Purchase Agreement",
        "label": "Institutional Purchase Agreement [Member]",
        "terseLabel": "Institutional Purchase Agreement"
       }
      }
     },
     "localname": "InstitutionalPurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_IschemicRepairCD34CellTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ischemic Repair CD34 Cell Technology [Member]",
        "label": "Ischemic Repair CD34 Cell Technology [Member]",
        "terseLabel": "CD34 cell technology"
       }
      }
     },
     "localname": "IschemicRepairCD34CellTechnologyMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_January2021PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2021 Purchase Agreement",
        "label": "January 2021 Purchase Agreement [Member]",
        "terseLabel": "January 2021 Private Placement"
       }
      }
     },
     "localname": "January2021PurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_LincolnParkAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Agreement [Member]",
        "label": "Lincoln Park Agreement [Member]",
        "terseLabel": "Lincoln Park Agreement"
       }
      }
     },
     "localname": "LincolnParkAgreementMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_MarketCapitalizationUsedInNetOperatingLossAnalysis": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market Capitalization Used In Net Operating Loss Analysis",
        "label": "Market Capitalization Used In Net Operating Loss Analysis",
        "terseLabel": "Market capitalization used in net operating loss analysis"
       }
      }
     },
     "localname": "MarketCapitalizationUsedInNetOperatingLossAnalysis",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MilestonePaymentOnGrantAwardCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment On Grant Award, Cash Received",
        "label": "Milestone Payment On Grant Award, Cash Received",
        "terseLabel": "Milestone payment received on grant award"
       }
      }
     },
     "localname": "MilestonePaymentOnGrantAwardCashReceived",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_NetOperatingLossAnalysisAnnualLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Analysis, Annual Limitation",
        "label": "Net Operating Loss Analysis, Annual Limitation",
        "terseLabel": "Annual limitation on usage of net operating losses"
       }
      }
     },
     "localname": "NetOperatingLossAnalysisAnnualLimitation",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_NumberOfOfficesUnderOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Offices Under Operating Leases",
        "label": "Number Of Offices Under Operating Leases",
        "terseLabel": "Number of offices under operating leases"
       }
      }
     },
     "localname": "NumberOfOfficesUnderOperatingLeases",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "clbs_OptionsVestedweightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options, Vested, weighted Average Remaining Contractual Term",
        "label": "Options, Vested, weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "OptionsVestedweightedAverageRemainingContractualTerm",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_PreferredStockLiquidationPreferenceShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Share",
        "label": "Preferred Stock, Liquidation Preference, Share",
        "terseLabel": "Preferred stock, liquidation value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceShare",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated",
        "label": "Preferred stock, shares designated",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_ProgressPaymentOnGrantAwardCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Progress Payment On Grant Award, Cash Received",
        "label": "Progress Payment On Grant Award, Cash Received",
        "terseLabel": "Progress payment received on grant award"
       }
      }
     },
     "localname": "ProgressPaymentOnGrantAwardCashReceived",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "label": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "terseLabel": "Maximum beneficial ownership allowable per agreement (percent)"
       }
      }
     },
     "localname": "RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "terseLabel": "Aggregate offering amount authorized per agreement"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "label": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "terseLabel": "Number of shares allowable to direct for Regular Purchase (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent",
        "label": "Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent",
        "terseLabel": "Commission on gross proceeds due to third party (percent)"
       }
      }
     },
     "localname": "SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "label": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "terseLabel": "Maximum obligation per directed purchase transaction for Regular Purchase"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement",
        "label": "Sale Of Stock, Maximum Number Of Shares Authorized Per Agreement",
        "terseLabel": "Maximum number of shares authorized per agreement (in shares)"
       }
      }
     },
     "localname": "SaleOfStockMaximumNumberOfSharesAuthorizedPerAgreement",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_Sharesvestedandexpectedtovest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares, vested and expected to vest",
        "label": "shares, vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "Sharesvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued As Consideration",
        "label": "Stock Issued During Period, Shares, Issued As Consideration",
        "terseLabel": "Commitment shares issued as consideration per agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedAsConsideration",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_StockOptionsActivityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Activity [Axis]",
        "label": "Stock Options Activity [Axis]",
        "terseLabel": "Stock Options Activity [Axis]"
       }
      }
     },
     "localname": "StockOptionsActivityAxis",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_StockOptionsActivityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Activity [Domain]",
        "label": "Stock Options Activity [Domain]",
        "terseLabel": "Stock Options Activity [Domain]"
       }
      }
     },
     "localname": "StockOptionsActivityDomain",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Of Agreement",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement (in months)"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_UsEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Equity Plan [Member]",
        "label": "US Equity Plan [Member]",
        "terseLabel": "US Equity Plan [Member]"
       }
      }
     },
     "localname": "UsEquityPlanMember",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_WarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Canceled",
        "label": "Warrants Canceled",
        "negatedLabel": "Warrants, Forfeited (in shares)"
       }
      }
     },
     "localname": "WarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised",
        "label": "Warrants Exercised",
        "negatedTerseLabel": "Warrants, Exercised (in shares)"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expired",
        "label": "Warrants Expired",
        "negatedTerseLabel": "Warrants, Expired (in shares)"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted",
        "label": "Warrants Granted",
        "terseLabel": "Warrants, Granted (in shares)"
       }
      }
     },
     "localname": "WarrantsGranted",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Vested",
        "label": "Warrants, Vested",
        "terseLabel": "Warrants, Vested (in shares)"
       }
      }
     },
     "localname": "WarrantsVested",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Warrants Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Canceled",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "terseLabel": "Warrants, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercised",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "terseLabel": "Warrants, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Expired",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Warrants, Expired (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Granted",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "terseLabel": "Warrants, Granted (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "terseLabel": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantsvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted Average Remaining Contractual Term, warrants vested",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "nsuri": "http://www.caladrius.com/20210331",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r13",
      "r37",
      "r38",
      "r39",
      "r325",
      "r341",
      "r342"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r73",
      "r74",
      "r75",
      "r238",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r209"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r178",
      "r202",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r71",
      "r110",
      "r112",
      "r116",
      "r134",
      "r233",
      "r239",
      "r255",
      "r308",
      "r324"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Balance Sheet Captions"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r33",
      "r71",
      "r134",
      "r233",
      "r239",
      "r255"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r121",
      "r141"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "verboseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "verboseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r119",
      "r122",
      "r141",
      "r311"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total estimated fair value",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r180",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California Franchise Tax Board"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r19",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r19",
      "r66"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Available-for-Sale-Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r66",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r61",
      "r66",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Cash and cash equivalents at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r256"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Stock Options and Warrants [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares called by each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r167",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Schedule of Stockholders' Equity Note, Stock Options and warrants [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r27",
      "r152",
      "r312",
      "r330"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,510,038 and 19,389,413 shares at March 31, 2021 and December 31, 2020, respectively; and outstanding, 59,498,958 and 19,378,333 shares at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r43",
      "r45",
      "r46",
      "r52",
      "r318",
      "r335"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r45",
      "r51",
      "r231",
      "r232",
      "r243",
      "r317",
      "r334"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r45",
      "r50",
      "r230",
      "r243",
      "r316",
      "r333"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r104",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r169",
      "r176",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r64",
      "r146"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r180",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r86",
      "r88",
      "r90",
      "r91",
      "r92",
      "r96",
      "r97",
      "r319",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r88",
      "r90",
      "r91",
      "r92",
      "r96",
      "r97",
      "r319",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Salaries, employee benefits and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r99",
      "r135",
      "r157",
      "r164",
      "r206",
      "r207",
      "r208",
      "r221",
      "r222",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r248",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r169",
      "r170",
      "r175",
      "r176",
      "r248",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r169",
      "r170",
      "r175",
      "r176",
      "r248",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r248",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r251",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Minimum Lease Payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r127",
      "r128",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants awarded"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails",
      "http://www.caladrius.com/role/TheBusinessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r228",
      "r230"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less - net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities - available for sale"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r23",
      "r71",
      "r113",
      "r134",
      "r234",
      "r239",
      "r240",
      "r255"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r71",
      "r134",
      "r255",
      "r310",
      "r328"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Liabilities and Equity, Total"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r71",
      "r134",
      "r234",
      "r239",
      "r240",
      "r255"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r31",
      "r71",
      "r134",
      "r255",
      "r309",
      "r327"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r41",
      "r44",
      "r48",
      "r65",
      "r71",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r84",
      "r85",
      "r89",
      "r110",
      "r111",
      "r114",
      "r115",
      "r117",
      "r134",
      "r255",
      "r314",
      "r331"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Caladrius Biosciences, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey Division of Taxation"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New York.",
        "label": "New York State Division of Taxation and Finance [Member]",
        "terseLabel": "New York State Division of Taxation and Finance"
       }
      }
     },
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r164",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest in Subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r110",
      "r111",
      "r114",
      "r115",
      "r117"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases (percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r267",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r34",
      "r35",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r45",
      "r47",
      "r49",
      "r157",
      "r257",
      "r262",
      "r263",
      "r315",
      "r332"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r34",
      "r37"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Available for sale securities - net unrealized loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Investment income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Caladrius Biosciences, Inc. Stockholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r17",
      "r18"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r205"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r41",
      "r44",
      "r60",
      "r71",
      "r76",
      "r84",
      "r85",
      "r110",
      "r111",
      "r114",
      "r115",
      "r117",
      "r134",
      "r230",
      "r236",
      "r237",
      "r242",
      "r243",
      "r255",
      "r320"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r147",
      "r329"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred",
        "terseLabel": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r212",
      "r346"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research Funding"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFunding"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r164",
      "r209",
      "r326",
      "r340",
      "r342"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r135",
      "r206",
      "r207",
      "r208",
      "r221",
      "r222",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross price for stock transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r125",
      "r126",
      "r129",
      "r130",
      "r131",
      "r132",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r178",
      "r201",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r180",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r185",
      "r194",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r28",
      "r69",
      "r100",
      "r101",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting terms (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of restricted stock issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Warrants, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r187",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options, Vested, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r68",
      "r180",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (shares)",
        "periodStartLabel": "Beginning Balance (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNetOperatingLossCarryForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r30",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r99",
      "r135",
      "r157",
      "r164",
      "r206",
      "r207",
      "r208",
      "r221",
      "r222",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r99",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r157",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (shares)",
        "verboseLabel": "Net proceeds from issuance of common stock and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Shares issued upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r157",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Number of restricted stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r9",
      "r10",
      "r157",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r157",
      "r164",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, Exercised (in shares)",
        "terseLabel": "Proceeds from option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r157",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r9",
      "r10",
      "r157",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Value of restricted stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r9",
      "r10",
      "r164",
      "r179",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r157",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r14",
      "r15",
      "r71",
      "r118",
      "r134",
      "r255"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Caladrius Biosciences, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r134",
      "r135",
      "r164",
      "r206",
      "r207",
      "r208",
      "r221",
      "r222",
      "r228",
      "r229",
      "r241",
      "r255",
      "r257",
      "r258",
      "r263",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r164",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r29",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r29",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r29",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 11,080 shares at March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r169",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal debt securities"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r102",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expiration term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r87",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r86",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r348": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r349": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r351": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r352": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r353": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0000320017-21-000067-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-21-000067-xbrl.zip
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M99(S')B1.@CJG;) )A)F(-MNZH@SPG-TA>=4:L5 G3'GA+;$"\R%=2A3ELQ
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MJ"':D6"75BLQA[KD.8J7DSCA#Q5*LG!"7M+-G=W9@F-/@2JR(HA\"SBF!%G
ML?'!L5H;NE]4;YIY/+9S '@)OEVMG32J!__4JQ\JU] O7FEL09__@><!GS4.
MKPYO[$,\!NW"]P&3[7PXQ(>-?71X\\_9SL89W-^^KC3^.3L$?'9TNG5:Q0_P
M&$%"6\%3I3"H4J5$J@-#*7 ?"RK ;<_Z>(S-.QZK[:Y5][8+U+4 9%-D=K9:
M[:1[XI,[44]*!)2$=JN1?/WFOW)<P_]V6X\\UO]O@0%>TLWU5J.1=^+J3K*5
M@SVO%F<KO&7P;+-8\(@?*[\UDQK^50$T^E421J@(.F4,/&;F,P&(U_H4:QL/
M4!4(.1K7CW!*:<;1#Z-H"Q9_HIMOSLN[_KC8 =;LQG747X^?K[]ZI 5A5*4X
M9"%E&3>I0I:GQDG-B<R"Q1ATS=K'M8W=[?V]Y._MG;WU[<WJ^N;><K)=75]Y
M=IQX6ICJM\TK;;L%*R2MD+1O62#1G:1S[FU<Y75)WDSR;B>Q)T60\?<I]+<$
M$C\3_N9T!2$^<H>+L16AGM?LSSM<)>-,%59]<\>K$Q,YSMNMB\BQ]\-0I1*+
M22%M\+B*_(XB[:.?:;C><K.ITP91\:U\Y\/^5:5V=E/Y\)E5-Z _C4UZ>+-]
M \_2ZH?/EX<'U9/#T[-OHN+@;;&CVN;53JUR"6-!U8W-:QCC:>6T"OK/HJ.-
MOT\.";3_Y;X7YI37R,DLS2Q":2PKDQJO=8I,5APGI; %=;CAZ_I2Q].J1NF&
M_0K,_9!W:_IJNY]94V[:GF%D.6ZNW;SE6DMPIC,C4DNH :X%UE6$\#0@AH05
MTAG*EE8)20EEE&?R2;Z=*^W\6Z$/$_!;6_'<O.1T*"DO6O]\6'<6C[6/=3._
M*?[^?>[D^;?ME=V5O96DOUNQG=P7OJ3:6OE]1,PP=4&E!S[/?$3*'AG4&Y%L
MNI#\>*S3FG-MW^GT?WR$#N"%9?J19;H9PE,/_=/+RL8QK7PXR@_)(=^I':,*
MV3T]//V,#F^.SJKD\_71QO[-(3DZ/?PBT5=NN)/(A#1XP5+&#$Z5HB2-E;9C
MK6UM,[2TBC%*UNIUWP26TFXY(4V7;-5;K?9#*[?\]K&Q/J>LPZ\[[5KKLKE@
MEW&Q"P/LCAS!(:3(>D!!6F>I852FQB%+J<F0<(#=_]:=,]!_R6[NCK\!\&_
M(B]VY_H\5 "7G?8G>!) RL*/&QLC756.O^*X"592G&9 XI0%ZE*393KEF<$"
M\'3 5"ZM1C-6;MYZ.@@V-_!Q7/KS4PNDI'Z4GR\B&,_D_#M?D'H,["I1BC).
M4@:.8:HIY6DFO;"90L8;N[2*A"+?7YR8/S>PSUC1Y3MO@S[-SW4]\5?>]F+Q
M-[@,+I#OS*'#=Y.?PRB<?\2M6ZQ]OZ2;=TM%_^<_)<'BCT[2]75_?M)J^J0\
MUWXYAA/JO<@>B6Y[74S\^[=$G1%HKL&79E9/OFKUZN8K5D))RDQJ"0%E9P#M
M2891ZH/W8*LU$@(@GT+?1+S2-R1*L?OS4^2+&0YFOHHP[*L-UEHB?2JS8.*R
M(DN59"(&(!56R,=38I=6)8MU8="/5\F?N]CVK39^J^4WN2(I^IGE-\I6"!_]
M\AM1*Q*/?E<+)2O9,[,S'P4,:B:C:GN "]IY-X<6R^5AW_8N.>^U.[VX3MQM
M)?!$$3#%Y#?S>T05,2UJS7;?SP.&$H\GY>7=>K%B[K4]26Q==SHS#)>^,\:V
M+JSWWG7#M.J_S30@?'R$U7[:0T%$?V5/=/,8+C23RY,<KMRQ^SPP\MB]V+[B
MN,;$%.(RDZ:_[[O>[.;54WMY=/J9')YNDNB['C6VKZL'_YQ6;RJL6K/71XW]
MJZ.-RD/?]:;Z89M4;_YN5#>.\@KTK[JQU2CZW:A0Z >NWOS3.*IMG56PO!Y>
M?5>&2Z>]2 45(666N%1*HU+.$7.>Z("D+Q,?@6&+2IO+R;EN)Q>ZWO/)?Z$5
MA'!R'NL[G(QI=1X0P?QQ<5\+EDIPP<+/8.&[\(NPR@$3D91DAJ?,$YYJY&4J
M>'!.<TFD4,#"'__>>_L<_I(YI\N7+LTL@*4W#[1'X_9MC'V@H3?[IF]F\S['
MS>+;WXNMXYW:]LWAS=;)T<$_>?7F,ZJ<[M/# Y@G4FU O_#1:25&.FD52_:5
M!2FD9#0-SK"42<Q3Y0-.';.49!F23&41I72<_O<WFP37]7G>U?6DHMMGOOM(
MD/WQN-;CWB-=H<"L?9%*H_R\9RM\Z%*[Y."5[_F5$ZGF\A+/Y/A1SV3,J+/H
M=E)M-?VTI=""+@+ \%-./+C_"GW_]B-N\>"!_K3T1_6HEN\/KS\=Y+R;=%KU
MW"4#,@VL (HV8.E)SI_*B.X/Q3 K*TS=ET.R0AX(XFFOT\W#=7DI;\9,IO>8
MKI13.XEQ;S==3*3RB;E.[(FW9PD,]0P\*U_DGD5!',HV_PW_GISH3A+R.HBP
MKM?A9MPW&27[W[T\RC6(L_']!Z#-6]&F,5.MW/C6%_ AO3"P;%'HX^VX\2UQ
M<!?\VOCH>=M;7WBYF"3%%O=.\ANT!_8SZ?3 !^R<M&+*>U(6&X-W=/=AWR_U
M_5[&+I8O]\?P^W*BFR[YC91C-&"%X;XYA1'$YXM'X:78BWX[<0MII^A$T4G=
MZ28*)4Y?=U;>/F]CO==NP_?+C:L1^G9UM]>925SPJL M^HHX#3R$+#5(ZI0Y
M0U-EN4A11C/N)/8DB*750]_YQCC?E@IYD9EY_?;GTL",Q[H]_O%J*[G=E[O0
M>4_IO*@+0 TT\FX7%(>O@SIHMYK1.M>O$P^6^CK9CNA*VV)9=D-W=;FY\8%*
MO&MC&/KL]N!)AGC4>KO^N%<ODUKWTEKR6[1)XH^$4++2?Z)[DA?;>\[C]IZW
M5I!EAPN=>-X"U390@+[S^QC4V]"<QBGM:[M?3KU]OOR*C%+!*I9JX6C*%#.I
MXCZD(F!'G)&.T(5Z6ZBWGU1OH%!T4H>Y\(FV%M1;6T<=%>6\'0'1HU<3X++T
MT1N=!NA%^$I[ $M -31@$JZ7(_Z#Y@ TQ7D_3H[;K<ONR>#V"L!!GS@?\F8^
MV.@0DQ8(C/ [G2MNXS\&CWWS0/_^\N"![W9MT%#4=$O?Z=]2W%Q9*&M,3$H&
M&'88N+Z?(V>1\!7Y3&?Q964,)7N#!5^Q0A ;?6??;@[4#!3Y&6GT]./C,CQW
M.UONFYP?C^I>/&3V)V#M%R3P'$GIVZ]O%-"^X(R(4(Y;[>O'MA-$]ZF]WG]@
M)B%_N=)Q>%J!]K?R2FT;56\VKZH?JO6CQC:#;U\='6Q?5DZ/SG9J:W2GMO]@
MI>,\A[Y<5@ZVKRJGGVFEMHD.R9?&(7SKL+95/SQ=NZXV/O/*AN75+_)J>#T:
M\Z T-ED*/SAX"\2GRGJ4(HD(PSY3UL7%BL?PVYQ7Z'K@#?UZVGGO>P!XS@@]
MN;J"I?HJYOGO7@<ZUIG-@.RXU=?G6_7%J!?&,I]BY%S*#'.IH5RD'EN5,<)C
M%N[S2CP_TRZ_0,;?YM%9D*C-QYWBA=X8J=X8S/*'8I+7;P,/"_WQI/ZX'M8?
M6FIGD2-IQE!(&0?D8S(O4RZ5H$99BK1\7DG2I_,RAJ-]-)M<K"\\$5.+>WL>
M#07FX;%%CF)I [!@LU6L3/0ZOG@*!NIAG"[IWE70[*\BQ-6%^*WZ=?SX90Z?
MAL\F31A;*\*,B[Q38,MX=E>NZ]'_CU6>XL/Q;"VGVZZ3Q'W%N?M>1@C]3?_^
M6+!MY=LRG8-_GP[[#A..H!5\1[OG'^7T:,A7SE+ MW/BZ_4!GR2_ ?6+T&M9
M0^[I,.?O*R^8H@G-R*'OW..&[S-+_+?:ZF=_O&5Q_JC[O6X&7>_X1R!CI,<L
M:_Q7+>&3K]P*D6$N4QWBWBN';*J4U:GWAF&FB=:!_1CVO62)YP?+.3^K$R:M
M J*TECL[H^P6.>6=I-7K%OHV*M[!/HJ^9.>=3L^W_[M3;H[QQ6YC6R:K=\ID
M==T9/%N'#W2ZH+#CLJPM%BSBD1/?UP=3L_6-XUA LEQH>7PEY!Y:O[^Z0/'@
MW>_%^G_RII13T/#CN7Z8/)'L-YV8_O&]0^M/[OG*IGX[T..CVAD2Z%(^*_HZ
MR0;GE'SK!3\D[U.YG--)WL==MO5[JFJPF^9V>\W0OIKO< !Y=-@H>63PA<68
MJM'W <M6H9!A&GK-O(0KI=Y?N@]A +50DUFL>?#,,2N-,TIBZYU@ 4!-<98Q
M1AR!5#AO\P9 E;^6MJM;]X$,6!?7ZO8?>"0ML:!(L=%IK^C%$*_"7,/,P>-H
M)C%._Z"-VAI\ZTMQT :T?QW?B0>65> Z/ \>;04P3[5>:7RS?0$\UMV\>A /
MVH"^;VQ'7,1W/FQ"?S\#)@*/]J:>5\C^]2&.4;&['3H9=\AKQE+P7F7*A)"I
M%)E,13"9Y@),E"-+JUPM,R67%;\M'3#@C.\4$GQ<X O>1\_G_#F)_I0R\X(0
MP/>1Y+<NX0]PY ]SD?!*M,@/P&O_XK>FZN<Z\>"PY/-6Z>R_;_N8E'CAOSD^
M^0ZD%=U&=Z]HTVG5>]UO7_G1B<LO/?E9+ W>.6G?T>78IZ;M]1EX$S =[W7]
M4E]WEM[]W/'0C_!A"#_#A_(92+XD'2C7?GG7]SV@8CL^!5W2T]*5Y*0=+<I_
M/HL^X)KXJS_?Z4?I/:L[G1[?,K2^MA]/^5G;/4RJ.[7-9'?SP]KNQG;U0[*U
MLWL OZ8?=W;^)_Y=',1=V:S6GG48]P_B32]2+O(9V8N3"V758H+SOP>'I/97
M*I/?BKSGI=O#4Y/^:5V_%P!'Y\W.(,</@,JE;KNTWFK%BHF#S+ZB@&&Y6R-&
M*?-FX<\VO&[V7>+XYZ=V?A%=Z*%]*1_AQW&9D0T8"D#0W085Q0O7^#+&T> G
M=+#;:D=;EN3-$B[!6RO)P8EOQE!J$5@KAO%P%,O#O2ORLL$.%4'8H>O1*R\S
MH&-D=>AC(9X+T0#P;V+V)#Q]NP/G_DP,-394\FFYF(Y6KYO4\T;>+?J\7.SK
M&?IVH?_+=F.PT%^=>UL^VBD/H[CPS9Z'9N.=9B?^9G7G) GUUF6\JMMQECNQ
MX_56$6,H3EYJG?M2L0R>'\X];P!1(V%O1UUDH==U,X8H[[]9;J^\K99]%VW.
M80"=/XH^WY_)(F$>VNK$J8_Y#\>1UO$+K6*W#]BZXCG@9C E\;4BTAUZW1Y0
MYN[K9=M%2_'[]R:F"(8#GCCO[QXZ;[=<#WZ%2SX>+;D,U+KP]=9Y8S"Z&'7Q
M[=CS?BGOX=)<[7)K0*M]G>CS&#$';%Y^OASU_0$.]V1Y,%28T)A^TRH[:WP]
M]Z%3)KU^.T7@-/<:Y^73I=XO0OS%!\L)A!GQQRVX"#P^S$.#'0FW]Y>+/R];
M,=;?E]+8HX?INS"H./</+\=F@#N^N0[?BYS]\'(Q2/?P*LC'PTN7>;W^\%HY
M;0^OUO,S7__F_6+^+OS#R[;5JW_S>0W3'JOW=;]YW(/R;3QR/:JU'(1J<#GN
MXH#)K>N"RV)5P $=2_)?Z':N;VE;A/7;11@-% T '5#>Q]>%6BGGIY2QO*RC
M?MW?V/&$OM#U2.#CDZ33:CRE68I/]#L(WW!Y"#Y*;_T:F"0N0D!?'/P :-#N
MZ[H?- 82 9,?M[?T"^"7<AH''?5Q'-!)_Q/#>_5Z30N>1=0AMY)=*@?0EJUV
M>25O7K3J%SXY:[8NF\657K/\O9UWSOK=*^@)2F:P& ;O]W3<]=CIU>/,@"XH
ME#U\;SFI1XDNQ2<J$7"&"PKUVO#W2>26OGBUX[H<V-WV]5U#I=*.O "4C#N+
M;B>OU)91\OH*:-0?'Z)8O-LXK^?EWLT?\,5*LM6?SF^FJOSL\%3% 99#&AYD
M?V@#\7 _[-(3[%(J2Y@)W6A%HQX)WGEN3KY\"#;CFNZ/<%(Z0:!4:(87;^T9
M81<>^*>LW/!2$-[D]<A^0/&6*8QXIQ=KE>:1F8?L]<#VVL3T<Z5 Y-MQF;&/
MA5K \5%TH<T[HUM(*K!'7(N.*]$#XS:PE WO"QL4W[K# BU3[P.YOCTK5&:K
MUP&C!2Y#IS1N[M::#GHVW*'2D,4N]4%C_(2%>2F 6#>R=+D9>&#K;8QZQ162
MSO) :WUKY0?V%/2<ORA6O[T]*37V<_<N+9CW39C7]/*Z*PAWBT8+K^$.%<9[
M)SVX$/46O&U]5$.A#7BE#0P0E773P\6.;E^7.RK/"W\F-M-/U>BST4 "%B0?
M+\D'.1*Z2)GP178$@#+ 3GGGQ)<9+H68@YN7&AT-4E^Z2T4$7;F(59A+Y7&?
M?T#5%2R@!XYFZ-7+U8C;K;SE1Q=$'R_1.X4IBB<(+=]SK**D1YP)VGS(.8N5
M(*Y;??)&8-YNU1<4FP98,:R:BV ,N,;U,C%AN723SZ-;!+JV=>';S4A,(&UI
M\ N;;&WT*[I#GE-<CQB<+%5<B7)<9+B5'OV)C[Z0C3)<UY>EV+=OM^UWRCVN
M Z=<NXMXTD+B ?;:(G!S%V7IE$BY +5WW1MJ:V$9IL0RE"&/0OCO(G!]5RPZ
M+1$'E'Q7TK5T88JS6&-NC>L_U(>/'0M0MM3_K<Z@@4?-QR-,WN>K(O1=X.,[
MK'@7/8/>.=_)2_]_4)L&]%8!21\R5;DN^)CQ&L*I_L[F#<*%$>7 E$4@W#MO
ME<#(UG7>Z ?8<O#1SG4;VNJ/<,&^DV/?\U81^=/U(<>F->P=&=_T(2\C?X_X
M1<=M?QL\K\>G8P@G\H5;4'6\5"T=Q3)$TA?E>V'D,O*3^\X?R8(RDT0H!6;P
MW3(25FKMP>K%PXC!;T5(#JA6'/I99FP7=WZ/-B2FS+==#/&5 "2V-X@:NP1^
M^MB_3N)ZO@BQ^;J^[L3P?<OFQ2/%6[X)H+6H7 ;J."]$N?]"D2\*^*/>O8WL
M=T&ZNY&?^A8K&H#!JDGY-FB4\P%,&00VFC[:GG#W@;B*XWWI[!;AF2)>8]MY
M$?V[^U@^M'ISF7?\@G4GH%2*31Y%Z+RLJ1ZOK>]\V=Y(L0)F;K>:^B)O]SK%
M4F/>.(^KCL- 8C@"]UA8+'+)G;V):*1(%"F7GQ;T'J^JNK<4XO*.[77Z"]1+
MNWGG;!#6+TK>1&*N-9LQDE\N5\>Z^UMQ)1RC]'_Z=1X+'?.@I&,D[.VVD9@4
MF!>+5G$MWR=+>YOK2[\737G3[L7P&.%E]BKH0_CD$OR*[KZS],2FD^>D-TPL
MF\$_,L]QP2J_M[I;^@+ELA-@=]"1ID^/[:Z'&5A;2>X3IHB!USO^,K8U(-/]
M*>NO<0T;H&+3%F"_LHAE9XALF^O+?<&/GJV^T'G]UGV(V[A@.G3WK0MZ%2V^
MCZL#N7W&Y%Y>7JYTO%T![WEYDJ7&[BU\/5CTBC2X%TKZT3)?R0E/+L@-+\"M
M 1Q_:@6U"^K7],H=%<66ON$56OCZOZ&S><@'V2D^!W !GD+; QJ [\&5.*:'
MRZ? C?TEW-@:##RJ\KN-@P!T *WTFA%AM &>%."E]!$[3^>EE"S8.??Z#%Z
M_MWM/7']S2W7R65D^09\?R7J%W_>38;K%D*OZ_H2FO+E.D]7GT6 ,[0 5$S$
M>=%>L:CZ9'_Z3E3<,M?WZZ$_<7_C4)+/\B :$!-ANIU[8.:Y:JM(=YN>-,U'
M<M F6D(\^7ZNZ"+O<Y'W.>F\S]K:WQ\WDYTM@,S5VI-)G0_ 2C'8!WOB[HU=
MC7&3W"O*!68K')&15\J3V0JBHZ_KQU9P]KQ6?U!"Q&A[=MQN@7RD?4ZSUGN0
MS!=4 ?EA&\_<.M'(G:O[-]%?ZEDR\&EMMY9LI\G6=G6MNKZ]]C'9KF[M[%;6
M8D;TL\^6?HOI&)LQ>^9$@9E*JJV51^;DQ?P6BO]FCE=*K^:Q&1C?P+^?9O]]
MMGB[.1F3_7]E5YYO_S%:6MVZC??LW6+J]X\ @HG3_4?:8#1S_3BR?4/B/@O<
M-5LOHRM=6N7?H>%KK>4HM==H%/CSCXJ9O$F;H/*:O(IZ*1=G<>=XLSBBJ%@D
M^5O7BRC%WHGW1=PD*7A\]D95B7M+9K3O"9W1CN,9[7<1<)_1OL_JG">_]9JZ
MYW+0.K\7D=4-;WU1KH?B2(\9'5:_XU-F$Q? [D5$'!FP>X#2?RH,,F\>WNR!
M)/4 ).W=VR&Z<[<C9Y!DV(6V_4PB)QAJ_]"L<G?DC(YA9M&?FE7TIV84B:@^
M^D,%!IE-V*%N8<?L=7P8!BY"8K.-G("<V2(D-NF0V +2_9A5"7D2TL7ZPVU_
M$M/^+WSRL=69 V@7ASSKT"Z.85:A7>S[3$*[V/%9A':QW[,:V)OE.9]=(!U[
M/[,='R&07H0@)PND(SG%&X4@?QD@/:,90;.F>?B30'KSW[VX#W#VP3.? _#,
M9Q@\\UD%SWQ&@1R?8? \PW,^P^"9SRIXY@^2$19AZ-E&ST!/N0A#3SH,O4@Z
M>!T7RZ<CU+%.^%:L*WX+KF=1]<I8= %\@AGM>S+S/H&<89] SJI/(&<4G\H9
M]@EF>,YGV">0L^H3R$5 ?9Y< B"G6@34)QU0GS:7H-KJ^J(2S?Y T)-[D/NQ
M?9O3-H$++?!L+4 Q8(#O;<^8ILC F^\X)Z_9<3Y_H8'*[4$&L5 =%G]TDHVR
M2-F@KN-:4]>O.WGA>M]IA?5!];[BF=V[<J1W6P*F;9X7ZN+YE7O4$[NYI@DU
MO+FZH(L"%<-S\KD7#VKJ%C7&"LG_'(O']?^.BJ/>ZO3:\+DU$RN$5\KS-&+=
MPFF;QH4V>+8V4  >R"P4?'AS;< 6X&%X3@ $Q(-0RA*7G]HMZUUO^/CL*9FC
MA:@_7]39*$5].K8 3[ 2VG::[-3^M;D[HC)H3\WG+Z6'7U4V;/[T\$=_#"Y9
MH8!]'--" \^N!L8(@0H>V5["&56?@Y+GOUX2]'"-]X7/-,-B3$<IQK-LK!<1
MUWMSLM]L^^.\ X(4,YMTW0_O%GAP=L9^ISAUIV_9%V9]EO5!MC#KBY#J(W.R
MX8,N%D_VXQF*>[Z9M]I#>F#:YFHA\R^0>;7  (O Z6.KKG %;'^(1^P,K9I,
MVQPM9/WYLH[)PKZ7LLX7]GUX3G:*TZ.V[XZ*FK;964CY"Z2<+RQZ*>79PJ(/
MS\GFU4EN\E?E2"Y,^*2%6\Z("5_D2H]5MO>@![K[2H"^,-T3EFX2LYB>+"WT
MKC@;;W!]<=KFO5EZ<&YC[OY:>MX)4(LC.L?>E3<YHG/\C/E49LW*<\X8?$;O
MOW/.[F2&MEW;K-P?VEYM#:X]>IKHT^<$/U,^Z=)S6QS)Y[*E*6:L];6/:QN[
MV_M[R=_;.WOKVYO5]<V]9>"N]95DK;J1[.W_O;>]L;VVN[WY_;-=IV8P.]6]
MG8_;&\ ^&\G?,#(83++WK\W-)\ZE??.^/P]8_+8=CPEO]: )UUE.?'F^=^<D
MGC/N=%?__LR#=:/)N'^L[M+;G)FKU(I (AJEEQZ9*\@*RL2SCJ%]2;,8KRBF
M?JK9I^]Q2M^DL_QY'?J!#_:"/-,G8'C)^@^I7?+46PO$-[*,RCU:;7L2CX8J
ME"]!!-]*P(]'.&^3,7Q4UF ^T+WY&%,8;I*3L+:W-ZS(?R+*U%=]43'BJ%WC
MQM]DT.^98HC?]H=*%?S\A(SBN.YG3>KKLK8?#R,DQ4^R0OBT\.TWIKV@55&Z
M*28VV?B+_W<OO]#U>UO+[YN 9XT?)5,EL8^/_+]>-<+AD;5CJ],TM#_SJQB,
MV6IK6VP([C7S[F[T/WL=MP1<W8R=+R[DPE&JF0O>:LF<UUH0E$6OP2MM,ZZ_
M;D?KABC%2PEXMGE#USM_+:4@$.7J&31QU7W?[#5<J]N_OY0T=</'CZ7'6I^_
MCRRVUG3QQ^8=?ZUUUW6[?0T3^D77>^ A=V#N?"%JA>OBZ)=KL]&Z^$AV+PYI
MI>=.-R^./JC3G=/=O'+ZY?2PYLZJIYN7E=IG7#W=/3G:.+Z!WZ\J9*NQ4SLZ
M.?JP3S[2:OWPIH4.3[?Q(=FD1QN'5Y6-352M':+#@\^L<K.)*K7JR='I&3D\
MV*U7Z_*JFJN&;6PU=QK;-SNU+?B6916R>5.M?>;5VI>\>EH]V=G8/:TV-CG<
MH]5:_?0CW3TY;%S5=TZWX=K^U4[M^'KGX!!5;SY?'VU\R0]O*O#^(:N2+]"W
M"CJJ'5\-WH%O]8[(?E8Y/;NNUC;YSL8V/SK]3*L;_YQ5#_XYK=Q48'S'].C@
MD%=N=NL[&UNADJ.KC[7-;F4/77XUVF42G+S42$M2Y@A.C5-9RK00CF169M@O
MK1*Y+!C[\]U]SG@86_X)21CHNA=(Q,AVV"S4TKRJI>!LEAGI+ ^$84P,,YX;
M)SSFA"/)"K6$,%FHI>E22S>W:BG3C@1,14JL8RE3/DLU$#05A'I!,J*T=$NK
M.%OFF$R16AJWJS(4*^DWD<;GWQ,T!!WSI@/>?)^J0O5-0'++J@%EH.:Y>;#D
M99/VJ'*>914V!F1U1Y:[[.2%QGJ)QKH> E(<*\*R#*<H* /P"?-4:<-22J2F
MGE-#'5Y:E6199.*U&NMQK?&F0.JY7O6O+K=C@!X+N7V]W-XA#8^94Y9E:0;*
M-65,FU03[ !N$$<%%8IS 4A#+J,,3Y'<_F*!ID]M?ZYS5\2:6D4"+G!^&V!-
MHCL=_VV\Z5GZZ+E.WBSKHS'@B#YM-J_.?;/CP2DJ,J37"KJLEU1:J*<7J*?J
M^A"L (II;+1(&5(R91S+5 <+.BH+-%."(1]A!5GF9)K\H%$7E/G5I?CG4<5"
M5-]85.^0!#462R5Y:IS/4F:I3)6P,L5( 9$"D\&CI57!Y10)ZH@"%L6W"2_3
M^J881M1:75T?!71XZ:KKW&FD,>"*A5KZ:;6T-QR8H P32;,4>4529DB6RL!5
M*JD6W%+E XT.#F;+0*T1>3@OR4:8E;#%KROK8XAI+&3]%;(^%,P@B#&%0BI1
M!A#$&!\=!9.BC%.$)>>&N:55RI=!+\^*J/]RD8[6.?3FN@AUQ(R:\UC,?3EI
M^NXBR#%R,/+0/2KG_E-=-[O@'6T.IK_J%TKI14II.,7$(<0T0SH56.$8QPBI
M\DR!4M)><$YYT*"4V*L5TB)^,;4".KKXQ4) 1R6@=ZA!T8 ILB8E&68I8YE-
M%=4H=80$)@BQR,NE5?[J9<LIC5O, "@H:XZ\/EXQUTIF5"A@*"9:;37MPB=Y
MN7893HS03FE""4V#HR)EBN!42N)3P01W2F:&9P*TR\AB#S,:7IAKT1R5_5^(
MY@A$\\[P&R,\YU*G$ON0LLSYU&293[EB('E6"F;]TBJ @BD2S5&& V9FQ>)Q
MR_^C(;\N8CEM,_'BU/;G#W]>U.S8%F46*O<%*G=G.)\C8.^) Y7KC* I,X*G
MV@65"N(RKX,5(;AR-29#HW*XIF8UYI6[<1;Z[!?39V-;>%KHLY?ILZ&DEPRP
MG=,L18&9E,F,I,9Q!V R8UA+I34*2ZLT6T9H5 EJXUIQ>E M#).RX,A$MZ%3
M&))K]>)6FB?WH<]&+\=4@W&2U0P^;J_]O?UQN[:]N5<6':KMK/_/OW8^;FSN
M[OUWLOEY?[MV^%-E#GX\%5.G^1\7]Y$NM,S_C/T"U5 ^YMKD]?N[!$=;>'<6
M"#T!%3[C,_:+98JL60N#Z7:2<WT==X,M:J[\$L4-QA'DZ7/6IY*Q%FEY/[''
ML+8=':0R\+/V54J-E:(V-:*L9T!3[7%(A3 V<$P(5O$D@F6*^12MLB^JK"P4
MT62C,PM%-!)%='VKB+03&:)6IHS$^'-PH(@RX5.<V<QKI#,63TW RT41QJE1
M1+]8N@^P?;OG75)_AB/TJZ<6C <.17(,N:4+1?0SBJ@RC(@$ID M9%+BJ4X9
MTB0UC&!0229(0$2,F6)C,]B/*<H^6"0&S2*&6$CO:*3W#D90995"'*=!8I!9
M)D*J)7@V6<@PE<AX:^)YZ<M,9E,DO;]D[M!@M_-KP<1(%N%G65>- 6DLE-0K
ME=3G88CA9(:9U29%U!-P> ))E<U4ZJG3Q"J1B7C(*UMF=%0E&68ETV8A\%,"
M3A8"_WJ!OT,E6<81H]RD F$% J]EJIT&[\(+9[),@J8V2ZMTF:-7HY(QYZ+\
M*I&/<J-3O=4\3KN^W5A$0,:][VE((2UV6/RD3MJ_!T(0M]%TI AC"IJ(VU1E
MQ*4&(Q<$XY)F?&D5\U>O^RRB'%,KH2/=_K20T)%(Z!UJ8)Q3I1%*+0DR94;1
M5*L@4L4R9I&):R)V:97PQ2ZH"4<RWCJ",=]*:+SABX5">I%".AR&# K\$Y9A
MDUI#++@Q&4^-8BH%)P8IA*GBE,6X!5>O7AIYD4C,0]!BOF5\O!&+A8R_5,;O
M0(=PEG(;<.I!7E,F0- EM2'%+"AM,/"PCOMFED4VJCR,MY7Q7R M?;W5:.3=
M6&VH4Q1G6X<WH.N^:5^9J/YCR@Q4X=M8^ZM._KZ9U_]:ZK;CF54/#KJZ&W4\
M[VIXS NI?X;4VV'+;KVF#'F4!H?B'CE)4FV,3EWF%#$T$.]TE*@' C\->[I&
MQIDOL5$+SGQ;SKRS1PH;PFC<C8ZYBKLW?:J%Q:DPW *5 LV0^RYGCF3#Y!ML
M\9K*-GX!2[G7;=FSDU8==$?GOY-8I*][/2U[FQ;[H\:VW?9[IQ/2[.'1A(2L
M\$F=3OBI[8-OMWU$T,"VRXGN=4]:;6C +2??M6N=$]V.=F8$[M=V=>MEI^V4
MW2V$;*_HQMIMCV]=,K0P@3\V@:=KW<J@.,NZ0D?_>X)LXTM3'ZC>3N,S@3'E
M1P='>77C++9U>=389(?D\+IZ^OGFL':45QK51N7#9_:_-Q7T%5-"&371E\MX
MRKQUJ<X,3Y&DBC,IK OX"9ST*#_]7,ANP4_SP$_> \$HR5*JJ4D9<CA5FLDT
M9(+RC"'%0K:T2M R*,?X_T>@V8,+2<EC]P]>_>X)LN*ACL9T<CIZ#]Z"QOZ.
MXE%8FUA: GC6^T9QK.SY?1V>U'/ '$X7(G813V(>HR8OQ<O63>>!;'V\ZU1Y
M WP57PC<0LHF(F6;5Y7/7Z7RG 01TF"I3YE6)E4FJ-0I*ZC-!):8CE%O+[AG
MIKA'4X0=YR3E0C.P^LBFAF*9$H,<1S0H1-C2*EI!Z-OR]M]1T$DK #<U&JUF
M'Y#.HL+^KZ<"0I]\N\^XH]6YCT.:3[J]T][KZJYW7Z(IN/OZ0FPF(38WU<NO
MVH-T(.%2I+$ Q&QM"BA'Q7,A$&(,.\K-TT'%[_#0JS7O@H=FA8>\" YE5J84
MQ;0=KUVJ.-&I(@CTL+><6UVHWN=HWG/=+H'B'U/D\C^" DK_;,-W\N-FY,8%
M TZ& 3'8?@Q\YH4DJ90(/#3*4:H9_)99133G1@!K3)/'OV"GJ68G9BP-*.8!
M^%@_4P><:NU,JC'%2LM@I4!+JY+P%WG[P"4#XOZ1Y)U.+"M0'*+>ZW:Z\ O@
MQY?ZQC_'H^B5,:GMHN\+!IT,@W(PN%1+[S$2X#"P *"-\U1G5(*G'"3./#-4
M/07:1F@^7\M+.W?,OV"HR3$4U\:;6!0+2^=3X)^0&NY#FB%.@:4\I^[%!G0R
M#+503I/F)0M,8S/F4\YC9HU4(C71+W!:$^?!:F::C >,+9337#!44"*S1,D4
M>6UBM2R6&H#[*;?"9$$8RD,LE/7,M9?GXS7=32JZ;4\2BF<R\A=%HD"8&][Z
MAO'M.) D*MWE!,9W[F&X%[Y^?7]LBQ,SWV2WQHUOMYSNG#RM=XJ0UB*9^Z6Z
MYBZMDUJ)"<8F!7T!NB)$9"RQ38/A@0D6@B<Z9N1(@LD?4U16;W',[31NOU@(
M[1L*[5W&JW-9P$:SE(9,ILQ)EQI*0NH(]4(SHY@3TRBTX\X?G0W8L3Z\8II,
M=/FQ[,IBW6AT<KOY!+"'[YZND4ICFU1/[?7AS>YI9>/O_+!Q"'TYPSL;,(Z;
M+V='!_^<16#_57+,K 53'8"4*3/,IIH$DQII!!(6 :+RDUUY7+#/%+./EC9@
MY7U*#0&DQUS<P&.C?\B9(3*><TR?G^]QN^HXG'0\10N0C[#D(D%T*ECQ,_K*
M2,BX=R*U60S'&TQ38PA.<:SGC0(P*'EQ.'X<"<<+9II"9G($.<JQ3IV+*>Q<
M9:EF3*66$6HIZ#F/^-(J1R]/-[Y==9P!3ER$\2?(A99_!8XS@2"?.JQ=RH3F
MJ62>I59SB:T,&",,7*B6>8R[/E*U<Q8#IC%6.@,F?R$;$Y2-8_*5>1LDUBKU
M'DM GE2DTDF;H@ *$6,C@LJ65K%:IE(M,_QM99C'%AB2YT;K__@F:60616T&
M3-!B]6_2LK9YN5,[PY7:)JF<'E_#W'RUAN/ @TLIP@".C VI1(& #X@R1!BG
MWIG"+#$EEQ7_UBPE,Z+C%\PW9<Q7._P*F(<B*W0:0-.GC%B?@H(%#I3$>TY(
MD#'-.>I](9<I';'>?\4J[:]0V'-4I7>')'&QKO-3TC=TL%  BF!)TD!%/&I1
MX]28F,)AG,ZX9$HHLK3Z^K):BWJ[4RN6HZJWNQ#+UXKE4)5=*A#FW($PHKA=
MQY)4B\RDTBIC%+9>6!7MV!2)Y:]VGC3T.LZXKB?G.G?@L256G^==77]-M=VY
M5C3C.'SPEBJ?@"C;S?62) M5]")5=.\P9I%IJ;P.J<\03QE2.)4:A=3%//1,
M8J81J"+.V'+VR#+>(EUK7J1W'(</+J1W--)[!R2LD0)G!*6$<Y2"UK6QT%*6
M2OA;4H\Q96)IE7&Y+-BHSO6:I[PMC LD,J%"_FVO.[WV]6VMM2[,1:?[TEW7
MXPC-#KHZ%!];!,5>)+:5[P?%3M<NCQI?ZD<'^U?5#9B'VF[C:,.RG8//E]6-
M30Q]NCDZ_3N'_E_][\TV_THPU0HYG<*/>$8PQJD"W1RW9#ABG419W(TQ?2'6
M!1--$1-IKD@07*3@?(KH@JI48F/2X)4(" =D! 47%"\C^8(-UL^,J_Z*D=3?
M)A!*O2=QBZC-3PG<G:L4-%9 $_"-BK/9A0CQF *5$JLPQL%8@?W2JD#? JW?
M%X'4.9#*4452%U+Y>JD<*M:N*3%"D!1KB6*I$)E*D66I =<G<RP$L'13))6_
M6AS5VEZC5X]9^R 3(;=Y]]<*H(['[,>R-O#;"\#XKN]JZ*S;U.TFS&AGB% ;
M)9T62NE%2NG>:>M6>\N0!"WDC 87+0B "EE(,T$S8H&^'-NE54;I<O9(=MKS
M%=,BH#J]TOSS<&$AS=,@S4-'J3O.,ZU1ZI7%\0Q"GRK %BF*Q>U0(,H8#-),
M^#+GWSK+$Y'F7^RH]&&8T2J.3;>MQGG;G_AF)[_P2;W5^<7.3!\S[GBPTG-'
MCN*8YO5A8FPW@3;^(U"DZKL[H::O%KKI1;KIWI'J')239E*F0=F0,H]1JB55
MJ<LTT@([PIP$]X=,A_>SB$E,'\A8B.Y817=H\=9AH3!E*:/12; @NH8PDX+,
M(J^X %J2I=57^0=3&KB8F5/6UW5=NW;>ZR1_YZV.S>,Y$YWE!.1@I5RUO3W8
MS3]]L-MKCFF>^Y.:QY Y-GP*7WD&WT)SO4ASW3^473#BN9(IF!J;,JQEJL -
M2K-@@^'2:Q8+AV",EDDVJK239XO'# 5 ?EV1'T.ZV4+D7R_R=V#%:R0P#>!B
M,"WB$6P^E5*%E/)@*?(N\_%H*$J6F<IF1>)_@=-GJZUFE+MVJP[WCI,<1+#M
M.]U%,&1\P9!*WFRU0?ML]^=^H85>I(7NG1E/:*#*"9<ZA0!X\"!3'?/6L>+8
M8<RD%&9IE7 V'3[3(MPQ[>&.A7"^5CCO( *00"$!;@ F,1/#"A!.14F*'9&"
M(2N]$5,DG+]D0&,1M)CIH,5VT]9[<4X_M=JQ@VO=;CLWO6X\^+?6N@_V%BKM
MIU3:\;UBY@(9RPQ*)=$Z93Y#J1$8I3RP3%+!F7.Z#'0@_*U:FU*W9Q'HF/=
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M? [DF(&&>"",1*FIK@2*DA0=PMRQ(!37E4M672ZP^FQ![NGI>1/3HJYH?]S
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M5J/(A)R(-$BM$ZE>G-YG*I2IT.4^$G=&N$QZFH!],]*#,2'(*@8<#A'[#,=
M::$!9]IJQQ23/)F &?<R[F7<*S3#3 OKJ V21GO0L$"LT4P:2QBT;AG,+D/B
M4T#BP5QC'4.51D: R M-I(/( :."!(9HP@7W#(74/Y#)=4$OM^?.N)AQ\7G@
MXFTZZQ"LE78>:>00C5:4(<((YKD('"*MT/7 .&VHDV&P 3"XGR"PA,*MO[F
M)')\#@*! E 5S6(%L02),3HJF/;>1VI(EM9>)Z-?1K_&O/EMT,]!@2G$WF H
M*&)0(V](< YC'1S"]@;HE_EATX%Q?PJ,%AOHC%> 6,\ =9$E:J9X-)Q#X((9
M' R.!!&S=<8NQTXS.F9T?%'HR*1R&B.CK"-446.88TIS&DUH+2WZ0=PT<\-F
M0>"'*01*JY#!1 +D)014:PJT9@)8Q3W5A!%GV=JF@)?MXPQ_&?Y6'OYN@7[&
M>AT)@<%(8NJ9D"820BAII U<"LJSRW!U\=!.\5 8'@*A$E K?,)##Z04%EAM
M$*$V4*G5VB;!ZU3Q[#+,N/A,<?$VM-!XB!''4D$2P1 %$Q2DC!MHO':(D4P+
M5P4&/T]AD+G(ZBW5T2@F E .;7(9$J"==\H(!(UP:YN8T4P+,_P]/_B[!?H%
M9SDW,II) 5.$L*'&,^.$1PRS2 \S+5Q9/#R=A5 (CAC(+0/1 *" *HJ!ALEJ
M)M$(8 RZ $-)"S'%JT,+<Q&Z?&6^LN%7WOJHYL_K532-:+3]J-7I#Z\_ZWW+
M\ARK<1:A/H!RR]WA:ND^*"V^Z6'D+*4LI2RE+*4LI2RE+*4LI2RE6_G1M7$*
M"JJ$"8HJI0TF@4NI#)=4,<_^WL$0(QC_#Y0_D&5DH;T=]$,Q2B5/LW_H5OZA
M#PN99-0@0ZAQ0(B  )5< 8DD 51#JH5$J=C VJ9<A_P^6;99>S/&9BG=!V-5
M%"@)$!$D)4662:\$LAQ!SAQDRF2,;1K&SE(S.):<"T0 IH0"Z@D"QD$(&,4&
M^R 5X2YC[*II[RV4US)&2- J&,NH\D1[;)RVTG*)@A?R!LI[DP(^65WOH:ZS
M% +$8 C26X )Y8 :Y8%R3 .LH[2<H")J\]*J\&2M;>Z>2V40PC$*E=&4&6P0
MY1&\:7!0!AQHWG,;IL3S<6\6;1?&-9#&.D")X4 ; @%4BF-''57&-VK/?5:%
M3:_6O0^]@8^C^.Y=&31K1>WKZL%G7V9_M(;>C@?%J/A!Y>0;%/Y:/42ZFZUV
MM?17I3Q;EE*64I92EE*64I92EM)CV3-"2F,"]!!*1Z$+F@>'"/*(<"V5O)4]
MLVBTE-WI%AK353WIDAFS]447G<3PWO0'A]&>.9SRO"UW.AZ.NKXW:OO103C2
MW[+)<RN3Y^-"M11/D?1,!<"YMX!:!8&VV )O B&046NA7MMDEPOIW?KD0];N
MC,%92EE**R6EIXJVY9VR(3OE+" '-<98>PBX) %0YA60S%C@L-,ZRI)2%/).
MN5+:G3%X%:3T5-&7C,'-P."Y (WD& 85S1/G*0.46@<490XXH:'65#L/&X3!
M+^ L4]G0 Q@]].D5NV=1,W2:\'RV*4?QLY2RE!Z\/Z,BR@6$@I..6AJDEM#R
M:(-!&FC\VPWV^RNJ#^P-AV/O=N(>WCM^&]^B[ZK&1>6_KQ/8;<]A7=[1;[6C
MVX4>1D0[(U@ @6H*:- (&(0(T$P31GU /M4DQ>)ROD56XT:K<0;;59#2;8I%
M4\E%0%P(9:D*0A$GD#%4J&"B;763\SHW0MK_Z,[89Z!="M#.=P?QDL/4))<Q
MY@$E7@"%A 0>:D*EU0Y1LK9)KRB+GU6XT2J<@39+*4LI2^GE2.EQ0W*9M#PR
M:5DX!(<,(=Y;H)2-K 4G?Z_0$CB%??P(,F-U9BTKJ,,9:5=!2H\;>,M(^]A(
M.W_T26-CG-(@E?@'U/, I/$!$*H(PY!8&%33D/8%G'Y*M0+/!OTX;C=LA4&_
MVRJB2NB>]:U^2!&W;C\-*:I*2_=<ZZL>#'1OE ]#Y32.+*4LI54(O]VN+OAU
MD;GX\N5'^?SS[4C \7PP3B*D.:,R]<3B@ I+@+3I: #6+'"B O2I[+=:C[;T
MDLI^9[U^:KV^HBGR(\742RJ?%??.BGL^55P.I3<<L4C9=0#41<55$!L D0DZ
MU2X(DB7RGI7VV2KM$L*S]]V)LS[?2Y_G@K68BL"L$$ 9A]-&S(#B00"-I)%"
M<,.]7-N4;)VB9;5ERSJ=S: LI2RE+*4LI96.UV86\Z0L9N'$)#,R0)J:*28:
M@[P%1E((%,;,(PH1#ZBB,4QD&K-:2IVA=Q6D]+@!W R]3PN]<^'<("F15@D
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MBK+Q&0XS'#YO.(3I[)^,2(@8H=(PXPSU4 ;M-3$:9?:W,ICW88IYS#'!O/:
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M/.D#1$00I$B@06%#B2.81<L86T*]NA[X<C/XE0''N6;P6L&@@P$("1FM98Q
M_(N),!D"#\PBY$.DADBLQZ6UW!9Y&1V;A!$9'6^"CCQ:R8(+KI4C5%AGL$?<
M,,PP"4'*']#"W"&T61 XZPV/(?>2*0AXX!10* *0*#@ @[#&1X%C(1Z@-WR&
MOR:!P,N%OUN@'V2$,Z:L@X91A9#&UFN,@F5<>T=$=A:N+A[.6L5S'JUB1R$@
MD"M &8; &*6!M=QZY'U$0A7M9;@N$<]&<\;%9XJ+MZ&%PD+A'/>":4R3VF@.
M+3=!.,,E1#^(HF1:V"P8G#6.UT$:1!$&W 8+J*4"2"(,X%'.&FFOC+41!CG)
MM###W_.#OUNA'W&*&1>@Q!0CI@(4,A@9R:+02"TE.S#CX9/@X5P?>1GW.&,$
M!8QS#*@B91A% R$4Q=YP#"$I:2%CER&QL;0PUZG+5^8K&W[EK0]I-JE8P\VV
MV[8?M3H_JL-TRXH=JW$*H3YZ<LO=X6KI/B@MONDQY"RE+*4LI2RE+*4LI2RE
M+*4LI5OYT9G76%A)+5$F_F.U0H%K'?]#I."*_;V#(880003*'\@RLM#>#OJA
M&*4BJ-D_="O_T(>%3#*.<5""<B"I$8!Z;H#Q$@$.I0A(6DZA7MLDZTK=)X\L
M:V_&V"RE>V&L\]1YI(@0F&K"M#(1<9'PS, 0.,H8VS2,G:5F>.:#5M@!*70
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MAPUQG(002CW4G'!HO/!42(.,OQY?;]\Y(Z/M$Z'MK&.@4)(J+A6 P3A B:!
M1NL%F"ATX34V3KM(9C%:)_?J9Y6!-@-M!MH%H&4":^,DH9)11I$TED@5F'<:
MRJA]-P#:C*:-0-,/LSJEP3"C"0$*!@&HH @8JB"@B"/"(\Q:*-<V!90923.2
M9B1=4GT<QRG1!F(#'2742R>$L,IKZ9U@3F:GZ^I"Z^Q NN#(<NH<X$H$0*'G
MP$@6@#,Z"*V#55JM;2*QCBG)7H$,L1EBETE6O7%**!OIJI'4I(+K$6$#"HSQ
M((.ZB5<@(VHC$'76+U=QJ'A<_\!%249$A0)HA @((7B(G:9&B[5-S"YG6F6R
MFI$T(^G=DMTYU5Q8B'"T^F$(DGM(L!"4,.^C=9C)ZLI"ZUQ-#RNDAHY#X*QD
M($H\DE4N-&!*:J5L7$6!1K+*UY6\=S_R!D!L/L2<K\Q7-OS*4DE_*S$__M<5
M7S;_&?^9?&-.X:U/6\"R=U($?[:5XJH\V0+XW728F_\T@]\V;_VUQWZ[0^];
MVJ9V';IW'E&WU>N/XMU'_4022E#6(^]:H>CIGBUT)XXO_B'UL!EN-.CE+ATA
MOXGHZFLIWA LWN^L/RS2=O=JX#MZ5'SQOW\MW.ADPJCFOEAO:7#V%6WB7(U'
MUW^E*?)N+<[&_+]IM"6OH@8SJX7C""+*(CUTDB"*B Z*:^?YWUBN3;YT,IB\
MP9D^]L ,O/X,=(@O^$IWONKSX=IO"_/0+7K@PKQ?G+)K)R:$!R',<5XJ=A'9
M:W]0EH][%=F,'Z2KXI!T4X;2.ADDQOX_/Q=0M)+WXM>^_?,WO7F5P!NHJ]M;
M?V[MO-_[<-AZO7=PN+VWV][>/5QO[;6W-UI;[9W6X8?7AWL[>UOO]W8/&P\\
MVP?MPX,_]W:VCG;CR(_B?_9WVT>'K8,WK>VMPW^UWOQY\%?SW^*7#ST=C;2(
M_[\^W5C5C6#ME[U>:W32'\=;N.'ET3:2.73UX#BB8;V9)"2L_Y)L(E:Z>DIN
M--MU2HLICKZCSX;^U>2'WR?<JNB58RB_=-$\BO>L@5:I#0%%PMK:/JIO7\/P
M1@G#%VR\ZC,!-SB\_F.X@:[][$>W17B#$7ZGV_[X,T;(0PPV8NV-;OL3&[01
MI7A^JEWPBH5\D>6KF[Q3A0Y/\U97%Q@ZBMNI;^W'ZTZ&K=VX7;I9H:&%=WTQ
M@IQS1E_GG;G"0=-L*6.(T;)>^-J"",]TXN!MU*#9-<=NIA_;>GC2"IW^UV$K
M#/K=5O_,)Q8>S>+D"?U2=G%]=9/5]!.?Z*V7QR,&&):-)'>N,O+"IW-)'6.K
M ![>P*S9JM?VHU:G/QS>IWCX$T<K;_:B-X]67O6&C5[%M\G?H#((X1B%RFC*
M##:(<D\0#0[*@ ,MFP2@29, M)SC'6\'_5",4I?NQ@03#[8GP<2]K^V=])Q_
MG^[OO.Y\/'W?.?ACEW[:V2/[W3?Q_N_0P='^>3M>-PLFOH/MOSY\.]C9)^WN
MQWCO=SC^S-JG>^1@YP/;__X1M?_X #]^M_A2,''G'?ITM!O'9/&G%*C<^1A_
M_HSW3RUM'WW^WC[] #\=O3]M?_\4IJ6S#N'7OPW%F#LE -$$ JHH!-('#CC4
MW$51,2WIVJ9<A_QRUMO-TS2:U]XC ]'S!*(E="O)0/1X0/1]"D0TR)05)H!0
M7 $:E 42D@ B.B'MF$<,AK5-LJXD;P80+<F 6A5&M^5.Q\-1&2I,\<2!CVIG
MBXYO]6JJE_Z:?K;)ZAH/O6L5O>6;7"MN!CR!5;7B,[8DP^G&JC7GTJ]O =+U
MKXB<4]&BYZ(BO *(;%2N_2>8J[(P)#"I5U;+SC7+NA AO$VUSP:V,[O97#RN
MI;*X^:=.9JFT_4$H$R.W>NXO/1CHB)-O^H-#/_A26#\\&&QW=-'-_. V_&!:
MN#/Q R0B$S"0 $(T M0& 23Q%'CA@]<Z<&VCH<*4:% ;LR79*EEW'ZH58=;=
M!]3=&;<WW$1NCP* (3! A8JZ:[$"G&K#N,302A9UES=)=Y=)[S&K<J,:3.]W
M_%FD]$7)(%JZYUJZFW+YOR]2BCN4#G_6@+1T,C$OAHA&6W-"R/!S&_@IYJB#
MM00A0QUP"&M =:0.QAL"%*7*H2"4(3Z=EEC228D&'2K+BOI0S"$KZM(4=<83
M!,-,*)CJF7@!J+$4J(BC<?&X$ $6<J]E5%36($5=N:-)SVW MR*!*T#$MJP=
M^!+.XO^Z>O#9UVFCWHX'I?_T3FSL)9B'RPQ"+Z+]5"CS.'\0=HJAC9,\&L8=
MX.W =XMQ=[C7^^)K/WG>"&ZQ$1S,.WNPMA:Q8("6*AF,@@%-8 "4.*-1W,NY
M$&N;!-^[$DMV]C16FY<9R<W:_/C:/*-U-BY3*AP"3'L.J',XTCIN4XZ)91[;
MH!B/M.[>'9>R]^?.F;(GNG<<[[88L1T._6A8.H,Z41N+3H[>YNCM$Z:]$M%L
M)8I[QIDN7*DP_=&)'[0B8Q_$K:/6I)?%VQ\Y>_3&N5I[O;CYZZ'?\=5_]WJU
MW'9\\%%<;O=;"J7[2 (.DA"W2MGES?\V>5U'"XVON4G]=UF4'9$(4,9XI/6.
M  ^U\<IX1%)_5K0NGEF*Z?/6[T8P^:S,CZ/,L]9_C 3O?+3'L>-EY2D*=& :
M" 81UY@@+J(R$W;OLE,-)?--)R'E,K\/X7@)T:"'<Q1>!J12( <3HRH#T!T
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MMK[XDHS1:58U?VE!]M-==G"T=;[_?3_><Q_N?_U;6X(XP0@(IP.@RCD@">0
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M_?)3,&LUZ)0]&C4ZW1*=R 2=M(J12X%8- 'QZ".R2E.49'!.)<:< 7U*D@O
M]&N-2>O#N$\8D];;T)L@U2QNU8"T'""Q,2 ERDSPC".!501UB0CDC(LH)>59
MPAX37QIX6LE:6ZJ1Z5$@$R'"XFC@OY@#MKTS5)D8(U6<"FY(@4R8T-H%M;8(
M)<8(Q7Q@A@:)/ %%B=MHD),I(:4\!P'$93)BXX7>Y+@&J!J@GA- U1ZH-0*L
M'P!6I=]\^[,3-HAD(](\$,19\L@8PI#C0CALL0R1U3ZH&K36X-66\4'='K5J
M']0:X-/9&)]$%%%S1U!T42(.1(MTDA$Y(KS31"8M_<:+BP=ZM1-JC3CW"8/2
M>IMZM1-J18C4FFA,BDL2G)0H>L80YSP@[;U#@B0I1)"*R)B-/&;,&NE+*XGP
M2L5_CRG"J]GKYK[N9:V]!*]R>:0K7>[%%P+O8X8GX[6+23OJ/>=.)JM3HC+H
MR(U6W-$Z&&J]8:KU<BH8BC,'0B4 /C'M$$]6(*L501(K#*:<#ERYC1=$;V+.
M[XI2BU'A7A6HN4=>GFM8\_0*>+IVWJP1CT_"AY2(RI.84"(F :.KB R6&'DL
MDT\<6R'IREPW-9/73%Y[0'X6DT^B<+B!3554(1,Q,+FT$3G84[ V*$AR;JVV
MLF;RFLGK"):U9>9)!(O641BF.8I:@FHN)$&.@9(N([',!R\B5K56_N1YV0FK
MA-%4.&(YT<0$^"VHH( ,DJ&ACOE8>YZ>Q'Q@%:(AE".I$T&<2(X,EQ%X6CK%
MO9#6@:6M-H6Y&"E;LW3-TK6AO:8L/ATE$1DH6R0W=; B@JF-@<F9U(AHB[F2
M) 2G:BV\9O.'8?/:U+X3FT^"#0)EH(-'@;"*&/$0*#+698\:QA(P@#M?>]1J
M-K\/!;TVME?$SE,G]9K3Y+2+*#(N$8]*(JV21%:JF+B*(0BR?JKY,ZW%T@1^
M+-O]7E.+Y48H==-(J<>,4EX;SYFT7'O/=4R&8$T#%9[*P)2H#^S7':T^3!W8
MDT0<\X8B3@A'W$6'+-8",2:E)-8&1^W&"VHV,7F"N2,U3Z^4IVL_PAKQ^.3
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M*B[__LJ;K_Q2X2*+8/4#DWL:=YD)7Y*!0:_(P+@V^>_BI0N4VY*0?HX6I^>
M0BTNV6G[_K#!R&8CRY%+ZW0^_85X%7T\=K$_6@L\LQ:74(QXM 5=KY<CQ:J\
MM(/#!B!IP^<?XO^>MD&4P-Y=J.AZW4L_%J/PANNR=#?LM3?Z;OCBZQ5E\[(X
MS7@*%MWQ7YWF\;L?^WM?<2N/?_3^J/7I-=^G.V?[>TVZNY?G_97!\]B\1;=_
M_/$,K$&P!-\1>)>SUMLFV=\[/-H_ F7X?%^T/H$EN!?@W4)J3M>K-;#\@4B&
M%!$&<>ER[3OG$;.42*>$5R07SN*;1*PJT7=MG&#7Y/37<%;#V<]W8M5PMCR<
M397FE3:XJ"-R6EG$"0<X \,>*>LLCHESIWPNY;DIU:K*;_\<[]-=]<[%N>)K
M#4@3Y]5=NP@L>/F'+KSR*%6M1>[$&JN6P:KVE.K%!: 2Y@$QQP+B2AKD<EL3
MSZ4BGDHM4]IXH>FFDJMRI:_1$6/-N#]1J:@9]^Z,.U$RO%;.,*L1%<$C'C%#
M6E."$C"N(8XJHT+9_E<^@H9$J_!?/7C-F1MRY7)%9V85O,<?['#/AN CCG9X
ME-I8MA3SG]<3C^QV-WPX[/6'>[%_O-/]%@?#X_QQ#?7+0/UTP1GE.>88[$DE
M1&X-$<">I+E3A,84#$I0U'!:68+9RMGI<3C0:F"M@76MM.4:6.\+6*=[:&G,
M;)"(89P0%S8B"[N)G(N1Y%8>1JXLCFQM</6N<62711;]_,"R*1YX6<7PQ/#G
MV4MX3-ZD4]MIVF$V-,]>V6'<RV_\?./.FO0SYSQ)SACR5"L$&@7/'FJ*M' R
M&*%]$O2JN+/UC3*[)LHKAVJ= '#")>W>]<%G[JP@U8J&&L<5$3VWB*Y[#)#"
MMP_:>IB(KAM/^!;^C6N=D^9Q!C)=$=&U>)4H64W<VS(B=+V7<%Q)H)%+"=P@
M*.Y&K_ZLEG 2@/PF!R#_DP.0ZX@Z6)C_Q$&.?X8'][JQ<19MOPZEJV-/'MZC
M>'4"5:71PV_OX['-FF=_-[UI9PMX'TCXR99>^>MK\_A]Y^#3#CXX^N>X=?2.
M-<\[[>:YY\U7AT>M5Z_YP2>8\]M]/F\=@U5]=O#VG\[^T?OCUJ=]VGKESW<_
M[9RWSK]\WWW;A'D>=O;WBERMV:-AP;AC45+$HB.()S <#$\)J40HB\DDS>/*
MZES787DU--;0>)_0F-6?0ONI$7$Y1)SX"Y.'G:7,(&8Q!D1,-C<5PPAKS046
MV*DQ(J[Z(*:.[%LU:[_M1S +^E>KP'6 T,-4V;\4V7H=>(LO&<_VOO?V#F$?
MOAR^:7^+M>)W-YB;/F_&W- H&$48AZSX:8Y,<@$Q++V6P43+5UX%J@X*K'E^
M69ZO-9I;LOI$HS':TF2E1V#+Y<;',2$MI426. WL3HW#JVM\_#C""-=:::EC
M!^L0E\>$_745Y8>"^=;+F01;Y;4C8*YB8A"/3" M9"Y&1YB4E%$E]3VY\NH(
MPAI>:WA=!WA]XI7H?AJL3FG/5FEMB0)#F>5"7MP@AS'\&G0N]XD)%?+I!6;?
M(( P_Y[)O=T]+8IJW;XTW5WN*XB99Z:R*DB""1>2VZ 9X8399*0-47[F<N/:
M&*[%-=;N'64N1#10_*]R'L#RO7ZQM+^?9D=_OFKC1:LWC W>*,PU\D?CGL,O
M7]M^%VAI\'?L?SBT_;6)K6RU*Q@YWN&M\^T?!\< &7MO.JU7[W#SN"E:>Q_Y
MP=Z[[\U7_\ S/XK=MSMX/K9R_^@+:[YZ<WQP](4T/WW$<._9_OE7T@(H:+W:
M_M[Z].9K:^\K!\A(S?,=\=D8K<!6)B@*YA"LKD3:<(N4)-SKF+10NA0!P!,Q
M;&< UU9)S(SCG@1.@M#618N%M,8*3668C\7<Z?K><6S\DHLR_]J 96\4ZWZ1
M^^9"<*<YL=R::Y_\:.L--D#8%?7[AH?]&!O'<,/AH!%A7J%1!*25J#N*2BM*
M2N58_<WBII>]8YCS6:/=!>'8AUNZ<=CHP'+GDH1P)5S3+ZIA-[J]HNY@+[\@
MD/QT1:K&=[BH<3IL%Q6T&T70:&P FOI<8KLJ,1C:G=,<E)0';YS 5@[R5C9L
M49+PK*A_:&'74'%=^UO<:MPW.W_PAS&<=N)NVH8'CYX[41->__"=4UC&-_W>
M<5ZGTV'Q,KNIQH$Q#IQ_)B1@%W $QJ<6<6LY BG#04,PA ;GJ-9I'@>2=]8&
MHSS1CBL,TLH(S1Q8:3 646X>![:'2Y!RK+:M^' 2(WT"H@+F4)37'.WU= ST
MA5CGJS!FB=CGC4L0Z=HUN)\(:6.VM&#_NCQ ^E^71?U*N26UN?1KO$4N_>ZJ
M80G?$E+>:MBKOQ.,WL=D%6$W&K9RV-ZB0N/:V;^+]?8G$ZV]*#CV&6S;4XQ]
MOE ]M X:O^7"7<,'3^)LZ4.AR.Z>9*%\NQ)7*PE^?$1NO4)G'\QY]K@QC&G.
MF#.:*PWZ.#<4JV0<:&&"QH6J^&U=?'?3U+>/8?>&:^/_NZ7"7OG_.H?[>TW>
M^O3N?/^\\S5?=W#\4< XO/GVG\/=3Z^_PUSHP=[.V;S_+W>O:)Y_(0>O6D>[
M>2ZO_CP^V/L*BO^7[P>?7HO]O3_AO0\ZS:._9B.D5> R,&60,UXBL/-!V<?<
M(&,)I\R#<1US#9Y-3.ECB09<T9E)#1<WA0NEE/-&,F(CY0X,1H&!F*R3V!IB
MA2K@ H_@ M=P\=C@8G)<0)5/>6N1LAS@0EJ"G+(*42JHIT9+A_-QP2;5=VYE
M^Y.#AY]TH/ GV^_;!97FGVN<X$(8 ^P2W"O0?:3AG JMG:'6$2$95U+K6NMY
MU# V'1XLJ%4\!8>8P !C2EADN"%(X4"E<!9K:\&$(IOL[M7:Z^C@M>;Z9%D"
M:26#5I(GPESTE#J6DO9)JQANH+S4K/W@K#W14+#6Q$@K$-$R!S1(8.T(5@W6
MPB?L!0])YX)(:\36UV@@H^, F&R\&@E^UI7/P97T/@Z&_;;/!YRE5^DCP,B=
M?$I/'DJ]#\Y@%2GVB7OBC,1,8N6HP0*T*'L#!:J&TH>%TM9T3YMHO01Q2!".
M)&M)Q"!-@D;2>&%!59*<IXT7RN@5F7J/U/GSY/F:,&HCL+7C.'%KO4N.B\ (
MMEI3$6FM(CT&OCZ?JHKA@K,Y3\HK@3@+$3FF7([R4)1KJTT 4<\6=')_.+Z>
MC=B\$)LYB>&\$+/Y,$%<<RNU;$"G>5H!G>)G!72.\RE?M0>^TQN<]M>G4?/N
MAU%L>.=H__B=:)X#/NPUO^_NP?69YU^UVJT]X.>WS>_[Y^^/FF\_LOE@KMU/
MK?;!JZ_G@"T_FN?;<,^7,^!YW*0[9/?5/U_WS_\\:L']![E.;!YW^[.GR8*,
M)KE&9E$#AR-C4T",2\5%Y#1R>R&<2VB-;?11 " X%1T!P/"YDXHCV;J:#^>:
MU"5K-*/-JWY<-K9<.JSS^B?/SC0("@:\3"H$PQ,-UE AC9 B)J]5<H\W#+0H
M"#IN.)T#+E.[:[M%DV@[&.3^S#E<KM.VKMTI(]Z&AW98Q%VZF /DCLNM",5U
M_9C+A^9?X/L04]%\NHS5S %VA[;[)9;-J<MAOO=..P$&@AM]!#D=&L->8Q [
M\/!N^?Q&K]\XL>WBBV$?WC3%?L..)Y1#4/.UA?^^<U9>4ND;+@Z_Q]AM'!?]
M5&"4C/SMD^RB'@6;PE2Z^:/.Z"*84_[\>$)?C=RTNO%+_-$>EC/_M6R6/0Z!
M'<#D__>TW2\G7S7)/IM>U:G1RH[8W3CJGCT)-/3PF"^]/JSP30NFKC=E_2=^
MBYT&@?<%'6LP3Q#_>]K+9%+U*?_EM&M#GG\,OQ8;ZHLPRW)/!MGA#7R;PS#]
MA"SALPM4F5>T),&\HOD&()##BOY&! .;9$%G& PNV^RM)[3^])+UKS[MY4#M
MLK++[(X 6Y31L-_;PT/8D=%NCIF_YW+O^"+2-%61Y LW9K,1V\5# G"('P*+
MYLWLCGZ;6^LK\V&JU^.T;%USTANT"SV@'W.X^+=8A:I6QL?4C=5^X<DMU@UZ
M.:[\TEL651Y^D##]N?69^OMPG-5_8K^ <MV/]BNR">;ZN^U\MV>#C=]FB1<H
M=VX)Y]_^TG=,:14Q9(M>\2JM[M]V7:;2..QGY?'_7*]4JYQ^$N*/?_]F7RS:
MNX7ZR-/5+TK<8)>@T&EW"D:J2ZY$DZW&F^O4D_P(/ZYRWW!V '_W2G$/HC8.
MAHU.,2F0P,4C2TP#,3Z ]8.;/"@(A;8QJQI-28D9!:"P.=0?@V(^@T$A12KA
M/AG0%P+?5CK(:<?V1\^^ZCDCQ6+0.#H-7XI/\ML>V[.&30GPL[@WWS9.EQE>
MT.<N6Z8R2P>N/.E87SZNPOJY,0[;L9]CGL_*=1ML75"P?X:IM5V\1J7WA]WN
M^^S1 >WM2U'QX!E;7VSWW6?J#>,V9]52GJTO$I&)QB#N).=&B1")OJIAP6-"
ME(4M#"HM<7B8>Q*4['T=,4_E_OSWX*+54YHG.4$-E,7L"004R= $GT[S%^BJ
MV78I23&#33L#0>:[!9E'FP77O0)3Y]C%_LQW>"Z1Z*8ZZ(,V3:!;5-RN:0(A
MXIYZ$-Q7;P,^?MEZPO6$[WG"]S5PO<3UA.\PX?OHV;+$I90\\HS!B_U=GME*
MC%2?T6(LS!U[*/)ZBOEYE=NNSFV\]=K1>NUNO7:L7KM;K-W"TJ4UH-6 5@/:
M0Z]=#6BK ;0G5Y7:W"@@LO1A_WX3(KIU*.D-QE@9A=:3K"=93[*>Y,^8Y"6=
M<-FC[;YT,Y'1+$*@JD.N<=$Y-&G,71Q*Y<;<MY(JU^1P+K.0#UR3^V;+>?.2
MW(O>\('2+6[V:DO4U$XI6N$Y3LX;C@TUB1 A@]*<"2=PNEN[FIWNMS@8%L&.
M"P*EUR:AXI9']55"Q?OC)FWBYM'.C];YF\/B^T]-WCK>/VOMO:.[>U_X04Z,
M./_GZWQ"1>OM_OG^^;NSYM%KUOST)A_E_]@__T(/8.ZM5_MB]]5AI_EVY[SU
MZ7W..3V;%-$17C!L/.*>\YQ.[I"3'OYRBIM L,0FK6,+FAJ+:BRZ'(L @I*)
MCG&F A<LN*B,-2XEKH)*XH98=&49C!J05@E(> Q(Q'L:2:)($D\0IY0"%LE<
MM8=%A8.)VL2-%YIN*OD$ZUO4>/0D\8B[D&3 ,GF?N+'1:&D\S]%UE$5B7*T;
MK0\4T4G#89NDI$X@J:0$*$H":<8Q4HXZ[F2TQIA:-ZJQ: U>;1DL$J 4>6X4
MSRJ^)DY(::0A0H2(G>"U;K1F@,3'@&0E98FQB$"6@+%F".A&Q!!D"7.:,$.%
MJW6C&H_6X-66P"-/A8W*$JDUY8);;2@3FDF+L<=:Q */,*&U;O3P4/2C.>IK
MN?V94:I%4APQ31UH1S8@%Y,"[<A[[JUC)JA:.ZK1: U>;0DT M1A/%)A!%9<
M$*9)4(1&0;PPEA!\,S2JM:.?"$GM,22I*+%GC*'(<QLXS /2PF!$:?(AJ[V.
MY8KP>A-+4B-2C4B/ I&(DD98H0%]/">*&5#R/1/":QU4"JG6C]8(C%K3^A&W
M44:%-*$><4<9,EHG%*5/WD9')(VU?E2CT1J\VC+Z4<B*D321>LXC\9HX8TR*
M3 GNJ;PA&M7ZT4^$I(E^E$ 98KF FK7>@LD6$M)6*H2)=XXJDI1(:Z@?W4=@
M[WW$JMTP/FT%S<.?&&"N?GV>"MS>;U!5&3I>@^S=0!9TODD\%1$1.R49V)R2
M(RY=0"8J@8+1(9(D!0#MRK2^E?/- Y>NK@&T!M#'%PE6H^B*4'02!&94I(EH
M@:+%"FQGS9%11J'@")C0/$6>470U!YTUB-8@6H/H X:OU?BY(OR<1*X9J[TE
ME"**A4!<:8,<(Q2)Z+!CP3-E<*V%U@!: ^B3B;FK471%*#H)MXL@ZXSV!+E(
M $4-\\CQ()#!7(-1GRRVI-9":Q"M0?0)! K6^+DB_)R.$30!"^:81E$6[;H4
MZ*&P;R@::PTGAE@A:SVTAM :0I],=&.-HRO#T<G!?>#:N60)TM1$L.<MX*A*
M8,^'8$Q@'@?A5W5P7\-H#:,UC#Y@2&:-H*M"T*EH3()55 :,=R<21CRZA'2@
M 5%O> Y] CCEM29:0V@-H4\FCK3&T97AZ$03Y3Z!S.,<62<XXI11T$DI0R01
M@8/2(L65A9"N#8S.=O >]Y2<:0]\>?_N%_]V_=]>W+:?MJ ;+YY2/VU9$D'5
M5+NBB/MM][9=]MH:_&W/\A9N=P-\TC^-X3^3UG43=%B3KF^DV:[ X?CU.3RC
M??"J\[7U"9C[Z!W;?;O#FT>'1[NY@]O1:QCCG^/]\[\.Y[N^[<.8+?K7U]U/
M[P@P-VV]\GS_Z,O9[MNF ) Y:^[!?#\='#6/WZ3FWNNSSX[)8'U0R$CN$!?,
M@J'I& HYO]<2&V@R\WVL'1/4V^2\]8Y+EDRB#+!;,Z^TY?Q"Q^UJ\1M3JW^+
M;MO7/O6^FPA^\(<QG';B;KI(37N9SIXO(6V+SY9'(T#A!A$A@9"84\@Y8E#>
M+\&3U0'T[>6;!SY\I\ 1]<ZTO;RL-]]5K?G*-H"#JNW@8*Y5WTW;=3]DJSZL
M1NVCEF[5QPC;PK?O6G7%ET;=T\#WU2M+ZYM/^.<T,WH4]?]7W__JD2[$RMM?
MK7=3A.MANEB5#[9C^V6G^..33N\LQH:+W9C:5=?BHKT[P/C0_LCJQZTLDK5W
M9]QPK6[KSUA?=\4-7WP)?X4*C%D>4O16\Q"M513+;+M%8[T4=@417*\K0GU?
MDN:4.OGRM-\'W%D7O\5M-<K2;W'\U]?]\_WO37KP=?^X!?-X1UN?_FHWS\-1
MZ_C]\3X%3?-H^ZRU]_%\WF^Q?_S^"+X[/SA^W]ZG^Z+U:I_L'^^<MRB,]O;@
M".9/FZ]V2&NOE9H?*I]%CN32TC*J:0)E'DL$ZF=$FG*%N&*,84*L%6+C!=DD
MQ*S6:?%47+LUU#T?J$O!2^ET\")13DBN=1J%"RH20076? 6NV1KJ5@QUYY.B
MM5HJQG'(YC8'J*, =<9SQ*2TVECB/.P;0)TB\K% W4ITV,7U"-8:K'9/8G:B
M=K\T.M$.XHS+ 35\R2F76CYTN<58B-^/&L=NK[+-@M5X&_Z3=V&$56<U4MT"
MJ=I32AEWS%@;)!**$5#%>$+&)8&\Y$H9S307>N,%T^M4BF1%Q9%J)KV[LE$S
MZ?TQZ42=,-H1C9U$WE.PE[@4R!F'4<16B6"8#C( DRJ\1DQ:Z0N7<>O(RPV3
MC5?S]<^Z\KDZZ7:'A[%_*P5FP<L^/6Q<F0*3E_GB(66-C<MCXSBBL,@/I(H)
M$Q7RCEK$<:+(!.,028HI2Y*S3&V\D)2MR-!:([=1S:0K5V!J)ETADYY/,2F-
M*J6(;" 1<4\$LHEY1+F$;R(WQMN-%T &:\2DS]7A<;&G^PTTQB<3?+QR%_;J
M%^C)H/9/.,ZKL7PE6#Y]C*= XXK<"Z2CT;ECK4*:48HDQ4)ZPXS-P<=TD]Q=
MY5HY[ZQY.>X:16L47<>3PAI%5X2B$XT8$\X]YA@)&@GBCAMD;7)(,B)C5)(2
MJ3.*<GWG$\*U0=$'S> 03RN#0_W\#([_Q,$@QED?_V!=XNM;HRRNXW^^[GYZ
M3??WWGR%L?#!T?O.P:?WAZV]SF'S_"L^V'L-3/KEK/FIR,B:B:\_^/1.[,,<
MFI_>?SW8>W_<>OM/Y^#M:P+CG>_NO>\T 4!V7^W\.,A%_?=>T]:7S]@%'HS4
M*!$%;!Q@^5SN?408$T"-GFO+YE,U9#"!@;++I,!<!^F$I4FYY!.S.% V'Y$_
M.8$NE_P6>1K7/W)VBE8JYH1GA.2BO9@Z#Y\HE<N=9W2R-TH3F.&B=<D<V#N,
MC9>]8WCR6>,PIPS,'N_G3(!^XU+IVTNI[>-*S)B=UIL9"0POY+,4_@XH/(C=
M$?/YCAO\#COM8G\W[1:/'WS,6##'AV-)C)\9([;.MS][;#%EB2#&"49<>(H,
MTQIAIG $.1M3!&$Z_-Z[($H;Y8X.&M_;P\/&,/:/!XWAH1TVXH^3=C\VVMT<
MS4V+:&7X@6TUI@DH FG#_L'M.:*YW?7]F#NFV$X#9&F_]SV3%6Q2W&S B&7X
MB.\=PR6^N&ZS,>P!1>2G IW"<V/CI!]A\X>-;SE9-N>SE'>=V+.B%<MF8P!/
MB8WCWF"8OQU.)O/?@Q$%AUZCVQO"4+UO[1!AZHWV\4FG[=O#8C+YOGX<GO:[
MLR_3!V'SI0NL5 V4ER!VX5]@  MLVK>9C5!FJ8:S@S;P#DC[8@KE]?D]MAIO
M@'_*W^V7?BS><] HXO5C@"6"-X8+^G#!((N3T+!I6(UB0^^D8#>8X%[O!"28
MYG1S^AT;L1-]$3#>:]@RG[#@5]A1-%[>DUZW>"8\H>?;17QYL;EYBZH5RKNY
MX/K\FK!EG3C_Y5;CM?6'ERXX;$GG%%:ZG'X)(=.SAMD"6$1XZ.QBY7G\!M<.
M3ETU?4!$7Q#=]\,>3 .^@Y]/;'^X=0'D[T'0%UBS2,K_:3L6R.[#88S#OTL*
M+83+6F78/8 &P)J /48J;%E$26"67=L$:2<-HA0T<<RS-AIND6.WEL+SJEBX
M(I^C0(A>0J>9_8O,_S+#+F,+&!<9  H>*-/M\D"P+"73 '/U3ON + 6I-0:9
MUIY >AXA6P+?,CV/BC7(=GLJZ7F\3L^KT_.62L^[BF(N>EE<BOR1G?2]K^"Z
M\1'@NBS4\OL-B.32=[^1 ^E6/=_F%O<N8RP_R960QR,\""Z"(2HQ?J>VFT_S
M+.)IGB;88**.C.GD!8\A:4.)"DXQS96G5W49N2H4N$":W00X4\#,VAP;W-)F
MJ&H_[=#F\<?S_?/7M EVP\'1.]H\W^'-O= YV#ML[Q]]9/M[?QXWX>?Y8X/F
MT?[9P5[KJ+FW_^/@5>>X]6K_O'GTY4>+_M/9??M7N[47#IMO]W_ S[/A^IJ1
MP'+142!+@C@8P4CCE)"G0I*$M>$);[S@AJY1)/#SZV5<0\XRD$.E-3)P;(C!
M/$H'_P8=M63,6!&,N5WV00TY=X*<J=@]@7FRA*#(542<4XQT=!8IXK$+U'HI
MQ<8+H?@:0<YSU>B+V+W&2*]'8[W^QGNPC)+\%(%VZ?=_,BA\/XF:-0K? 87/
MIA0_HH@@1G(DC?&(4V&1P5:@Q(Q+TKLD&%N)XK<L!]RW5GB-Z5\C68UD/R6;
MM4:R.R'91)\4AL'_8+TR*23*"C_2Q!CX27G.HLQ:Y4KTR9^%9/?A'[R5AW,V
MT"^_\((HOU4\X8%F^5RU^KD L.F:O7?RUZ^+2[[VND]M]H+2MK7S_9EXPHR/
M@2:%I1>,)Q(,<<IYZ2S+71E,>F+%<AZ#ZM*:]KXG91UHD@9YL(H19R*K+LDC
M ;JEI5B#GNF?:+&<&G.>*.9HIZ3&*G*I!2>).VV38C$8#^A#4WABM7\>">9,
MS"7.)658>62UTBA+!615U"@ISH)U3/"TKK5_GI^B7D1,='K=+ZB([[U"A[M1
M[8X%2_#T:G<P%073UG"#.0]!64^C(D+Y@*7QE-Y1Z6GUNK[&H.4Q:-KY'(F,
M0FF,0"!XQ+V3R!(74#3$ZN!!0W5RXP418D4NFS7R+]=\.N+3:*T!1I4)S!(>
M$K5.1H4#)Q9+#E1P1T6AYM/;\NE$5V#8&QR40(D(BK@6"EFI#9+6!$&<T$"E
M&R^H6)5K=6UTA4?HYRF/ZJ]P[=4E>.KB$8_TU'\,ZC64+P'EN]-E#4D0DB>+
MD226(>Z80B[("%#.DE8^"I'+&@KV=*I#U#5V:IA<5YB\YP+9-4PN!Y,3C9=Z
MY@GA#BE%<S !(\A$HE%,088LT:(7N?KKJH)3'QXF;U!$9RH1]@'*V2Q.'1Z5
MJYG_^X8IO.N=%[U]6>O1LGI!>6^N=0 [:[_D=.ACV^Y.\J@+9V&N&I SH"]4
M)/EN!XVK,OZ7T>'F"XZ$T_Y9M/VK<>I3-?_M<OKO1[,OOMR#N9/'"5NW3OW/
M;=T_.R&D25P@97/G#)$TTJ"/(69BX$$3IU7N\;,EY_FSD5=\L%EDS"\DC] >
ME+4MBG(=-Z&+BS*L6Y2,68FV+Y:BCE?5Y-_#W/^.?3_MT$'TF1%*<V^;-K<_
M@UB202:),'$"<4H],B1Q1(BPU";,60 I9;8DO>A!_=?6E<Q_3W6]QJI)TPY/
M^_#O<R_U05OO/AN)/6=2(.M@!SD.!%F?* H)1V(%H]3P^4I:ACMJ0'$,2AL>
MO;$N$;@'4XNC(%C.EP9Y<PKK'1O' +#'I\=SY7\:116XJ2HR4R5V+F]_?6T1
MC:O*B2TLR#?GK..T*/OPQTEOT"Z*U15]7=O?8E4$HU*WIVZLI#J>W&(=J$JG
MP\MO652QXR%D?6-N?:;^/AQ[,4\ ")'K1_L5%?6-?K>=[_9LL/';K(H#^LW<
M$LZ__:7OF-(JJB4L>L6K2@_^VZ[+5!J'_8Q__^?ZRH]JX\4.W/;CW[_9>=I>
M2=F8A07W;E! ;^%]U\+%?96IH5OTEEWD.;^O:C(2CR9UVZHOE-V@ZLN#>G',
MC>J7[&>-L1&!C,,255P>N#3+S5[M8G7+BY59[K7ATT_M)G6K$)AE? IK[8N\
ML@K1#0[8[^::?=0>R%4=U%RI[/]=Z9FEA9^+C*8W[6R[[1<^@B?AI/QZUMK[
M"L_:^0[_?C]X!6.>=PY;1ZUCF -KPC-;1V_RN&+>2;F[MT-V]^"]CK;AWS^_
MMMY^9/GY37H [^M_P/L5CL_]O<YL[F8R1&,=!))2)<29T\APK1%U2NG J" "
M!#LCCR9W\[F>V>=2L'6KW]5"%+X50KTZC2UX\-[WV/D6FS"+PT&-3TO@TTP+
M/:$="\D[9&/NSN6(1&""Y&[EQE.IA4J) _$S4X<8/S@_YB+4=2SQ6FA)@$%9
M+]K[WJNA9QGHF6XF%37'FA"':&0,<=APY!QGB(E@ G:!>9/;H*@Z8/'!V; ,
M6)QU2-]%&:J-N9\&4S4^+8-/TQF?-CAJJ/*($D,0USPBYRG8;SIJ0ZV-GL9<
MK$*O-KYDS4VW1Z@W95;YO;%]G(^F!XU^K!IM9+]CNVA.,;A0).V)JU6_/ !@
MO6EW<W7_6:#ZV!T%/,3P^H>'C2JWJ4:M95!KVN%DK);,4X>2I GQB"URRBO$
M=.)"6<)5,ALO^$5_TZ^U0O7S&/#OQ;U^[E#XHXYMKF.;ZQ201XSB,RD@U)$4
M;!)(>*,09THB0[Q&*0<U$VVMC_AII8#,QC9?B#Q:\,DH@F,E+4+UQBWCD.^=
MR6_5(E0WJNZ@]QU ^&'8\U\/>QUX_.#U_YX6R;S#(A"TTQN<]M<F;'#W984
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M'\N0/KIN7>YJ7_>C3ONR<PE&\(\6&-*M+RWKZ^5ATMK_9!_O']CMLX.;F42
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MQU9CVPY4RP>E*@@LKC)N>)YKA:'-[-N*B:]ODH>P=R=LW##-ATHF$K:48:H
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MH>=[5HAN9.8YMA,S>\L%-XP+5E%_9G$KMJ* H&.JY=BV"LJ^H^JZ&W,G\+W
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M4^$PL"4!J#C(H%7,98^#* IBG6\RBFBRF+WHZ:D4R*$I?-"MS4+RVO,7V(Q
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MP5B-^("3G5D!<0N,M]3CY_*\J HLR0#L=8=3_=4<?LM[ Z"V;*Q$"##+T%F
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MF*L4.=VQL(!$-(S!TV$R8%4<+^>WS44F?>'XN)(K$,7I"&8/;TZS*< OCD_
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M$B3IH,.R'@OYB&I2D].5=%A4=.OEJNJ92J2.@Q&-%4 G0JLA[W9'74;SR-@
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M]+H_SX1[/6'#X9YVY]NQXKP*<W&>CCTAU*6R+R6MC$H5NA*&B4;4,F-<ZC]
MZH4F1)/+"Y@YIRK37=($TA]C$"ETVH+&X%4=SKK#SEC>.218!%-E%'I"YU15
M8Y5-*BL3F@46 4/.P+_CF'4K>]J8K^AY@1U;6,(9Q^7UPTRH:S3?N)M>%[L+
MAA"C^!@8Z8RL]8D8&*O5FIZ[<\+Q/A8EMB7C%W<83P5O/[P!9E:K-(N^K[HV
M59%0Y6H,1D,*R!4)"5ABY>-10P&KHZ& IB2RYE!ZOA"I^9,LJ)5FM<XVU8K;
M2W+VK*ZI[14&T$<T@(IK_V(X=087).V5-=,06:5VP0#IHIEY4?(?M;0FA8<
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M%@EN:Y(4M'+6VYL@C<;PG\ZPUWW__P%02P,$%     @ #H&F4H5:YMPL#@
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MTGM?*D#TV.^F>+,1YH[/[UILAJA:;F-3)<'9<;O+NFH71ET<7M,1E>8)4'6
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MDT+!!Y$=E'JI(C$WU4M=YM2[_N^B?\*KTO#@ M79!29)F31* ('%%07 * F
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M/TE^?/VA0?]]&=7E2LSF'.4>NRKMO+B:Q?93P8QMP6;(5KL4M)'920LT>&8
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M)A*G/+I'2:*CE))"0UKOF+(T)?X0F+%F\__0Q-A&[37"W/$Y#*_.=3=;R"$
MT^ I80(]+*FCQ14V"6)I#N68>&*Y2G9P#LGA/=&VS#3K@>ZEXQK'=N<V :\Z
MVH#U23A%M/&22)%1WA)9>QMDH#2 2G4ZDRT!]& HT(K&:PW_FQAY'I^C7L3H
M$G%9EVM"R@%S*@/A1EN16=GBJ[(JK /V8)C1J@4.U$9H9C?KU>7X<@B_XY,O
M+B^:'[WS/R;7V;2V(;C^'16V!+<4;&934&K&F 03DY>R7#*@G$$?(98KP8S+
M;'93<"L1M[18TY_J?-!#3HQ^^]_+DN?9P28+GM*&UM>!F]&K!JT4.F(9U2JE
M1OK[",PIC:,A>&\[JV'NK;G=*S:6/JN.%C>HVQ#HN0KG*4L*M6F8IY$!RZA7
M,-(+OD"7>Y=NS#]R\N_KT>BRS+#[S!H;/[N.QC<19+:J0XG@!.C,LI/2F=(P
MP1II>: QY*P66&#)6_:\=[)<Y?0V-V^[2;>E9$%*#'H\,QCT2 [HGM!,6-:
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MDL8C\8,RCCKGF:')BUD5+H"[I28GAZ4^^N^[M3JZ_>=MZ&PIG%FN4::MU$8
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MJ'#*CNI]!<?\T'$++]!M"GI'YE7SG#?SFBU6]9/Z%F]IO:X(6\^02#.4IBE
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MY8PFDF72V&'UJMK4G-W. O7U;TR(5AL;>I4N'D45D8W5T0_JGTS]Q2;MUN\
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M:5!ZTL"S[4E/7WU=A?9NZ^VX2*SZ^Q>UFJ])D]CX;E4=EXH]5]49EYRE92E
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M\]=V!-\WP/MSO =0\.EZGQ(SJO,]8.>A^SUTJ1O?O2;U_2QE<49%4H LYP3
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M0N;4B.#UWAG<]O2M*:+]5/,FQ+\Y3K,,03.!WW"+W2^HH7?@6SR[4S.EL&Y
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MYK$TC;;8>_+4*&FK7*2U,X^FV(=KF&*N B'T2829_5;A$2=MO2(>8O]YHP5
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MMO=H&7OA<O>]^,.]M25OV]#I()C/.E:B^2!VX4*QX F'F2**O-1\K" F*4V
M9"F6O,QEBJU24AUTF!I7WSZ3^4+K"M0B"^@ /K#3VGZOWG9$S'?N ^(\PC[^
MS:E-?+7$W=D0[8R(?@T2P'4%BK[W^6W5&'W7WQ&G4V< KH_R&LRUY>!=F,1,
M,.4^82(!C4L=YUIP0&(LU#\5&68"E7G);,H7FHNV(L$1*A/JF*+FG/*I#2.*
M5ENO81>]Y25XZ]0XF"Z/0Z ;?)T\&*RU<\YN+\/L*T)K +$1(K-.29]"1-8
M*H:16$-/L.]V\G:Y5C[B:\68%5F\7W+Q[7^)[[-"QG&1RA1(+!( "TS4@CI%
M($[5VAJF/$F@42K?60E3<\]:):-.RZA1,U)ZFO=!.0WD,.=X@2<PM5@C8]4A
M9=#Z*SJEG'[N:!U3!LWJ=TX9OO#*1)Q7WWM-=-]5XC^?Q))]O_TVKV?*($IR
MG@&<BE1]X(FNX2%RP%E")2092Y!16R,+F5/[Y'MZ1EM%HU^UJJ[]N < -W,^
M/,,8F!J<$'3/A[F,29 4F &Q+Y/U<AF'LXDN!K<Z]Z']OX*MNX.HM,2(QH0
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M(V<;GC7M.-_P_*5NCL';A\?%ZKL0GT3CBIRHZ"MH02E*.)"D8.JC+R30[;^
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MO5[+9/6?/VZ5K!.6'17).G6-8XQ?78NFAGAOM_J#4#_<5>\H(((T10R0(N8
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MX2B=;H%&/&E@-]C-6CM]VY=/^O7;ZKV7J;!\:M/_%EEL>KMD"J04)GH7Q"#
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MI1G((=<.$9$(D$*;'D9BD7*2<!A+QS#:Y9'F9FA:0;L&QCDX=@53"A42.4-
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M-_:)T4F-UR ZZLN(;>WQ*UQ-/\PK7Q/.#(5'@2)QK(.W<JH=YA2G"$II5JQ
M:_(!INOV>\8^,#J=P3I*PMV9J2TW/Z]69\0)!I4HG)4@5:+(@VL+,5D$CM)3
M^,M-,DTJKQXF:>S#HA%\J0-TT2FJKO>ILYF19R@$\"0U*'2U_6F2H%F624A9
MK&YR!>\)NL8^#AH!7X=JI0.07:L:>G#K-MS:R*P$*UQ-%N92IQ4;"#QDC]J3
M0WG/<(1!R[:.\JT:'A4U!MO0VND+<'<"W:*54UXQ,(H)4,IX"$A?6/&1^1!9
M:9-\>(2FL<^63@>PH[31([ N=GWNG-76@29YU-RO .<( UD(HYU4);5IBO
M/6,?"9T:4 =HH4<P7=_BI2DY)HI)A,YQ4WP-SK.ZSSL;>4D2S3T#Q1H@:E^O
MBP\^:FP\7!VJD [ =:-H<LO-A.)<%:,(8(.A]2$H0(E*)L@.&3<FII*:.//W
MT+(;E)YOMOU8\3^+GM^74EPMRIO/N-P\_>BSP0>>.ORQX"[D#W0BN"WFNWSA
M)<24D2['4(M+2YT[@[P&<A37D>_CHC<BZ2:9FP?H.?I>^U:*\P_GW3JO[N(Z
M(YST-6+-M>61Y Z\%AH,A:J9"QEM:<+H@Q2->]HW!![NW&P?1/@=;%WO2!=$
M0&U _0J_X&RQ:<1XSM6$*^8U3PJB(UNLLI$0/1;@,DM)H:A!T:1!PJ-4C8NF
M@31_IS9^*#5T@*G?<%,8]C><DZAFQ-*+_&DZGU8QU4G$%UPEG9/*R4/A+M/Z
MBQZ<<1QBC+;&HCJ$)H=\NY$W[NER&Y0U4$P'<+LCJXG44O-<)P21MP>*9XH<
M1 RPJ>A7B9$CV.2.V!U*QCTI;@.BX\3=0>'G)0-7MSXFBC/Z/]*H$)S"CU1;
MJ'E$8$)JG4LHV;;I!'27EG$-3U-GZ4"!=X"97Q?SQ4TN+GKD7P@H^.(HQ"(E
M^TP!)[((WL1,*PQMBDA[M&K2,?Q)RL:U02WP-*PR>MC!ZH6T![F:D#EFMEZ#
M3$+7 Z':W5BAA<Q3"!Y=M;U-C-.C9(WKA@^,@?L:EPVCD [@]3 C0BN)(1NP
MR1(C+M >3O$$>7J6I".<,VTNI!X'JF:;7UM0#:.&#C;#M\M%F:XWVWB(.FK#
M)$BGR)%,V8%#44 R'A,/.AG;:D[&.0GC%M6UV-X.%&\'P+CR[WXB26U[KYT1
MVJ\2OH]=)/MQ,\ESDDHISMH(LDYQ4,;6)<85Y&)Y,#GDDANF:8\C?MQ2O!9@
M/+E*>]@O<7T]4C%9>.4#H&.;RQJ%XEP7(2J3;.0<K6ARC?X&%>/6X#5QX@\6
M<@>&[J*%R47-U@]A-4TU=SN=G5TTF'@U7:798G6VO)9WD<AK8:J!Z),!E;$.
M.8X"C),JIAPCEB98.I#><8OQ6J#N%(KKP(+=R^;$NLP"1K*[)I";65B=KIW(
M%KO C)#&)=VD[/->:L8-'T^"@UVPMY=2.D36N< F)FEED%GPT01:E%I32*P=
MB!H="^ZTN'V%I@VVSND9-X[L 5V'**8#?/T=IQ\^$MTOOI!_^0%_/?L4<?FF
MW"D1NY29H,7B=$I@O:#UPVLC^6@81=$E"NZC3IZU -Z^A(Y;=]QB+VVJJF<$
MQ:T=9\7Z&!.QE$K-X9 X0\P>4L*<E>"B\":NW5Y4CKOIM@7,@>C<7WO]0O/<
MYM^MI^5>:%Y'MCA=$XRJ3E7P7H-$)T+(FD?7I&1^3SK'W;5[@.<@&GQV]:PW
M>C%NTAT#EK7>?7C;ZM8GF!F^[<UV;]\,N[C3TO(2J\9QJ1S+8*P0M:*^.H1U
MRG(I 3%*[7.31/V>= YX-,%9(4>7EH@WM454,AF"2?4&NL[1HG"RS:6./8\F
M3E%V/SA"'CFRV$?L'>RD#_6"_7V^Q#"KU^;^YV)6+?#?PG1>&7PS_PW3V7+;
MFVPY7=&?7M&/\P\4>$T7^;)_+'/H8MT2LB"W@F(Y\JR#%8 E)K+64A?6I@:M
M$4/==-MI#N8N(-'QTKC1)CD*DFCV!KP3$524#*+DM/"MT#X8';QM-^E^B#[6
MI^C3,QID#U95!V<L][!SP<IA[4EE\*XX#<6&VL>!OH00#' O<\XI22V:)(H&
MYJ.;)D+-03TF /K&_T[L%A<164&PMDX+LHR6>QW0B%9B\(K)Y)O4=AU)=S?=
MC,;$]^ *[L"=>(3=B2U:6\4,%"$3B3'1)A5)H#(+0S]A$>K4MKF;KD=CXG O
MQ3R+/LO7,S7G[;0'S#5=;]#=+,%T']G#9Y4>Z>R=4M:I: G>U_MA FLS/Q.!
MIV2U92Z'V&BPR [4'3_FX/PE[ZOQG2AN6>#D+QN7ZETXI(45#'T12@AI74G8
MYI+B#3*ZR20-A(J[$P@.%GH'.]LE]5N)5'NZF->U^N+/Z6JBHQ4A: M,QCH4
MQD7P+%+H[X.3]7#)YB:-0!ZEJA- ':#NAY!SM.P[ -(M'EXM/H7I?,)8CI$V
M7+!*4-SBI* (O@30BH>LC"NM2FONHZ83X!RO[=OE,T>+O@/\;,<M_(+U+'&B
M>18Y2@<ZU;L#-@9PBKZ8G#U7PG#5IH[^.A$C%_D=K]/;YQR'"K@'<-SH<WK.
M Q9;:H48N?:%EDP1"$[P ,E*+:UTIDC;!"3W$#,N6 Y7[:/]9 ^0<P=8N=:<
M[9P!\NTRYYX#=VG3,<!#,$X!2T$S:3DOI4F>_PXEXYY##8:2XR1\,$2^X#(N
MVL[W/F<G26OY9FJP,JKVK-%D9F4"F6+@6M2[_TT \RA5XYX(#0:>X23?@:W9
M83#K.6-&H*3M&D%SQ>HE(0G!FUJNIPQ/PAO=YA[\SA2.>S8S'+R::*0#J-V>
M0'VQ8)Q&+#Z""+7LWB8&L>0$)9IHN+<*<Y-2C?O)&?< 9# 0#2#K#A!SH[7H
MA2^G-7K,$C#3]EPG+(&SPH'-1::22@Z^R36J>V@9]Y!B,*P<*^4.@'+_&=TY
M+SY'FY00@%P$4!$S!)M)5-8YH4K(^?9HM,':;#Q(U,@WI 8/S0=30 =@NDQS
MO28+^C-]NYHD&XSU)D/T]8(T,P%"\AH*RJ0THU@R-('075(Z*00<,'5\F)0[
MP GY8M5RXBO<_O?G^=WSF7>T('Y:+/\(RSR14JK I 21!:_# A/XY#.D9(0A
M47K5IMW/GG1VDF,^$!9W&V@TTU$'$+Q[4\5'Z9V.$@QF8D"*VLG=,,@8K#.B
M.(M-0';@!(56,&JJ]]N6["@E'(RBSYOR9EHOR_5 V]X@<^@9XS9FC. C)\^1
M)?(<C2G@'$I-[J@AV;;9*H<@?_3VGZ=#[>G5W0W4KUV8D4I;VD%T'6(H0/'(
MP D9(%INF"&FC&]23;/G/:66'4)/!KD#Q=[!/OM8A?^++V$ZJVN$1/1;F.&U
MVRCY?Y^MUM69N:SH4\)ESZ0&+VN93JF=EKBF&(LYG4D,.80FV8NA&!B]W]_)
MP#J*RCN ^D:BVRECUZ]1;9V<BWXJN"F');%L5#_)3K$HD%& C[6=M++@$CHP
M"7/23!6=FUQP/X#6T7L$GG:#;ZC(?K&Z&>CY (=<"AV<)@?%"U.[!B@(2*O1
M6QU\DB%9T>@F]KZDCMYT<&RD#J7&?H&Z78N_XA^;/ZTF2BKF+5JP>M/(0I!;
M3?P 1V^\U$%$URC-N MYH_<C'!N0QZBKBYJ1QQ;:%5LRFERRM>"S),EY4QN!
M*D'^"^/"EY ";U0RO0-UHS?R&AN$1RBK=T.X^>.;SYN^QC_^B<LT);,_D:B9
ME3)"TL6!BAXA%A\(/<(6(4ULU-IK?U+'G47< 3:'4F._0-WZ)/<RZ+PWQG*$
M%*(E>9(7[6@C "L"FFPXK<J3F\W#8=INMG$'.!U(BSW ],[90XXE8 J&0KA:
MZRQJFQ/)$S ;B ?+LG<]'0!]HR= ^VCAR+3XC_/<T_E/0N(=C02&7M6:@ 0Q
M>P]%.,/JO64GFMR7.N'Y#___#X .T_>@2#]9>\2P^OC3;/''L&T1+Q_:N!WB
M_<0/?V']\D67-Y)][:J%R8-BEDP@]Y(</M04GC 4M+GZ$)L<=3Q&U "S2>HS
MWRX77Z8DOA^^_DX^P\_SRQ&++])Z^F5[$' AAB*0V<0LT'\D*"TU!&2T7%00
MPC@1>6IRA7U_4CLI_#D62_>,.FFILPZ<P&OGJI4XEU@!O2FUE,Y#3"C!AQ23
MEBRE^$VWW6RM[(=/M/>1? >8N3JH7+U?O$/:V=-TAC?& KU?["M*3$D4H2.(
M*&FMBJ+ 69E@4X2>K,ZQ#?I:,#/R+,33XGAT-'2P(FJ:(,P3GK=9>3'/?P_+
M92"1U%-^7'Z9)HKQEB]G8?II-?'<,96"!(=6$'/10% I@7(V2BLX[5=-;BWM
M1>6XMGA\4-TN!FZFX0[@^PKIS6FZU>X\O_A48[C_W)Z66LZ#B-&#5G6^0B98
MQ4 !H\E*:&8-8[')H?<C-(UK7KN#YE#:ZP"(+U):XH:/:TS4V0JKM#BKS6+F
M^>T2/TW//JU^GG_!<S5,JHRP. O)T,ZE3.;@R+T')YE1$377MDD-T6'DCENT
MV1U\3Z#S_9'MM\B>XX>:%7G?\-[/I5C/6P%<RI0" J6B*"1)ZVCI.DWQ0.%@
M-<O<>Q2V37_NW4D<%\@G=G,;::X#HWN7,UIOG\,TOSJGYV*4^GS;5.#%:H6T
M &F)J9A"!I?JH6SP%H+/"H+ I$6P*ODF9Y:'D=O;E:)AP/,D1@?79->FM/)T
MM?ZWS/$BM9>%00B:F&,E0N#:$+"L<"4%U*Q)*GDW\GJ[,W0B6!ZMJ?%A6,]K
M[N&,O)F-U_(V?*U'7]6Y.;M<=ZN+A?=Z&N)TMMF<)E%$YKTO$#4WQ+93X",*
ML *52(X%FV\=NM\]*AJ*F-[N$PT*QU$TUL'^OKNC-$D>D^7)@B!"R*D.'ES1
MM315$V_:"*^;U,OM3N*XEXA.[',VTEP'(S(>X&P;X-TO2,N"*YD32T'G.@3'
M$8=<UOLE7'D?;#!-LJ;[D]I)GXT3'88.I;,.+"5M >>)D1?I/\ZF2_PE+/^!
MFQJ6JVMZ$R6ERUIDL,4@*$_B\SDEX**P9!4+P;3IO+H+=5T>H0X&D3M-?8?6
MU_A^Y;7CX8285S^1D.L]47)$?@GKRM/7-^5>/F-)RKA<(&6V::)M(<HH@+L2
MZ-?1>]>D6F1O2KL\'FV&T:9Z[-%H$L?DH*R_OIV%^9K8K06"G^M')D(*9KG)
MX#0G)R5:0RXT,I#.6V9-BB$U:FR^*XE=IC1/9CZ'T5P_-G1W>4X046^&#V!F
M@3:)D,AUC@8X)_J<\UPT:O2W,XE=1CZMH-E(<_U&/C]-YV&>[A>D1FYBSO5@
M39,#PU6=U&,<L*A$1%%24$W,YOZD=C.W]221SU ZZV$3O^ZEW'^YR2FF?05)
M20X49MH+!#$DC(TL:1NQM&IV]#AE748\@T'C,6_R:#UU<;'\P@MYAYN^Y>\7
M[\.??Y^N/W[<CNJNY57W]W$(6L@@E0=4-0VKC8? 2)@E:..81&\4MO0F]R6X
MR["G&5!/H=5^/,WKZ_*J5/#:J) )RTHRJR.D6 ]9?1T2DKV%5#AS6GB2=9/T
MY9.4=1GRG,)^'J^G#C;NW>4W4;I$+1@MJMK%7YE<P)?J-W,F0N(^HQG9C>PR
MQ&D%Q4::ZR#$J6S5_Z_I@R]AMMT&2&+31#:W_N'%/-_\Q;5/;F_9WSVF/;]>
M^N.?Z6.8?\!W9+]_+ 5)"=EPH3*Y\LGH.D'9<U)"$4"JH=B/F^QRDPJ/T[(Y
M[MIH%EIUC)7GOI(F7*62N5*@=<CG!Q_UHC5% D8QXZ6235R.HZ@>M\EBGSC?
M2Y/==$H^BN7+1?QJNOJ\6(79WY:+L\_T+S9UX?/U='Z&^;P0@N+?"6V".2?N
MP">>0%D;R&TS <B7L[KV6(NQR16 4S(Y;E?'/I=&2YP,YMX/W6[B_4?\X6PU
MG>/JH,82U__Y,"TD'B1HH&81;Y8?POS\:LA5NXKM?:>WU\A^4\[=YS"[ZF1Q
M=2 14A2("(5'!2H&PF=, HQ&8U&6*'F3*\:#4']4G>J%<MZ3/GZ8U3!7!DD<
M4TC!2Z!U0.@ YYR Q%P2(K%BK'\*1_<_>MQ\[.F1<J.\]#A!/P>#\VN]]DJ1
M*;G;ZS"='6N [CQN<(/T.,%=&2BNF6.9><B<$**B-+479X 4F326,4X[[#=G
MH"[]B_01\]D,WQ3:[)$60=WW7^$7G"TV-0@OZG7K#YMWOJR]I.B5[Q<4 9;%
M\M-/B^6F2GNUG2U6O$W1.P,I*TG>2.806410DI8;4N27V]29#,?"MV!$]T'S
MG09CXX"A@X3N^4V'Z7_6<Y'5>O6F_#[_O%Q\P7Q>G3/%U8]_5J<7<\UB7[\U
M^\/7BPJ>-TOZ[G]C6K_X<[J:A!S99AAGP#I7VEE!3B\6R)Y+@UX$+$VNZC7@
M9>1&4R/!\D[$-"Y&.E@FYZ1?#DX744>10:&J(X&$AU"=-HS!F)R*0]DD^K]!
MQ;C0'!T3=T_:#E30B.C:7A%;T2K_-$WOZM79Y<M74KW$V>P]IH_SQ6SQX>LY
M2UG7JST!(:DB:B;!U@8$ 7**TG.>C+5AIPAJM_>-BZXCM+EH*]H.;-$1>\'K
MRTFEF(5WTB$XFVD_R"185_-4B,44C);S-J>S0Q _\H6G/C;EDZ.@ ^3_;=,!
MZQTFG'[9"##K+"+G&;S!6GU&R]=KKD$SVDB2E-[E)I[F;4+&M9:GA\)B0+UT
MFX7Z[>S3I[#\NBB_33_,IV6:ZBV%[>WM3>/IV335(I(#$E([/GF8W-0A; R4
MIKK[FJN49T2AD]/U2D>=E.TSQ'IMV8A4DO)1LMRDW=##)!V=4'I,O%<)VAC)
MEW5"@/7UFH*UO Z@99"B8.A-1N1M>DWO1-[(;1B'P<N=[,[PFGGF1JN]\1K%
MB(UES P7UCEA"9QUNEHD<!(B.7!D22LOG&E3$M;.F/T05E.*Z6^]X.OVZ]62
MT<%[IU,"'6NAB(L,?&8,"M=2:*T"LTUJXG<CKUMCM@]>;ANS!IKIP+/_?47Q
MU(^K]?136.-J$E00,M7BTVKC50D,0I("A.2A1&:UU$WNEM\D8^3&KVWP<X2D
M.\#)C>.AVYC/+BL5H@,ME*XWV1%";4HC,6CMA"N8F\SS>8RHD;NOML'08%KH
M U$):WA<>7DW7?WC)=$P7=?O)H5%=#DI8"K5SEO)@B^6@5 4UP9NBFDS). 1
MFL:MRVZ'IT%TT &<[K]FMKTV^6)>B\>)T>D7K#T/MO[JUXE)%,$H8C$[5K;=
M#H)%!ZEHM%:4*%P3+^H 6L<MEVX$O]8ZZP"6O^(?UX2W7,SIV[0MH+C??RRJ
M.%.GEHO-O<AD#'BO#+C(;0FY,)1-,+DOH>,6*3<"9%-M=9NZ>/$E3&<U?5P6
MR]JZZ%H'IP/2%(\\;9B4Q*[D#I5^N'C=3[=?=W4]4.MB+$&.:8NT51H! 3.#
MY)AP,D>TK,U<@B=):W"W8]/8ZFX[JZLUX:(7,8I(H8RD\$:5!%Z0K4XA*8J,
MN6&L28;Y %I'3E0,BZP=[EL,JKMG:,\VI[\#6[7S9[:V;?>1?CH+QR/7WF*!
M:).@?2XJ",$YL+IPBUK&(M+SM'!7504/O^MB?,IV]LY&$]<*_[F)*6=1&PFP
M6DM _@9/'C JQX5RQ;0Y"C^6\.YMWSZ8>[BN^ 1:[2#,>-RJFV@*IDA6'6N1
M2Q 2R",68*P7(HN"V*8GR?%[;[LD;UO\#:>/#L!U;1S3RUE8K:9E6OM87!2W
MG(791:?35V&-MQ82)QZEDPIT0@O*E !!UE'@.03)K'2A-(EGCR%ZY-QQ6VB>
M3)O/T#^\V#86Y>'/W-PVCK@=UX*,UE[H0 (ZG>,:@BTQR S9(04T,6_J[#PH
M&571V2O%FK0S[,-QW5:["HXJ&R&@))-!96' (\5X3D67%;>Q^#:53[M2V+TK
MN@^*#G%%]]=3!V[!Y9W G^<DIK--Z6N]39*82EK(VD\MD^LLO0#G0^UDXFCO
M8$4&W>3P[@%Z>KE)-JCV%\.KH@-$O5^&^8K>7/-4VUG+T_F':Y=/K[A;O:='
MKN[_TZO%IS"=3W*P01MO (VO*S59B)X\%R$Y#T%9X423@<9#,C$N=@=!U:(3
M%7< [Y>+Y>?%DISJ5QC75\O_XK(5<]:GR"D*)#Y4G7(6HW90A)68+<.H&M4\
M/$+5N  <#RQWZB2&TEP',/QE,<>OVP3%3V?S?,$%K>/(%-):%CF!0D;KFX<,
MWGGR=VA/XJ&)EW@_.>-FA[H!W@"ZZ@!QO_^V:1NQ&?&]J,,5*>;\[2SFZ9?I
MJG;K.N=*!RDBPP"R3L51#C/M,#P 8XY<;"<4RVV*3W<B;]RD4#>(;*#+#A"Z
MBYO^^O+*7A8V%,\R%),=**,-.(T%-!HI;2$_OLV@CKVH[.6R;LNXIYW:.L#D
M;99N^A[G?1VV72 V=Q,FNJALO7!0OZ$UIR4XER)P(823.L5HVMR&V9/0_B/R
M S&S.*$".^A:_ 1_*9U].MM,A?C;<K%:_3Y?XK9OR=]H#_JAYHWQ??ASDATQ
MZHE?5+0C*5X#26TS<)82!93:NS8%CX-0W[^1/0F4&ZBZ?P/\(-.OZ:<KIA4Q
M5[3GD$NH1V:H(=3NSBD%ALK$F%A7^+Y!_<B#OKK']^&J[F>FS<.RO2F%B6.<
M&8V>]J-:>H_&4OQ9-%@3(H^UI8IMDE'=E<"11R>,!M9!%#;@C+#3G==?%#"D
MS4L>.Y1N<DZ__^M;G\\?*9#3G<L3Q@57 @&=213U$?0]64V")OD!-A@5VLRL
M.$W)_*2D4F>8U5X97D*=ZP->9 XAH76<U:;3S6;5='^:OH_N[RMJWTNZ'?B1
M]T[_SH8[Q)0@2\5!*:W %1^ ^R!5;?ODI6J!D/X&M3=&S-'2[P!!]U_E^.WC
M8KDF/_#3M9*^B;/<YAPV!8$*E$T27$@*K$0*L'*VWK4Y1MR9Q.ZK*X^U3PTT
M-5BVYW2^V<-_B?<6F[9PT ZDH;67-H1H3N>J%:VD$K6_N\H9E,@!7$H>HG8Y
M"*MXM&TZQC5WU1X/I,[%?SM5>U44:+(*F!&25G6"J'3@9>04;''#DR41J9.D
MV_>BNGOG<!^T[1<8#ZG/#GR"79E]A_7,E_1:CX179*?^'</RGL.'F%$R7AR(
M4D<F<IX@6%E')OJ(TOD<^4GRE$?RT2O !T?@@=AO 8<NYLOO+(#%C![QH;+]
M_H_%^X_+Q=F'CS]-O^ ]0C NL12R A]JEBZQ#!ZS!:FR#YK^)K%)14H#7GJ-
M\;I9%XU@T>7:>/(D6DB5+"\1N!2!=N'$( K-*3;9%/ P$GB3CFY-2@E&B"5/
MC>I!%=IA:<%#DOTI3)?_%F9G>&T:E1%8^Y['F)"DZC1$%PHXBQ*%DB8G-J;)
MOD-QKX;YI![Y<7I\[M[X)?<3\K.XRPI!*&%!D=AICTD9G' !,3 A3GTLL@_Y
MS\/W/A)K0_K=ARG^.<'](:_JBO.,7/I,_"81(ZC .02#!3AJJ:QUIK@3IY?V
M9:%7"]X%[(<%0/?0OW;&%)*S09D$WFH)BC$-H0@D&<M<E'8ZM:D2'[1<9G3?
M^92P/5!YW1[._#RG;['6J+W%Y:;9ZB''*_<\99@#DJ?(&^B(X\>PG),)NGS)
M)9"2+(79.G?$\FIX,D&*J0@RFFB<]X2Q)@OT(8*.M4RWGWNM;4M0WF=/K#E'
M+KS""+ZX6*=-^6R20]7F;NF#%(WK*0Z"B-NF91CI=]LTY^YB/;R9XH//:F57
M&C9/?!!+T=HDZOB/I UY]+52R6M1 !GM5EQ)KMOT'VAE7:[5M\[7TSR=G=76
MW%=;YO6AL[6=]]G%[/!'%D9,M!IX9:$FI5"7.H$V050L%N^,-&VFV S/2J?V
M;!\,/G*W;@Q]/R-#>$3IRL,/:V4*6Q:3/(A#H:UR/$6PJH9XAEORJX6'S(IF
M+A5G5),8OW];N+D"ZU@H*3$/*!5%-"52V.&# 2G19N6<3++U?>(!V.C4!NZ#
MO78V<&\]]Y#I.([G'[[>_X!-#Z&24\E,U.:5*.J@V@S!FP"YSO907$7NVYRL
MM^.IFVO-)X?J[21+)[CI=@G]&C[A>2L.JY-/&1/4T8 4&R95\U@(O'80DN0F
MA&A/MPZN"!OY**<7!.V$[ /5V0$\?R0?=?$5\;<UN>?;N4L7_5NRCX%Y"]+3
MTE>"@@:B/P/+UC"I9>2L2</_!RGJ$9"'*OYVYF@0+70 I[^'91U(?TZ\R;$8
M+A.I.-)"BR%NLN= 89]Q+EJF4I/6NS>H&/ELKB5L#I=V!U!YA^2>3],:\P;U
MO\^GZ]6[WWX_9X9;;H-E CC+DGQVJ2'***$H;N@/P43?)#'T*%4CGY>UA-)P
MVN@ 6D<Z#Z\O[^@;Y0OW3 $/MK9),PE""!J$1,5+S"[K-KW#!V*@F^8TSSP@
M.0P1SW\EO/A4)R%.O#0^:AZ@E*A!94=.2.$"/!,ZJ2*BUTUN*@]"?8]N8VO@
M#8O^ U#0;>[^LICD%PRKL^5VLN<A>?O['S1,SGX'(@?*UU^^Z=5TE6:+^K*K
MLM^D@T3G$W!1SXXBB^1/> :II,)-Y%A8D[EFCQ%U],B">YY]=3RE?-9.Z  B
M"H(X<@DNVTTC/FY9+L1TDPN=CU(U<@OXH1!R9V+!8)IX7L;F\**)QQ[7T/ T
M+)UX%%S"<<>B4E"S=;6!,.UXA2L(3-BHG @E-$E G<3\O%BM<+TZ%W-^,W]7
MM^4E[;J;RSI7ZP"5XUXB X%6;L_OHR@(R<AB4&1?VIR;[DMHQT9J'QP]:*1:
MZ.MYV:V;$@CKRP\M;@GCB&*(85[<T!8>)X136,T899W7S$%;6M4J2=J2N4.0
MQ:F2,\7/I<F]S9-8S=?3$*>S3?3RT%+\?;Z(*UQ^J9O6SW,*:NX9\CHASR*%
MF#G%+K4*LUYRCX:1&Y,HIBI6DOS:6M6!&.G8ZNZ#PP>M[ACZ[B!K<\G_#U\O
MO_V?4UP241^_OL8O.-N<8WK)O<A!UJIB\I')\P:?G85LDG<IUGY234Z.=R.O
M$VR. J&'\#R</GM"Z?4-\BY_YX<36J=2N/? @B(O3'D-D4MRC*0-%.Q9[1J'
MUKM0V0EF!X3)0T@<7&<] 7*SB%<;B?'S$ZQLLT\6/1A6&W:$7,!;58 ;B\YF
M3*Q-;Z-':.H$;,,CX2',':F63A$FSEEA2?!B?09C"D5^4G (3G,0 J.0)IA4
MVJ8K[M(T[O'?N @[1"V=(DQ>S'RS*FM=#W[HS:"T(<.O0@1DQ4210O*YR6GT
M(S2-6Q$Q+L(.44M/"/OAZS6Q_;3$_SC#>?JZ<3&BX)A9\H"ZEDG&I,$9E0D;
MY'P821SY)@>^.]#6B4WK+*P81),]@?,^ABYF%V:A&=H$,:?-'3($5^>Q\^1%
M#,YS)9OT=]J!MDY<NJ'PL$/P<(QR.L7;ZG(97U2_):>CEQ8,\E#;DQ@R]9Q!
M,@EUX@FS:9LM?(2X3A W%")V"5>/44]/D-N>);R8Y\?W$OK KXOY\L;6\OJR
M+"BBBX(B?RA9)U#)2G"%18C>!ZV%88WN50[*12=>9%=[^LG1T<'2N#8;X9ZS
MA8G+!5$$0?8CD5RM,1 3MV"5<"K*DFUJ<DGV<;(ZL<"GQ\NBF?(Z@.)6G/<Q
MXATW)OL,0KA4&0D03+)U6K'24ID82IMN=0]1U$E$-#H AU%9MZV\7J2T/,/K
MTCVDPN*>IPPTZ^0)\H::5G+G-2\)2$3S%E?I_(>+4VCR-+VP3D-B6"C<(:OC
MLZJ3QG7@0MABT319K'N1>;2Q2JE6:*_>AJ_5 :%WW'W_U7*X5F2)0J:HB0&6
M/2C/$7R0C!9?[;PH/<^-KN ?1N_(E?SMD'?'DIU G]T6G]UE]?"*V0>?U<KF
M-:R5W1-_.O(0$L% "X^TDQ;:1)6CC<\GGC./033JWW]2RW?MBMG]NKA:'%;[
M;)FRH&5M8JXB0D"BG].J276F26ES KP[B<_*ONV#KT>:Z@RIM6=DTHZ9=??@
MPUH9M:;3Y_;<53$JC#H EEPG)H9"420!(Z-&+XR6-K0)ODYJU2[:0;S#S<3Y
MNV^=1.N8DC)"YDG33F\3!&:(<AUTB#G2=M^FM>13E#TK&[8/FAYJV3&,CCK(
M>+SYC$M2U/S#:PK:+W.A7R^X$8F"9X&.'%AG0+DZ>]DFA"A%4LB=MVW*6QXG
M:^3F'J>#VX#:Z0%KZX^X?%!Z$T5!4M9L,Q=7@"KTQ04;0#KR-:1B7C3"VJ-D
MC=S]XX18&TX['6#M84;0&YND1'""'$P54H2@;!UU2-8Y)6VU:M/=XRB$J6\
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M26*&)0/96XXR!<FQ24;M4:I&OKHR, 0>39$?HX^#P?4%EW%QFLLJ0:<Z[K)
MJ%ZDTH'<B5@TV&RCBS)GUJ;HM.O+*J<$V%$:Z1EA5W[FQ JG$R_$B'/DLVHG
MR> +!XIQXUWTS.<F-8E/4C;R1951<':@7KK;*2\9FJ0D7';:@S$8B7AO:<40
M&@1+*EG#C. GJ&.XI&?DNRFC@&HO'3R7<^*?SM9G2_QE.I]^.ONT^=7;\'73
MMFNXD^*GW]'DK'A/UMJ<%D=,GC&NH7A).%3U+I-C$H0)J(R,5L4F9V'#GA;_
M-)W77,V-]4!K[E*>9]<7GL@ID]\8?*3 )T8.3FH%)1=N8^'2JS;]>'<F<>S
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MN%A._Q/S6UQ>+I2)-\2,Q;H;U[# %07>R@A)**,Q\J)N%R8^8(H.I6#<8&P
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MI(\W/SOQANRZ00_,\]H_K!Z":I5J7YR@-,G2YMS!7GV7\MWJL)_!F<DXNNP
MO(]&9IMAWQ-96.W8K("^6.*(23+T7$!1T0<3:EZ@38_")TG;#7[/X+"CD38Z
MP-?UN.Q\I5QX%JN)K/<\3:%H#!69=^$,^" M2)9B$L'KX$4+9#U&U&Z8>@9'
M&H-KX!FU8+O>LY,<BPN/8]!6;$^\HU5+MGU8:].:+1<;C5$90F($QI+(\2?/
MC"P0A:325'0VF94Z;&NV>W?Z[:W38@7W/G+PODZRQ3H,S3H%4:;(7- VJR:1
MP,,D==68;1_][^1?[2_UT<^Y[ND)O&D'94U4+$B$S'-M!^S)GBK)0,LZ!\HH
M'<5N12$/O:&+F[5'J^_.]<=C9=DC(,Y[(<A2$.N@DV3$YO*!@%!;-M4>IYYI
M=)X_N?L\\8YQ0#&@]I["PP&B'!L1OY_OUV]G87[>N4(3_;KVZ')<T1()J=0E
M$B%RESSQI:WF.R'A[K,[0\ A^EH,)[P.XIY[+>650T\>.;W5.N"^-@M4.D$T
M* "UY]F***5K<O?T<;*ZN%8_U.;20!,=X.K^&04O*F\?-O5"/WR]^LCY-*47
M?X1E/E^A_[9ITOUBGG_\\S/6+MWO%_57E\X=!7],1VMIC:("99V#>@ %4DAK
M&$8;C&L!S,9\=>@V'0C!VQFCCO#P#2R/:T<1[Q:SV4^+9?WC1&J*:YQ5H+,.
M=6*=)F>&U)1D<M*FZ)QK<ZF["3LCMTKM";$#KZ8!X/-M+:+MT<E$>U\,N8*0
M=#*@N$)P#&O[&EUD#%Z)T.6N<H>3Y[UTAH!GNQ5S %8.7BR?M^<JZ[!<=[%D
M_K9)XOX\/[]5)9.-;%-ORQ-IA!&R(YDUX)9+P;263#29?C$L&R/W%?SV%LL1
M*.EA6WGL</-Z%N'B>"I/2BA2%;( !K6NE2 (,=8R.,Z=*-SF<+O;R0F.GN\E
M=>3^SQUBO:VV^YD.?JSL2=@%IW40\M7*]H$;+90%$R,)WHH $9,#-!R-]BRI
M1E/-AN=EY [7'2Z,D?%R[,KI8M%0[#?=7@N^$H*URAB?$G"1)*A2FS DE\%*
M650L2/)I4O'>@)>1&WQ_>XOF6+Q\.]O-W8#+6A$Y#PA:Z5C/\S,X27)P5D?D
M6LEBFM1SC!.<-[O3] VNFN.P<F1P_N.\CZWFFA#^CC5QC_G%%UR&#WCCBD35
M63G761'*\.15':6#Y+ZZVA2%M">S4LDX4EUI4L]]>E:?=XC_3%+)+6#70S[@
M-!*:E%@$*3$!*YS$8IF#2)8+BG"&<U*E[?-(<T?^OIF4=!.8C[,J]\+<\TEB
MK_;*3SXJ()T#JVWD(3-&IK686*?-*0I;(WGEC&&);9JOGX['Y[TW]K8P1\+>
M<]@GGQ+-Y76/G:3CLI4YD=6RV7)0J3 (1=6K1M[E4I)6ML^5N1>;WTR^_EDL
MSG8(_!;6YST9W4?EDX7VP9DZ71,UJ&@I_N:9062.M"RL%V&<\')@1K^9HX-G
ML49;HO!;6*7WI) ?MV*<)\Z] 9MB;6:%$7Q2-7N'5B3&BKX]A*^35;HGH]_,
M6<6S6*4M4?@<5NE \;F6G&N=!!CN$X4 *"%:DDV)WD4MBY%2?NLYH>=P$M+%
MFAP!<SV=G<2G11/W%LT[K#?$Z/<O%_--LOTLS&KS'S$QJ7;X,0QR4>3],U_
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MC#)B,C(/!K!Q4R3]X>L@+3P'>%T$XNAMMC8RR#)ZDIY%<*@L!!]*D=EP(<N
MYFO$E$E_X#I$!\\!6S=<R\(M5X462@J;XJ0"GD>2I^<R,QY\B;L=9;9P\P?/
MF/2'L4-UT4469+=ZU3^VK"ZN<6H,AFA1 F?&@?*,W,V@(V14P15$$_2.AYN'
MDO"M'ERURHR<1-5C&\\'*CCO6ZLDJ^BS5;4_(>T)R!5$80SHX),4*%QPNV7T
M=G_GMWHLU@BRC90Y-D:W&?-M5I[(Q_-JY/6B_HHXD<K5JP$22QU%R6HK!E,;
M: :1DI3"F=W.9!]]S;=ZIM8(B<.I;&SP[>+1/% H/^$R.B&4 *%%'0W&% 3&
M!:TTYWV4RG#/!O,T'R#B6SVG.\VNWTS=G<'Z(>_F)LOA@N7UEF'C3,Z69^ :
M:Z<,6M'!*@FHI;:(5J;"A_1I'Z7FF?96Z03H[0$P-N*?<(X>W*N2"0)I41M=
M^W-C,10%(P+WV@FM7(IQ-QM^V/N?:<N13CW@(90\-HYOKL@)#RFS8@)844M3
MDI7@F8C@A2DZ>T$"VS$7?^.YS[2]QMAE% <H970\[7ZF5:]\3@S3-F0FH6P+
MEX2!6&>+A.243-J0_/Q@3NVU%S_73A*=;/"#ZK4SS#Z1FSLW^Q,MLLN1^'):
M4]@9Y*8"7=,B-9Y(C!22IB'=U9NO?Z[](#K!;P,=CXWBG9R5B<_$DE8<F&$"
ME$?BJ*0$D:3(F&-,YP$=T.?:3J%KAW,O'0Z&RG_Y_HX.7],O-G_:_*7^JW=8
MOJO__?W=SS>>G\(LY.7T;/77M/BT??ZFBOGC8D806&W%_8ZXH^V$.-S\C?SJ
M6[_Y?3Y=KU[A.DQGJYO\K::?/L_P*=P>^\KOKYB]+8;S-]]!;VO&\<\U4OR1
M_W+<7?HM'9?XE59XQNM1?=&NGM='<(9%0&>]BIS3ER9WW6^2<72#@/01\]D,
MWY0G[<"#8[C>;YP96Y@-43(0FPRS9AJB]<2!%B0AFXW(;5H-#\7!N+>ACT#7
MG=OVH^BT@VX76\KIPR_^G*XF.J4D?%"@N23OVODZYLUY8$R))+6+I309V7*#
MBI&OV(^#A,50:ND 4X<+[HKM>7X["_-?PR=\M:@N]83B.V:S**"5#*!,[: ;
MD4',0:./ILC;7?+&GH/Y,#/C(OP(; TVAG(@17< ]ELNU2^X:3I+KCB2%(EJ
MPS,HE1&<3;4(EDM;.(DV-C&D]U+3><^2YB!9#*VQ_F"W\>3?_?;[.3,4O^5H
MF01MC :5C0<O:8UC3MI*;G12Y@3PNTE5YW<>1X;A$1KL (X'9T1>7[6V<TG)
MS T4)VMRHRY%Q3G$DABKI[0YCS.._DG21P9V%P[KB0'0 ^3KJOUYM3K#_.IL
M.9U_V([1WM:4W5K<&T[_MERL_K_VKJRWC2,)O^]_*:#OXV4!K[(.$CCVPLYB
MD2>ACVJ;B$P&).5=Y]=O]9 Z3(L2CVFR9>=%D"AIIJKKZ^JZ>W'I4E8A%PU<
M)T8J@^PMI\A?9>B\825KVO1-8'X0N9V;#B.#:A/3[27<+XZ' /%V)A-WB#G2
MR:?K_6*J2/ Q%! A&^:*L3F=$L:/4]NYY7$6%(\HWQY W"PC,S1B+WZ:KE9M
M(]TW_/*'L,2783)?#Y4N(02F L14RRN-$^!S2+5A*&O'LP_!=F7&C+T"S[2!
M9Z3-UHL4]L+A<][ PY=:T'2KV?@EG;GUUA +B7/B79>:)T4'10658V)<N;XN
ML7F B6?:5'3F;70L&OI-:S^X(@=EJQ]^TDA)Z!W('"FWO 4C-]E LL$112#;
M.RD%*EL#$:6$E(J4C/%H3IHO&"GW?%<5\J;<?_Y;O*H3^RYFB_7HMOL[8_$K
M+?D_Z#&_7^KBZ]BV!"P:OZH@"<@4H';HZF[E;6ZI/I+N+MW00Y"VJ>A.*<]G
MIMN&F-1A]3B//:^EGGN(Y--H.V%%#($+0(R,<!#(VF.E1J,5S]8JKP5[?MKN
M+K3Y3Y+[[#/B.YQ_FB3<\MJKX9'TW9OR%M/L_73R)VV:P0P8=M+=OBDAINR%
M!NT*[5F-$8(R!E(TQ2A!+FZ,3=:K%4==:\A]T+F],N><&.C 0[I_5!P1Z;]E
MG^ELH[,$T6SKS8H)Z0"39!NSF.M40^=\D^*SD?GH,K8W!O#/*>\.X/Y06NL^
M8T/ \N8*N'!UO5J1Q>+ZX^JSX2R^XQYUR $%!Y:\K!=P)PC6:U!&Y2(R=YPU
MR8B/RT:7L;5QM?S)I?W,S.*'/ZW]SM,%'E/$?OC;6IK4^[-[&H/;""-2JKV3
MA1'8DS;@AUDAPF(,-C/+V^2_3F1P'UM+H)7DD2L-.1NYJE\)5EG0L93D2@U%
MMTF#?!NE[2.BKUVI^SXR[L"B^&E*N@;?D1 'YEZM_815%6Q!3ZJPME*I!$K5
M,3\N98@8-5-<QL";Q,4>H>E;*8/?"R6S-B+K%WWK0D)K!8L\6L@EU0N4:Q6V
M$Q:B3"IK'9-)3>[8?92J\R)P--GOAJD#!-$!JMZ23(B #R^F^0?\A%>S/RI/
M:_-H74HJLM \,P,A(!T6CFL(AKZ(G%%$*XSFK6K1GZ*M2X0=@H2O:WM'%4L'
M2'N'5_2K]S_B%.?ABAA[D3].II-JD"PGGW#-VV+-G*/=*&06P+/FH&*=F*L,
M V0R)F&-3=CF5N-]J#QOZ*@=^MJ)J@<<'E^9P',)PI-%DA*O23/IP1>,X$*.
M3C&.#/LJ#WGUK56:'V,3GA@ '4!^G=/ _&@PY)(GBUSQ# (EKP4WKHYOD.!*
MSL[2THK-ZWI&:M[=B;PN_>EFH-ELYQU?@L\L;/GE]XOEZ]GR-US>9>A&CUSN
M^L*6P<N#F#Y-_-*AL,YY7>=H62!U3*=^L@*,BM9ECT9O#OK_ON*7+!DK$U.@
MK1%DG8<(45D'24<GG TZBC;QW>\B?KD/^MK%+_>1<0]FP!=]^]ESRZKGJ <'
M(;LZ)!\1,N?,Q5R]Q]3DM/\61W7LA81'1W7L(Y8.,-6D*SK0R8RF7O3E:E<T
M^9$0;7' 2T!R)[7-C7+MW_BHCKVP=8I1'?L(N@.PWQ:0W143K&,@6J(78FAZ
MMKG&XB1XA9R YG)6FL7$FRC3K11U>7J?$"RS%I+K (*/#WT03J:@44+.@9;(
MYU*OLM.0+6?1J!!T%BU@^+V-[3@&BN-)L#\XKIGP5A11> :#=?:(-1R"(^.(
MB108*LZPS?E]^/"B\[63GAE^!TBL ]B-$(V3P69DVH+)=>*C+AEBU@P\DTQF
M7CQKE&#Z*X8_@L]T8@!T /F=FA=>SZ:K4<P#KXM?9\MP]50,\=(DALE$!39E
M TIF!UY;#74"E9+2HL<F8?]F''5N^XX,S6V6[EEQ\BUOF%4OT,O9?/U1_;O:
M),XU0U> :UHB):2$&+T#HY(Q3$GKL4D!UFG9[-R6?Z9;ZWA$/;-DWNV4D=G*
MBKB[=VWS.I?%<O*QYCV_^H]A8DF#M-_XI+5,$#9>R)%2B3LWJ<?[3>JWR1YE
M4TE:> B1MJN2M5C=! ;)2LY%*BA3$U/].++[246B4][&PLFY$TC.G5 0DI%U
MKHJ(D1O-4IM)%M]&*O*$Z&V7JMP' QT8;QLCQK$$)S@GNEV@);3U_DUIP247
M=>+">-=$ 7R3J<J]D/#XK0)[B*4#3#4)Q3F;98E. ^U^!XHG P&5K*-<A&3%
M98Y_I2H/2%7NA:U3I"KW$70'8-^>\'(2K>*>@1"<&"F1@U=*UQ]%,MD(9]O<
MH?0=I2KW LO.J<I])-<!!$?PUA5G*K-,"^=UJ;83N<"%SBH9M)7,NHCZ/'>V
M?#=!^F.LA1,#H!?(QZ<YCIL<WTRF&+SWFQFMMZXZOV1>%L.3 &EJKH0CN1/>
M>3#)%6MLY+G-Q7>M&.I<YX\,S(?VQ;E1TLMN.40,!TXTCMZ;I"()R2B262;I
M>2L5I%@LYAQK_UI7ITG#^=D]Q^B/WEN=8JK;(/U-M_'+ZVF>3-\?$DS??,0X
M0>]'"1LI./UPJ_7=4*J V4=EP910*V,$^:"13'DF'+,VE)QRDSZ.Q\D:J^W_
M_J.GPY:Y)K"]FY4E[0F\BWS>3<82#KTJ=+)P)8<:8DVN30[ 2PK&<&<M]RW7
M8V^*SVMJC(BN;3,"VLKPN2BM(Q*!6Y[41(6U3+,]@346E=.<,8@L)B#YUVOF
M= ):"<>YRUAXDXE:;379ZL!^BPDGGP:/E5MDVEL/.DC:4M()")DKB#+7PC*N
M,V\RF7>3D*[USCY8V-0[1ZWX&=V.NO$OU]OP31FX&"R_B[#XL.)F*'+R+HN<
M0=@Z^-$E30HY!BBQ,(,I9L7S4_IDEQ>=UTAO@([15_?<2/EE<D5^]FR*:R_A
MS70+4SE&*4K)(#&0"U#H- _9.O#.NA)*8MX]>03M]<;S5K2WPDZ3]3XWB/XU
MG[TG^2R>XBD6J1DF!=+7,&O0&5P@YS<F'8T;IN*ZG3"TXPO/>SE0*PBU6.T.
MXF1;ENLNIO&?R?+#2\QU6-./LT\XG]8/+ZYI-WW$^5HG_SI[4\H"ET.YRD_3
M=%T9N60V^1@]0E!(GH 1'$+1&KSQ13&IBVHSA;8=2SLA6S\C9'>&@G-KU!<?
M9_/EY,]!HF_*BY3FUYB'?;YF\=4DQ,G59/GYAM>;X3CU?$ E!=A2NZ9R'5TO
M:I2Q8.))"Q.LW4G''DS"3M@TSPB;)Y1(MW&(U1B^7\/_#KMKZ/Z_CQ-QV$K0
M2&&&V^??A99N061+MM)8!B*9N+JZ.-8QJP6C*5G(*-J,"GV$IG'F[G[QZ'M7
MP) E2LI3@=/UDDRFR.MEQD%FJD1RBI56328!/D94#S-1CT?'PU-W1Q##<U D
MKW'YY@^LTS9)>\X6BXLPGW]^.9M72_:(0.>>;QA='>W-U@DTELB#O5_ HW0K
M7\!SKJ'$S,E%,$JH)E'1AAKKZS4NJS5>K!MOO=2:(T+TRH.2Y$H';20(3"%9
M= )5DV*2)^CJ5V_M@Y%-O36F,#KP16^7Z<7U\L-L3D;=4*YKLF.>\0B&5^.1
MC#<(TM4IEPQE<D'8QN?^%^2<%TFC2GS;*7CX\G<)HIO!%C8J&XJ!9!PYHL73
M1F,QDY6 Q3BI$$.3"IUM!'6BDHX0]I/X.6#E.T 045WOZ$X7L^OI<OYY72 M
MHT,3' ?&!-F7PM'.XAX!BQ62Z2**;]*,\2 UO6'G$$%OWBAX]*IW )UA8/Z+
M:7Y%?WGU\_5\LLB3=*_*7O$0=4@&;*D57756<\A9 'HE3-#*86DR0^L)NGJX
M:V!D.(TIB0Z ]?4:U8Z0064S;U74R,'4B)K*04.T5H*5G$5.#@X3)S*/;D@Z
M+YQ.:R(=)(9N ;7>>!H-YSXJT"ACO<$H0B0R@2$7M'0.M<ZG@U2?YM)A@M\)
M3P=(H0-$O<;__EP?]OF'R:?)8HC7$V/AGLXUC MO@H<BR<$EG>L@UJH>ES%D
M<H)-E$TZKIZDK$=L'0*"64N)= "QBW U(64^G827\S"E95W49?O'C)3[FJ%4
M(K.*CG59>QF5JVV,47 ZY:V3J5BE8Q/-]21EO9E8(T%L7(ET #':,[_-YK\/
MYN/7VX8,RI>3*3%Z<T\:*?KL0B%MKPR"\MY#5)*XL\9QSWWBN8GQM1^9YRWJ
M:JG?6LFJ R1NMV-?W78SN9R$MCR#D]J!8K2OHDQ(;E(RO-"W;+,\L'6T_=5>
M3<K-,-?2"1A;,%UC[=)&5E":.A\NDOX6Q(F+%@&%-J(80]0TJ>+:3E*O$?@#
MI;\SNO82Q;E+J7X)\]]Q>1'^F"S)1%@5\/Q[43N+-Q.U+Z;AZO.B.E(AD;ZO
M_8W:&%#((P0I(CAODZ0UDX9O!,>VU3KO_>Y>(Q;'0>H4@C@WSK8Q\6(ZO0Y7
MKR8?)RLY7B:K6*XJ7@T!/^\->.X<2('DY 19&(L[H6O7-_9Z (Z J2:+WFWM
MS,5L6AG%:9H<5H;WY0/&J7QYA*B1"ELN9A])CJMY@[7U\][['BAC",YZ;XT&
MX1V=34H+<")B[9ZPAAF5#39IW=V+RJ/C#[N\[*YR+.GLG24C,Z3$:7_5WC69
MP^!P9)>*B6TF#.U'YGG-J78H^RI4T4YX[577^A?U2YW<\O>__1]02P,$%
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M<RTR,#(Q,#,S,5]P<F4N>&UL4$L! A0#%     @ #H&F4FTJZ8YI!P  L24
M !H              ( !_JP" &-L8G,M97@S,3%?,C R,3 S,S%X<3$N:'1M
M4$L! A0#%     @ #H&F4LOMB!2I!0  W!H  !@              ( !G[0"
M &-L8G,M97@S,E\R,#(Q,#,S,7$Q+FAT;5!+!08     "  ( !@"  !^N@(
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
